WO2023138362A1 - Wee1抑制剂及其制备和用途 - Google Patents

Wee1抑制剂及其制备和用途 Download PDF

Info

Publication number
WO2023138362A1
WO2023138362A1 PCT/CN2023/070285 CN2023070285W WO2023138362A1 WO 2023138362 A1 WO2023138362 A1 WO 2023138362A1 CN 2023070285 W CN2023070285 W CN 2023070285W WO 2023138362 A1 WO2023138362 A1 WO 2023138362A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkylene
membered
compound
added
Prior art date
Application number
PCT/CN2023/070285
Other languages
English (en)
French (fr)
Inventor
宋利
唐海
马晓慧
周水平
蔡金勇
董利明
宋壮
Original Assignee
江苏天士力帝益药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏天士力帝益药业有限公司 filed Critical 江苏天士力帝益药业有限公司
Priority to CA3234845A priority Critical patent/CA3234845A1/en
Priority to AU2023209945A priority patent/AU2023209945A1/en
Publication of WO2023138362A1 publication Critical patent/WO2023138362A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present application relates to compounds that inhibit the activity of WEE1 kinase, in particular to compounds represented by formula (I), or their stereoisomers, or pharmaceutically acceptable salts thereof, and also to methods for preparing these compounds, their pharmaceutical compositions, and their use in the preparation of medicines for treating diseases related to WEE1 activity.
  • the WEE1 tyrosine kinase is a cell cycle G2 phase checkpoint.
  • the cell cycle is tightly regulated. When the DNA of the cell is not damaged, the G1 phase, S phase and G2 phase checkpoints promote the cell to enter the division phase and ensure the smooth completion of the cell cycle. (Clinical Cancer Research, 2011, 17(13): 4200-4207.)
  • the cell cycle is regulated by cyclin-dependent kinases (CDKs), and there are 14 serine/threonine protein kinases in the CDKs family. CDK activity is regulated by phosphorylation and binding to various cycle proteins.
  • CDKs cyclin-dependent kinases
  • CDK1 also known as CDC2
  • WEE1 is a negative regulator of the cell cycle, negatively regulating cells from G2 phase into division by preventing cyclin B and activated CDK1 complexes from entering the nucleus.
  • MYT1 myelin transcription factor
  • PLK1 polo-like protein kinase 1
  • WEE1 phosphorylates WEE1
  • PLK1 also phosphorylates and activates the protein phosphatase cell division cycle 25 analogue (CDC25), which activates CDK1 by dephosphorylation.
  • Active CDK1 can bind to cyclin B to promote cell division.
  • the G1 phase, S phase and G2 phase inspection delay the cell to enter the division phase, buying time for the cell to repair the damaged DNA before the cell enters division, thereby ensuring the integrity of the genome.
  • the key regulator of the G1 phase checkpoint, p53 is mutated in many malignant tumor cells. (Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(10): 3753-3758.) Tumor cells with defective P53 function cannot arrest the cell cycle in the G1 phase when DNA is damaged, so they are more dependent on the G2 phase checkpoint.
  • the G2 phase checkpoint inhibits the phosphorylation of CDK1 through two parallel and interconnected pathways, thereby delaying cell division.
  • Ataxia telangiectasia variant (ATM) protein kinase or ataxia telangiectasia-related (ATR) protein kinase is activated.
  • ATM is activated by ionizing radiation, radioactive agents, and agents that cause double-strand DNA breaks.
  • ATM phosphorylates and activates checkpoint kinase 2 (CHK2), which phosphorylates Ser216 of cell division cycle 25C phosphatase (CDC25C).
  • CHK2 checkpoint kinase 2
  • CDC25C cell division cycle 25C phosphatase
  • Inhibition of CDC25C activity leads to inhibition of phosphorylation of the CDK1/CDK2-binding cyclin B complex, leaving CDK1 in an inactive form and inhibiting cell entry into division.
  • ATR is activated by a wide range of genotoxic stimuli that lead to single-strand DNA breaks.
  • ATR is the main kinase responsible for phosphorylating and activating CHK1.
  • CHK1 can be activated by both ATM and ATR.
  • CHK1 simultaneously phosphorylates WEE1 and CDC25C, activates the kinase activity of WEE1, and inhibits the phosphatase activity of CDC25C.
  • WEE1 phosphorylates CDK1-bound cyclin B, leading to cell cycle arrest in G2 phase, allowing time for DNA repair.
  • WEE1 is overexpressed in many malignant tumors, such as liver cancer, breast cancer, malignant glioma, melanoma, adult and childhood brain tumors. Some of the tumor cells have abnormal G1 checkpoints. If WEE1 activity is inhibited, the G2 phase checkpoints will fail. At this time, cells with damaged DNA that has not been repaired will continue to divide and eventually divide to death.
  • Patents WO2007126122, WO2008133866, WO2013012681, WO2013126656, WO2014167347, WO2015092431, WO2018011569, WO2018011570, WO2018090939, WO2018133829, Small molecule compounds with WEE1 kinase inhibitory activity are described in WO2018171633 and others.
  • the most leading compound is AZD1775, which has entered phase II clinical trials and has shown good cancer treatment effect.
  • AZD1775 also has relatively obvious adverse reactions, and the drug activity and curative effect need to be improved. Therefore, it is urgent to provide a WEE1 inhibitor with better safety and wider application population.
  • the object of the present invention is to provide a compound shown in formula I, or its stereoisomer, or a pharmaceutically acceptable salt thereof:
  • the R 1 is selected from -C 1 ⁇ 6 alkyl , -C 2 ⁇ 6 alkenyl, -C 2 ⁇ 6 alkynyl, -C 0 ⁇ 2 alkylene-CN, -C 0 ⁇ 2 alkylene-(3 ⁇ 10 membered cycloalkyl), -C 0 ⁇ 2 alkylene- (3 ⁇ 10 membered heterocycloalkyl); ⁇ 10-membered cycloalkyl, 3-10-membered heterocycloalkyl can be further substituted by one, two, three or four independent R 11 ;
  • the R 11 is selected from hydrogen, C 1-6 alkyl, halogen-substituted C 1-6 alkyl, halogen;
  • R2 is selected from The R21 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkyl substituted by halogen, -C 0-2 alkylene-C(O)OC 1-6 alkyl, -C 0-2 alkylene-COOH, -C(O)C 1-6 alkyl, halogen;
  • the R3 is selected from
  • X 1 is selected from chemical bonds, O, NR N1 or CR C1 R C2 ;
  • X 2 is selected from N or CR C1 ;
  • the X 3 is selected from O, NR N1 or CR C1 R C2 ;
  • n is selected from 1, 2 or 3;
  • R N1 is selected from hydrogen, halogen, -OH, -C 1 ⁇ 6 alkyl, C 1 ⁇ 6 alkyl substituted by halogen, -O(C 1 ⁇ 6 alkyl), -O (C 1 ⁇ 6 alkyl substituted by halogen), -NH 2 , -NH(C 1 ⁇ 6 alkyl), -N(C 1 ⁇ 6 alkyl)(C 1 ⁇ 6 alkyl), -C(O)(C 1 ⁇ 6 alkyl);
  • R C1 and R C2 are independently selected from hydrogen, halogen, cyano, nitro, -OH, -C 1 ⁇ 6 alkyl, C 1 ⁇ 6 alkyl substituted by halogen, -O(C 1 ⁇ 6 alkyl), -O(C 1 ⁇ 6 alkyl substituted by halogen), -NH 2 , -C 0 ⁇ 2 alkylene-NH(C 1 ⁇ 6 alkyl), -C 0 ⁇ 2 alkylene-N(C 1 ⁇ 6 alkyl)(C 1 ⁇ 6 alkyl);
  • R 4 is selected from -(5-12 member bridge heterocycloalkyl); said bridge heterocycloalkyl can be further substituted by one, two, three or four independent R 41 ;
  • the R 41 selected from hydrogen, oxo, -C 1 ⁇ 6 Alkyl, -C 2 ⁇ 6 Alkenyl, halogen substituted C 1 ⁇ 6 Alkyl, hydroxyl substituted C 1 ⁇ 6 Alkyl, halogen, cyano, nitro, -OH, -C 0 ⁇ 2 Alkylene-O(C 1 ⁇ 6 Alkyl), -O(halogen substituted C 1 ⁇ 6 Alkyl), -NH 2 , -NH(C 1 ⁇ 6 Alkyl), -N(C 1 ⁇ 6 Alkyl) (C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-C(O)R 42 ⁇ -C 0 ⁇ 2 Alkylene-C(O)NR 42 R 43 ⁇ -C 0 ⁇ 2 Alkylene-C(O)OR 42 ⁇ -C 0 ⁇ 2 Alkylene-S(O)R 42 ⁇ -C 0 ⁇ 2 Alkylene-S(O)NR 42 R 43 ⁇ -C 0 ⁇ 2 Alkylene
  • R 42 , R 43 independently selected from hydrogen, halogen, cyano, nitro, -OH, -C 1 ⁇ 6 Alkyl, halogen substituted C 1 ⁇ 6 Alkyl, -O(C 1 ⁇ 6 Alkyl), -O(halogen substituted C 1 ⁇ 6 Alkyl), -NH 2 , -NH(C 1 ⁇ 6 Alkyl), -N(C 1 ⁇ 6 Alkyl) (C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered cycloalkyl),-C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered heterocycloalkyl),-C 0 ⁇ 2 Alkylene-(5 ⁇ 10 membered aromatic ring),-C 0 ⁇ 2 Alkylene-(5-10 membered aromatic heterocyclic ring);
  • R 44 is selected from hydrogen, oxo, halogen, cyano, nitro, -OH, -C 1 ⁇ 6 alkyl, halogen substituted -C 1 ⁇ 6 alkyl, -O(C 1 ⁇ 6 alkyl), -O (halogen substituted C 1 ⁇ 6 alkyl), -NH 2 , -C 0 ⁇ 2 alkylene -NH(C 1 ⁇ 6 alkyl), -N(C 1 ⁇ 6 alkyl)(C 1 ⁇ 6 alkyl);
  • said R 41 and R C1 or R C2 form a 3-10-membered carbocycle or a 3-10-membered heterocycle together with the atoms directly connected to them;
  • the R 5 selected from hydrogen, oxo, halogen, cyano, nitro, -OH, -NH 2 ⁇ -C 1 ⁇ 6 Alkyl, halogen substituted C 1 ⁇ 6 Alkyl, hydroxyl substituted C 1 ⁇ 6 Alkyl, -O(C 1 ⁇ 6 Alkyl), -O(halogen substituted C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-NH(C 1 ⁇ 6 Alkyl), -O-C 0 ⁇ 2 Alkylene-N(C 1 ⁇ 6 Alkyl) (C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-N(C 1 ⁇ 6 Alkyl) (C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-(C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered cycloalkyl),-C 0 ⁇ 2 Alkylene-(3-10 membered heterocycloalkyl), -O-(3-10
  • the R 51 is selected from hydrogen, C 1-6 alkyl, halogen-substituted C 1-6 alkyl, oxo, halogen, cyano, nitro, -OH, -O(C 1-6 alkyl), -O (halogen-substituted C 1-6 alkyl ), -NH 2 , -C 0-2 alkylene-NH(C 1-6 alkyl), -N(C 1-6 alkyl)(C 1-6 alkyl);
  • each R 6 independently selected from hydrogen, C 1 ⁇ 6 Alkyl, halogen substituted C 1 ⁇ 6 Alkyl, halogen, cyano, nitro, -OH, -O(C 1 ⁇ 6 Alkyl), -O(halogen substituted C 1 ⁇ 6 Alkyl), -NH 2 , -NH(C 1 ⁇ 6 Alkyl), -N(C 1 ⁇ 6 Alkyl) (C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered cycloalkyl),-C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered heterocycloalkyl),-C 0 ⁇ 2 Alkylene-(5 ⁇ 10 membered aromatic ring),-C 0 ⁇ 2 Alkylene-(5-10 membered aromatic heterocycle), -C 0 ⁇ 2 Alkylene-(5 ⁇ 12-membered spiro ring),-C 0 ⁇ 2 Alkylene-(5-12 membered spiroheterocycle), -
  • the ring A is selected from 5-12 membered spiro rings, 5-12 membered spiro heterocyclic rings, 5-12 membered bridged rings, and 5-12 membered bridged heterocyclic rings; wherein the spiro ring, spiro heterocyclic ring, bridged ring, and bridged heterocyclic ring can be further substituted by one, two, three or four independent R A1 ;
  • each R A1 independently selected from hydrogen, halogen, cyano, nitro, -OH, -C 1 ⁇ 6 Alkyl, halogen substituted C 1 ⁇ 6 Alkyl, -O(C 1 ⁇ 6 Alkyl), -O(halogen substituted C 1 ⁇ 6 Alkyl), -NH 2 , -NH(C 1 ⁇ 6 Alkyl), -N(C 1 ⁇ 6 Alkyl) (C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered cycloalkyl),-C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered heterocycloalkyl),-C 0 ⁇ 2 Alkylene-(5 ⁇ 10 membered aromatic ring),-C 0 ⁇ 2 Alkylene-(5-10 membered aromatic heterocycle), -C 0 ⁇ 2 Alkylene-(5 ⁇ 12-membered spiro ring),-C 0 ⁇ 2 Alkylene-(5-12 membered spiroheterocycle
  • the B ring is selected from 3-10 membered carbocyclic rings, 3-10 membered heterocyclic rings, 5-10 membered aromatic rings, 5-10 membered aromatic heterocyclic rings, 5-12 membered spirocyclic rings, 5-12 membered spiro heterocyclic rings, 5-12 membered bridged rings, 5-12 membered bridged heterocyclic rings, 3-10 membered fused rings, 3-10 membered fused heterocyclic rings;
  • the fused ring and the fused heterocyclic ring can be further substituted by one, two, three or four independent R B1 ;
  • each R B1 independently selected from hydrogen, -C 1 ⁇ 6 Alkyl, halogen substituted C 1 ⁇ 6 Alkyl, halogen, cyano, nitro, -OH, -O(C 1 ⁇ 6 Alkyl), -O(halogen substituted C 1 ⁇ 6 Alkyl), -NH 2 , -NH(C 1 ⁇ 6 Alkyl), -N(C 1 ⁇ 6 Alkyl) (C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered cycloalkyl),-C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered heterocycloalkyl),-C 0 ⁇ 2 Alkylene-(5 ⁇ 10 membered aromatic ring),-C 0 ⁇ 2 Alkylene-(5-10 membered aromatic heterocyclic ring);
  • R 7 , R 8 independently selected from hydrogen, halogen, cyano, nitro, -OH, -C 1 ⁇ 6 Alkyl, halogen substituted C 1 ⁇ 6 Alkyl, -O(C 1 ⁇ 6 Alkyl), -O(halogen substituted C 1 ⁇ 6 Alkyl), -NH 2 , -NH(C 1 ⁇ 6 Alkyl), -N(C 1 ⁇ 6 Alkyl) (C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered cycloalkyl),-C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered heterocycloalkyl),-C 0 ⁇ 2 Alkylene-(5 ⁇ 10 membered aromatic ring),-C 0 ⁇ 2 Alkylene-(5-10 membered aromatic heterocyclic ring);
  • R 7 and R 8 form a 3-10-membered fused ring, a 3-10-membered fused heterocyclic ring, a 3-10-membered spiro ring, or a 3-10-membered spiro heterocyclic ring with the atoms directly connected to them;
  • the condensed ring, condensed heterocyclic ring, spiro ring, and spiro heterocyclic ring can be further substituted by one, two, three or four independent R 71 ;
  • Each R 71 is independently selected from hydrogen, C 1 ⁇ 6 alkyl, halogen substituted C 1 ⁇ 6 alkyl, halogen, cyano, nitro, -OH, -O(C 1 ⁇ 6 alkyl), -O(halogen substituted C 1 ⁇ 6 alkyl), -NH 2 , -NH(C 1 ⁇ 6 alkyl), -N(C 1 ⁇ 6 alkyl)(C 1 ⁇ 6 alkyl);
  • the C ring is selected from a 5-12-membered spiro ring, a 5-12-membered spiro heterocycle, a 5-12-membered bridged ring, a 5-12-membered bridged heterocycle, a 3-10-membered fused ring, and a 3-10-membered fused heterocycle; wherein the spiro ring, spiro heterocycle, bridged ring, bridged heterocycle, fused ring, and fused heterocycle can be further substituted by one, two, three or four independent R C1 ;
  • each R C1 independently selected from hydrogen, halogen, cyano, nitro, -OH, C 1 ⁇ 6 Alkyl, halogen substituted C 1 ⁇ 6 Alkyl, -O(C 1 ⁇ 6 Alkyl), -O(halogen substituted C 1 ⁇ 6 Alkyl), -NH 2 , -NH(C 1 ⁇ 6 Alkyl), -N(C 1 ⁇ 6 Alkyl) (C 1 ⁇ 6 Alkyl), -C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered cycloalkyl),-C 0 ⁇ 2 Alkylene-(3 ⁇ 10 membered heterocycloalkyl),-C 0 ⁇ 2 Alkylene-(5 ⁇ 10 membered aromatic ring),-C 0 ⁇ 2 Alkylene-(5-10 membered aromatic heterocycle), -C 0 ⁇ 2 Alkylene-(5 ⁇ 12-membered spiro ring),-C 0 ⁇ 2 Alkylene-(5-12 membered spiroheterocycle),
  • the R 10 is selected from hydrogen, C 1-6 alkyl, and halogen-substituted C 1-6 alkyl;
  • the R 9 is selected from -C 0 ⁇ 2 alkylene-C(O)NR 91 R 92 , -C(O)C 1 ⁇ 6 alkyl; each R 91 , R 92 is independently selected from hydrogen, C 1 ⁇ 6 alkyl, and C 1 ⁇ 6 alkyl substituted by halogen;
  • R 91 , R 92 and the atoms directly connected to them form a 3-10 membered heterocyclic ring, and the heterocyclic ring can be further substituted by one, two, three or four independent R 93 ;
  • Each R 93 is independently selected from hydrogen, C 1 ⁇ 6 alkyl, halogen substituted C 1 ⁇ 6 alkyl, halogen, cyano, nitro, -OH, -O(C 1 ⁇ 6 alkyl), -O(halogen substituted C 1 ⁇ 6 alkyl), -NH 2 , -NH(C 1 ⁇ 6 alkyl), -N(C 1 ⁇ 6 alkyl)(C 1 ⁇ 6 alkyl);
  • R3 is R 7 and R 8 are hydrogen respectively, and R1 is When, R 3 is not
  • R3 is X 1 is the bond, R 4 is R1 is , R2 is not
  • R3 is X 1 is the bond, R 4 is R1 is , R2 is not
  • R3 is R1 is , R 2 is
  • R3 is R1 is , R2 is not
  • R2 is R 21 is methyl, R1 is , R 3 is not
  • R2 is R21 is hydrogen, R1 is , R 3 is not
  • R2 is R21 is hydrogen, R1 is , R 3 is not
  • R2 is R21 is hydrogen, R1 is , R 3 is not
  • R2 is R1 is , R 3 is not
  • the compound of the present invention, or its stereoisomer, or its pharmaceutically acceptable salt, described R is selected from methyl, ethyl, propyl, isopropyl, cyclopropyl,
  • the R2 is selected from
  • said X1 is selected from a chemical bond, O, NR N1 or CR C1 R C2 ;
  • R C1 and R C2 are independently selected from hydrogen, C 1-3 alkyl, halogen, halogen-substituted C 1-3 alkyl, -C 1-2 alkylene-N(C 1-6 alkyl)(C 1-6 alkyl);
  • R N1 is selected from hydrogen, C 1-3 alkyl, C 1-3 alkyl substituted by halogen, -(3-10 membered heterocycloalkyl).
  • the R is selected from: Wherein, X is selected from O, NR 41 ; X 4 is selected from O, NH or CH 2 ; n 1 is selected from 1 or 2; said R 4 can be further substituted by one, two, three or four independent R 41 ;
  • the R 41 selected from hydrogen, oxo, C 1 ⁇ 3 Alkyl, -C 2 ⁇ 6 Alkenyl, halogen substituted C 1 ⁇ 3 Alkyl, hydroxyl substituted C 1 ⁇ 6 Alkyl, -C 0 ⁇ 2 Alkylene-O(C 1 ⁇ 3 Alkyl), -NH 2 , -NH(C 1 ⁇ 3 Alkyl), -N(C 1 ⁇ 3 Alkyl) (C 1 ⁇ 3 Alkyl), -C(O)R 42 , -C(O)NR 42 R 43 , -C(O)OR 42 , -(3 ⁇ 10 membered cycloalkyl), -(3 ⁇ 10 membered heterocycloalkyl), -C 1 ⁇ 2 Alkylene-(5-10 membered aromatic ring); wherein, the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aromatic ring can be further replaced by one, two, three or four independent R 44 replace;
  • R 42 and R 43 are independently selected from hydrogen, halogen, -OH, C 1-3 alkyl, and C 1-3 alkyl substituted by halogen;
  • R 44 is selected from hydrogen, C 1-3 alkyl, C 1-3 alkyl substituted by halogen, -O(C 1-3 alkyl).
  • the R4 is specifically selected from:
  • the compound of the present invention or its stereoisomer, or its pharmaceutically acceptable salt, said R 5 selected from hydrogen, halogen, -C 1 ⁇ 3 Alkyl, halogen substituted C 1 ⁇ 3 Alkyl, hydroxyl substituted C 1 ⁇ 3 Alkyl, -O(C 1 ⁇ 3 Alkyl), -NH(C 1 ⁇ 3 Alkyl), -O-C 2 Alkylene-N(C 1 ⁇ 3 Alkyl) (C 1 ⁇ 3 Alkyl), -O-(3-10 membered cycloalkyl), -O-(3-10 membered heterocycloalkyl), wherein, said alkyl, alkylene, cycloalkyl, heterocycloalkyl can be further replaced by one, two, three or four independent R 51 replace;
  • the R 51 is selected from hydrogen, C 1-3 alkyl, and C 1-3 alkyl substituted by halogen.
  • the compound of the present invention or its stereoisomer, or a pharmaceutically acceptable salt thereof, said R 5 is specifically selected from methyl, ethyl, ethoxy, F, methyl substituted by hydroxyl,
  • the R6 is selected from hydrogen, C 1-3 alkyl, -NH(C 1-3 alkyl), -N(C 1-3 alkyl)(C 1-3 alkyl).
  • the A ring is selected from
  • the ring B is selected from 3-10 membered heterocycles, 5-12 membered bridged heterocycles, and 3-10 membered condensed heterocycles; wherein, the said heterocycles, bridged heterocycles, and condensed heterocycles can be further substituted by one, two, three or four independent R B1 ;
  • Each R B1 is independently selected from hydrogen, C 1-3 alkyl, and halogen-substituted C 1-3 alkyl.
  • the B ring is selected from
  • the C ring is selected from
  • R 7 and R 8 are independently selected from -OH, Or R 7 , R 8 and the atoms directly connected to form
  • the R3 is selected from
  • the compound described in the present invention or its stereoisomer or its pharmaceutically acceptable salt is specifically:
  • the compound of the present invention is characterized in that: the compound described in formula I is specifically:
  • the compound of the present invention is characterized in that: the compound described in formula I is specifically:
  • the present invention also provides a use of any one of the compounds described above, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating WEE1-mediated diseases.
  • the disease mediated by WEE1 is one or more of diseases related to inflammation, autoimmune disease, infectious disease, cancer and precancerous syndrome.
  • the present invention also provides a pharmaceutical composition, which is a preparation prepared by using the compound described in any one of the above, or its stereoisomer, or its pharmaceutically acceptable salt as the pharmaceutically active ingredient, together with pharmaceutically acceptable auxiliary materials.
  • Cancer or “malignancy” means any of a variety of diseases characterized by uncontrolled abnormal proliferation of cells, the ability of affected cells to spread to other parts of the body locally or through the bloodstream and lymphatic system (i.e. metastasis), and any of a number of characteristic structural and/or molecular characteristics.
  • Cancer cell refers to cells that undergo early, intermediate or late stages of multi-step tumor progression. Cancers include sarcomas, breast cancer, lung cancer, brain cancer, bone cancer, liver cancer, kidney cancer, colon cancer and prostate cancer.
  • the compound of Formula I is used to treat a cancer selected from colon cancer, brain cancer, breast cancer, fibrosarcoma, and squamous cell carcinoma.
  • the cancer is selected from melanoma, breast cancer, colon cancer, lung cancer, and ovarian cancer.
  • the cancer treated is a metastatic cancer.
  • autoimmune diseases are caused by the body's immune response to substances and tissues normally present in the body.
  • autoimmune diseases include myocarditis, lupus nephritis, primary biliary cirrhosis, psoriasis, type 1 diabetes, Graves' disease, celiac disease, Crohn's disease, autoimmune neutropenia, juvenile arthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barré syndrome, multiple sclerosis, and autoimmune retinopathy.
  • Some embodiments of the invention relate to the treatment of autoimmune diseases such as psoriasis or multiple sclerosis.
  • Inflammatory diseases include a variety of conditions characterized by histopathic inflammation.
  • inflammatory diseases include acne vulgaris, asthma, celiac disease, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, vasculitis, airway inflammation caused by house dust mites, and interstitial cystitis.
  • Some embodiments of the invention relate to the treatment of the inflammatory disease asthma.
  • the immune system is often involved in inflammatory diseases, as seen in anaphylaxis and some myopathies, and many immune system disorders result in abnormal inflammation.
  • IL-17A-mediated diseases also include autoimmune inflammatory diseases.
  • the compounds and derivatives provided in the present invention may be named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service, Columbus, OH) nomenclature system.
  • substitution means that a hydrogen atom in a molecule is replaced by a different atom or molecule.
  • C a-b alkyl indicates any alkyl group containing "a" to "b” carbon atoms.
  • C 1-4 alkyl refers to an alkyl group containing 1 to 4 carbon atoms.
  • Alkyl means a saturated hydrocarbon chain having the indicated number of member atoms.
  • C 1 to 6 alkyl refers to an alkyl group having 1 to 6 member atoms, eg 1 to 4 member atoms.
  • Alkyl groups can be straight or branched. Representative branched alkyl groups have one, two or three branches. Alkyl groups may be optionally substituted with one or more substituents as defined herein.
  • Alkyl groups include methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl and tert-butyl), pentyl (n-pentyl, isopentyl and neopentyl) and hexyl. Alkyl groups may also be part of other groups such as C 1 -C 6 alkoxy groups.
  • Cycloalkyl and “cycloalkane” refer to saturated or partially saturated cyclic groups having carbon atoms and no ring heteroatoms and having a single ring or multiple rings (including fused and combined).
  • cycloalkyl applies when the point of attachment is at a non-aromatic carbon atom (eg 5,6,7,8,-tetralin-5-yl).
  • cycloalkyl includes cycloalkenyl groups such as cyclohexenyl.
  • cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclooctyl, cyclopentenyl, and cyclohexenyl.
  • cycloalkyl groups including multiple bicycloalkyl ring systems are bicyclohexyl, bicyclopentyl, bicyclooctyl and the like.
  • (Ca-Cb)alkenyl refers to an alkenyl group having a to b carbon atoms and is intended to include, for example, ethenyl, propenyl, isopropenyl, 1,3-butadienyl, and the like.
  • Alkynyl means a linear or branched monovalent hydrocarbon radical containing at least one triple bond.
  • alkynyl is also intended to include those hydrocarbyl groups having one triple bond and one double bond.
  • (C2-C6)alkynyl is intended to include ethynyl, propynyl, and the like.
  • Halogen is fluoro, chloro, bromo or iodo.
  • Haloalkyl means that the hydrogen atoms in the alkyl group may be replaced by one or more halogen atoms.
  • C 1-4 haloalkyl refers to an alkyl group containing 1-4 carbon atoms whose hydrogen atoms are replaced by one or more halogen atoms.
  • Heterocycle refers to a saturated ring or a non-aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to a nitrogen atom, an oxygen atom, or a sulfur atom;
  • Heteroaromatic ring refers to an aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to nitrogen atom, oxygen atom, sulfur atom;
  • Stepoisomer includes enantiomers and diastereomers; compounds of the present invention may contain asymmetric centers or chiral centers and thus exist as different stereoisomers. All stereoisomeric forms of the compounds of the invention, including but in no way limited to, diastereomers, enantiomers, atropisomers, and mixtures thereof, such as racemic mixtures, form part of the invention. Many organic compounds exist in optically active forms, that is, they have the ability to rotate the plane of plane-polarized light. When describing optically active compounds, the prefixes D, L or R, S are used to indicate the absolute configuration of the molecular chiral center. The chemical structures of these stereoisomers are the same, but their three-dimensional structures are different.
  • a particular stereoisomer may be an enantiomer, and a mixture of isomers is often referred to as an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is known as a racemic mixture or racemate, which can result in no stereoselectivity or stereospecificity during a chemical reaction.
  • the terms "racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomers, devoid of optical activity.
  • the C atom marked with "*" on the ring in the compound numbered Wee1-92 in the table of the present invention is a chiral center.
  • pharmaceutically acceptable means that a certain carrier, carrier, diluent, excipient, and/or formed salt are usually chemically or physically compatible with other ingredients constituting a pharmaceutical dosage form, and physiologically compatible with the recipient.
  • the pharmaceutical composition of the present invention can be any reusable pharmaceutical preparation form, such as: oral, injection, external use and other forms, oral dosage forms include but not limited to: tablet, capsule, oral liquid, granule, pill, suspension, injection is selected from water injection, powder injection, external preparation is selected from patch, ointment. All preparations can be prepared according to conventional techniques of pharmacy, such as using the compound of the present invention, or any one of its stereoisomers, or pharmaceutically acceptable salts thereof as the active pharmaceutical ingredient, and adding a pharmaceutically acceptable carrier if necessary, to prepare the above-mentioned pharmaceutical dosage form suitable for taking.
  • the active pharmaceutical ingredient in a unit dose can be 0.1mg-1000mg, such as each tablet contains 0.1mg-1000mg, preferably 5-500mg active pharmaceutical ingredient.
  • salts and “pharmaceutically acceptable salt” refer to the above-mentioned compounds or their stereoisomers, acidic and/or basic salts formed with inorganic and/or organic acids and bases, and also include zwitterionic salts (inner salts), and quaternary ammonium salts, such as alkylammonium salts. These salts may be obtained directly in the final isolation and purification of the compounds. It can also be obtained by mixing the above-mentioned compound, or its stereoisomer, with a certain amount of acid or base as appropriate (for example, equivalent).
  • salts may form precipitates in solution and be collected by filtration, or may be recovered after evaporation of the solvent, or may be obtained by freeze-drying after reaction in an aqueous medium.
  • Said salt in the present invention may be hydrochloride, sulfate, citrate, benzenesulfonate, hydrobromide, hydrofluoride, phosphate, acetate, propionate, succinate, oxalate, malate, succinate, fumarate, maleate, tartrate or trifluoroacetate of the compound.
  • one or more compounds of the invention may be used in combination with each other.
  • the compound of the present invention may be used in combination with any other active agents for the preparation of drugs or pharmaceutical compositions for regulating cell functions or treating diseases. If a group of compounds is used, the compounds may be administered to the subject simultaneously, separately or sequentially.
  • the compound of the present invention has better wee1 kinase inhibitory activity and tumor cell proliferation inhibitory activity; the inhibitory effect on cytochrome P450 enzyme and hERG potassium ion channel is reduced, and the safety is better.
  • NMR nuclear magnetic resonance
  • MS mass spectroscopy
  • LC-MS Shimadzu LC-MS 2020 (ESI)).
  • HPLC measurement used a Shimadzu high pressure liquid chromatograph (Shimadzu LC-20A).
  • MPLC Medium Pressure Preparative Chromatography
  • Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates are used for thin-layer chromatography silica gel plates, and the specifications used for thin-layer chromatography separation and purification products are 0.4mm to 0.5mm.
  • Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
  • the known starting materials of the present invention can be adopted or synthesized according to methods known in the art, or can be purchased from companies such as Anaiji Chemical, Chengdu Kelong Chemical, Shaoyuan Chemical Technology, and Bailingwei Technology.
  • the reaction is carried out under a nitrogen atmosphere.
  • the solution refers to an aqueous solution.
  • the temperature of the reaction is room temperature.
  • M is moles per liter.
  • THF tetrahydrofuran
  • DIPEA N,N-diisopropylethylamine
  • DCM dichloromethane
  • TFA trifluoroacetic acid
  • m-CPBA m-chloroperoxybenzoic acid
  • DMF dimethylformamide
  • PTSA p-toluenesulfonamide
  • DMSO dimethylsulfoxide
  • NBS N-bromosuccinimide
  • AIBN azobisisobutyronitrile
  • HPLC test conditions are as follows:
  • the separation conditions of SFC are: column size: 3 ⁇ m, 150mm*3mm, mobile phase: A: CO 2 , mobile phase B: ethanol; flow rate: 1mL/min, column temperature: 40°C.
  • Substrate IM-1-3 (9.16g, 27.5mmol) and DCM (18mL) were added into a dry one-necked flask, stirred and dissolved, then slowly added TFA (18mL), heated to 75°C for reaction, monitored by LC-MS. After the reaction, the organic solvent was concentrated under reduced pressure, dissolved in ethanol, added with 6M NaOH solution and stirred at room temperature, monitored by LC-MS. After the reaction was completed, solids were precipitated after concentration under reduced pressure.
  • Substrate IM-1-4 (5.20g, 23.4mmol), potassium carbonate (4.53g, 32.8mmol) and IM-1-5 (5.55g, 25.7mmol) were added to a dry two-necked flask. After nitrogen replacement three times, copper iodide (4.46g, 23.4mmol), N,N'-dimethylethylenediamine (4.13g, 46.8mmol) and 1,4 - Dioxane (100 mL), after stirring evenly, the temperature was raised to 120° C. for reaction, monitored by LC-MS and TLC.
  • Substrate IM-2-1 (7.12 g, 50 mmol) and DMSO (30 mL) were added to a dry single-necked flask, stirred and dissolved, then IM-2-2 (9.9 g, 50 mmol) was added, heated to 90°C for reaction, and monitored by LC-MS. After the reaction was completed, it was cooled to room temperature, and the precipitated solid was filtered out, washed three times with water and three times with a small amount of methanol, and dried to obtain the product IM-2-3 (12.12g, 76% yield), LCMS (ESI + ) m/z: 320.3[M+H] + .
  • Substrate IM-2-3 (12.12g, 38mmol) and DCM (18mL) were added into a dry one-necked flask, stirred and dissolved, then TFA (18mL) was added slowly, monitored by LC-MS. After the reaction, the solvent was concentrated under reduced pressure to obtain a residue. Add methanol (70mL) to the residue, stir to dissolve, add paraformaldehyde (7g) and acetic acid (1mL), stir at room temperature for 30min, add sodium cyanoborohydride (3.8g, 60mmol), and heat up to 50°C for reaction.
  • Substrate IM-2-4 (5g, 21.5mmol) and methanol (40mL) were added to a dry single-necked flask, stirred and dissolved, then Pd/C (500mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with diatomaceous earth, and the organic phase was concentrated under reduced pressure to obtain product IM-2 (4.0 g, crude), LCMS (ESI + ) m/z: 204.2[M+H] + .
  • Substrate IM-1-4 (138 mg, 620.88 ⁇ mol), potassium carbonate (101 mg, 620.88 ⁇ mol) and IM-3-1 (130 mg, 521.82 ⁇ mol) were added to a dry two-necked flask. , 4-dioxane (10mL), after stirring evenly, the temperature was raised to 120°C for reaction, monitored by LC-MS. After the reaction was completed, return to room temperature, add ammonia water, extract with ethyl acetate three times, and concentrate the organic phase under reduced pressure. The residue was purified by medium pressure liquid chromatography (alkaline method) to obtain compound IM-3 (130 mg, 53.62% yield), LCMS (E+) m/z: 391.2 [M+H] + .
  • Substrate IM-2-3 (1g, 3.13mmol) and methanol (10mL) were added to a dry one-necked flask, stirred and dissolved, then Pd/C (200mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with diatomaceous earth, and the organic phase was concentrated under reduced pressure to obtain product IM-4 (700 mg, crude), LCMS (ESI + ) m/z: 290.2[M+H] + .
  • Step 1 Synthesis of Compound IM-5:
  • Substrate IM-3 (0.2g, 0.51mmol) was added to a single-port reaction flask, stirred and dissolved in anhydrous THF (5ml), m-CPBA (208.2g, 1.02mmol, purity 85%) was added, stirred at room temperature for 40 minutes, and monitored by LC-MS. The reactant was concentrated under reduced pressure and separated by medium-pressure liquid chromatography to obtain IM-5 (160 mg), LCMS (ESI + ) m/z: 407.1[M+H] + .
  • Substrate IM-1 (0.2g, 0.56mmol) was added to a single-port reaction flask, anhydrous THF (5ml) was stirred and dissolved, m-CPBA (144.9mg, 0.84mmol, purity 85%) was added, stirred at room temperature for 40 minutes, and monitored by LC-MS. The reactant was concentrated under reduced pressure and separated by medium pressure liquid chromatography to obtain IM-6 (150 mg, 0.40 mmol, 71.8% yield), LCMS (ESI + ) m/z: 374.1[M+H] + .
  • Embodiment 1 the synthesis of compound 1
  • substrate 1-3 (93mg, 336.77 ⁇ mol), IM-1-4 (89.82mg, 404.13 ⁇ mol), cuprous iodide (64.14mg, 336.77 ⁇ mol), potassium carbonate (65.17mg, 505.16 ⁇ mol) and N,N'-dimethylethylenediamine (29.64mg, 336.77 ⁇ mol) under nitrogen protection ⁇ mol), and then 1,4-dioxane (5 mL) was added. Under a nitrogen atmosphere, the reaction was heated at 120° C. for 10 hours.
  • Embodiment 2 the synthesis of compound 2
  • Substrate IM-1 (43mg, 120.30 ⁇ mol) and toluene (1mL) were added to a dry single-necked flask, stirred and dissolved, then m-CPBA (43.60mg, 252.64 ⁇ mol) was added, reacted at room temperature for 30min, and monitored by LC-MS. After the reaction, DIPEA (80.6mg, 623.65 ⁇ mol, 108.63 ⁇ L) was added, and after stirring for 10min, IM-4 (45.14mg, 0.156mmol) was added and monitored by LC-MS.
  • Substrate 2-1 (40.00 mg, 66.81 ⁇ mol) and DCM (3 mL) were added to a dry one-necked flask, stirred and dissolved, and TFA (3 mL) was added slowly, monitored by LC-MS. After the reaction was completed, the solvent was concentrated under reduced pressure to obtain a residue, which was purified by medium-pressure liquid chromatography (acid method) to obtain compound 2 (25 mg, 61.08% yield).
  • Embodiment 3 the synthesis of compound 3
  • Substrate IM-1 (3.57g, 10mmol) and tetrahydrofuran (30mL) were added to a dry single-necked flask. After stirring and dissolving, m-CPBA (2.5g, 15mmol, purity 85%) was added, reacted at room temperature for 1h, and monitored by LC-MS. After the reaction, DIPEA (6.45g, 50mmol) was added, and after stirring for 10min, IM-2 (2.1g, 10mmol) was added, monitored by LC-MS. After the reaction was completed, the solvent was concentrated under reduced pressure, and the residual impurities were purified by medium-pressure liquid chromatography (alkaline method) to obtain compound 3 (2.1 g, 41% yield).
  • Embodiment 4 the synthesis of compound 4
  • Substrate 4-1 (114mg, 910.78 ⁇ mol) and methanol (2mL) were added to a dry single-necked flask. After stirring and dissolving, NaBH 4 (38mg, 1.00mmol) was added and reacted at room temperature for 1h, monitored by LC-MS.
  • Substrate IM-1 (71mg, 0.2mmol) and toluene (2mL) were added to a dry single-necked flask. After stirring and dissolving, m-CPBA (52mg, 0.3mmol, purity 85%) was added, reacted at room temperature for 1h, and monitored by LC-MS. After the reaction, DIPEA (83.58 mg, 646.69 ⁇ mol, 112.64 ⁇ L) was added, and after stirring for 10 min, compound 4-4 (52.39 mg, 0.24 mmol) was added, monitored by LC-MS.
  • Embodiment 5 the synthesis of compound 5
  • Substrate IM-3 (30mg, 77 ⁇ mol) and tetrahydrofuran (2mL) were added to a dry single-necked flask. After stirring and dissolving, m-CPBA (20mg, 116 ⁇ mol) was added and reacted at room temperature for 1h, monitored by LC-MS. After the reaction, DIPEA (50 mg, 385 ⁇ mol) was added, and after stirring for 10 min, compound IM-2 (20 mg, 98.39 ⁇ mol) was added, monitored by LC-MS. After the reaction was completed, it was concentrated under reduced pressure to obtain a residue which was purified by medium pressure liquid chromatography (alkaline method) to obtain compound 5 (15 mg, 55.87% yield).
  • Embodiment 6 the synthesis of compound 6
  • Substrate 6-1 (103mg, 0.4mmol) and methanol (5mL) were added to a dry single-necked flask, stirred and dissolved, then Pd/C (15mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed by filtration with celite, and the organic phase was concentrated under reduced pressure to obtain crude product 6-2 (80 mg, crude), LCMS (ESI + ) m/z: 231.2[M+H] + .
  • Substrate IM-3 (30mg, 77 ⁇ mol) and tetrahydrofuran (2mL) were added to a dry single-necked flask. After stirring and dissolving, m-CPBA (20mg, 116 ⁇ mol) was added and reacted at room temperature for 1h, monitored by LC-MS. After the reaction, DIPEA (50 mg, 385 ⁇ mol) was added, and after stirring for 10 min, compound 6-2 (20 mg, 86.84 ⁇ mol) was added, monitored by LC-MS. After the reaction was completed, it was concentrated under reduced pressure to obtain a residue which was purified by medium pressure liquid chromatography (alkaline method) to obtain compound 6 (5 mg, 17.74% yield).
  • Embodiment 7 the synthesis of compound 7
  • Substrate IM-3 (30mg, 77 ⁇ mol) and tetrahydrofuran (2mL) were added to a dry single-necked flask. After stirring and dissolving, m-CPBA (20mg, 116 ⁇ mol) was added and reacted at room temperature for 1h, monitored by LC-MS. After the reaction, DIPEA (50 mg, 385 ⁇ mol) was added, and after stirring for 10 min, compound 4-4 (20 mg, 91.62 ⁇ mol) was added, monitored by LC-MS. After the reaction was completed, the solvent was concentrated under reduced pressure, and the residue was purified by medium pressure liquid chromatography (alkaline method) to obtain compound 7 (5 mg, 19.08% yield).
  • Embodiment 8 the synthesis of compound 8
  • Substrate 4-2 (1g, 7.09mmol), compound 8-1 (1.70g, 8.50mmol) and potassium carbonate (2.45g, 17.72mmol) were added to a dry single-necked flask, dissolved in DMF (10mL), heated to 90°C, reacted for 1h, and monitored by LC-MS. After the reaction was completed, it was extracted three times with water and ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the organic solvent was concentrated under reduced pressure to obtain a crude product without purification, which could be directly used in the next reaction to obtain compound 8-2 (2.1 g, crude) as a yellow oil.
  • Substrate 8-2 (2.1 g, 6.53 mmol) was added into a dry one-necked flask and dissolved in HCl/1,4-dioxane (10 mL), reacted at room temperature for 1 h, and monitored by LC-MS. After the reaction was completed, it was concentrated under reduced pressure, extracted three times with saturated sodium carbonate solution and ethyl acetate, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated the organic solvent under reduced pressure to obtain a crude product without purification. The crude product can be directly used in the next reaction to obtain compound 8-3 (1.3 g, crude) as a yellow oil.
  • Substrate 8-3 (700mg, 3.16mmol) was added to a dry single-necked flask, compound 4-1 (396.00mg, 3.16mmol) was dissolved in MeOH/AcOH (10mL), and reacted at room temperature for 1h, monitored by LC-MS. After the reaction was completed, it was concentrated under reduced pressure, extracted three times with water and ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, the organic solvent was concentrated under reduced pressure, and residual impurities were removed by MPLC to obtain compound 8-4 (300 mg, 907.93 ⁇ mol, 28.70% yield) as a yellow solid.
  • Substrate 8-4 300 mg, 907.93 ⁇ mol
  • formaldehyde 136.31 mg, 4.54 mmol
  • MeOH/AcOH 8 mL
  • NaCNBH 3 142.64 mg, 2.27 mmol
  • Substrate 8-5 (1.5g, 4.74mmol) was added to a dry single-necked flask, dissolved in MeOH/AcOH (10mL), Pd/C (172.73mg, 1.42mmol) was added, replaced with H 2 for 3 times, reacted at room temperature for 3h, monitored by LC-MS. After the reaction was completed, it was filtered with diatomaceous earth, and the filtrate was concentrated under reduced pressure without purification. The crude product could be directly used in the next reaction to obtain compound 8-6 (1.5 g, crude) as a black oil.
  • Substrate 8-6 (50 mg, 159.00 ⁇ mol) was added to a dry single-necked flask, and compound IM-5 (64.63 mg, 159.00 ⁇ mol) was dissolved in THF (3 mL), then PTSA (54.76 mg, 318.00 ⁇ mol) was added, the temperature was raised to 110 ° C, and the reaction was stirred for 5 h, monitored by LC-MS.
  • Embodiment 9 the synthesis of compound 9
  • Substrate 4-1 (161 mg, 1 mmol) was added to a dry single-necked flask, stirred and dissolved with ethanol/water (10:1, 10 mL), and then 9-1 (186 mg, 1.1 mmol) and sodium hydroxide (100 mg, 2.5 mmol) were added, reacted at room temperature, and monitored by LC-MS. After the reaction was completed, the precipitated solid was filtered off, washed three times with a small amount of ethanol, and dried to obtain compound 9-2 (150 mg, 50% yield), LCMS (E+) m/z: 303.1[M+H] + .
  • Substrate 9-2 (81mg, 0.27mmol) and methanol (5mL) were added to a dry single-necked flask, stirred and dissolved, then Pd/C (15mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with diatomaceous earth, and the organic phase was concentrated by distillation under reduced pressure to obtain product 9-3 (42 mg, crude), LCMS (ESI + ) m/z: 275.2[M+H] + .
  • Substrate IM-3 (40mg, 110.71 ⁇ mol) and THF (2mL) were added to a dry single-necked bottle, stirred and dissolved, then m-CPBA (29mg, 116 ⁇ mol) was added, reacted at room temperature for 1h, monitored by LC-MS. After the reaction, DIPEA (75.12 mg, 581.26 ⁇ mol) was added, and after stirring for 10 min, compound 9-3 (36.45 mg, 132.85 ⁇ mol) was added, monitored by LC-MS. After the reaction was completed, it was concentrated under reduced pressure to obtain a residue which was purified by medium pressure liquid chromatography (alkaline method) to obtain compound 9 (35 mg, 51.26% yield).
  • Embodiment 10 the synthesis of compound 10
  • Substrate 10-1 (103mg, 0.4mmol) and methanol (5mL) were added to a dry single-necked flask. After stirring and dissolving, Pd/C (15mg) was added, hydrogen was replaced five times, and the reaction was stirred at room temperature and monitored by LC-MS. After the reaction, Pd/C was removed with diatomaceous earth, and the organic phase was concentrated by distillation under reduced pressure to obtain product 10-2 (65 mg, crude), LCMS (ESI + ) m/z: 231.2[M+H] + .
  • Substrate IM-3 (40mg, 110.71 ⁇ mol) and THF (2mL) were added to a dry single-necked bottle, stirred and dissolved, then m-CPBA (29mg, 116 ⁇ mol) was added, reacted at room temperature for 1h, monitored by LC-MS. After the reaction, DIPEA (85.85 mg, 664.24 ⁇ mol) was added, and after stirring for 10 min, compound 10-2 (30.6 mg, 132.85 ⁇ mol) was added, monitored by LC-MS. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by medium pressure liquid chromatography (alkaline method) to obtain compound 10 (15 mg, 22.22% yield).
  • Embodiment 11 the synthesis of compound 11
  • Substrate 4-2 (2g, 14.17mmol), compound 11-1 (3.17g, 17.01mmol) and potassium carbonate (4.89g, 35.44mmol) were added to a dry single-necked flask, dissolved in DMF (10mL), heated to 90°C, reacted for 1h, and monitored by LC-MS. After the reaction was completed, it was extracted three times with water and ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the organic solvent was concentrated under reduced pressure to obtain a crude product without purification. The product could be directly used in the next reaction to obtain compound 11-2 (4 g, crude) as a yellow solid. LCMS (E+) m/z: 308.3 [M+H] + .
  • Substrate 11-2 (4 g, 13.01 mmol) was added into a dry one-necked flask and dissolved in HCl/1,4-dioxane (10 mL), reacted at room temperature for 1 h, and monitored by LC-MS. After the reaction was completed, the organic phase was concentrated under reduced pressure, extracted three times with saturated sodium carbonate and ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the organic solvent was concentrated under reduced pressure to obtain a crude product without purification. The product can be directly used in the next reaction to obtain compound 11-3 (2.5 g, crude) as a yellow solid. LCMS (E+) m/z: 208.2 [M+H] + .
  • Substrate 11-3 (1 g, 4.83 mmol) was added to a dry one-necked flask, and the free base of compound 4-1 (724.81 mg, 5.79 mmol) was dissolved in MeOH/AcOH (10 mL), reacted at room temperature for 1 h, and monitored by LC-MS. After the reaction was complete, the organic phase was concentrated under reduced pressure, extracted three times with saturated sodium carbonate and ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, the organic solvent was concentrated under reduced pressure, and residual impurities were removed by MPLC to obtain compound 11-4 (1.5 g, 4.27 mmol, 88.42% yield) as a yellow solid. LCMS (E+) m/z: 317.4 [M+H] + .
  • Substrate 11-4 (1.5g, 4.74mmol) was added to a dry one-necked flask, Pd/C (172.73mg, 1.42mmol) was dissolved in MeOH/AcOH (10mL), replaced with H 2 for 3 times, reacted at room temperature under H 2 for 3h, monitored by LC-MS. After the reaction was completed, it was filtered with celite, and the filtrate was concentrated under reduced pressure without purification. The crude product could be directly used in the next reaction to obtain compound 11-5 (1.5 g, crude) as a black oil. LCMS (E+) m/z: 287.4 [M+H] + .
  • Substrate 11-5 35 mg, 122.20 ⁇ mol was added to a dry single-necked flask. After dissolving compound IM-5 (49.67 mg, 122.20 ⁇ mol) in THF (3 mL), PTSA (52.61 mg, 305.50 ⁇ mol) was added, and the temperature was raised to 110° C., stirred for 5 h, and monitored by LC-MS.
  • Embodiment 12 the synthesis of compound 12
  • Substrate IM-2-1 (416mg, 2.1mmol) and DMSO (8mL) were added to a dry single-necked flask, stirred and dissolved, potassium carbonate (387mg, 2mmol) and compound 12-1 (310mg, 2mmol) were added, heated to 90°C for reaction, and monitored by LC-MS. After the reaction, cool to room temperature, add water and stir until a solid precipitates, filter the solid, wash three times with water, wash three times with a small amount of methanol, and dry to obtain the product 12-2 (200 mg, 30% yield), LCMS (ESI + ) m/z: 334.2[M+H] + .
  • Substrate 12-2 (200mg, 0.6mmol) and DCM (5mL) were added into a dry one-necked flask, stirred and dissolved, then TFA (5mL) was added slowly, monitored by LC-MS. After the reaction was completed, it was concentrated under reduced pressure. Add methanol (5 mL) to the residue, stir to dissolve, then add paraformaldehyde (180 mg) and acetic acid (500 ⁇ L), stir at room temperature for 30 min, add sodium cyanoborohydride (75 mg, 1.2 mmol), heat up to 50 ° C for reaction, and monitor by LC-MS.
  • Substrate IM-1 52mg, 0.15mmol
  • THF 3mL
  • m-CPBA 121mg, 0.6mmol, purity 85%
  • DIPEA 98 mg, 758.28 ⁇ mol
  • 12-4 33 mg, 151.86 ⁇ mol
  • Embodiment 13 the synthesis of compound 13
  • Substrate 13-1 (1.03g, 10mmol) and DMSO (15mL) were added to a dry one-necked flask, stirred and dissolved, then potassium carbonate (2g, 14mmol) and p-fluoronitrobenzene (1.43g, 10mmol) were added, heated to 100°C for reaction, and monitored by LC-MS. After the reaction was completed, it was cooled to room temperature, and the solid was filtered off. The filtrate was concentrated and purified by medium-pressure liquid chromatography (acid method) to obtain compound 13-2 (2 g, 89% yield), LCMS (ESI + ) m/z: 225.1 [M+H] + .
  • Substrate 13-2 (44mg, 0.2mmol) and THF (2mL) were added to a dry one-necked flask, stirred and dissolved, then HATU (84mg, 0.22mmol) and DIPEA (28mg, 0.22mmol) were added, stirred at room temperature for 30min, methylamine hydrochloride (67mg, 1mmol) was added, and the temperature was raised to 65°C for reaction, monitored by LC-MS.
  • Substrate 13-3 (24mg, 0.1mmol) and methanol (4mL) were added to a dry one-necked flask. After stirring to dissolve, Pd/C (5mg) was added, hydrogen was replaced five times, and the reaction was stirred at room temperature and monitored by LC-MS. After the reaction, Pd/C was removed by filtration with celite, and the organic phase was concentrated by distillation under reduced pressure to obtain crude product 13-4 (18 mg, crude), LCMS (ESI + ) m/z: 208.2[M+H] + .
  • Embodiment 14 the synthesis of compound 14
  • Substrate 13-2 (44mg, 0.2mmol) and THF (2mL) were added to a dry single-necked flask, stirred and dissolved, then HATU (84mg, 0.22mmol) and DIPEA (28mg, 0.22mmol) were added, stirred at room temperature for 30min, N-methylpiperazine (40mg, 0.4mmol) was added, and the temperature was raised to 65°C for reaction, monitored by LC-MS. After the reaction, it was cooled to room temperature, extracted three times with ethyl acetate, and the organic phase was concentrated under reduced pressure to obtain crude product 14-1 (50 mg, crude), LCMS (ESI + ) m/z: 307.2[M+H] + .
  • Substrate 14-1 50mg, 0.16mmol
  • methanol 4mL
  • Pd/C 5mg
  • hydrogen was replaced five times
  • the reaction was stirred at room temperature and monitored by LC-MS.
  • Pd/C was removed with diatomaceous earth, and the organic phase was concentrated under reduced pressure to obtain product 14-2 (40 mg, crude), LCMS (ESI + ) m/z: 277.2[M+H] + .
  • Substrate IM-1 38mg, 106 ⁇ mol
  • THF 2mL
  • m-CPBA 40mg, 200 ⁇ mol
  • DIPEA 65 mg, 500 ⁇ mol
  • compound 14-2 40 mg, crude
  • the temperature was raised to 80° C. for reaction, monitored by LC-MS.
  • the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by medium pressure liquid chromatography (alkaline method) to obtain compound 14 (12.2 mg, 17.58% yield).
  • Embodiment 15 the synthesis of compound 15
  • Substrate 15-1 (2.44g, 12.50mmol), NBS (3.33g, 18.70mmol), AIBN (0.2g, 1.21mmol) were added to a single-port reaction flask, dissolved in CCl 4 (20ml), replaced with nitrogen three times, and the reaction flask was placed in an oil bath at 85°C under nitrogen protection and stirred overnight, monitored by TLC. Concentrate under reduced pressure to remove the solvent, without purification, the crude product can be directly used in the next reaction to obtain the crude product 15-2 (3 g, 11.03 mmol, 88.1% yield).
  • Substrate 15-3 (0.6 g, 1.70 mmol) was added to the reaction flask, dissolved in anhydrous methanol (10 ml), and Pd/C (10% wt.) (60 mg) was added. After being replaced with hydrogen for 3 times, the mixture was stirred overnight at room temperature and monitored by LC-MS. After the reaction, filter with diatomaceous earth, the filtrate was concentrated under reduced pressure and purified by column chromatography to obtain compound 15-4 (474 mg, 1.92 mmol, 88.7% yield), LCMS (ESI + ) m/z: 246.2 [M+H] + .
  • Substrate IM-5 39.3 mg, 0.097 mmol
  • substrate 15-4 47.43 mg, 0.19 mmol
  • anhydrous acetonitrile 4 ml
  • TFA 55.18 mg, 0.48 mmol
  • Microwave reaction at 90°C for 4 hours, monitored by LC-MS. After the reaction was completed, it was quenched with saturated NaHCO solution, extracted three times with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure and purified by medium-pressure liquid chromatography to obtain product 15 (10 mg, 0.017 mmol, 17.6% yield).
  • Embodiment 16 the synthesis of compound 16
  • Substrate 16-4 (500mg, 1.68mmol) and methanol (15mL) were added to a dry one-necked flask, stirred evenly, Pd/C (50mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with Celite, washed with methanol, and the organic phase was concentrated under reduced pressure to obtain product 16-5 (310 mg, 69% yield), LCMS (ESI + ) m/z: 268.1[M+H] + .
  • Substrate IM-1 70mg, 200 ⁇ mol
  • tetrahydrofuran 4mL
  • m-CPBA 60mg, 300 ⁇ mol, purity 85%
  • DIPEA 129.24mg, 1.00mmol
  • 16-5 53.47mg, 200.00 ⁇ mol
  • Embodiment 17 the synthesis of compound 17
  • Embodiment 18 the synthesis of compound 18
  • 18-4 (1.35g, 6.2mmol) and 18-5 (1.47g, 7.4mmol) were dissolved in methanol (15ml), added acetic acid (1ml) and reacted at room temperature for 30 minutes. Then sodium cyanoborohydride (584mg, 9.3mmol) was added, the temperature was raised to 60°C, and the mixture was stirred for 4 hours.
  • step 3 in Example 17 According to the synthesis method of step 3 in Example 17, 17-4 (51 mg, 0.15 mmol) in step 3 was replaced by 18-8 (42.1 mg, 0.15 mmol), and the synthesis method was the same to obtain compound 18 (20 mg, 33.6 ⁇ mol, 22.9% yield).
  • Embodiment 19 the synthesis of compound 19
  • Substrate 19-2 (50mg, 0.19mmol) and methanol (2mL) were added to a dry one-necked flask. After stirring to dissolve, Pd/C (10mg) was added, hydrogen was replaced five times, and the reaction was stirred at room temperature and monitored by LC-MS. After the reaction, Pd/C was removed with diatomaceous earth, and the organic phase was concentrated by distillation under reduced pressure to obtain product 19-3 (40 mg, crude), LCMS (ESI + ) m/z: 232.2[M+H] + .
  • Substrate IM-1 (52mg, 0.15mmol), tetrahydrofuran (3mL) was added to a dry single-necked flask, stirred and dissolved, then m-CPBA (121mg, 0.6mmol, purity 85%) was added, reacted at room temperature for 1h, and monitored by LC-MS. After the reaction, DIPEA (95.17 mg, 736.42 ⁇ mol) was added, stirred for 10 min, and 19-3 (40 mg, crude) was added, monitored by LC-MS. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by medium pressure liquid chromatography (alkaline method) to obtain compound 19 (35 mg, 40.96% yield).
  • Embodiment 20 the synthesis of compound 20
  • Substrate 20-1 (136mg, 1mmol) and DMSO (8mL) were added to a dry single-necked flask, stirred and dissolved, then potassium carbonate (332mg, 2.4mmol) and p-fluoronitrobenzene (141mg, 1mmol) were added, heated to 90°C for reaction, and monitored by LC-MS. After the reaction, cool to room temperature, add water and stir to form a solid precipitate, filter the solid, wash three times with water, wash three times with a small amount of methanol, and dry to obtain the product 20-2 (180 mg, 81.8% yield), LCMS (ESI + ) m/z: 221.2[M+H] + .
  • Substrate 20-2 (180mg, 0.82mmol) and methanol (7mL) were added to a dry one-necked flask, Pd/C (18 mg) was added under stirring, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with diatomaceous earth, and the organic phase was concentrated under reduced pressure to obtain the crude product 20-3 (120 mg, crude), LCMS (ESI+) m/z: 191.1 [M+H]+.
  • Substrate IM-1 52mg, 0.15mmol
  • tetrahydrofuran 3mL
  • m-CPBA 121mg, 0.6mmol, purity 85%
  • DIPEA 98 mg, 758.28 ⁇ mol
  • compound 20-3 46 mg, 151.86 ⁇ mol
  • Embodiment 21 the synthesis of compound 21
  • Substrate 21-1 (3.0g, 19.34mmol) and DMSO (20mL) were added to a dry one-necked flask, and after stirring to dissolve, potassium carbonate (2.67g, 19.34mmol) and 21-2 (3.82g, 19.34mmol) were added, heated to 100°C for 3 hours, and monitored by LC-MS. After the reaction, cool to room temperature, add water and stir to form a solid, filter out the solid, wash with water three times, wash with a small amount of methanol three times, and dry to obtain the product 21-3 (6g, 18.00mmol, 93.06% yield), LCMS (ESI + ) m/z: 334.4[M+H] + .
  • Substrate 21-3 (6.67g, 20.01mmol), TFA (2.28g, 20.01mmol) and DCM (50mL) were added to a dry one-necked flask, stirred and dissolved, and reacted at room temperature for 18 hours, monitored by LC-MS. After the reaction, concentrated under reduced pressure, added water and ethyl acetate to extract three times, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated the filtrate under reduced pressure to obtain the crude product 21-4 (4 g, crude), LCMS (ESI + ) m/z: 234.3[M+H] + .
  • Substrate 21-4 (3g, 12.86mmol), compound 21-5 (1.46g, 12.86mmol), NaBH 3 CN (1.2g, 19.11mmol) and methanol (30mL) were added to a dry single-necked flask, stirred and dissolved, then heated to 60°C for 18 hours, monitored by LC-MS.
  • Substrate 21-6 200mg, 0.61mmol
  • methanol (10mL) 10mL
  • Pd/C 40mg
  • hydrogen was replaced five times
  • the reaction was stirred at room temperature, and monitored by LC-MS.
  • Pd/C was removed with celite, washed with methanol, and the organic phase was concentrated under reduced pressure to obtain product 21-7 (50 mg, 27.5% yield), LCMS (ESI + ) m/z: 301[M+H] + .
  • Substrate IM-1 (17.8mg, 50.08 ⁇ mol) and tetrahydrofuran (2mL) were added to a dry single-necked flask. After stirring and dissolving, m-CPBA (12.9mg, 74.74 ⁇ mol) was added and reacted at room temperature for 1h, monitored by LC-MS. After the reaction, DIPEA (6.47 mg, 50.08 ⁇ mol, 8.72 ⁇ L) was added, and after stirring for 10 min, compound 21-7 (15.05 mg, 50.08 ⁇ mol) was added, monitored by LC-MS.
  • Embodiment 22 the synthesis of compound 22
  • Substrate 22-1 (158mg, 499.31 ⁇ mol), TFA (3mL) and DCM (3mL) were added to a dry one-necked flask, stirred and dissolved, and reacted at room temperature for 18 hours, monitored by LC-MS. After the reaction, concentrated under reduced pressure, added water and ethyl acetate to extract three times, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated the filtrate under reduced pressure to obtain the crude product 22-2 (100 mg, crude), LCMS (ESI + ) m/z: 217.3[M+H] + .
  • Substrate 22-2 (100 mg, 462.28 ⁇ mol) and DMSO (4 mL) were added to a dry single-necked flask, stirred to dissolve, potassium carbonate (97 mg, 701.88 ⁇ mol) and compound 4-2 (72 mg, 510.28 ⁇ mol) were added, heated to 100°C for 3 hours, monitored by LC-MS. After the reaction, cool to room temperature, add water and stir to form a solid, filter out the solid, wash three times with water and three times with a small amount of methanol, and dry to obtain the product 22-3 (150 mg, 444.56 ⁇ mol, 96.17% yield), LCMS (ESI + ) m/z: 338.4[M+H] + .
  • Substrate 22-4 (24.70mg, 80.34 ⁇ mol) and tetrahydrofuran (2mL) were added to a dry single-necked flask, stirred to dissolve, DIPEA (51.91mg, 401.68 ⁇ mol, 69.96 ⁇ L) and compound IM-6 (30mg, 80.34 ⁇ mol) were added, reacted at room temperature for 1h, and monitored by LC-MS. After the reaction, it was concentrated under reduced pressure, and the residue was purified by medium-pressure liquid chromatography to obtain compound 22 (5 mg, 7.30 ⁇ mol, 9.09% yield).
  • Embodiment 23 the synthesis of compound 23
  • Substrate 22-1 200 mg, 632.04 ⁇ mol
  • methanol 5 mL
  • Pd/C 20 mg
  • hydrogen was replaced five times
  • the reaction was stirred at room temperature, and monitored by LC-MS.
  • Pd/C was removed with celite, washed with methanol, and the organic phase was concentrated under reduced pressure to obtain product 23-1 (140 mg, crude), LCMS (ESI + ) m/z: 227.3[M+H] + .
  • Substrate 23-1 (128.31mg, 566.97 ⁇ mol) and DMSO (3mL) were added to a dry single-necked flask, stirred and dissolved, then potassium carbonate (96.74mg, 0.7mmol) and p-fluoronitrobenzene (4-2, 80mg, 566.97 ⁇ mol) were added, heated to 90°C for 6 hours, monitored by LC-MS. After the reaction, cool to room temperature, add water and stir to form a solid, filter out the solid, wash with water three times, wash with a small amount of methanol three times, and dry to obtain the product 23-2 (120 mg, crude), LCMS (ESI + ) m/z: 348.4[M+H] + .
  • Substrate 23-2 (69mg, 198.61 ⁇ mol), TFA (3mL) and DCM (3mL) were added to a dry one-necked flask, stirred and dissolved, and reacted at room temperature for 18 hours, monitored by LC-MS. After the reaction, concentrated under reduced pressure, added water and ethyl acetate to extract three times, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated the filtrate under reduced pressure to obtain the crude product 23-3 (49 mg, crude), LCMS (ESI + ) m/z: 248.3[M+H] + .
  • Substrate 23-3 (49.46mg, 0.2mmol) was added to a dry single-necked flask, methanol (4mL) was added and stirred to dissolve, then formaldehyde (34.06mg, 1.00mmol) and acetic acid (11mL) were added, after stirring for 10 minutes, NaCNBH 3 (25.14mg, 400.00 ⁇ mol) was added, and the temperature was raised to 50°C for 2 hours, monitored by LC-MS.
  • Substrate 23-4 (30 mg, 114.80 ⁇ mol) and methanol (3 mL) were added to a dry one-necked flask, stirred evenly, Pd/C (8 mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with celite, washed with methanol, and the organic phase was concentrated under reduced pressure to obtain the product 23-5 (20 mg, crude), LCMS (ESI + ) m/z: 232.3[M+H] + .
  • Substrate 23-5 (18.58 mg, 80.34 ⁇ mol) and tetrahydrofuran (2 mL) were added to a dry single-necked flask, stirred to dissolve, DIPEA (51.91 mg, 401.68 ⁇ mol, 69.96 ⁇ L) and compound IM-6 (30 mg, 80.34 ⁇ mol) were added, reacted at room temperature for 1 h, and monitored by LC-MS. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by medium-pressure liquid chromatography to obtain compound 23 (8 mg, 13.58 ⁇ mol, 16.91% yield).
  • Embodiment 24 the synthesis of compound 24
  • Substrate 24-1 (2g, 10.25mmol) and carbon tetrachloride (40mL) were added to a dry single-necked flask, stirred evenly, NBS (2.74g, 15.37mmol) and AIBN (269.24mg, 1.64mmol) were added, nitrogen was replaced five times, the temperature was raised to 70°C and stirred and refluxed for 12 hours, monitored by LC-MS. After the reaction, it was concentrated under reduced pressure, and the residue was purified by medium-pressure liquid chromatography to obtain 24-2 (1.3 g, 4.74 mmol, 46.3% yield), LCMS (ESI + ) m/z: 274.1[M+H] + .
  • Substrates 24-2 200mg, 0.73mmol
  • 24-3 166.42mg, 1.46mmol
  • Substrate 24-4 (180mg, 0.65mmol) and methanol (3mL) were added to a dry one-necked flask, stirred evenly, Pd/C (36mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with celite, washed with methanol, and the organic phase was concentrated under reduced pressure to obtain product 24-5 (100 mg, crude), LCMS (ESI + ) m/z: 246.3[M+H] + .
  • Substrate IM-3 (0.2g, 0.51mmol) was added to a single-port reaction flask, stirred and dissolved in anhydrous THF (5ml), m-CPBA (208.2g, 1.02mmol, purity 85%) was added, stirred at room temperature for 40 minutes, and monitored by LC-MS. The reactants were concentrated under reduced pressure and separated by medium pressure liquid chromatography to obtain compound 24-6 (130 mg, 0.31 mmol, 60.0% yield), LCMS (ESI + ) m/z: 423.5[M+H] + .
  • Substrates 24-6 31 mg, 73.38 ⁇ mol
  • 24-5 36.00 mg, 146.75 ⁇ mol
  • TsOH 50.48 mg, 293.50 ⁇ mol
  • anhydrous ACN 0.3 mL
  • Embodiment 25 the synthesis of compound 25
  • Substrate 25-1 (0.5g, 2.36mmol) and DMSO (10mL) were added to a dry single-necked flask, stirred and dissolved, then potassium carbonate (651.05mg, 4.71mmol) and p-fluoronitrobenzene (4-2, 332.33mg, 2.36mmol) were added, heated to 100°C for 6 hours, monitored by LC-MS.
  • Substrate 25-2 (0.5g, 1.50mmol) and methanol (10mL) were added to a dry one-necked flask, stirred evenly, Pd/C (910mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with diatomaceous earth, washed with methanol, and the organic phase was concentrated under reduced pressure to obtain product 25-3 (0.4g, 1.32mmol, 87.91% yield), LCMS (ESI + ) m/z: 304.2[M+H] + .
  • Substrate 25-3 (150mg, 0.5mmol) and THF (4mL) were added to a dry one-necked flask. After stirring to dissolve, LiAlH 4 (112.57mg, 2.97mmol) was added, heated to 65°C for 2 hours, and monitored by LC-MS. After the reaction, cool to room temperature, add water and stir to form a solid precipitate, filter the solid, wash three times with water, wash three times with a small amount of methanol, and dry to obtain the product 25-4 (80 mg, 0.36 mmol, 74.46% yield), LCMS (ESI + ) m/z: 218.3 [M+H] + .
  • Substrate IM-1 (21.70 mg, 99.88 ⁇ mol) and tetrahydrofuran (2 mL) were added to a dry single-necked flask, stirred and dissolved, then m-CPBA (25.86 mg, 149.82 ⁇ mol) was added, reacted at room temperature for 1 h, and monitored by LC-MS. After the reaction, DIPEA (64.54 mg, 499.40 ⁇ mol, 86.98 ⁇ L) was added, and after stirring for 10 min, 25-4 (21.70 mg, 99.88 ⁇ mol) was added, monitored by LC-MS.
  • Embodiment 26 the synthesis of compound 26
  • Substrates 26-1 (1.27g, 12.72mmol), 26-2 (2g, 8.48mmol), t-BuONa (1g, 10.17mmol) and toluene (15mL) were added to a dry microwave tube, stirred and dissolved, deoxygenated with N 2 for 10min, Pd 2 (dba) 3 (778mg, 0.85mmol), BINAP (264.6mg, 0 .43mmol), and deoxygenated with N 2 for 10min. After the tube was sealed, the oil bath was heated to 110°C to react for 12 hours, monitored by LC-MS.
  • Substrate 26-3 (650mg, 2.55mmol) was added to a dry single-necked flask, dissolved in acetone (6mL) and water (7mL), and 26-4 (637.87mg, 3.82mmol), Pd(OAc) 2 (57.25mg, 0.25mmol) and sodium carbonate (542mg, 2.55mmol) were added, replaced with nitrogen three times, and heated to 50°C under nitrogen protection to react 1 2 hours, LC-MS monitoring. After the reaction, cool to room temperature, add water and ethyl acetate to extract three times, combine the organic phases, wash with saturated brine, and dry over anhydrous sodium sulfate. The residual impurities are purified by medium-pressure liquid chromatography to obtain product 26-5 (240 mg, 807.13 ⁇ mol, 31.68% yield), LCMS (ESI + ) m/z: 298.4 [M+H] + .
  • Substrate 26-5 (240 mg, 807.13 ⁇ mol) and methanol (10 mL) were added to a dry single-necked flask, stirred evenly, Pd/C (30 mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with diatomaceous earth, washed with methanol, and the organic phase was concentrated under reduced pressure to obtain product 26-6 (160 mg, 598.43 ⁇ mol, 74.14% yield), LCMS (ESI + ) m/z: 268.4[M+H] + .
  • Substrate IM-1 (47.5 mg, 132.89 ⁇ mol) and tetrahydrofuran (0.5 mL) were added to a dry single-necked flask, stirred and dissolved, then m-CPBA (54 mg, 265.79 ⁇ mol) was added, reacted at room temperature for 1 h, and monitored by LC-MS. After the reaction, DIPEA (85.88 mg, 664.47 ⁇ mol, 115.74 ⁇ L) was added, and after stirring for 10 min, compound 26-6 (21.70 mg, 99.88 ⁇ mol) was added, monitored by LC-MS.
  • Embodiment 27 the synthesis of compound 27
  • Substrate 27-1 400mg, 2.02mmol
  • DMSO DMSO
  • potassium carbonate 836.50mg, 6.05mmol
  • p-fluoronitrobenzene 313.14mg, 2.22mmol
  • Substrate 27-2 (633mg, 1.98mmol) and methanol (5mL) were added to a dry one-necked flask, stirred evenly, Pd/C (60mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with celite, washed with methanol, and the organic phase was concentrated under reduced pressure to obtain product 27-3 (459 mg, crude), LCMS (ESI + ) m/z: 290.4[M+H] + .
  • Substrate 27-3 (150 mg, 518.36 ⁇ mol) and THF (5 mL) were added to a dry one-necked flask, stirred and dissolved, then LiAlH 4 (19.67 mg, 518.36 ⁇ mol) was added, heated to 65°C for 4 hours, monitored by LC-MS. After the reaction was completed, it was quenched by adding 10% aqueous sodium hydroxide solution in an ice bath. After filtration, the filtrate was concentrated under reduced pressure and purified by medium-pressure liquid chromatography to obtain product 27-4 (36.59 mg, 180.00 ⁇ mol, 34.73% yield), LCMS (ESI + ) m/z: 204.3 [M+H] + .
  • Substrate IM-1 53.61mg, 0.15mmol
  • tetrahydrofuran 0.5mL
  • m-CPBA 38.83mg, 225.00 ⁇ mol
  • DIPEA 96.93 mg, 750.00 ⁇ mol, 130.63 ⁇ L
  • compound 27-4 36.59 mg, 180.00 ⁇ mol
  • Embodiment 28 the synthesis of compound 28
  • Substrate 28-1 (332mg, 1.56mmol) and DMSO (5mL) were added to a dry single-necked flask, and after stirring to dissolve, potassium carbonate (648.42mg, 4.69mmol) and p-fluoronitrobenzene (242.73mg, 1.72mmol) were added, heated to 80°C for 12 hours, and monitored by LC-MS.
  • Substrate 28-2 (640mg, 1.92mmol) and methanol (5mL) were added to a dry one-necked flask, stirred evenly, Pd/C (60mg) was added, hydrogen was replaced five times, the reaction was stirred at room temperature, and monitored by LC-MS. After the reaction, Pd/C was removed with celite, washed with methanol, and the organic phase was concentrated under reduced pressure to obtain product 28-3 (570 mg, crude), LCMS (ESI + ) m/z: 304.2[M+H] + .
  • Substrate 28-3 200 mg, 659.20 ⁇ mol
  • THF 5 mL
  • LiAlH 4 125.08 mg, 3.30 mmol
  • the reaction was completed, it was quenched by adding 10% aqueous sodium hydroxide solution in an ice bath. After filtration, the filtrate was concentrated under reduced pressure and purified by medium-pressure liquid chromatography to obtain product 28-4 (89 mg, 409.55 ⁇ mol, 62.13% yield), LCMS (ESI + ) m/z: 218.2[M+H] + .
  • Substrate IM-1 (53.61mg, 0.15mmol) and tetrahydrofuran (1mL) were added to a dry one-necked flask. After stirring and dissolving, m-CPBA (38.83mg, 225.00 ⁇ mol) was added and reacted at room temperature for 1h, monitored by LC-MS. After the reaction, DIPEA (96.93 mg, 750.00 ⁇ mol, 130.63 ⁇ L) was added, and after stirring for 10 min, compound 28-4 (32.60 mg, 150.00 ⁇ mol) was added, monitored by LC-MS.
  • Embodiment 29 Synthesis of Compound 29
  • Substrate 29-1 (233 mg, 891.63 ⁇ mol) and methanol (10 mL) were added to a dry one-necked flask, stirred and dissolved, then palladium carbon (10 mg) was added, replaced by hydrogen five times, and reacted at room temperature for 2 hours, monitored by LC-MS. After the reaction, filter with celite, wash with methanol, and concentrate the organic phase by distillation under reduced pressure to obtain compound 29-2 (200 mg, 866 ⁇ mol), LCMS (ESI) m/z: 232.2 [M+H] + .
  • the substrate IM-1 38.63 mg, 108.07 ⁇ mol
  • tetrahydrofuran 1 mL
  • Add m-chloroperoxybenzoic acid (30mg, 162.10 ⁇ mol) and react at room temperature for one hour, then add N,N-diisopropylethylamine (20.95mg, 162.10 ⁇ mol) and 29-2 (25mg, 0.18mmol) to the reaction solution, and react overnight at room temperature.
  • Embodiment 30 the synthesis of compound 30
  • Substrate 30-1 (200 mg, 912.24 ⁇ mol) was dissolved in tetrahydrofuran (3 mL) in a dry one-necked flask, and triethylamine (461 mg, 4.56 mmol) and trifluoroethyl trifluoromethanesulfonate (317 mg, 1.37 mmol) were added. The room temperature was raised to 80°C and stirred overnight. LC-MS monitoring. After the reaction was completed, it was concentrated by distillation under reduced pressure to obtain compound 30-2 (235 mg, 780 ⁇ mol), LCMS (ESI) m/z: 302.1 [M+H] + .
  • Substrate 30-2 (235mg, 780 ⁇ mol) and methanol (3mL) were added to a dry one-necked flask, stirred and dissolved, then palladium carbon (25mg) was added, replaced by hydrogen five times, and reacted at room temperature for 2 hours, monitored by LC-MS. After the reaction, filter with celite, wash with methanol, and concentrate the organic phase by distillation under reduced pressure to obtain compound 30-3 (183 mg, 675 ⁇ mol), LCMS (ESI) m/z: 272.2 [M+H] + .
  • the substrate IM-1 (27 mg, 75.54 ⁇ mol) was added, and tetrahydrofuran (1 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 23 mg, 113.31 ⁇ mol
  • N,N-diisopropylethylamine 48.81 mg, 377.1 ⁇ mol
  • 30-3 30.7 mg, 113.31 ⁇ mol
  • Embodiment 31 the synthesis of compound 31
  • Substrate 31-1 (2.0g, 7.80mmol) and methanol (10mL) were added to a dry one-necked flask. After stirring and dissolving, palladium carbon (200mg) was added, replaced by hydrogen five times, and reacted at room temperature for 2 hours, monitored by LC-MS. After the reaction, filter with celite, wash with methanol, and concentrate the organic phase by distillation under reduced pressure to obtain compound 31-2 (1.6 g, 7.07 mmol), LCMS (ESI) m/z: 232.2 [M+H] + .
  • the substrate IM-1 100 mg, 279.78 ⁇ mol
  • tetrahydrofuran 1.5 mL
  • Add m-chloroperoxybenzoic acid 120 mg, 559.55 ⁇ mol
  • react at room temperature for one hour then add N,N-diisopropylethylamine (180.79 mg, 1.40 mmol) and 31-2 (126.61 mg, 559.55 ⁇ mol) to the reaction solution, and react overnight at room temperature.
  • Embodiment 32 the synthesis of compound 32
  • Trimethylsulfoxide iodide (2.94g, 13.37mmol), sodium hydroxide (1.07g, 26.73mmol) dissolved in tetrahydrofuran (20mL) were added to a single-necked flask, nitrogen was replaced, and the reaction was carried out at room temperature for 1 hour.
  • 32-1 (863mg, 3.34mmol) was added, nitrogen was replaced again, stirred at 65°C for 1 hour, and the reaction was monitored by LCMS.
  • Substrate 32-2 (493mg, 1.81mmol) and methanol (5mL) were added to a dry one-necked flask. After stirring and dissolving, palladium carbon (50mg) was added, replaced by hydrogen five times, and reacted at room temperature for 2 hours, monitored by LC-MS. After the reaction, filter with celite, wash with methanol, and concentrate the organic phase by distillation under reduced pressure to obtain compound 32-3 (395 mg, 1.63 mmol), LCMS (ESI) m/z: 243.2 [M+H] + .
  • the substrate IM-1 (36 mg, 100.72 ⁇ mol) was added, and tetrahydrofuran (1.5 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 26 mg, 151 ⁇ mol
  • N,N-diisopropylethylamine 65 mg, 504 ⁇ mol
  • 32-3 48.8 mg, 201 ⁇ mol
  • Embodiment 33 the synthesis of compound 33
  • Embodiment 34 the synthesis of compound 34
  • Substrate 23-5 (100 mg, 404.38 ⁇ mol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (3 mL), 2-bromoethyl methyl ether (84 mg, 606 ⁇ mol), potassium carbonate (111.77 mg, 808.76 ⁇ mol) and potassium iodide (13.43 mg, 80.88 ⁇ mol) were added, and reacted at 85°C for 3 hours.
  • LC-MS monitoring After the reaction was completed, the reaction solution was cooled to room temperature, added with water, and extracted three times with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 34-1 (65 mg, 212.86 ⁇ mol).
  • Embodiment 35 the synthesis of compound 35
  • the substrate IM-1 (71.5 mg, 0.2 mmol) was added, and tetrahydrofuran (1 mL) was added to dissolve.
  • m-chloroperoxybenzoic acid (51.8mg, 0.3mmol) and react at room temperature for 30 minutes, then add N,N-diisopropylethylamine (129.2mg, 1.00mmol) and 35-3 (61.9mg, 0.3mmol) to the reaction solution, and react at room temperature for 4 hours.
  • LC-MS monitoring after the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 35 (16 mg, 31.03 ⁇ mol).
  • Embodiment 36 the synthesis of compound 36
  • Substrate 36-3 (3.85g, 21.01mmol) was dissolved in methanol (40mL) in a dry one-necked flask, formaldehyde (1.26g, 42.03mmol) and acetic acid (2mL) were added, and stirred at room temperature for 30 minutes.
  • Sodium cyanoborohydride (3.30 g, 52.54 mmol) was added, and the temperature was raised to 50° C. for 12 hours. After the reaction, it was diluted with water, adjusted to alkalinity by adding saturated sodium bicarbonate, and extracted three times with dichloromethane.
  • the substrate IM-1 (45.51 mg, 225.00 ⁇ mol) was added, and tetrahydrofuran (1 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 38.83 mg, 225.00 ⁇ mol
  • N,N-diisopropylethylamine 96.93 mg, 750.00 ⁇ mol
  • 36-7 53.61 mg, 0.15 mmol
  • Embodiment 37 the synthesis of compound 37
  • Substrate 23-5 (150 mg, 606.57 ⁇ mol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (3 mL), 1,2-fluorobromoethane (84 mg, 661.65 ⁇ mol), potassium carbonate (165 mg, 1.19 mmol) and potassium iodide (20 mg, 120.5 ⁇ mol) were added, and reacted at 90°C for 3 hours.
  • LC-MS monitoring After the reaction was completed, the reaction liquid was cooled to room temperature, added with water, filtered, and washed with methanol. The organic phase was concentrated under reduced pressure to obtain compound 37-1 (80 mg, 272.7 ⁇ mol).
  • Substrate IM-6 (42mg, 112.47 ⁇ mol) and tetrahydrofuran (3mL) were added to a dry one-necked flask, stirred and dissolved, then N,N-diisopropylethylamine (72.68mg, 562.36 ⁇ mol) and 37-2 (30mg, 113.92 ⁇ mol) were added and reacted at room temperature for 2 hours. LC-MS monitoring. After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 37 (25 mg, 42.65 ⁇ mol).
  • Embodiment 38 the synthesis of compound 38
  • Substrate 38-1 (100 mg, 456.12 ⁇ mol) was added to a dry single-necked flask, dissolved in N,N-dimethylformamide (2 mL), 2-bromoethanol (57.00 mg, 456.12 ⁇ mol), potassium carbonate (94.55 mg, 684.18 ⁇ mol) and potassium iodide (15.14 mg, 91.22 ⁇ mol) were added, and reacted at 90°C for 2 hours.
  • LC-MS monitoring After the reaction, the reaction solution was cooled to room temperature, added with water, filtered and washed with methanol. The organic phase was concentrated under reduced pressure to obtain compound 38-2 (93 mg, 353 ⁇ mol).
  • the substrate 38-2 (93 mg, 353.22 ⁇ mol) was added to a dry one-necked flask, dissolved in tetrahydrofuran (2.5 mL), and triethylamine (142.97 mg, 1.41 mmol) was added. The temperature of the system was lowered to 0°C, and acetyl chloride (41.59 mg, 529.83 ⁇ mol) was added. Slowly warm to room temperature and stir for 1 hour. LC-MS monitoring. After the reaction was completed, it was concentrated under reduced pressure to obtain compound 38-3 (96 mg, 314.8 ⁇ mol). LCMS (ESI) m/z: 292.1 [M+H] + .
  • Embodiment 39 the synthesis of compound 39
  • the substrate IM-3 (30.49 mg, 150.00 ⁇ mol) was added, and tetrahydrofuran (1 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 25.88 mg, 150.00 ⁇ mol
  • N,N-diisopropylethylamine (19.39 mg, 150.00 ⁇ mol)
  • compound 27-4 (30.49 mg, 150.00 ⁇ mol)
  • Embodiment 40 the synthesis of compound 40
  • the substrate 40-2 (71.4 mg, 300 ⁇ mol) was added to a dry one-necked flask, dissolved in tetrahydrofuran (2.5 mL), and triethylamine (121.4 mg, 1.2 mmol) was added. The temperature of the system was lowered to 0°C, and acetic anhydride (61.2 mg, 600 ⁇ mol) was added. Slowly warm to room temperature and stir for 12 hours. LC-MS monitoring. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 40-3 (25.3 mg, 87.4 ⁇ mol). LCMS (ESI) m/z: 290.2 [M+H] + .
  • the substrate IM-1 (35.7 mg, 100 ⁇ mol) was added, and tetrahydrofuran (1 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 25.85mg, 150 ⁇ mol
  • N,N-diisopropylethylamine 64.54mg, 500 ⁇ mol
  • 40-4 51.81mg, 0.2mmol
  • LC-MS monitoring concentrated under reduced pressure after the reaction, the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 40 (18 mg, 31.65 ⁇ mol).
  • Embodiment 41 the synthesis of compound 41
  • Substrate 38-1 (140 mg, 638.57 ⁇ mol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (3 mL), 2-iodopropane (131 mg, 770.63 ⁇ mol) and potassium carbonate (124 mg, 897.25 ⁇ mol) were added, and reacted at 90°C for 3 hours.
  • LC-MS monitoring After the reaction was completed and the reaction solution was cooled to room temperature, water was added, extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 41-1 (80 mg, 306.14 ⁇ mol).
  • Substrate IM-6 (45mg, 120.50 ⁇ mol) and tetrahydrofuran (3mL) were added to a dry one-necked flask, stirred and dissolved, then N,N-diisopropylethylamine (77.87mg, 602.52 ⁇ mol) and 41-2 (30mg, 129.68 ⁇ mol) were added and reacted at room temperature for 2 hours.
  • LC-MS monitoring After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 41 (20 mg, 36.99 ⁇ mol).
  • Embodiment 42 the synthesis of compound 42
  • Substrate 42-1 (300mg, 1.37mmol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (3mL), 2-iodopropane (348.92mg, 2.05mmol), and potassium carbonate (567.35mg, 4.11mmol) were added, and reacted at 70°C for 12 hours.
  • LC-MS monitoring After the reaction was completed, the reaction solution was cooled to room temperature, added with water, and extracted three times with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 42-2 (280 mg, 1.07 mmol).
  • Embodiment 43 the synthesis of compound 43
  • Substrate 27-1 (0.33g, 1.66mmol) was dissolved in methanol (4mL) into a dry one-necked flask, followed by formaldehyde (226.77mg, 6.66mmol) and acetic acid (0.5mL), and stirred at room temperature for 10 minutes. Add sodium cyanoborohydride (1.41 g, 6.66 mmol) and react at room temperature for 12 hours. After the reaction, it was diluted with water and extracted three times with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 43-1 (300 mg, 1.41 mmol). LCMS (ESI) m/z: 213.2 [M+H] + .
  • Embodiment 44 the synthesis of compound 44
  • Substrate 38-1 (300mg, 1.37mmol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (2mL), 1,2-fluorobromoethane (173.72mg, 1.37mmol), potassium carbonate (378mg, 2.74mmol) and potassium iodide (45.43mg, 273.67 ⁇ mol) were added, and reacted overnight at 90°C. LC-MS monitoring. After the reaction was completed, the reaction liquid was cooled to room temperature, added with water, filtered, and washed with methanol. The organic phase was concentrated under reduced pressure to obtain compound 44-1 (320 mg, 1.21 mmol). LCMS (ESI) m/z: 266.1 [M+H] + .
  • the substrate IM-1 (74 mg, 207.03 ⁇ mol) was added, and tetrahydrofuran (1 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid (90 mg, 414.07 ⁇ mol) and react at room temperature for 30 minutes, then add N,N-diisopropylethylamine (133.79 mg, 1.04 mmol, 180.30 ⁇ L) and 44-2 (97.43 mg, 414.07 ⁇ mol) to the reaction solution, and react at room temperature for 4 hours.
  • Embodiment 45 the synthesis of compound 45
  • the substrates 36-1 (1.13g, 9.99mmol), 45-1 (2.20g, 10.99mmol), cuprous iodide (1.90g, 9.99mmol), potassium carbonate (1.38g, 9.99mmol) and N,N'-dimethylethylenediamine (880.93mg, 9.99mmol) were added under nitrogen protection, and then 1,4- Dioxane (15 mL). Under a nitrogen atmosphere, the reaction was heated at 120° C. for 3 hours. After the reaction was monitored by LCMS, the reaction system was cooled to room temperature, filtered, and extracted three times with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by MPLC to obtain compound 45-2 (0.8 g, 3.44 mmol). LCMS (ESI) m/z: 233.1 [M+H] + .
  • the substrate IM-1 39 mg, 109.11 ⁇ mol
  • tetrahydrofuran 1 mL
  • Add m-chloroperoxybenzoic acid 28.25 mg, 163.67 ⁇ mol
  • N,N-diisopropylethylamine 70.51 mg, 545.56 ⁇ mol, 95.02 ⁇ mol
  • 45-3 33.10 mg, 163.67 ⁇ mol
  • Embodiment 46 the synthesis of compound 46
  • Substrate 46-3 (1g, 4.34mmol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (10mL), potassium carbonate (1.2g, 8.68mmol) and chloroacetyl chloride (540.40mg, 4.78mmol) were added, and reacted at room temperature for 5 hours. After the reaction was completed, it was diluted with water and extracted three times with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 46-4 (480 mg, 1.56 mmol). LCMS (ESI) m/z: 266.1 [M+H] + .
  • Substrate 46-4 (60 mg, 195.58 ⁇ mol) was added to a dry one-necked flask, dissolved in isopropanol (6 mL), potassium tert-butoxide (112 mg, 998.13 ⁇ mol) was added, and stirred at room temperature for 3 hours. After the reaction was completed, it was concentrated under reduced pressure, extracted three times with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude product 46-5 (50 mg, crude). LCMS (ESI) m/z: 215.1 [M+H] + .
  • Substrate 46-5 (26 mg, 96.18 ⁇ mol) was added to a dry one-necked flask, dissolved in tetrahydrofuran (4.4 mL), 2M borane tetrahydrofuran solution (0.19 mL, 384.72 ⁇ mol) was added, and stirred at 70° C. for 2 hours. After the reaction was completed, it was concentrated under reduced pressure, methanol and N,N,N',N'-tetramethylethylenediamine were added, and stirred overnight at 78°C.
  • Substrate 46-8 (13 mg, 46.88 ⁇ mol) was dissolved in methanol (2 mL) into a dry one-necked flask, followed by formaldehyde (16 mg, 469.76 ⁇ mol) and acetic acid (50 ⁇ L), and stirred at room temperature for 10 minutes. Add sodium cyanoborohydride (10 mg, 159.13 ⁇ mol) and react at 50° C. for 2 hours. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 46-9 (10 mg, 34.32 ⁇ mol). LCMS (ESI) m/z: 262.2 [M+H] + .
  • Substrate IM-6 (42mg, 112.47 ⁇ mol) and tetrahydrofuran (4mL) were added to a dry single-necked flask, stirred and dissolved, then N,N-diisopropylethylamine (72.68mg, 562.36 ⁇ mol) and 46-10 (30mg, 114.78 ⁇ mol) were added and reacted at room temperature for 2 hours. LC-MS monitoring. After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 46 (32 mg, 56.07 ⁇ mol).
  • Embodiment 47 the synthesis of compound 47
  • the substrates 47-3 (58mg, 0.16mmol), 47-2 (70mg, 0.23mmol), cuprous iodide (61mg, 320.29 ⁇ mol), potassium carbonate (44.2mg, 319.83 ⁇ mol) and N,N'-dimethylethylenediamine (56mg, 635.28 ⁇ mol) were added under the protection of nitrogen, and then 1,4-dioxane ( 4mL). Under a nitrogen atmosphere, the reaction was heated at 110° C. for 6 hours. After the reaction was monitored by LCMS, the reaction system was cooled to room temperature, concentrated under reduced pressure to remove the solvent, and the residue was purified by MPLC to obtain compound 47 (61 mg, 104.33 ⁇ mol).
  • Embodiment 48 the synthesis of compound 48
  • Substrate 27-2 (100 mg, 456.12 ⁇ mol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (2 mL), 1-bromo-2-fluoroethane (86.86 mg, 684.18 ⁇ mol), potassium carbonate (88.25 mg, 638.57 ⁇ mol) and potassium iodide (8 mg, 48.19 ⁇ mol) were added, and reacted at 100°C for 7.5 hours. LC-MS monitoring.
  • Embodiment 49 the synthesis of compound 49
  • Substrate 27-2 (100 mg, 456.12 ⁇ mol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (2 mL), cyclobutyl bromide (92.37 mg, 684.18 ⁇ mol), potassium carbonate (158 mg, 1.14 mmol) and potassium iodide (8 mg, 48.19 ⁇ mol) were added, and reacted at 100°C for 32 hours.
  • LC-MS monitoring After the reaction, the reaction solution was cooled to room temperature, extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 49-1 (32 mg, 117.07 ⁇ mol).
  • Substrate IM-6 (35.7mg, 95.60 ⁇ mol) and tetrahydrofuran (3mL) were added to a dry single-necked flask, stirred and dissolved, then N,N-diisopropylethylamine (61.78mg, 478.00 ⁇ mol) and 49-2 (25.59mg, 105.16 ⁇ mol) were added and reacted at room temperature for 4 hours.
  • LC-MS monitoring After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 49 (20.8 mg, 33.31 ⁇ mol).
  • Embodiment 50 the synthesis of compound 50
  • Substrate 50-1 (2g, 14.91mmol) was dissolved in methanol (40mL) into a dry one-necked flask, formaldehyde (358.09mg, 11.92mmol) and acetic acid (89.51mg, 1.49mmol) were added, and stirred at room temperature for 15 minutes. Add sodium triacetoxyborohydride (15.80 g, 74.53 mmol) and react at room temperature for 3 hours. After the reaction was completed, the mixture was concentrated under reduced pressure and extracted three times with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by MPLC to obtain compound 50-2 (200 mg, 1.35 mmol). LCMS (ESI) m/z: 149.1 [M+H] + .
  • the substrate IM-1 13.98 mg, 39.11 ⁇ mol
  • tetrahydrofuran (1 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 24.75 mg, 143.41 ⁇ mol
  • 50-4 7.80 mg, 32.59 ⁇ mol
  • Embodiment 51 the synthesis of compound 51
  • the substrate 51-1 44 mg, 195.48 ⁇ mol
  • IM-1-4 44 mg, 197.96 ⁇ mol
  • cuprous iodide 37.70 mg, 197.96 ⁇ mol
  • potassium carbonate 38.3 mg, 227.14 ⁇ mol
  • N,N'-dimethylethylenediamine 34.90 mg, 395.92 ⁇ mol
  • the substrate 51-2 (56 mg, 152.82 ⁇ mol) was added, and tetrahydrofuran (4 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 42.06mg, 244.52 ⁇ mol
  • N,N-diisopropylethylamine (98.75mg, 764.11 ⁇ mol) and 27-4 (37.28mg, 183.39 ⁇ mol) to the reaction solution, and react at 50°C for 16 hours.
  • Embodiment 52 the synthesis of compound 52
  • Substrate 52-1 (1g, 3.94mmol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (10mL), methyl iodide (1.40g, 9.84mmol) and cesium carbonate (5.13g, 15.74mmol) were added, and reacted at 50°C for 2 hours.
  • LC-MS monitoring After the reaction, the reaction solution was cooled to room temperature, added water, extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 52-2 (1 g, 3.54 mmol).
  • LCMS (ESI) m/z: 283.1 [M+H] + .
  • the substrate 52-2 (167.55mg, 593.88 ⁇ mol), IM-1-4 (110mg, 494.90 ⁇ mol), cuprous iodide (9.43mg, 49.49 ⁇ mol), potassium carbonate (95.76mg, 692.86 ⁇ mol) and N,N'-dimethylethylenediamine (8.73mg, 98.98 ⁇ mol) were added under the protection of nitrogen. ), followed by the addition of N,N-dimethylformamide (2 mL). Under a nitrogen atmosphere, the reaction was heated at 110° C. for 12 hours.
  • the substrate 52-3 (18.00 mg, 42.50 ⁇ mol) was added, and tetrahydrofuran (0.5 mL) was added to dissolve it.
  • tetrahydrofuran 0.5 mL
  • Add m-chloroperoxybenzoic acid 11.00 mg, 63.76 ⁇ mol
  • react at room temperature for 10 minutes then add N,N-diisopropylethylamine (27.47 mg, 212.52 ⁇ mol) and 27-4 (8.64 mg, 42.50 ⁇ mol) to the reaction solution, and react at room temperature for 4 hours.
  • Embodiment 53 the synthesis of compound 53
  • Substrate 53-1 (2.1g, 10.66mmol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (25mL), iodoethane (4.99g, 31.97mmol) and potassium carbonate (4.22g, 31.97mmol) were added, and reacted at 90°C for 12 hours.
  • LC-MS monitoring After the reaction, the reaction liquid was cooled to room temperature, water was added, and extracted three times with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 53-2 (1.38 g, 6.13 mmol).
  • Substrate 53-3 (0.47 g, 1.73 mmol) was added to a dry one-necked flask, dissolved in ethanol (12 mL). Add 6M hydrochloric acid solution (0.3mL, 1.73mmol) and react at 90°C for 7 hours. LC-MS monitoring. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 53-4 (180 mg, 0.95 mmol). LCMS (ESI) m/z: 192.1 [M+H] + .
  • Substrate 53-4 (217.99 mg, 1.15 mmol) was added to a dry one-necked flask, and dissolved in dichloromethane (20 mL). Add IM-1-4 (170mg, 764.85 ⁇ mol), pyridine (242.00mg, 3.06mmol), copper acetate (277.84mg, 1.53mmol), and stir at room temperature for 24 hours. LC-MS monitoring. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 53-5 (31 mg, 84.60 ⁇ mol). LCMS (ESI) m/z: 368.1 [M+H] + .
  • the substrate 53-5 (39 mg, 106.43 ⁇ mol) was added, and tetrahydrofuran (6 mL) was added to dissolve it.
  • tetrahydrofuran (6 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid (20.20 mg, 117.07 ⁇ mol) and react at room temperature for 30 minutes, then add N,N-diisopropylethylamine (137.55 mg, 1.06 mmol) and 27-4 (23.80 mg, 117.07 ⁇ mol) to the reaction solution, and react at room temperature for 2 hours.
  • Embodiment 54 the synthesis of compound 54
  • Substrate 54-1 (300mg, 1.60mmol) was added to a dry one-necked flask, dissolved in tetrahydrofuran (3mL), N,N'-carbonyldiimidazole (344.52mg, 2.39mmol) was added, and reacted at 80°C for 2 hours.
  • LC-MS monitoring After the reaction, the reaction solution was cooled to room temperature, added with water, and extracted three times with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 54-2 (260 mg, 1.22 mmol).
  • Substrate 54-2 (620mg, 2.90mmol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (6mL), iodoethane (451.83mg, 2.90mmol) and cesium carbonate (1.12g, 3.19mmol) were added, and reacted at room temperature for 12 hours.
  • LC-MS monitoring After the reaction, the reaction solution was cooled to room temperature, added with water, extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 54-3 (279mg, 1.15mmol).
  • Substrate 54-4 ((140mg, 484.20 ⁇ mol) was added to a dry single-necked flask, dissolved in acetonitrile (2mL). 6M hydrochloric acid solution (80.70 ⁇ L) was added and reacted at 80°C for 4 hours. LC-MS monitoring. After the reaction was completed, the residue was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 54-5 (33mg, 159.43 ⁇ mol). LCMS (ESI) m/z: 208.1 [M+H ] + .
  • Substrate 54-5 (30 mg, 144.93 ⁇ mol) was added to a dry one-necked flask, and dissolved in dichloromethane (3 mL). Add IM-1-4 (32.2mg, 222.27 ⁇ mol), pyridine (11.46mg, 144.93 ⁇ mol), copper acetate (52.65mg, 289.87 ⁇ mol), and stir at room temperature for 24 hours. LC-MS monitoring. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 54-6 (30 mg, 78.24 ⁇ mol). LCMS (ESI) m/z: 384.1 [M+H] + .
  • the substrate 54-6 (30 mg, 78.24 ⁇ mol) was added, and tetrahydrofuran (2 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid (20.25 mg, 117.36 ⁇ mol) and react at room temperature for 30 minutes, then add N,N-diisopropylethylamine (50.56 mg, 391.21 ⁇ mol) and 27-4 (19.09 mg, 93.89 ⁇ mol) to the reaction solution, and react at room temperature for 1.5 hours.
  • Embodiment 55 the synthesis of compound 55
  • the substrate IM-1 (42.27 mg, 118.27 ⁇ mol) was added, and tetrahydrofuran (1 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid (30.61 mg, 177.40 ⁇ mol) and react at room temperature for 30 minutes, then add N,N-diisopropylethylamine (76.43 mg, 591.35 ⁇ mol) and 55-6 (27 mg, 118.27 ⁇ mol) to the reaction solution, and react at room temperature for 4 hours.
  • Embodiment 56 the synthesis of compound 56
  • Embodiment 57 the synthesis of compound 57
  • the substrate 57-2 (7.4 mg, 19.98 ⁇ mol) was added, and tetrahydrofuran (0.5 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid (7.64 mg, 44.27 ⁇ mol) and react at room temperature for 10 minutes, then add N,N-diisopropylethylamine (5.72 mg, 44.27 ⁇ mol) and 27-4 (6 mg, 29.52 ⁇ mol) to the reaction solution, and react at room temperature for 4 hours. Monitored by LC-MS, concentrated under reduced pressure after the reaction, and purified the residue by preparative high performance liquid chromatography (basic) to obtain compound 57 (8 mg, 15.22 ⁇ mol).
  • Embodiment 58 the synthesis of compound 58
  • Embodiment 59 the synthesis of compound 59
  • Substrate 46-6 (250 mg, 975.27 ⁇ mol) was dissolved in methanol (2 mL) in a dry one-necked flask, followed by formaldehyde (16 mg, 469.76 ⁇ mol) and acetic acid (0.5 mL), and stirred at room temperature for 30 minutes. Add sodium cyanoborohydride (306.43mg, 4.88mmol) and react at 50°C for 2 hours. TLC monitoring. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 59-1 (130 mg, 480.83 ⁇ mol). LCMS (ESI) m/z: 262.2 [M+H] + .
  • Substrate IM-6 (42.86mg, 114.78 ⁇ mol) and tetrahydrofuran (2mL) were added to a dry one-necked flask, stirred and dissolved, then N,N-diisopropylethylamine (74.17mg, 573.92 ⁇ mol) and 59-4 (30mg, 114.78 ⁇ mol) were added and reacted at room temperature for 2 hours. LC-MS monitoring. After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 59 (3 mg, 4.75 ⁇ mol).
  • Embodiment 60 the synthesis of compound 60
  • IM-1-5 (250mg, 1.16mmol) was dissolved in tetrahydrofuran (2ml) in a dry one-necked bottle, the temperature was lowered to 0°C, NaH (83.30mg, 3.47mmol) was added, and stirred at 0°C for 10 minutes. Add iodomethane (492.7 mg, 3.47 mmol), warm to room temperature and stir for 6 hours.
  • LC-MS monitoring after the reaction was quenched with water, extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain compound 60-1 (210 mg, 912.64 ⁇ mol).
  • the substrate 60-1 (207.05mg, 899.82 ⁇ mol), IM-1-4 (200mg, 899.82 ⁇ mol), cuprous iodide (342.74mg, 1.80mmol), potassium carbonate (174.10mg, 1.26mmol) and N,N'-dimethylethylenediamine (705mg, 2.00mmol) were added under nitrogen protection, Then 1,4-dioxane (4 mL) was added. Under a nitrogen atmosphere, the reaction was heated at 110°C for 2 hours.
  • Embodiment 61 the synthesis of compound 61
  • Substrate 61-2 (130 mg, 715.77 ⁇ mol) was added to a dry one-necked flask, dissolved in acetonitrile (2 mL), trimethylbromosilane (109.58 mg, 715.77 ⁇ mol) was added, and reacted at 90°C for 4 hours. LC-MS monitoring. After the reaction, the reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 61-3 (60 mg, 265.40 ⁇ mol). LCMS (ESI) m/z: 266.2 [M+H] + .
  • the substrate 61-3 (36.99 mg, 163.60 ⁇ mol), IM-1-4 (40 mg, 179.96 ⁇ mol), cuprous iodide (62.32 mg, 327.21 ⁇ mol), potassium carbonate (31.65 mg, 229.05 ⁇ mol) and N,N’-dimethylethylenediamine (57.69 mg, 654.42 ⁇ mol), and then 1,4-dioxane (4 mL) was added. Under a nitrogen atmosphere, the reaction was heated at 110° C. for 3 hours. After the reaction was monitored by LCMS, the reaction system was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 61-4 (19 mg, 51.71 ⁇ mol).
  • the substrate 61-4 (19 mg, 51.71 ⁇ mol) was added, and tetrahydrofuran (0.7 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 13.39 mg, 77.57 ⁇ mol
  • N,N-diisopropylethylamine 33.42 mg, 258.55 ⁇ mol
  • 27-4 10.51 mg, 51.71 ⁇ mol
  • Embodiment 62 the synthesis of compound 62
  • the substrates 62-1 (36.99mg, 163.60 ⁇ mol), 62-2 (40.39mg, 123.75 ⁇ mol), cuprous iodide (47.14mg, 247.50 ⁇ mol), potassium carbonate (68.41mg, 495.01 ⁇ mol) and N,N'-dimethylethylenediamine (21.78mg, 247. 50 ⁇ mol), and then 1,4-dioxane (2 mL) was added. Under a nitrogen atmosphere, the reaction was heated at 110°C for 16 hours. After the reaction was monitored by LC-MS, the reaction system was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 62 (0.7 mg, 1.23 ⁇ mol).
  • Embodiment 63 the synthesis of compound 63
  • Substrate 63-3 (43 mg, 156.75 ⁇ mol) was dissolved in methanol (3 mL) into a dry one-necked flask, followed by formaldehyde (26.69 mg, 783.76 ⁇ mol) and acetic acid (0.2 mL), and stirred at room temperature for 10 minutes. Add sodium cyanoborohydride (19.70 mg, 313.51 ⁇ mol) and react at 50°C for 6 hours. LC-MS monitoring. After the reaction was completed, it was concentrated under reduced pressure, extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 63-4 (35 mg, 121.38 ⁇ mol). LCMS (ESI) m/z: 289.2 [M+H] + .
  • Substrate IM-6 (16.89mg, 65.36 ⁇ mol) and tetrahydrofuran (2mL) were added to a dry single-necked flask, stirred and dissolved, then N,N-diisopropylethylamine (42.24mg, 326.82 ⁇ mol) and 63-5 (28mg, 71.90 ⁇ mol) were added and reacted at room temperature for 4 hours.
  • LC-MS monitoring After the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 63 (11 mg, 18.49 ⁇ mol).
  • Embodiment 64 the synthesis of compound 64
  • Substrate 38-1 (109 mg, 497.17 ⁇ mol) was added to a dry one-necked flask, dissolved in acetone (3 mL), allyl bromide (90.1 mg, 745.76 ⁇ mol) and potassium carbonate (207 mg, 745.76 ⁇ mol) were added, and reacted at room temperature for 2 hours under a nitrogen atmosphere. LC-MS monitoring. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 64-1 (128 mg, 497.03 ⁇ mol). LCMS (ESI) m/z: 260.2 [M+H] + .
  • the substrate IM-1 (18 mg, 50.36 ⁇ mol) was added, and tetrahydrofuran (1 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 13 mg, 137.36 ⁇ mol
  • N,N-diisopropylethylamine 9.7 mg, 75.05 ⁇ mol
  • 64-2 21 mg, 91.58 ⁇ mol
  • LC-MS monitoring concentrated under reduced pressure after the reaction, the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 64 (6.2 mg, 11.51 ⁇ mol).
  • Embodiment 65 the synthesis of compound 65
  • Substrate 38-1 (87mg, 396.83 ⁇ mol) was added to a dry one-necked flask, dissolved in acetone (3mL), iodoethane (92.84mg, 595.25 ⁇ mol) and potassium carbonate (83mg, 1.19mmol) were added, and reacted at room temperature for 2 hours under nitrogen atmosphere. LC-MS monitoring. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 65-1 (87 mg, 351.81 ⁇ mol). LCMS (ESI) m/z: 248.1 [M+H] + .
  • the substrate IM-1 (18 mg, 50.36 ⁇ mol) was added, and tetrahydrofuran (1 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 13 mg, 137.36 ⁇ mol
  • N,N-diisopropylethylamine 9.7 mg, 75.05 ⁇ mol
  • 65-2 19.9 mg, 91.58 ⁇ mol
  • Embodiment 66 the synthesis of compound 66
  • Substrate 38-1 (80 mg, 364.90 ⁇ mol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (3 mL), 2-bromoethanol (68 mg, 544.16 ⁇ mol), potassium carbonate (99 mg, 716.35 ⁇ mol) and potassium iodide (5 mg, 30.12 ⁇ mol) were added, and reacted at 100°C for 2 hours.
  • LC-MS monitoring After the reaction, the reaction liquid was cooled to room temperature, extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 66-1 (70 mg, 265.86 ⁇ mol).
  • Embodiment 67 the synthesis of compound 67
  • Substrate 38-1 (80 mg, 364.90 ⁇ mol) was added to a dry single-necked flask, dissolved in N,N-dimethylformamide (3 mL), 2-bromoethyl methyl ether (76 mg, 546.80 ⁇ mol), potassium carbonate (99 mg, 716.35 ⁇ mol) and potassium iodide (5 mg, 30.12 ⁇ mol) were added, and reacted at 100°C for 6 hours. LC-MS monitoring.
  • Embodiment 68 the synthesis of compound 68
  • Embodiment 69 the synthesis of compound 69
  • Substrate 38-1 (241.29mg, 1.10mmol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (5mL), methyl chloroformate (104mg, 1.10mmol) and potassium carbonate (194mg, 1.40mmol) were added, and reacted at room temperature for 5 hours.
  • LC-MS monitoring After the reaction was completed, it was extracted three times with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 69-1 (60 mg, 216.39 ⁇ mol).
  • Embodiment 70 the synthesis of compound 70
  • 70-1 (100mg, 507.53 ⁇ mol) was dissolved in tetrahydrofuran (3ml) in a dry one-necked bottle, the temperature was lowered to 0°C, NaH (14.62mg, 609.04 ⁇ mol) was added, and stirred at 0°C for 10 minutes. Ethyl iodide (94.99 mg, 609.04 ⁇ mol) was added, the temperature was raised to room temperature and stirred for 2 hours.
  • the substrate 70-3 32.78 mg, 122.70 ⁇ mol
  • IM-1-4 (30 mg, 134.97 ⁇ mol)
  • cuprous iodide 46.74 mg, 245.41 ⁇ mol
  • potassium carbonate 23.74 mg, 171.78 ⁇ mol
  • N,N'-dimethylethylenediamine 43.27 mg, 490.81 ⁇ mol
  • 1,4-dioxane 2 mL
  • the substrate 70-4 (59.71 mg, 146.17 ⁇ mol) was added, and tetrahydrofuran (1.5 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 45.40 mg, 263.10 ⁇ mol
  • N,N-diisopropylethylamine (94.45 mg, 730.83 ⁇ mol) and 1-5 (33.55 mg, 175.40 ⁇ mol) to the reaction solution, and react at room temperature for 12 hours.
  • Embodiment 71 the synthesis of compound 71
  • 71-1 (230 mg, 576.62 ⁇ mol) was dissolved in tetrahydrofuran (1.5 mL) in a dry one-necked flask, zinc powder (45.57 mg, 696.93 ⁇ mol) and saturated ammonium chloride solution (1.5 mL) were added, and stirred at room temperature for 10 minutes. After the reaction was monitored by LC-MS, it was filtered with celite, the filtrate was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 71-2 (44 mg, 182.51 ⁇ mol). LCMS (ESI) m/z: 241.0 [M+H] + .
  • the substrate 71-3 (17.61 mg, 65.44 ⁇ mol), IM-1-4 (16 mg, 71.99 ⁇ mol), cuprous iodide (24.93 mg, 130.88 ⁇ mol), potassium carbonate (12.66 mg, 91.62 ⁇ mol) and N,N'-dimethylethylenediamine (23.07 mg, 261.77 ⁇ mol) were added under nitrogen protection , then 1,4-dioxane (1 mL) was added. Under a nitrogen atmosphere, the reaction was heated at 110° C. for 3 hours.
  • the substrate 71-4 (2.01 mg, 4.91 ⁇ mol) was added, and tetrahydrofuran (2 mL) was added to dissolve it.
  • m-chloroperbenzoic acid (1.52 mg, 8.83 ⁇ mol) and react at room temperature for 1 hour, then add N,N-diisopropylethylamine (3.17 mg, 24.54 ⁇ mol, 4.27 ⁇ L) and 1-5 (938.70 ⁇ g, 4.91 ⁇ mol) to the reaction solution, and react at room temperature for 8 hours.
  • Embodiment 72 the synthesis of compound 72
  • Substrate 72-1 (88 mg, 395.92 ⁇ mol) was added to a dry one-necked flask, and dissolved in dichloromethane (20 mL). Add IM-1-4 (170 mg, 764.85 ⁇ mol), pyridine (0.4 mL), copper acetate (146 mg, 803.83 ⁇ mol), and stir at 30° C. for 24 hours. LC-MS monitoring. After the reaction was completed, it was concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 72-2 (28 mg, 79.00 ⁇ mol). LCMS (ESI) m/z: 354.95 [M+H] + .
  • the substrate 72-2 (28 mg, 79.00 ⁇ mol) was added, and tetrahydrofuran (2 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid 27.26 mg, 157.99 ⁇ mol
  • N,N-diisopropylethylamine (16 mg, 83.65 ⁇ mol) and 1-5 (938.70 ⁇ g, 4.91 ⁇ mol)
  • LC-MS monitoring concentrated under reduced pressure after the reaction, the residue was purified by preparative high performance liquid chromatography (basic) to obtain compound 72 (9 mg, 17.72 ⁇ mol).
  • Embodiment 73 the synthesis of compound 73
  • Substrate 73-1 (0.5 g, 3.28 mmol) was added to a dry one-necked flask, dissolved in acetonitrile (5 mL). Add pyridine (1.5 mL) and Selectfluor reagent (1.05 g, 2.95 mmol), and stir at 15° C. for 16 hours. LC-MS monitoring. After the reaction was completed, water was added, extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by prep-HPLC to obtain compound 73-2 (112 mg, 656.62 ⁇ mol). LCMS (ESI) m/z: 171.0 [M+H] + .
  • the substrate 74-3 (0.04g, 201.39 ⁇ mol), IM-1-4 (44.76mg, 201.39 ⁇ mol), cuprous iodide (76.71mg, 402.77 ⁇ mol), sodium iodide (60.37mg, 402.77 ⁇ mol), potassium carbonate (69.58mg, 503.46 ⁇ mol) and N , N'-Dimethyl-1,2-cyclohexanediamine (114.58 mg, 805.54 ⁇ mol), then anisole (1.5 mL) was added. Under nitrogen atmosphere, the reaction was heated by microwave at 130° C. for 4 hours.
  • the substrate 73-4 (20 mg, 52.03 ⁇ mol) was added, and tetrahydrofuran (1.5 mL) was added to dissolve it.
  • m-chloroperoxybenzoic acid (19.01 mg, 93.65 ⁇ mol, 85% purity) and react at room temperature for 1 hour, then add N,N-diisopropylethylamine (67.24 mg, 520.25 ⁇ mol, 90.62 ⁇ L) and 1-5 (11.94 mg, 62.43 ⁇ mol) to the reaction solution, and react at room temperature for 5 hours.
  • Embodiment 74 the synthesis of compound 74
  • Substrate 74-1 (1.01g, 3.99mmol) was added to a dry one-necked flask, dissolved in N,N-dimethylformamide (30mL), methyl oxide (345.57mg, 4.79mmol) and potassium carbonate (1.66g, 11.98mmol) were added, and the temperature was raised to 120°C for 8 hours.
  • LC-MS monitoring After the reaction was completed, it was lowered to room temperature and extracted three times with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 74-2 (680 mg, 2.09 mmol).
  • 74-2 (98mg, 301.54 ⁇ mol) was dissolved in tetrahydrofuran (4ml) in a dry single-necked bottle, the temperature was lowered to 0°C, NaH (24.12mg, 603.08 ⁇ mol, 60% purity) was added in portions, the temperature was raised to 60°C and stirred for 30 hours.
  • LC-MS monitoring after the reaction was completed, it was cooled to room temperature, quenched with saturated aqueous ammonium chloride, extracted three times with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by MPLC to obtain compound 74-3 (48 mg, 196.65 ⁇ mol).
  • the substrate 74-3 (47 mg, 192.56 ⁇ mol), IM-1-4 (31.77 mg, 142.96 ⁇ mol), cuprous iodide (36.67 mg, 192.56 ⁇ mol), potassium carbonate (38.30 mg, 277.14 ⁇ mol) and N,N'-dimethylethylenediamine (33.95 mg, 385.11 ⁇ mol), and then 1,4-dioxane (3 mL) was added. Under nitrogen atmosphere, the reaction was heated by microwave at 120° C. for 4 hours.

Abstract

本发明涉及一种式(I)所示的化合物、或其立体异构体、或其药学上可接受的盐，及其在制备用来治疗跟WEE1活性相关的疾病的药物中的用途。

Description

WEE1抑制剂及其制备和用途 技术领域
本申请涉及抑制WEE1激酶活性的化合物，特别涉及式(I)所示的化合物，或其立体异构体，或其药学上可接受的盐，还涉及这些化合物的制备方法及其药物组合物和制备用来治疗跟WEE1活性相关的疾病的药物中的用途。
背景技术
WEE1酪氨酸激酶是细胞周期G2期检查点。细胞周期受到严密调控，当细胞的DNA未受到损伤时，G1期、S期和G2期检查点促进细胞进入分裂期，保证细胞周期顺利完成。(Clinical Cancer Research，2011，17(13)：4200-4207.)细胞周期受细胞周期蛋白依赖激酶(CDKs)调控，CDKs家族有14个丝氨酸/苏氨酸蛋白激酶。CDK的活性被磷酸化和结合不同周期蛋白所调控。细胞从G2期到进入分裂期的转换被CDK1(也被称为CDC2)的磷酸化及其相关周期蛋白B正调控。细胞分裂前，CDK1处于非活性状态，它的第15位酪氨酸被WEE1磷酸化，然后它的第14位苏氨酸被髓鞘转录因子(MYT1)磷酸化。因此，WEE1是细胞周期的负调控因子，通过阻止周期蛋白B和激活的CDK1复合物进入细胞核，负调控细胞从G2期进入分裂期。WEE1在S期和G2期的表达量和活性都提高，在高度磷酸化的M期降低。当细胞进入G2期，没有DNA损伤发生时，polo样蛋白激酶1(PLK1)磷酸化WEE1，通过泛素连接酶复合物将WEE1降解。PLK1也磷酸化并且激活蛋白磷酸酶细胞分裂周期25类似物(CDC25)，CDC25通过去磷酸化激活CDK1。活性的CDK1可以和周期蛋白B结合，促进细胞进入分裂期。(Molecular&CellularBiology，2012，32(20)：4226.)
当细胞的DNA受到损伤时，G1期、S期和G2期检查延迟细胞进入分裂期，为细胞进入分裂之前修复损伤的DNA争取了时间，从而保证了基因组的完整性。G1期检查点的关键调控因子P53在很多恶性肿瘤细胞中是突变形式。(Proceedings of the National Academy of Sciences of the United States of America，2007，104(10)：3753-3758.)P53功能缺陷的肿瘤细胞，在DNA受到损伤时，不能将细胞周期阻滞在G1期，因此更加依赖于G2期检查点。针对DNA损伤，G2期检查点通过平行且互相联系的两条路径抑制CDK1的磷酸化，从而延迟细胞进入分裂期。根据DNA损伤类型，共济失调性毛细血管扩张症变异(ATM)蛋白激酶或者共济失调性毛细血管扩张相关(ATR)蛋白激酶被激活。(Oncotarget，2016，7(31)：49902-49916.)
ATM被离子辐射、放射剂和引起双链DNA断裂的试剂激活。ATM磷酸化和激活检查点激酶2(CHK2)，CHK2磷酸化细胞分裂周期25C磷酸酶(CDC25C)的Ser216。这就导致CDC25C的向核输出和细胞质分离，从而抑制它的磷酸化活性。抑制CDC25C的活性导致CDK1/CDK2结合周期蛋白B复合物磷酸化被抑制，使CDK1处于失活形式，抑制细胞进入分裂期。(MolecularCancer，2014，13(1)：72.)
ATR由广泛的导致单链DNA断裂的基因毒性刺激因素激活的。ATR是负责磷酸化和激活CHK1的主要激酶。与CHK2只能被ATM激活相比，CHK1可以被ATM和ATR激活。CHK1同时磷酸化WEE1和CDC25C，激活WEE1激酶活性，抑制CDC25C的磷酸酶活性。WEE1磷酸化CDK1-结合周期蛋白B，导致细胞周期阻滞在G2期，为DNA修复提供时间。(Drug News&Perspectives，2010，23(7)：425.)
WEE1在很多恶性肿瘤中过表达，比如肝癌、乳腺癌、恶性胶质瘤、黑色素瘤、成人和儿童脑瘤。其中一部分肿瘤细胞G1检查点异常，如果抑制WEE1活性会导致G2期检查点故障，此时带有没有修复的损伤DNA的细胞会持续进行分裂，最终分裂致死。(Molecular Cancer Therapeutics，2013，12(12)：2675-2684.)无论通过嘧啶衍生物(PD0166285)或者小干扰RNA敲低方式，抑制WEE1的活性都会使卵巢癌、结肠癌、宫颈癌、骨肉瘤、恶性胶质瘤和肺癌 细胞对放射和拓扑异构酶抑制产生的DNA损伤更敏感。因此，WEE1抑制剂单药和联合用药都具有广阔的发展空间。(Cancer Biology&Therapy，2010，9(7)：523-525.)
专利WO2007126122，WO2008133866，WO2013012681，WO2013126656，WO2014167347，WO2015092431，WO2018011569，WO2018011570，WO2018090939，WO2018133829，WO2018171633等中描述了具有WEE1激酶抑制活性的小分子化合物。目前最领先的化合物是AZD1775，已经进入临床II期试验，显示出良好的癌症治疗效果。然而，AZD1775也具有较为明显的不良反应，药物活性和疗效也有待提高，因此亟需提供一种安全性更好的、应用人群更广泛的WEE1抑制剂。
发明内容
本发明的目的是提供了一种如式I所示的化合物、或其立体异构体、或其药学上可接受的盐：
Figure PCTCN2023070285-appb-000001
其中，所述的R 1选自-C 1～6烷基、-C 2～6烯基、-C 2～6炔基、-C 0～2亚烷基-CN、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)；所述的-C 0～2亚烷基、-C 1～6烷基、-C 2～6烯基、-C 2～6炔基、3～10元环烷基、3～10元杂环烷基可进一步被一个、两个、三个或四个独立的R 11取代；
所述的R 11选自氢、C 1～6烷基、卤素取代的C 1～6烷基、卤素；
R 2选自
Figure PCTCN2023070285-appb-000002
Figure PCTCN2023070285-appb-000003
Figure PCTCN2023070285-appb-000004
所述的R 21选自氢、C 1～6烷基、卤素取代的C 1～6烷基、-C 0～2亚烷基-C(O)OC 1～6烷基、-C 0～2亚烷基-COOH、-C(O)C 1～6烷基、卤素；
所述的R 3选自
Figure PCTCN2023070285-appb-000005
Figure PCTCN2023070285-appb-000006
X 1选自化学键、O、NR N1或者CR C1R C2；X 2选自N或者CR C1；所述的X 3选自O、NR N1或者CR C1R C2；
n选自1、2或3；
R N1选自氢、卤素、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C(O)(C 1～6烷基)；
R C1、R C2分别独立地选自氢、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-C 0～2亚烷基-NH(C 1～6烷基)、-C 0～2亚烷基-N(C 1～6烷基)(C 1～6烷基)；
R 4选自-(5～12元桥杂环烷基)；所述的桥杂环烷基可进一步被一个、两个、三个或四个独 立的R 41取代；
所述的R 41选自氢、氧代、-C 1～6烷基、-C 2～6烯基、卤素取代的C 1～6烷基、羟基取代的C 1～6烷基、卤素、氰基、硝基、-OH、-C 0～2亚烷基-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-C(O)R 42、-C 0～2亚烷基-C(O)NR 42R 43、-C 0～2亚烷基-C(O)OR 42、-C 0～2亚烷基-S(O)R 42、-C 0～2亚烷基-S(O)NR 42R 43、-C 0～2亚烷基-S(O)OR 42、-C 0～2亚烷基-S(O) 2R 42、-C 0～2亚烷基-S(O) 2NR 42R 43、-C 0～2亚烷基-S(O) 2OR 42、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；其中，所述的烷基、亚烷基、环烷基、杂环烷基、芳环、芳杂环可进一步被一个、两个、三个或四个独立的R 44取代；
R 42、R 43分别独立选自氢、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；
R 44选自氢、氧代、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的-C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-C 0～2亚烷基-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)；
或者，所述的R 41与R C1或R C2与其直接相连的原子一起形成3～10元碳环、3～10元杂环；
所述的R 5选自氢、氧代、卤素、氰基、硝基、-OH、-NH 2、-C 1～6烷基、卤素取代的C 1～6烷基、羟基取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-C 0～2亚烷基-NH(C 1～6烷基)、-O-C 0～2亚烷基-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-O-(3～10元环烷基)、-O-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；其中，所述的烷基、亚烷基、环烷基、杂环烷基、芳环、芳杂环可进一步被一个、两个、三个或四个独立的R 51取代；
所述的R 51选自氢、C 1～6烷基、卤素取代的C 1～6烷基、氧代、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-C 0～2亚烷基-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)；
每个R 6分别独立选自氢、C 1～6烷基、卤素取代的C 1～6烷基、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)、-C 0～2亚烷基-(5～12元螺环)、-C 0～2亚烷基-(5～12元螺杂环)、-C 0～2亚烷基-(5～12元桥环)、-C 0～2亚烷基-(5～12元桥杂环)；
其中，所述的A环选自5～12元螺环、5～12元螺杂环、5～12元桥环、5～12元桥杂环；其中螺环、螺杂环、桥环、桥杂环可进一步被一个、两个、三个或四个独立的R A1取代；
每个R A1分别独立选自氢、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)、-C 0～2亚烷基-(5～12元螺环)、-C 0～2亚烷基-(5～12元螺杂环)、-C 0～2亚烷基-(5～12元桥环)、-C 0～2亚烷基-(5～12元桥杂环)；
其中，所述的B环选自3～10元碳环、3～10元杂环、5～10元芳环、5～10元芳杂环、5～12元螺环、5～12元螺杂环、5～12元桥环、5～12元桥杂环、3～10元稠环、3～10元稠杂环；其中，所述的碳环、杂环、芳环、芳杂环、螺环、螺杂环、桥环、桥杂环、稠环、稠杂环可进一步被一个、两个、三个或四个独立的R B1取代；
每个R B1分别独立选自氢、-C 1～6烷基、卤素取代的C 1～6烷基、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、 -C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；
R 7、R 8分别独立选自氢、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；
或R 7、R 8与其直接相连的原子形成3～10元稠环、3～10元稠杂环、3～10元螺环、3～10元螺杂环；所述的稠环、稠杂环、螺环、螺杂环可进一步被一个、两个、三个或四个独立的R 71取代；
每个R 71分别独立选自氢、C 1～6烷基、卤素取代的C 1～6烷基、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)；
其中，所述的C环选自5～12元螺环、5～12元螺杂环、5～12元桥环、5～12元桥杂环、3～10元稠环、3～10元稠杂环；其中螺环、螺杂环、桥环、桥杂环、稠环、稠杂环可进一步被一个、两个、三个或四个独立的R C1取代；
每个R C1分别独立选自氢、卤素、氰基、硝基、-OH、C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)、-C 0～2亚烷基-(5～12元螺环)、-C 0～2亚烷基-(5～12元螺杂环)、-C 0～2亚烷基-(5～12元桥环)、-C 0～2亚烷基-(5～12元桥杂环)；
所述R 10选自氢、C 1～6烷基、卤素取代的C 1～6烷基；
所述R 9选自-C 0～2亚烷基-C(O)NR 91R 92、-C(O)C 1～6烷基；每个R 91、R 92分别独立选自氢、C 1～6烷基、卤素取代的C 1～6烷基；
或R 91、R 92与其直接相连的原子形成3～10元杂环，所述杂环可进一步被一个、两个、三个或四个独立的R 93取代；
每个R 93分别独立选自氢、C 1～6烷基、卤素取代的C 1～6烷基、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)；
当R 3为
Figure PCTCN2023070285-appb-000007
且B环为3元碳环，R1为
Figure PCTCN2023070285-appb-000008
时，R 2不为
Figure PCTCN2023070285-appb-000009
R 3为
Figure PCTCN2023070285-appb-000010
R 7、R 8分别为氢，R1为
Figure PCTCN2023070285-appb-000011
时、R 3不为
Figure PCTCN2023070285-appb-000012
R 3为
Figure PCTCN2023070285-appb-000013
X 1为键，R 4为
Figure PCTCN2023070285-appb-000014
R1为
Figure PCTCN2023070285-appb-000015
时，R 2不为
Figure PCTCN2023070285-appb-000016
R 3为
Figure PCTCN2023070285-appb-000017
X 1为键，R 4为
Figure PCTCN2023070285-appb-000018
R1为
Figure PCTCN2023070285-appb-000019
时，R 2不为
Figure PCTCN2023070285-appb-000020
R 3为
Figure PCTCN2023070285-appb-000021
R1为
Figure PCTCN2023070285-appb-000022
时，R 2为
Figure PCTCN2023070285-appb-000023
Figure PCTCN2023070285-appb-000024
R3为
Figure PCTCN2023070285-appb-000025
R1为
Figure PCTCN2023070285-appb-000026
时，R 2不为
Figure PCTCN2023070285-appb-000027
R 2为
Figure PCTCN2023070285-appb-000028
R 21为甲基，R1为
Figure PCTCN2023070285-appb-000029
时，R 3不为
Figure PCTCN2023070285-appb-000030
R 2为
Figure PCTCN2023070285-appb-000031
R 21为氢，R1为
Figure PCTCN2023070285-appb-000032
时，R 3不为
Figure PCTCN2023070285-appb-000033
R 2为
Figure PCTCN2023070285-appb-000034
R 21为氢，R1为
Figure PCTCN2023070285-appb-000035
时，R 3不为
Figure PCTCN2023070285-appb-000036
R 2为
Figure PCTCN2023070285-appb-000037
R 21为氢，R1为
Figure PCTCN2023070285-appb-000038
时，R 3不为
Figure PCTCN2023070285-appb-000039
R 2为
Figure PCTCN2023070285-appb-000040
R1为
Figure PCTCN2023070285-appb-000041
时,R 3不为
Figure PCTCN2023070285-appb-000042
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的R 1选自甲基、乙基、丙基、异丙基、环丙基、
Figure PCTCN2023070285-appb-000043
Figure PCTCN2023070285-appb-000044
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的R 2选自
Figure PCTCN2023070285-appb-000045
Figure PCTCN2023070285-appb-000046
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的X 1选自化学键、O、NR N1或者CR C1R C2；R C1、R C2分别独立地选自氢、C 1～3烷基、卤素、卤素取代的C 1～3烷基、-C 1～2亚烷基-N(C 1～6烷基)(C 1～6烷基)；
R N1选自氢、C 1～3烷基、卤素取代的C 1～3烷基、-(3～10元杂环烷基)。
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的R 4选自：
Figure PCTCN2023070285-appb-000047
其中，X选自O、NR 41；X 4选自O、NH或者CH 2；n 1选自1或2；所述的R 4可进一步被一个、两个、三个或四个独立的R 41取代；
所述的R 41选自氢、氧代、C 1～3烷基、-C 2～6烯基、卤素取代的C 1～3烷基、羟基取代的C 1～6烷基、-C 0～2亚烷基-O(C 1～3烷基)、-NH 2、-NH(C 1～3烷基)、-N(C 1～3烷基)(C 1～3烷基)、-C(O)R 42、-C(O)NR 42R 43、-C(O)OR 42、-(3～10元环烷基)、-(3～10元杂环烷基)、-C 1～2亚烷基-(5～10元芳环)；其中，所述的烷基、亚烷基、环烷基、杂环烷基、芳环可进一步被一个、两个、三个或四个独立的R 44取代；
R 42、R 43分别独立选自氢、卤素、-OH、C 1～3烷基、卤素取代的C 1～3烷基；
R 44选自氢、C 1～3烷基、卤素取代的C 1～3烷基、-O(C 1～3烷基)。
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的R 4具体选自：
Figure PCTCN2023070285-appb-000048
Figure PCTCN2023070285-appb-000049
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的R 5选自氢、卤素、-C 1～3烷基、卤素取代的C 1～3烷基、羟基取代的C 1～3烷基、-O(C 1～3烷基)、-NH(C 1～3烷基)、-O-C 2亚烷基-N(C 1～3烷基)(C 1～3烷基)、-O-(3～10元环烷基)、-O-(3～10元杂环烷基)，其中，所述的烷基、亚烷基、环烷基、杂环烷基可进一步被一个、两个、三个或四个独立的R 51取代；
所述的R 51选自氢、C 1～3烷基、卤素取代的C 1～3烷基。
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的R 5具体选自甲基、乙基、乙氧基、F、羟基取代的甲基、
Figure PCTCN2023070285-appb-000050
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的R 6选自氢、C 1～3烷基、-NH(C 1～3烷基)、-N(C 1～3烷基)(C 1～3烷基)。
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的A环选自
Figure PCTCN2023070285-appb-000051
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的B环选自3～10元杂环、5～12元桥杂环、3～10元稠杂环；其中，所述的杂环、桥杂环、稠杂环可进一步被一个、两个、三个或四个独立的R B1取代；
每个R B1分别独立选自氢、C 1～3烷基、卤素取代的C 1～3烷基。
进一步地：所述B环选自
Figure PCTCN2023070285-appb-000052
Figure PCTCN2023070285-appb-000053
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述C环选自
Figure PCTCN2023070285-appb-000054
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的R 7、R 8分别独立选自-OH、
Figure PCTCN2023070285-appb-000055
或R 7、R 8与其直接相连的原子形成
Figure PCTCN2023070285-appb-000056
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，所述的R 3选自
Figure PCTCN2023070285-appb-000057
Figure PCTCN2023070285-appb-000058
Figure PCTCN2023070285-appb-000059
Figure PCTCN2023070285-appb-000060
Figure PCTCN2023070285-appb-000061
作为优选：本发明所述的化合物、或其立体异构体、或其药学上可接受的盐，式I所述的化合物具体为：
Figure PCTCN2023070285-appb-000062
Figure PCTCN2023070285-appb-000063
Figure PCTCN2023070285-appb-000064
Figure PCTCN2023070285-appb-000065
Figure PCTCN2023070285-appb-000066
Figure PCTCN2023070285-appb-000067
Figure PCTCN2023070285-appb-000068
Figure PCTCN2023070285-appb-000069
Figure PCTCN2023070285-appb-000070
Figure PCTCN2023070285-appb-000071
Figure PCTCN2023070285-appb-000072
Figure PCTCN2023070285-appb-000073
Figure PCTCN2023070285-appb-000074
Figure PCTCN2023070285-appb-000075
Figure PCTCN2023070285-appb-000076
Figure PCTCN2023070285-appb-000077
Figure PCTCN2023070285-appb-000078
Figure PCTCN2023070285-appb-000079
Figure PCTCN2023070285-appb-000080
Figure PCTCN2023070285-appb-000081
Figure PCTCN2023070285-appb-000082
Figure PCTCN2023070285-appb-000083
作为优选，本发明的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：式I所述的化合物具体为：
Figure PCTCN2023070285-appb-000084
Figure PCTCN2023070285-appb-000085
Figure PCTCN2023070285-appb-000086
Figure PCTCN2023070285-appb-000087
Figure PCTCN2023070285-appb-000088
Figure PCTCN2023070285-appb-000089
作为优选，本发明的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：式I所述的化合物具体为：
Figure PCTCN2023070285-appb-000090
Figure PCTCN2023070285-appb-000091
本发明还提供一种上述任一项所述的化合物、或其立体异构体、或其药学上可接受的盐在制备治疗WEE1介导的疾病的药物中的用途。
所述WEE1介导的疾病是与炎症、自身免疫性疾病、感染性疾病、癌症、癌前期综合征相关的疾病中的一种或几种。
本发明还提供一种药物组合物，它是以上述任一项所述的化合物、或其立体异构体、或其药学上可接受的盐作为药物活性成份，加上药学上可接受的辅料制备而成的制剂。
“癌症”或“恶性肿瘤”是指以不受控制的细胞异常增殖为特征的多种疾病中的任何一种，受影响的细胞在局部或通过血流和淋巴系统扩散到其他部位的能力的身体(即转移)以及许多特征结构和/或分子特征中的任何一个。“癌细胞”是指经历多步骤肿瘤进展的早期，中期或晚期阶段的细胞。癌症包括肉瘤、乳腺癌、肺癌、脑癌、骨癌、肝癌、肾癌、结肠癌和前列腺癌。在一些实施方案中，式I的化合物用于治疗选自结肠癌、脑癌、乳腺癌、纤维肉瘤和鳞状细胞癌的癌症。在一些实施方案中，癌症选自黑素瘤、乳腺癌、结肠癌、肺癌和卵巢癌。在一些实施方案中，所治疗的癌症是转移性癌症。
自身免疫性疾病是由身体对体内正常存在的物质和组织的免疫反应引起的。自身免疫疾病的例子包括心肌炎、狼疮性肾炎、原发性胆汁性肝硬化、牛皮癣、1型糖尿病、格雷夫氏病、腹腔疾病、克罗恩病、自身免疫性中性白细胞减少症、幼年型关节炎、类风湿性关节炎、纤维肌痛、吉兰巴利综合征、多发性硬化症和自身免疫性视网膜病变。本发明的一些实施方案涉及治疗自身免疫疾病如牛皮癣或多发性硬化症。
炎症疾病包括以组织病理性炎症为特征的多种病症。炎性疾病的例子包括寻常性痤疮、哮喘、腹腔疾病、慢性前列腺炎、肾小球性肾炎、炎症性肠病、盆腔炎、再灌注损伤、类风湿性关节炎、结节病、血管炎、房尘螨引起的气道炎症和间质性膀胱炎。炎性疾病与自身免疫性疾病之间存在显著重叠。本发明的一些实施方案涉及炎性疾病哮喘的治疗。免疫系统通常涉及炎症性疾病，在过敏反应和一些肌病中都有表现，许多免疫系统疾病导致异常炎症。IL-17A介导的疾病也包括自身免疫性炎症性疾病。
本发明中提供的化合物和衍生物可以根据IUPAC(国际纯粹与应用化学联合会)或CAS(化学文摘服务社，Columbus，OH)命名系统命名。
关于本发明的使用术语的定义：除非另有说明，本文中基团或者术语提供的初始定义适用于整篇说明书的该基团或者术语；对于本文没有具体定义的术语，应该根据公开内容和上下文，给出本领域技术人员能够给予它们的含义。
“取代”是指分子中的氢原子被其它不同的原子或分子所替换。
碳氢基团中碳原子含量的最小值和最大值通过前缀表示，例如，前缀C a～b烷基表明任何含“a”至“b”个碳原子的烷基。因此，例如，“C 1～4烷基”是指包含1～4个碳原子的烷基。
“烷基”是指具有指定数目的成员原子的饱和烃链。例如，C 1～ 6烷基是指具有1至6个成员原子，例如1至4个成员原子的烷基基团。烷基基团可以是直链或支链的。代表性的支链烷基基团具有一个、两个或三个支链。烷基基团可任选地被一个或多个如本文所定义的取代 基取代。烷基包括甲基、乙基、丙基(正丙基和异丙基)、丁基(正丁基、异丁基和叔丁基)、戊基(正戊基、异戊基和新戊基)和己基。烷基基团也可以是其他基团的一部分，所述其他基团为例如C 1～C 6烷氧基。
“环烷基”、“环烷烃”是指具有碳原子且没有环杂原子且具有单个环或多个环(包括稠合、并和)的饱和或部分饱和的环状基团。对于具有不含环杂原子的芳族和非芳族环的多环体系，当连接点位于非芳族碳原子时，适用术语“环烷基”(例如5,6,7,8,-四氢化萘-5-基)。术语“环烷基”包括环烯基基团，诸如环己烯基。环烷基基团的实例包括例如，金刚烷基、环丙基、环丁基、环己基、环戊基、环辛基、环戊烯基和环己烯基。包括多双环烷基环体系的环烷基基团的实例是双环己基、双环戊基、双环辛基等。例如
Figure PCTCN2023070285-appb-000092
“烯基”是指具有2至10个碳原子和在一些实施方案中2至6个碳原子或2至4个碳原子且具有至少1个乙烯基不饱和位点(>C＝C<)的直链或支链烃基基团。例如，(Ca-Cb)烯基是指具有a至b个碳原子的烯基基团并且意在包括例如乙烯基、丙烯基、异丙烯基、1,3-丁二烯基等。
“炔基”是指含有至少一个三键的直链一价烃基或支链一价烃基。术语“炔基”还意在包括具有一个三键和一个双键的那些烃基基团。例如，(C2-C6)炔基意在包括乙炔基、丙炔基等。
“卤素”为氟、氯、溴或碘。
“卤素烷基”指烷基中的氢原子可被一个或多个卤素原子取代。例如C 1～4卤素烷基指氢原子被一个或多个卤素原子取代的包含1～4个碳原子的烷基。
“杂环”、“杂环烷基”、“杂环烷烃”指包含至少一个杂原子的饱和环或非芳香性的不饱和环；其中杂原子指氮原子、氧原子、硫原子；
“芳杂环”指包含至少一个杂原子的芳香性不饱和环；其中杂原子指氮原子、氧原子、硫原子；
“立体异构体”包括对映异构体和非对映异构体；本发明的化合物可以包含不对称中心或手性中心，因此存在不同的立体异构体。本发明的化合物所有的立体异构形式，包括但绝不限于，非对映体，对映异构体，阻转异构体，和它们的混合物，如外消旋混合物，组成了本发明的一部分。很多有机化合物都以光学活性形式存在，即它们有能力旋转平面偏振光的平面。在描述光学活性化合物时，前缀D、L或R、S用来表示分子手性中心的绝对构型。这些立体异构体的化学结构是相同的，但是它们的立体结构不一样。特定的立体异构体可以是对映体，异构体的混合物通常称为对映异构体混合物。50：50的对映体混合物被称为外消旋混合物或外消旋体，这可能导致化学反应过程中没有立体选择性或立体定向性。术语“外消旋混合物”和“外消旋体”是指等摩尔的两个对映异构体的混合物，缺乏光学活性。例如，本发明表格中编号Wee1-92的化合物中环上“*”所标记的C原子是手性中心。
Figure PCTCN2023070285-appb-000093
术语“药学上可接受的”是指某载体、运载物、稀释剂、辅料，和/或所形成的盐通常在化学上或物理上与构成某药物剂型的其它成分相兼容，并在生理上与受体相兼容。
本发明所述药物组合物，可以是任意一种可复用的药物制剂形式，如：口服，注射，外 用等形式，口服剂型包括但不限于：片剂，胶囊剂，口服液，颗粒剂，丸剂，混悬剂，注射剂选自水针，粉针，外用制剂选自贴剂，膏剂。所有制剂均可以按照制剂学常规技术制备，如以本发明化合物，或其立体异构体、或其药学上可接受的盐中的任意一项作为药物活性成份，必要时加入药学上可接受的载体，制备成适于服用的上述药物剂型，其中，单位剂量的药物活性成份可以是0.1mg-1000mg，如片剂的每片含有0.1mg-1000mg优选5-500mg的药物活性成份。
术语“盐”和“可药用的盐”是指上述化合物或其立体异构体，与无机和/或有机酸和碱形成的酸式和/或碱式盐，也包括两性离子盐(内盐)，还包括季铵盐，例如烷基铵盐。这些盐可以是在化合物的最后分离和纯化中直接得到。也可以是通过将上述化合物，或其立体异构体，与一定数量的酸或碱适当(例如等当量)进行混合而得到。这些盐可能在溶液中形成沉淀而以过滤方法收集，或在溶剂蒸发后回收而得到，或在水介质中反应后冷冻干燥制得。本发明中所述盐可以是化合物的盐酸盐、硫酸盐、枸橼酸盐、苯磺酸盐、氢溴酸盐、氢氟酸盐、磷酸盐、乙酸盐、丙酸盐、丁二酸盐、草酸盐、苹果酸盐、琥珀酸盐、富马酸盐、马来酸盐、酒石酸盐或三氟乙酸盐。
在某些实施方式中，本发明的一种或多种化合物可以彼此联合使用。也可选择将本发明的化合物与任何其它的活性试剂结合使用，用于制备调控细胞功能或治疗疾病的药物或药物组合物。如果使用的是一组化合物，则可将这些化合物同时、分别或有序地对受试对象进行给药。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
本发明的有益效果在于：
相比现有技术，本发明化合物具有较好的wee1激酶抑制活性和肿瘤细胞增值抑制活性；对细胞色素P450酶与hERG钾离子通道抑制降低，安全性更好。
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
化合物的结构是通过核磁共振(NMR)和质谱(MS)来确定的。NMR位移(δ)以10-6(ppm)的单位给出。NMR的测定是用(Bruker AvanceIII 400和Bruker Avance 300)核磁仪，测定溶剂为氘代二甲基亚砜(DMSO-d6)，氘代氯仿(CDCl 3),氘代甲醇(CD3OD)，内标为四甲基硅烷(TMS)。
LC-MS的测定使用岛津液质联用仪(Shimadzu LC-MS 2020(ESI))。HPLC的测定使用岛津高压液相色谱仪(Shimadzu LC-20A)。MPLC(中压制备色谱)使用Gilson GX-281反相制备色谱仪。薄层层析硅胶板用烟台黄海HSGF254或青岛GF254硅胶板，薄层层析分离纯化产品采用的规格是0.4mm～0.5mm。柱层析一般使用烟台黄海硅胶200～300目硅胶为载体。
本发明的已知的起始原料可以采用或按照本领域已知的方法来合成，或可购买于安耐吉化学、成都科龙化工、韶远化学科技、百灵威科技等公司。
实施例中无特殊说明，反应在氮气氛围下进行。实施例中无特殊说明，溶液是指水溶液。实施例中无特殊说明，反应的温度为室温。实施例中无特殊说明，M是摩尔每升。
THF：四氢呋喃；DIPEA：N,N-二异丙基乙胺；
DCM：二氯甲烷；TFA：三氟乙酸；m-CPBA：间氯过氧苯甲酸；
DMF：二甲基甲酰胺；PTSA：对甲苯磺酰胺；
DMSO：二甲基亚砜；NBS：N-溴代琥珀酰亚胺；AIBN：偶氮二异丁腈；
实施例中无特殊说明时，HPLC测试条件如下：
方法A：
柱规格:Boston Green C18 150mm*4.6mm 5um；流动相:A:0.05％TFA Water B:0.05％TFA Acétonitrile；梯度:B from 5％to 95％in 10.0min and hold 95％for 5.0min；流速:1.5mL/min；柱内温度:40℃。
方法B：
柱规格:Boston Green ODS 150mm*4.6mm 5um；流动相:A:0.01M NH 4HCO 3Water B:Acétonitrile；梯度:B from 5％to 95％in 10.0min and hold 95％for 5.0min；流速:1.5mL/min；柱内温度:40℃。
无特殊说明时，SFC的拆分条件为，柱规格:3μm,150mm*3mm，流动相:A:CO 2，流动相B:乙醇；流速:1mL/min，柱温：40℃。
中间体实施例1：中间体IM-1的合成:
Figure PCTCN2023070285-appb-000094
步骤1：化合物IM-1-3的合成：
在干燥的单口瓶中加入底物IM-1-2(8.15g,35mmol)和THF(50mL)，搅拌溶解后加入IM-1-1(6.3g,37mol)和DIPEA(15mL,75mol)，加热至110℃反应，LC-MS监测。反应结束后，待体系恢复至室温，析出固体后滤出，烘箱烘干，即为粗产物IM-1-3(9.87g,76.6％yield)，LCMS(ESI +)m/z:369.2[M+H] +。
步骤2：化合物IM-1-4的合成：
在干燥的单口瓶中加入底物IM-1-3(9.16g,27.5mmol)和DCM(18mL)，搅拌溶解后，缓慢加入TFA(18mL)，加热至75℃反应，LC-MS监测。反应结束后有机溶剂减压浓缩，用乙醇溶解后，加入6M NaOH溶液室温搅拌，LC-MS监测。反应完成后，减压浓缩后有固体析出，滤出固体，用水洗涤三次，冷的乙醇洗涤三次，室温晾干，即为粗产物IM-1-4(5g,81.7％yield)，LCMS(ESI +)m/z:223.1[M+H] +。
步骤3：化合物IM-1的合成：
在干燥的双口瓶中加入底物IM-1-4(5.20g,23.4mmol)，碳酸钾(4.53g,32.8mmol)和IM-1-5(5.55g,25.7mmol)，氮气置换三次后，加入碘化亚铜(4.46g,23.4mmol)，N,N’-二甲基乙二胺(4.13g,46.8mmol)和1,4-二氧六环(100mL)，搅拌均匀后，升温至120℃反应，LC-MS和TLC监测。反应结束后加入氨水搅拌，乙酸乙酯萃取3次，合并有机相，无水硫酸钠除水，有机相减压浓缩后，残余物用中压液相色谱(碱法)纯化得到化合物IM-1(5.1g,61％yield)，LCMS(ESI +)m/z:358.1[M+H] +。
中间体实施例2：中间体IM-2的合成
Figure PCTCN2023070285-appb-000095
步骤1：化合物IM-2-3的合成：
在干燥的单口瓶中加入底物IM-2-1(7.12g,50mmol)和DMSO(30mL)，搅拌溶解后，加入IM-2-2(9.9 g,50 mmol)，加热至90℃反应，LC-MS监测。反应结束后，冷却至室温，将析出的固体滤出，水洗涤三次，少量的甲醇洗三次，烘干得到产物IM-2-3(12.12g,76％产率)，LCMS(ESI +)m/z:320.3[M+H] +。
步骤2：化合物IM-2-4的合成：
在干燥的单口瓶中加入底物IM-2-3(12.12g,38mmol)和DCM(18mL)，搅拌溶解后，缓慢加入TFA(18mL)，LC-MS监测。反应结束后，减压浓缩除去溶剂，得到残余物。向残余物中加入甲醇(70mL)，搅拌溶解后加入多聚甲醛(7g)和乙酸(1mL)，室温下搅拌30min，加入氰基硼氢化钠(3.8g,60mmol)，并升温至50℃反应。反应结束后，冷却至室温，滤除固体，有机相减压浓缩除去溶剂，残余物用中压液相色谱(碱法)纯化得到化合物IM-2-4(7.6g,85.8％yield)，LCMS(ESI +)m/z:234.2[M+H] +。
步骤3：化合物IM-2的合成：
在干燥的单口瓶中加入底物IM-2-4(5g,21.5mmol)和甲醇(40mL)，搅拌溶解后，加入Pd/C(500mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，有机相进行减压浓缩，得到产物IM-2(4.0g,crude)，LCMS(ESI +)m/z:204.2[M+H] +。
中间体实施例3：中间体IM-3的合成
Figure PCTCN2023070285-appb-000096
步骤1：化合物IM-3的合成：
在干燥的双口瓶中加入底物IM-1-4(138mg,620.88μmol)，碳酸钾(101mg,620.88μmol)和IM-3-1(130mg,521.82μmol)，氮气置换三次后，加入碘化亚铜(99mg,519.82μmol)，N,N’-二甲基乙二胺(106mg,1.20mmol)和1,4-二氧六环(10mL)，搅拌均匀后，升温至120℃反应，LC-MS监测。反应结束后，恢复至室温，加入氨水，乙酸乙酯萃取3次，有机相减压浓缩后，残余物用中压液相色谱(碱法)纯化得到化合物IM-3(130mg,53.62％产率)，LCMS(E+)m/z:391.2[M+H] +。
中间体实施例4：中间体IM-4的合成
Figure PCTCN2023070285-appb-000097
步骤1：化合物IM-4的合成：
在干燥的单口瓶中加入底物IM-2-3(1g,3.13mmol)和甲醇(10mL)，搅拌溶解后，加入Pd/C(200mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，有机相进行减压浓缩，得到产物IM-4(700mg,crude)，LCMS(ESI +)m/z:290.2[M+H] +。
中间体实施例5：中间体IM-5的合成
Figure PCTCN2023070285-appb-000098
步骤1：化合物IM-5的合成：
向单口反应瓶中加入底物IM-3(0.2g,0.51mmol)，无水THF(5ml)搅拌溶解，加入m-CPBA(208.2g,1.02mmol,纯度85％)，常温下搅拌40分钟，LC-MS监测。反应物经减压浓缩后用中压液相色谱分离，得到IM-5(160mg)，LCMS(ESI +)m/z:407.1[M+H] +。
中间体实施例6：中间体IM-6的合成
Figure PCTCN2023070285-appb-000099
步骤1：化合物IM-6的合成：
向单口反应瓶中加入底物IM-1(0.2g,0.56mmol)，无水THF(5ml)搅拌溶解，加入m-CPBA(144.9mg,0.84mmol,纯度85％)，常温下搅拌40分钟，LC-MS监测。反应物经减压浓缩后用中压液相色谱分离，得到IM-6(150mg,0.40mmol,71.8％产率)，LCMS(ESI +)m/z:374.1[M+H] +。
实施例1：化合物1的合成
Figure PCTCN2023070285-appb-000100
步骤1：化合物1-2的合成
向干燥的圆底烧瓶中加入2-溴-6-氟吡啶(3g,15mmol)，四氢呋喃(25mL)。温度降至-40℃，向体系中缓慢滴加NaHMDS(12.79g,85.23mmol)。在-40℃下搅拌30分钟后加入二甲亚砜(3.21g,34.09mmol)，在此温度下继续搅拌3小时。反应用水淬灭，乙酸乙酯萃取三次，有机相用无水硫酸钠干燥，过滤，减压蒸馏，通过MPLC纯化得到化合物1-2(1.5g,6.00mmol)，LCMS(ESI)m/z:252.0[M+H] +。
步骤2：化合物1-3的合成
在室温下向干燥烧瓶中加入化合物1-2(1.5g,6.00mmol)、四丁基溴化铵(193.1mg,0.6mmol)、二氯甲烷(10mL)。室温搅拌10分钟后，加入氢氧化钠(9.60g,239.9mmol)和水(10mL)。反应室温下搅拌12小时，用水淬灭并用乙酸乙酯萃取3次。将合并的有机相用盐水洗涤，无水硫酸钠干燥，过滤并减压浓缩。将残余物通过MPLC纯化，得到化合物1-3(450mg，1.63mmol)，LCMS(ESI)m/z:278.0[M+H] +。
步骤3：化合物1-4的合成
在干燥的微波管中，氮气保护下加入底物1-3(93mg,336.77μmol)、IM-1-4(89.82mg, 404.13μmol)、碘化亚铜(64.14mg,336.77μmol)、碳酸钾(65.17mg,505.16μmol)和N,N’-二甲基乙二胺(29.64mg,336.77μmol)，然后加入1，4-二氧六环(5mL)。在氮气环境下，120℃加热反应10小时。LC-MS监测，反应结束后反应体系冷却至室温，过滤，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物通过MPLC纯化得到化合物1-4(50mg,119.76μmol)，LCMS(ESI)m/z:418.1[M+H] +。
步骤4：化合物1的合成
向溶有1-4(30mg，71.9μmol)的四氢呋喃(1mL)中加入间氯过氧苯甲酸(18.74mg，107.8μmol)，室温搅拌1小时。LC-MS监测，原料消失后加入N,N-二异丙基乙胺(43mg，0.33mmol)和1-5(15.3mg，80.1μmol)，室温搅拌12小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(酸性)纯化，得到化合物1(30mg,53.51μmol)。LCMS(ESI)m/z:561.3[M+H] +,HPLC method A:R T＝5.05min,purity:98.2％. 1H NMR(400MHz,Methanol-d 6)δ8.79(s,1H),8.05–8.01(m,1H),7.93(d,J＝8.4Hz,1H),7.61(d,J＝7.6Hz,1H),7.57-7.42(m,2H),7.03-6.88(m,2H),5.71–5.67(m,1H),5.06–5.05(m,1H),4.98–4.95(m,1H),4.80–4.78(m,2H),3.20–3.18(m,5H),3.04(s,4H),2.65–2.63(m,5H),2.36(s,4H),1.92-1.75(m,2H),1.53(d,J＝2.4Hz,2H)。
实施例2：化合物2的合成
Figure PCTCN2023070285-appb-000101
步骤1：化合物2-1的合成：
在干燥的单口瓶中加入底物IM-1(43mg,120.30μmol)，甲苯(1mL)，搅拌溶解后，加入m-CPBA(43.60mg,252.64μmol)，室温反应30min，LC-MS监测。反应结束后，加入DIPEA(80.6mg,623.65μmol,108.63μL)，搅拌10min后，加入IM-4(45.14mg,0.156mmol)，LC-MS监测。反应完成后，反应液减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物2-1(45mg,62.64％产率)。 1H NMR(400MHz,DMSO-d 6)δ10.08(s,1H),8.80(s,1H),8.00(t,J＝8.0Hz,1H),7.74(d,J＝8.2Hz,1H),7.59(d,J＝7.7Hz,1H),7.51(s,2H),6.61(d,J＝8.5Hz,2H),5.71-5.61(m,1H),5.31(s,1H),4.99(dd,J＝10.2,1.5Hz,1H),4.83(dd,J＝17.1,1.5Hz,1H),4.68(d,J＝5.9Hz,2H),4.49(s,1H),4.42(d,J＝23.5Hz,1H),3.55(t,J＝10.6Hz,1H),3.27–3.20(m,2H),2.96(t,J＝9.0Hz,1H),1.93(s,2H),1.46(s,6H),1.39(s,5H),1.32(s,4H). 1H NMR(400MHz,DMSO-d 6,D 2O)δ8.81(s,1H),8.02(t,J＝7.9Hz,1H),7.73(d,J＝7.8Hz,1H),7.60(d,J＝7.7Hz,1H),7.51(s,2H),6.62(d,J＝8.5Hz,2H),5.71–5.61(m,1H),5.04–5.01(m,1H),4.85–4.81(m,1H),4.69(d,J＝5.9Hz,2H),4.49–4.41(m,2H),3.57(t,J＝9.0Hz,1H),3.36–3.25(m,2H),2.96(t,J＝8.4Hz,1H),1.94(s,2H),1.47(s,6H),1.39(s,5H),1.32(s,4H).LCMS(E+)m/z:599.4[M+H] +,HPLC method B:R T＝8.23min,purity:91.5％.
步骤2：化合物2的合成：
在干燥的单口瓶中加入底物2-1(40.00mg,66.81μmol)和DCM(3mL)，搅拌溶解后，缓慢加入TFA(3mL)，LC-MS监测。反应结束后减压浓缩除去溶剂，得到残余物，用中压液相色谱(酸法)纯化得到化合物2(25mg,61.08％产率)。 1H NMR(400MHz,Methanol-d 4)δ8.77(s,1H),7.97(t,J＝7.9Hz,1H),7.76(d,J＝8.1Hz,1H),7.63(dd,J＝7.8,0.8Hz,1H),7.54(d,J＝8.4Hz,2H),6.67(d,J＝8.6Hz,2H),5.70(m,1H),5.03(dq,J＝10.2,1.2Hz,1H),4.92(d,J＝1.2Hz,1H),4.80(d,J＝6.1Hz,2H),4.66(s,1H),4.48(s,1H),3.76(dd,J＝10.6,2.5Hz,1H),3.42–3.34(m,3H),2.32(d,J＝11.1Hz,1H),2.05(d,J＝11.3Hz,1H),1.57(s,6H).LCMS(E+)m/z:499.2[M+H] +,HPLC method A:R T＝5.03min,purity:99.2％.
实施例3：化合物3的合成
Figure PCTCN2023070285-appb-000102
步骤1：化合物3的合成：
在干燥的单口瓶中加入底物IM-1(3.57g,10mmol)，四氢呋喃(30mL)，搅拌溶解后，加入m-CPBA(2.5g,15mmol,纯度85％)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(6.45g,50mmol)，搅拌10min后，加入IM-2(2.1g,10mmol)，LC-MS监测。反应完成后，减压浓缩除溶剂，残余杂质用中压液相色谱(碱法)纯化得到化合物3(2.1g,41％产率)。 1H NMR(400MHz,DMSO-d 6)δ10.04(s,1H),8.79(s,1H),8.00(t,J＝7.9Hz,1H),7.75(s,1H),7.59(d,J＝7.7Hz,1H),7.48(s,2H),6.56(d,J＝8.5Hz,2H),5.71-5.61(m,1H),5.32(s,1H),4.99(dd,J＝10.3,1.5Hz,1H),4.82(d,J＝17.1,1H),4.67(d,J＝6.0Hz,2H),4.27(s,1H),3.42(s,1H),3.13(d,J＝9.0Hz,1H),2.78(d,J＝9.5,1H),2.52(d,J＝9.7Hz,2H),2.25(s,3H),1.87(d,J＝9.3Hz,1H),1.76(d,J＝9.2Hz,1H),1.46(s,6H). 1H NMR(400MHz,DMSO-d 6,D 2O)δ8.80(s,1H),8.02(t,J＝7.9Hz,1H),7.73(s,1H),7.61(d,J＝7.8Hz,1H),7.48(s,2H),6.58(d,J＝8.6Hz,2H),5.71-5.60(d,J＝10.3Hz,1H),5.03(m,1H),4.83(d,J＝17.1Hz,1H),4.68(d,J＝5.9Hz,2H),4.29(s,1H),3.49(s,1H),3.35(d,J＝9.5Hz,1H),3.17(d,J＝9.4Hz,1H),2.82(d,J＝9.7Hz,1H),2.56(d,J＝9.7Hz,1H),2.27(s,3H),1.91(d,J＝9.6Hz,1H),1.81(d,J＝9.6Hz,1H),1.47(s,6H).LCMS(E+)m/z:513.2[M+H] +,HPLC method B:R T＝6.02min,purity:98.4％.
实施例4：化合物4的合成
Figure PCTCN2023070285-appb-000103
步骤1：化合物4-3的合成：
在干燥的单口瓶中加入底物4-1(114mg,910.78μmol)，甲醇(2mL)，搅拌溶解后，加入NaBH 4(38mg,1.00mmol)，室温反应1h，LC-MS监测。反应结束后，冰浴下缓慢加入稀盐酸淬灭反应，减压浓缩除去溶剂，向残余物中加入DMSO(4mL)，搅拌溶解后，加入叔丁醇钾(337mg,2.36mmol)，加入化合物4-2(141mg,999.29μmol)，升温至80℃反应，LC-MS监测。反应完成后，用乙酸乙酯萃取三次，有机相减压浓缩后，用中压液相色谱(碱法)纯化得到化合物4-3(99mg,50.71％产率)，LCMS(ESI +)m/z:249.2[M+H] +。
步骤2：化合物4-4的合成：
在干燥的单口瓶中加入底物4-3(99mg,398.75μmol)，乙醇(4mL)，搅拌溶解后，加入Fe(67mg,1.20mmol)和CH 3COOH(47.89mg,797.50μmol,45.65μL)，升温至80℃反应，LC-MS监测。反应完成后，用硅藻土过滤，乙酸乙酯洗涤，有机相减压浓缩后，得到粗产物4-4(80mg,crude)，LCMS(ESI +)m/z:219.2[M+H] +。
步骤3：化合物4的合成：
在干燥的单口瓶中加入底物IM-1(71mg,0.2mmol)，甲苯(2mL)，搅拌溶解后，加入m-CPBA(52mg,0.3mmol,纯度85％)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(83.58mg,646.69μmol,112.64μL)，搅拌10min后，加入化合物4-4(52.39mg,0.24mmol)， LC-MS监测。反应完成后，减压浓缩除去溶剂，得到残余物用中压液相色谱(碱法)纯化得到化合物4(8mg,6.32％产率)。 1H NMR(400MHz,DMSO-d 6)δ10.18(s,1H),8.84(s,1H),8.04(t,J＝7.9Hz,1H),7.73(d,J＝7.2,1H),7.62-7.60(m,3H),6.90(d,J＝7.7Hz,2H),5.71-5.62(m,1H),5.33(s,1H),4.99(dd,J＝10.3,1.4Hz,1H),4.82(dd,J＝10.3,1.4Hz,1H),4.68(d,J＝5.9Hz,2H),4.44-4.42(m,1H),2.77-2.60(m,6H),2.04-2.03(m,1H),1.84-1.81(m,1H),1.66–1.63(m,1H),1.57-1.54(m,1H),1.46(s,6H),1.36–1.33(m,1H). 1H NMR(400MHz,DMSO-d 6,D 2O)δ8.85(s,1H),8.04(t,J＝7.9Hz,1H),7.72(d,J＝7.6Hz,1H),7.64-7.59(m,3H),6.92(d,J＝8.5Hz,2H),5.72-5.62(m,1H),5.03(d,J＝10.3Hz,1H),4.83(d,J＝17.1Hz,1H),4.69(d,J＝5.9Hz,2H),4.49(s,1H),2.81–2.63(m,6H),2.06(s,1H),1.86(s,1H),1.70-1.68(m,1H),1.62(d,J＝7.4Hz,1H),1.47(s,6H),1.42-1.37(m,1H).LCMS(E+)m/z:528.2[M+H] +,HPLC method B:R T＝6.34min,purity:82.9％.
实施例5：化合物5的合成
Figure PCTCN2023070285-appb-000104
步骤1：化合物5的合成：
在干燥的单口瓶中加入底物IM-3(30mg,77μmol)，四氢呋喃(2mL)，搅拌溶解后，加入m-CPBA(20mg,116μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(50mg,385μmol)，搅拌10min后，加入化合物IM-2(20mg,98.39μmol)，LC-MS监测。反应完成后，减压浓缩，得到残余物用中压液相色谱(碱法)纯化得到化合物5(15mg,55.87％产率)。 1H NMR(400MHz,DMSO-d 6)δ10.01(s,1H),8.77(s,1H),7.76(t,J＝8.0Hz,1H),7.50(s,2H),7.30(d,J＝7.9Hz,1H),6.59-6.55(m,3H),5.68-5.58(m,1H),5.00(d,J＝10.1Hz,1H),4.89(d,J＝17.0Hz,1H),4.74(s,2H),4.26(s,1H),3.40(s,1H),3.37(s,6H),3.30(s,1H),3.13(d,J＝9.0Hz,1H),2.78-2.76(m,1H),2.47(s,1H),2.24(s,3H),1.85(d,J＝9.3Hz,1H),1.75(d,J＝9.1Hz,1H). 1H NMR(400MHz,DMSO-d 6,D 2O)δ8.79(s,1H),7.80(t,J＝7.9Hz,1H),7.50-7.48(m,2H),7.30(d,J＝7.8Hz,1H),6.64(d,J＝8.0Hz,1H),6.58(d,J＝8.7Hz,2H),5.69–5.59(m,1H),5.05–5.03(m,1H),4.92–4.87(m,1H),4.74(s,2H),4.27(s,1H),3.44(s,1H),3.36(s,6H),3.35–3.32(m,1H),3.16(d,J＝9.4Hz,1H),2.79(d,J＝9.7Hz,1H),2.48(d,J＝9.9Hz,1H),2.24(s,3H),1.89(d,J＝9.5Hz,1H),1.78(d,J＝9.4Hz,1H).LCMS(E+)m/z:546.3[M+H] +,HPLC method B:R T＝5.56min,purity:92％.
实施例6：化合物6的合成
Figure PCTCN2023070285-appb-000105
步骤1：化合物6-1的合成：
在干燥的单口瓶中加入底物4-1(1g,6.2mmol),乙醇/水(10:1,20mL)，搅拌溶解后，加入对硝基苯甲醛(1g,6.6mmol)和氢氧化钠(620mg,15.5mmol)，室温反应，LC-MS监测。反应完成后，将析出的固体滤出，少量乙醇洗涤三次，自然晾干得到化合物6-1(1g,63％产率)，LCMS(E+)m/z:259.2[M+H] +。
步骤2：化合物6-2的合成：
在干燥的单口瓶中加入底物6-1(103mg,0.4mmol)，甲醇(5mL)，搅拌溶解后，加入Pd/C(15mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土过滤除去Pd/C，有机相进行减压浓缩，得到粗产物6-2(80mg,crude)，LCMS(ESI +)m/z:231.2[M+H] +。
步骤3：化合物6的合成：
在干燥的单口瓶中加入底物IM-3(30mg,77μmol)，四氢呋喃(2mL)，搅拌溶解后，加入m-CPBA(20mg,116μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(50mg,385μmol)，搅拌10min后，加入化合物6-2(20mg,86.84μmol)，LC-MS监测。反应完成后，减压浓缩，得到残余物用中压液相色谱(碱法)纯化得到化合物6(5mg,17.74％产率)。 1H NMR(400MHz,DMSO-d 6)δ10.18(s,1H),8.85(s,1H),7.78(t,J＝7.9Hz,1H),7.61(d,J＝8.1Hz,2H),7.30(d,J＝7.9Hz,1H),7.20(d,J＝8.4Hz,2H),6.61(d,J＝7.9Hz,1H),5.69–5.60(m,1H),5.02-4.99(m,1H),4.90(dd,J＝17.1,1.7Hz,1H),4.74(d,J＝6.0Hz,2H),3.37(s,6H),2.99–2.86(m,4H),2.76–2.69(m,3H),2.33–2.29(m,2H),1.92–1.88(m,3H). 1H NMR(400MHz,DMSO-d 6,D 2O)δ8.86(s,1H),7.83(t,J＝7.9Hz,1H),7.60(d,J＝8.0Hz,2H),7.31(d,J＝7.8Hz,1H),7.22(d,J＝8.2Hz,2H),6.68(d,J＝8.0Hz,1H),5.70–5.61(m,1H),5.07–5.04(m,1H),4.90(d,J＝17.2Hz,1H),4.75(d,J＝5.9Hz,2H),3.36(s,6H),3.09–2.85(m,4H),2.79–2.72(m,3H),2.38–2.32(m,2H),1.91-1.89(m,3H).LCMS(E+)m/z:573.6[M+H] +,HPLC method B:R T＝5.05min,purity:87.7％.
实施例7：化合物7的合成
Figure PCTCN2023070285-appb-000106
步骤1：化合物7的合成：
在干燥的单口瓶中加入底物IM-3(30mg,77μmol)，四氢呋喃(2mL)，搅拌溶解后，加入m-CPBA(20mg,116μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(50mg,385μmol)，搅拌10min后，加入化合物4-4(20mg,91.62μmol)，LC-MS监测。反应完成后，减压浓缩除去溶剂，残余物用中压液相色谱(碱法)纯化得到化合物7(5mg,19.08％产率)。 1H NMR(400MHz,DMSO-d 6)δ10.16(s,1H),δ8.82(s,1H),7.79(t,J＝8.0Hz,1H),7.61(s,2H),7.28(d,J＝7.8Hz,1H),6.89(d,J＝9.0Hz,2H),6.60(d,J＝8.1Hz,1H),5.69–5.59(m,1H),5.02–4.99(m,1H),4.89(d,J＝17.2Hz,1H),4.74(s,2H),4.41(d,J＝7.8Hz,1H),3.18(s,3H),3.16(s,3H),2.79-2.70(m,6H),2.03-2.02(m,1H),1.91-1.80(m,1H),1.67-1.63(m,1H),1.57-1.54(m,1H),1.38-1.33(m,1H). 1H NMR(400MHz,DMSO-d 6,D 2O)δ8.83(s,1H),7.82(t,J＝8.0Hz,1H),7.60(s,2H),7.29(d,J＝7.8Hz,1H),6.92(d,J＝8.8Hz,2H),6.66(d,J＝8.0Hz,1H),5.68-5.62(m,1H),5.05(d,J＝10.4Hz,1H),4.89(d,J＝16.9Hz,1H),4.75(s,2H),4.48(s,1H),3.36(s,6H),2.78-2.72(m,6H),2.05(s,1H),1.84(s,1H),1.70-1.59(m,2H),1.40-1.33(m,1H).LCMS(E+)m/z:561.5[M+H] +,HPLC method B:R T＝5.10min,purity:90.2％.
实施例8：化合物8的合成
Figure PCTCN2023070285-appb-000107
步骤1：化合物8-2的合成：
在干燥的单口瓶中加入底物4-2(1g,7.09mmol)、化合物8-1(1.70g,8.50mmol)和碳酸钾(2.45g,17.72mmol)，用DMF(10mL)溶解，升温至90℃，反应1h，LC-MS监测。反应完成后，用水和乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，无水硫酸钠干燥，有机溶剂减压浓缩，得到粗产物，无需纯化，产物可直接用于下步反应，得到化合物8-2(2.1g,crude)，为黄色油状物。LCMS(E+)m/z:322.4[M+H] +。
步骤2：化合物8-3的合成：
在干燥的单口瓶中加入底物8-2(2.1g,6.53mmol)用HCl/1,4-二氧六环(10mL)溶解，室温反应1h，LC-MS监测。反应完成后，减压浓缩，用饱和碳酸钠溶液和乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，无水硫酸钠干燥，有机溶剂减压浓缩，得到粗产物，无需纯化，粗产物可直接用于下步反应，得到化合物8-3(1.3g,crude)，为黄色油状物。LCMS(E+)m/z:222.4[M+H] +。
步骤3：化合物8-4的合成：
在干燥的单口瓶中加入底物8-3(700mg,3.16mmol)，化合物4-1(396.00mg,3.16mmol)用MeOH/AcOH(10mL)溶解，室温反应1h，LC-MS监测。反应完成后，减压浓缩，用水和乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，无水硫酸钠干燥，有机溶剂减压浓缩，残余杂质用MPLC除去，得到化合物8-4(300mg,907.93μmol,28.70％产率)，为黄色固体。LCMS(E+)m/z:331.4[M+H] +。
步骤4：化合物8-5的合成：
在干燥的单口瓶中加入底物8-4(300mg,907.93μmol)，甲醛(136.31mg,4.54mmol)用MeOH/AcOH(8mL)溶解，升温至50℃，反应3h后，向体系中加入NaCNBH 3(142.64mg,2.27mmol)升温至70℃，反应过夜，LC-MS监测。反应完成后，减压浓缩，用水和乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，无水硫酸钠干燥，有机溶剂减压浓缩，残余杂质用MPLC除去，得到化合物8-5(283mg,739.44μmol,81.44％产率)，为黄色固体。LCMS(E+)m/z:345.5[M+H] +。
步骤5：化合物8-6的合成：
在干燥的单口瓶中加入底物8-5(1.5g,4.74mmol)用MeOH/AcOH(10mL)溶解，加入Pd/C(172.73mg,1.42mmol)，H 2置换3次，室温反应3h，LC-MS监测。反应完成后，用硅藻土过滤，滤液减压浓缩，无需纯化，粗产品可直接用于下步反应，得到化合物8-6(1.5g,crude)，为黑色油状物。LCMS(E+)m/z:315.5[M+H] +。
步骤6：化合物8的合成：
在干燥的单口瓶中加入底物8-6(50mg,159.00μmol)，化合物IM--5(64.63mg,159.00μmol)用THF(3mL)溶解后，加入PTSA(54.76mg,318.00μmol)，升温至110℃，搅拌反应5h，LC-MS监测。反应完成后，减压浓缩有机溶剂，用水和乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，无水硫酸钠干燥，减压浓缩，残余杂质用MPLC除去，得到化合物8(23 mg,35.02μmol,22.02％yield)，为黄色固体。 1H NMR(600MHz,DMSO-d 6)δ10.11(s,1H),8.80(s,1H),7.79(s,1H),7.56(s,2H),7.30(d,J＝7.9Hz,1H),6.91(d,J＝8.6Hz,2H),6.59(d,J＝8.2Hz,1H),5.68–5.59(m,1H),5.00(d,J＝10.1Hz,1H),4.89(d,J＝17.0Hz,1H),4.74(s,2H),3.74–3.66(m,2H),3.37(s,6H),2.94–2.91(m,1H),2.79–2.57(m,9H),2.06(s,3H),1.97–1.93(m,1H),1.75–1.53(m,6H),1.42(d,J＝11.1Hz,1H),1.24(d,J＝11.7Hz,1H).LCMS(ESI+)m/z:657.4[M+H] +,HPLC method B:R T＝5.54min,purity:98.9％.
实施例9：化合物9的合成
Figure PCTCN2023070285-appb-000108
步骤1：化合物9-2的合成：
在干燥的单口瓶中加入底物4-1(161mg,1mmol),用乙醇/水(10:1,10mL)搅拌溶解后，加入9-1(186mg,1.1mmol)和氢氧化钠(100mg,2.5mmol)，室温反应，LC-MS监测。反应完成后，将析出的固体滤出，少量乙醇洗涤三次，干燥得到化合物9-2(150mg,50％产率)，LCMS(E+)m/z:303.1[M+H] +。
步骤2：化合物9-3的合成：
在干燥的单口瓶中加入底物9-2(81mg,0.27mmol)，甲醇(5mL)，搅拌溶解后，加入Pd/C(15mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，有机相减压蒸馏浓缩，得到产物9-3(42mg,crude)，LCMS(ESI +)m/z:275.2[M+H] +。
步骤3：化合物9的合成：
在干燥的单口瓶中加入底物IM-3(40mg,110.71μmol)，THF(2mL)，搅拌溶解后，加入m-CPBA(29mg,116μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(75.12mg,581.26μmol)，搅拌10min后，加入化合物9-3(36.45mg,132.85μmol)，LC-MS监测。反应完成后，减压浓缩，得到残余物用中压液相色谱(碱法)纯化得到化合物9(35mg,51.26％产率)。 1H NMR(400MHz,DMSO-d 6)δ10.12(s,1H),8.82(s,1H),7.77-7.75(m,1H),7.59(s,1H),7.45(d,J＝8.9Hz,1H),7.29(d,J＝7.4Hz,1H),6.89(d,J＝8.8Hz,1H),6.58(d,J＝8.0Hz,1H),5.67-5.60(m,1H),5.00(d,J＝10.2Hz,1H),4.88(d,J＝17.1Hz,1H),4.74(s,2H),4.01(q,J＝7.0Hz,2H),3.37(s,6H),3.06-3.03(m,2H),2.85-2.84(m,1H),2.71-2.64(m,4H),2.28(s,1H),1.95–1.87(m,4H),1.32(t,J＝6.9Hz,3H). 1H NMR(400MHz,DMSO-d 6,D 2O)δ8.82(s,1H),7.81-7.77(m,1H),7.58(s,1H),7.45(d,J＝8.7Hz,1H),7.29(d,J＝7.9Hz,1H),6.90(d,J＝8.9Hz,1H),6.61(d,J＝8.1Hz,1H),5.67-5.60(m,1H),5.02(d,J＝10.2Hz,1H),4.88(d,J＝17.1Hz,1H),4.73(s,1H),4.01(q,J＝7.0Hz,2H),3.36(s,6H),3.03(d,J＝14.9Hz,2H),2.86(s,1H),2.71-2.65(m,4H),2.29(s,1H),1.96-1.87(m,4H),1.32(t,J＝6.9Hz,3H).LCMS(E+)m/z:617.2[M+H] +,HPLC method B:R T＝6.66min,purity:95.4％.
实施例10：化合物10的合成
Figure PCTCN2023070285-appb-000109
步骤1：化合物10-1的合成：
在干燥的单口瓶中加入底物4-1(1g,6.2mmol),乙醇/水(10:1，20mL)，搅拌溶解后，加入间硝基苯甲醛(1g,6.6mmol)和氢氧化钠(620mg,15.5mmol)，室温反应，LC-MS监测。反应完成后，将析出的固体滤出，少量乙醇洗涤三次，自然晾干得到化合物10-1(1g,63％产 率)，LCMS(E+)m/z:259.2[M+H] +。
步骤2：化合物10-2的合成：
在干燥的单口瓶中加入底物10-1(103mg,0.4mmol)，甲醇(5mL)，搅拌溶解后，加入Pd/C(15mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，有机相减压蒸馏浓缩，得到产物10-2(65mg,crude)，LCMS(ESI +)m/z:231.2[M+H] +。
步骤3：化合物10的合成：
在干燥的单口瓶中加入底物IM-3(40mg,110.71μmol)，THF(2mL)，搅拌溶解后，加入m-CPBA(29mg,116μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(85.85mg,664.24μmol)，搅拌10min后，加入化合物10-2(30.6mg,132.85μmol)，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物10(15mg,22.22％产率)。 1H NMR(400MHz,DMSO-d 6)δ10.22(s,1H),8.87(s,1H),7.83(t,J＝7.9Hz,1H),7.76(s,1H),7.47(d,J＝8.2Hz,1H),7.31(d,J＝7.8Hz,1H),7.21(t,J＝7.8Hz,1H),6.95(d,J＝7.6Hz,1H),6.61(d,J＝8.1Hz,1H),5.69-5.60(m,1H),5.01(d,J＝10.1Hz,1H),4.89(d,J＝17.0Hz,1H),4.74(d,J＝6.0Hz,2H),3.41(s,6H)3.03–2.98(m,2H),2.89-2.86(m,1H),2.78–2.71(m,4H),2.32-2.31(m,1H),1.97-1.89(m,4H). 1H NMR(400MHz,DMSO-d 6,D 2O)δ8.87(s,1H),7.84(t,J＝7.9Hz,1H),7.74(s,1H),7.47(d,J＝8.2Hz,1H),7.31(d,J＝7.7Hz,1H),7.23(t,J＝7.8Hz,1H),6.96(d,J＝7.7Hz,1H),6.64(d,J＝8.0Hz,1H),5.70-5.60(m,1H),5.03(d,J＝10.2Hz,1H),4.89(d,J＝17.0Hz,1H),4.74(d,J＝6.0Hz,2H),3.36(d,J＝2.1Hz,6H),3.03–2.98(m,2H),2.93-2.86(m,1H),2.78–2.69(m,4H),2.33-2.32(m,1H),1.99-1.84(m,4H).LCMS(E+)m/z:573.1[M+H] +,HPLC method B:R T＝6.24min,purity:93.9％.
实施例11：化合物11的合成
Figure PCTCN2023070285-appb-000110
步骤1：化合物11-2的合成：
在干燥的单口瓶中加入底物4-2(2g,14.17mmol)、化合物11-1(3.17g,17.01mmol)和碳酸钾(4.89g,35.44mmol)，用DMF(10mL)溶解，升温至90℃，反应1h，LC-MS监测。反应完成后，用水和乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，无水硫酸钠干燥，有机溶剂减压浓缩，得到粗产物，无需纯化，产物可直接用于下步反应，得到化合物11-2(4g,crude)，为黄色固体。LCMS(E+)m/z:308.3[M+H] +。
步骤2：化合物11-3的合成：
在干燥的单口瓶中加入底物11-2(4g,13.01mmol)用HCl/1,4-二氧六环(10mL)溶解，室温反应1h，LC-MS监测。反应完成后，减压浓缩有机相，用饱和碳酸钠和乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，无水硫酸钠干燥，有机溶剂减压浓缩，得到粗产物，无需纯化，产物可直接用于下步反应，得到化合物11-3(2.5g,crude)，为黄色固体。LCMS(E+)m/z:208.2[M+H] +。
步骤3：化合物11-4的合成：
在干燥的单口瓶中加入底物11-3(1g,4.83mmol)，化合物4-1的游离碱(724.81mg,5.79 mmol)用MeOH/AcOH(10mL)溶解，室温反应1h，LC-MS监测。反应完成后，减压浓缩有机相，用饱和碳酸钠和乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，无水硫酸钠干燥，有机溶剂减压浓缩，残余杂质用MPLC除去，得到化合物11-4(1.5g,4.27mmol,88.42％产率)，为黄色固体。LCMS(E+)m/z:317.4[M+H] +。
步骤4：化合物11-5的合成：
在干燥的单口瓶中加入底物11-4(1.5g,4.74mmol)，Pd/C(172.73mg,1.42mmol)用MeOH/AcOH(10mL)溶解，H 2置换3次，H 2下室温反应3h，LC-MS监测。反应完成后，用硅藻土过滤，滤液减压浓缩，无需纯化，粗产品可直接用于下步反应，得到化合物11-5(1.5g,crude)，为黑色油状物。LCMS(E+)m/z:287.4[M+H] +。
步骤5：化合物11的合成：
在干燥的单口瓶中加入底物11-5(35mg,122.20μmol)，化合物IM-5(49.67mg,122.20μmol)用THF(3mL)溶解后，加入PTSA(52.61mg,305.50μmol)，升温至110℃，搅拌反应5h，LC-MS监测。反应完成后，减压浓缩有机溶剂，用水和乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，无水硫酸钠干燥，减压浓缩，残余杂质用MPLC除去，得到化合物11(21mg,32.56μmol,26.65％产率)，为绿色固体。 1H NMR(600MHz,DMSO-d 6)δ10.13(s,1H),8.80(s,1H),7.80(s,1H),7.59(s,2H),7.30(d,J＝7.7Hz,1H),6.91(d,J＝8.5Hz,2H),6.59(d,J＝7.9Hz,1H),5.64(ddt,J＝18.3,13.6,6.4Hz,1H),5.00(d,J＝10.1Hz,1H),4.90(d,J＝17.0Hz,1H),4.75(s,2H),3.37(s,6H),3.13–3.09(m,6H),2.98–2.91(m,2H),2.80–2.63(m,4H),2.63–2.55(m,2H),2.03–2.00(m,2H),1.77–1.60(m,2H),1.43–1.39(m,1H),1.29–1.25(m,1H).LCMS(ESI +)m/z:629.5[M+H] +,HPLC method B:R T＝5.94min,purity:97.5％
实施例12：化合物12的合成
Figure PCTCN2023070285-appb-000111
步骤1：化合物12-2的合成：
在干燥的单口瓶中加入底物IM-2-1(416mg,2.1mmol)和DMSO(8mL)，搅拌溶解后，加入碳酸钾(387mg,2mmol)和化合物12-1(310mg,2mmol)，加热至90℃反应，LC-MS监测。反应结束后，冷却至室温，加入水搅拌至有固体析出，滤出固体，水洗涤三次，少量的甲醇洗三次，烘干得到产物12-2(200mg,30％产率)，LCMS(ESI +)m/z:334.2[M+H] +。
步骤2：化合物12-3的合成：
在干燥的单口瓶中加入底物12-2(200mg,0.6mmol)和DCM(5mL)，搅拌溶解后，缓慢加入TFA(5mL)，LC-MS监测。反应结束后，减压浓缩。向残余物中加入甲醇(5mL)，搅拌溶解后加入多聚甲醛(180mg)和乙酸(500μL)，室温下搅拌30min，加入氰基硼氢化钠(75mg,1.2mmol)，升温至50℃反应，LC-MS监控。反应结束后，冷却至室温，滤除固体，有机相减压浓缩，中压液相色谱(碱法)纯化得到化合物12-3(120mg,81％产率)，LCMS(ESI +)m/z:248.2[M+H] +。
步骤3：化合物12-4的合成：
在干燥的单口瓶中加入底物12-3(120mg,0.48mmol)和甲醇(5mL)，搅拌溶解后，加入Pd/C(12mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，有机相进行减压蒸馏浓缩，得到产物12-4(90mg,86.4％产率)。LCMS(ESI +)m/z:218.2[M+H] +。
步骤4：化合物12的合成：
在干燥的单口瓶中加入底物IM-1(52mg,0.15mmol)，THF(3mL)，搅拌溶解后，加入m-CPBA(121mg,0.6mmol,纯度85％)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA (98mg,758.28μmol)，搅拌10min后，加入12-4(33mg,151.86μmol)，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物12(13mg,15.38％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.09(s,1H),8.82(s,1H),8.00-7.98(m,1H),7.78(d,J＝8.1Hz,1H),7.61(d,J＝7.7Hz,2H),7.28(dd,J＝8.8,2.6Hz,1H),6.74(d,J＝8.7Hz,1H),5.69-5.63(m,1H),5.32(s,1H),4.99(dd,J＝10.3,1.5Hz,1H),4.82(d,J＝17.1Hz,1H),4.68(d,J＝6.0Hz,2H),3.97(s,1H),3.39(s,1H),3.25–3.21(m,2H),2.80-2.74(m,2H),2.32(s,3H),2.22(s,3H),1.83(d,J＝9.3Hz,1H),1.72(d,J＝9.2Hz,1H),1.46(s,6H). 1H NMR(600MHz,DMSO-d 6,D 2O)δ8.82(s,1H),8.03-8.01(m,1H),7.76(d,J＝8.1Hz,1H),7.65–7.57(m,2H),7.29(dd,J＝8.7,2.7Hz,1H),6.76(d,J＝8.7Hz,1H),5.70-5.63(m,1H),5.03-5.01(m,1H),4.82(d,J＝17.1Hz,1H),4.69(d,J＝5.8Hz,2H),3.98(s,1H),3.42(s,1H),3.27–3.23(m,2H),2.81–2.74(m,2H),2.31(s,3H),2.23(s,3H),1.86(d,J＝9.5Hz,1H),1.75(d,J＝9.4Hz,1H),1.47(s,6H).LCMS(E+)m/z:527.3[M+H] +,HPLC method B:R T＝6.53min,purity:94.6％.
实施例13：化合物13的合成
Figure PCTCN2023070285-appb-000112
步骤1：化合物13-2的合成：
在干燥的单口瓶中加入底物13-1(1.03g,10mmol)和DMSO(15mL)，搅拌溶解后，加入碳酸钾(2g,14mmol)和对氟硝基苯(1.43g,10mmol)，加热至100℃反应，LC-MS监测。反应结束后，冷却至室温，滤除固体，滤液浓缩后用中压液相色谱(酸法)纯化得到化合物13-2(2g,89％产率)，LCMS(ESI +)m/z:225.1[M+H] +。
步骤2：化合物13-3的合成：
在干燥的单口瓶中加入底物13-2(44mg,0.2mmol)和THF(2mL)，搅拌溶解后，加入HATU(84mg,0.22mmol)和DIPEA(28mg,0.22mmol)，室温搅拌30min后，加入甲胺盐酸盐(67mg,1mmol)，升温至65℃反应，LC-MS监测。反应结束后，冷却至室温，乙酸乙酯萃取三次，有机相减压浓缩，得到粗产物13-3(24mg,crude)，LCMS(ESI +)m/z:238.3[M+H] +。
步骤3：化合物13-4的合成：
在干燥的单口瓶中加入底物13-3(24mg,0.1mmol)和甲醇(4mL)，搅拌溶解后，加入Pd/C(5mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土过滤除去Pd/C，有机相进行减压蒸馏浓缩，得到粗产物13-4(18mg,crude)，LCMS(ESI +)m/z:208.2[M+H] +。
步骤4：化合物13的合成：
在干燥的单口瓶中加入底物IM-1(31mg,86μmol)，THF(2mL)，搅拌溶解后，加入m-CPBA(26mg,129μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(55mg,425μmol)，搅拌10min后，加入13-4(18mg,85μmol)，升温至80℃反应，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物13(7mg,16％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.05(s,1H),8.79(s,1H),7.97-4.95(m,1H),7.75(d,J＝4.4Hz,2H),7.60(d,J＝7.6Hz,1H),7.49(s,2H),6.59(d,J＝8.0Hz,2H),5.69-5.62(m,1H),5.33(s,1H),5.04–4.95(m,1H),4.98(d,J＝10.0Hz,1H),4.82(d,J＝17.0Hz,1H),4.67(d,J＝5.9Hz,2H),3.78(s,2H),3.41-3.40(m,2H),2.60(d,J＝4.7Hz,3H),1.46(s,6H),1.08(t,J＝7.0Hz,3H). 1H NMR(600MHz,DMSO-d 6,D 2O)δ8.80(s,1H),8.00-7.97(m,1H),7.82(d,J＝4.4Hz,1H),7.72(s,1H),7.61(d,J＝7.6Hz,1H),7.49(s,1H),6.59(d,J＝8.2Hz,2H),5.69-5.63(m,1H),5.02(d,J＝10.2Hz,1H),4.83(d,J＝17.0Hz,1H),4.68(s,2H),3.81(s,2H),3.42(q,J＝7.0Hz,2H),2.62(d,J＝4.6Hz,3H),1.47(s,6H),1.08(t,J＝7.0Hz,3H).LCMS(E+)m/z:517.3[M+H] +,HPLC method B:R T＝6.25min,purity:90.5％.
实施例14：化合物14的合成
Figure PCTCN2023070285-appb-000113
步骤1：化合物14-1的合成：
在干燥的单口瓶中加入底物13-2(44mg,0.2mmol)和THF(2mL)，搅拌溶解后，加入HATU(84mg,0.22mmol)和DIPEA(28mg,0.22mmol)，室温搅拌30min后，加入N-甲基哌嗪(40mg,0.4mmol)，升温至65℃反应，LC-MS监测。反应结束后，冷却至室温，乙酸乙酯萃取三次，有机相减压浓缩，得到粗产物14-1(50mg,crude)，LCMS(ESI +)m/z:307.2[M+H] +。
步骤2：化合物14-2的合成：
在干燥的单口瓶中加入底物14-1(50mg,0.16mmol)和甲醇(4mL)，搅拌溶解后，加入Pd/C(5mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，有机相减压浓缩，得到产物14-2(40mg,crude)，LCMS(ESI +)m/z:277.2[M+H] +。
步骤3：化合物14的合成：
在干燥的单口瓶中加入底物IM-1(38mg,106μmol)，THF(2mL)，搅拌溶解后，加入m-CPBA(40mg,200μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(65mg,500μmol)，搅拌10min后，加入化合物14-2(40mg,crude)，升温至80℃反应，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物14(12.2mg,17.58％产率)。 1H NMR(600MHz,Methanol-d 4)δ8.76(s,1H),7.96-7.93(m,1H),7.76(s,1H),7.62(d,J＝7.7Hz,1H),7.43(d,J＝8.4Hz,2H),6.68(d,J＝8.6Hz,2H),5.73-5.67(m,1H),5.03(d,J＝10.2Hz,1H),4.91(d,J＝10.2Hz,1H),4.80(d,J＝5.8Hz,2H),4.59(s,2H),4.23(s,2H),3.76(s,2H),3.44(q,J＝7.0Hz,2H),2.90-2.85(m,4H),2.62(s,3H),1.57(s,6H),1.18(t,J＝7.0Hz,3H).LCMS(E+)m/z:586.4[M+H] +,HPLC method B:R T＝6.23min,purity:91.9％.
实施例15：化合物15的合成
Figure PCTCN2023070285-appb-000114
步骤1：化合物15-2的合成：
向单口反应瓶中加入底物15-1(2.44g,12.50mmol)，NBS(3.33g,18.70mmol)，AIBN(0.2g,1.21mmol)，用CCl 4(20ml)溶解，氮气置换3次后，将反应瓶置于油浴85℃下氮气保护下搅拌过夜，TLC监测。减压浓缩去除溶剂，无需纯化，粗产品可直接用于下步反应，得到粗产品15-2(3g,11.03mmol,88.1％产率)。
步骤2：化合物15-3的合成：
向15-2(3g,11.03mmol)粗品中加入4-氨基-1-甲基哌啶(1.8g,15.77mmol)溶解后，将反应升温至40℃搅拌2小时，LC-MS监测至反应结束。反应物经柱层析分离得化合物15-3(1.3g,4.72mmol,42.86％产率)，LCMS(ESI +)m/z:276.1[M+H] +。
步骤3：化合物15-4的合成：
向反应瓶中加入底物15-3(0.6g,1.70mmol)用无水甲醇(10ml)溶解，加入Pd/C(10％ wt.)(60mg)。使用氢气置换3次后，室温搅拌过夜，LC-MS监测。反应结束后，使用硅藻土过滤，滤液经减压浓缩后经柱层析分离纯化得化合物15-4(474mg,1.92mmol,88.7％产率)，LCMS(ESI +)m/z:246.2[M+H] +。
步骤4：化合物15的合成：
向微波反应管中加入底物IM-5(39.3mg,0.097mmol)，底物15-4(47.43mg,0.19mmol)，无水乙腈(4ml)，TFA(55.18mg,0.48mmol)。微波90℃反应4小时，LC-MS监测。反应结束后，用饱和NaHCO 3溶液淬灭，乙酸乙酯萃取3次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，减压浓缩后中压液相色谱纯化得产物15(10mg,0.017mmol,17.6％产率)。 1H NMR(600MHz,Chloroform-d 6)δ8.89(s,1H),8.03(s,1H),7.79(d,J＝8.3Hz,1H),7.75(s,1H),7.71–7.68(m,1H),7.56(d,J＝8.2Hz,1H),7.31(d,J＝7.7Hz,1H),6.74(d,J＝8.0Hz,1H),5.69–5.63(m,1H),5.05–4.96(m,2H),4.92(d,J＝6.3Hz,2H),4.37(s,3H),3.34(s,6H),3.11(s,2H),2.44(s,3H),2.33(s,2H),2.05(s,2H),1.89(d,J＝12.5Hz,2H).LCMS(ESI +)m/z:588.1[M+H] +,HPLC method B:R T＝5.34min,purity:96.5％
实施例16：化合物16的合成
Figure PCTCN2023070285-appb-000115
步骤1：化合物16-2的合成：
在干燥的单口瓶中加入吡啶(7.91g,100mmol)和乙腈(40mL)，搅拌均匀，加入2-氯乙酰胺(9.35g,100mmol)，升温至90℃反应过夜。反应结束后，冷却至室温，滤出固体，石油醚洗涤三次，用乙醇进行重结晶，得到产物16-2(10.8g,62％产率)。
步骤2：化合物16-4的合成：
在干燥的单口瓶中加入底物16-2(3.6g,21.15mmol)和正丁醇(50mL)，搅拌均匀，加入16-3(1.82g,7.05mmo)，醋酸(1.5mL)和哌啶(2.5mL)，升温至120℃反应，LC-MS监测。反应结束后，滤出固体，滤液用CHCl 3(含5％MeOH)萃取三次，有机相减压浓缩，所得到的固体用甲醇重结晶，得到产物16-4(1.92g,91％产率)，LCMS(ESI +)m/z:298.2[M+H] +。
步骤3：化合物16-5的合成：
在干燥的单口瓶中加入底物16-4(500mg,1.68mmol)和甲醇(15mL)，搅拌均匀，加入Pd/C(50mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物16-5(310mg,69％产率)，LCMS(ESI +)m/z:268.1[M+H] +。
步骤4：化合物16的合成：
在干燥的单口瓶中加入底物IM-1(70mg,200μmol)，四氢呋喃(4mL)，搅拌溶解后，加入m-CPBA(60mg,300μmol,纯度85％)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(129.24mg,1.00mmol)，搅拌10min后，加入16-5(53.47mg,200.00μmol)，微波80℃反应，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物16(6.3mg,5.22％产率)。 1H NMR(600MHz,DMSO-d 6)δ11.81(s,1H),10.43(s,1H),8.93(s,1H),8.08-8.05(m,1H),7.81-7.78(m,3H),7.64(d,J＝7.7Hz,1H),7.58(d,J＝8.2Hz,2H),6.22(s,1H),5.71-5.65(m,1H),5.35(s,1H),5.01(d,J＝10.2Hz,1H),4.84(d,J＝17.2Hz,1H),4.69(d,J＝5.9Hz,2H),3.47(s,2H),3.09(s,1H),3.00(s,2H),1.84(s,2H),1.56(s,2H),1.47(s,6H). 1H NMR(600MHz,DMSO-d 6,D 2O)δ8.93(s,1H),8.09-8.06(m,1H),7.81-7.76(m,3H),7.65(d,J＝7.6Hz,1H)7.59(d,J＝8.4Hz,2H),6.27(s,1H),5.71-5.64(m,1H),5.04(d,J＝10.2Hz,1H),4.84(d,J＝17.1Hz,1H),4.70(d,J＝5.8Hz,2H),3.93(s,2H),3.16(s,1H),3.02(s,2H),1.88(s,2H),1.57(s,2H),1.48(s,6H).LCMS(E+)m/z:577.3[M+H] +,HPLC method B:R T＝5.96min,purity:95.5％.
实施例17：化合物17的合成
Figure PCTCN2023070285-appb-000116
步骤1：化合物17-3的合成
向干燥的圆底烧瓶依次将17-2(130mg,0.88mmol)，DIPEA(0.58g,4.4mmol)溶于DMSO(1ml)，随后加入17-1(1.1mmol,148mmol)。室温下搅拌2小时。LC-MS监测，反应结束后用水稀释，乙酸乙酯萃取三次，饱和食盐水洗，有机相用无水硫酸钠干燥后减压浓缩，无需纯化，直接投入下一步反应，得到的粗产物17-3(150mg,0.64mmol,65.6％产率)，LCMS(ESI+)m/z:235.1[M+H]+。
步骤2：化合物17-4的合成
向50mL圆底烧瓶中加入17-3(150mg,0.64mmol)，催化量的Pd/C(45mg)和MeOH(3mL)，氢气置换3次，在氢气环境下室温下剧烈搅拌12小时。LC-MS监测，硅藻土过滤，滤液减压浓缩并通过中压液相色谱纯化得到化合物17-4(100mg,0.49mmol,76.1％产率)，LCMS(ESI+)m/z:205.1[M+H]+。
步骤3：化合物17的合成
向溶有IM-1(51mg,0.18mmol)的THF(1mL)溶液中加入m-CPBA(39mg,0.18mmol)，室温搅拌10分钟。LC-MS监测，TLC监测，原料消失后加入DIPEA(122mg,0.75mmol)，室温搅拌20分钟。随后加入17-4(51mg,0.15mmol)，室温搅拌1小时。LC-MS监测，反应结束后加入水，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥后减压浓缩，得到的粗产物通过酸性制备高效液相色谱法纯化得到化合物17(26mg,0.05mmol,35.5％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.13(s,1H),8.81(s,1H),8.04(s,1H),7.74(d,J＝7.6Hz,1H),7.60(d,J＝7.7Hz,1H),7.57(s,1H),6.82(d,J＝8.5Hz,2H),5.69-5.64(m,1H),5.32(s,1H),4.99(d,J＝10.2Hz,1H),4.82(d,J＝17.1Hz,1H),4.68(s,2H),4.42(s,2H),2.82–2.72(m,2H),1.84(s,4H),1.49(s,1H),1.46(s,6H),1.38(s,2H).LCMS(E+)m/z:514.5[M+H] +,HPLC method A:R T＝7.13min,purity:>99.9％.
实施例18：化合物18的合成
Figure PCTCN2023070285-appb-000117
步骤1：化合物18-2的合成
在干燥的单口瓶中加入18-1(4g,20mmol)溶于DCM(50ml)，室温下加入TFA(25mL)，搅拌30分钟，LC-MS监测。反应结束后真空除去溶剂，用水稀释，乙酸乙酯萃取三次，有机相用无水硫酸钠干燥后减压浓缩，得到的粗产物18-2无需纯化，直接投入下一步反应(1.8g,crude)。LCMS(ESI+)m/z:100.1[M+H] +
步骤2：化合物18-4的合成
在干燥的单口瓶中将18-2(1g,7mmol)溶于DMSO(10mL)，依次加入18-3(1g,10.5mmol)，K 2CO 3(4.8g,35mmol)。反应混合物在室温下搅拌过夜。LC-MS监测，反应结束后用100mL水稀释，乙酸乙酯萃取三次，有机相用无水硫酸钠干燥后减压浓缩，得到的粗产物18-4无需纯化，直接投入下一步反应(1.35g,crude)。LCMS(ESI+)m/z:221.1[M+H] +
步骤3：化合物18-6的合成
干燥的圆底烧瓶中，将18-4(1.35g,6.2mmol)、18-5(1.47g,7.4mmol)溶于甲醇(15ml)，加入醋酸(1ml)后室温反应30分钟。随后加入氰基硼氢化钠(584mg,9.3mmol)，升温至60℃，搅拌4小时。LC-MS监测，反应结束后减压除去溶剂，加入水，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥后减压浓缩，得到的粗产物18-6(1.75g,crude)，LCMS(ESI+)m/z:403.2[M+H] +
步骤4：化合物18-7的合成
向50mL圆底烧瓶中加入18-6(1.75g,4.4mmol)，催化量的Pd/C(200mg)和MeOH(20mL)。在氢气氛围下室温搅拌12小时。LC-MS监测。反应结束后将反应液减压浓缩，残余物用柱层析纯化得到化合物18-7(1.46g,3.9mmol,90.2％产率)。LCMS(ESI+)m/z:373.3[M+H] +。
步骤5：化合物18-8的合成
干燥的圆底烧瓶中，将18-7(1.46g,3.9mmol)溶于THF中，0℃下N 2保护下缓慢加入2M LiAlH 4的四氢呋喃溶液(10ml，20mmol)。反应温度升至65℃，并在该温度下搅拌6小时，LC-MS监测。反应结束后将反应温度降至0℃，依次加入水(0.76ml)、10％NaOH的水溶液(0.76ml)、水淬灭(2.3ml)。室温下搅拌30分钟，无水Na 2SO 4干燥，并用硅藻土过滤。将滤液真空浓缩后通过柱层析纯化得到化合物18-8(736mg,2.5mmol,65.6％产率)。LCMS(ESI+)m/z:287.2[M+H] +。
步骤6：化合物18的合成
按照实施例17中步骤3的合成方法，将步骤3中的17-4(51mg,0.15mmol)替换为18-8(42.1mg,0.15mmol)，合成方法相同，得到化合物18(20mg,33.6μmol,22.9％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.19(s,1H),8.84(s,1H),8.04(s,1H),7.76(d,J＝8.1Hz,1H),7.62(d,J＝7.7Hz,3H),7.00(d,J＝8.5Hz,3H),5.70–5.63(m,1H),5.00(d,J＝10.2Hz,1H),4.83(d,J＝17.2Hz,1H),4.68(s,3H),4.45(s,1H),3.82(s,6H),3.37(s,2H),2.92(s,3H),2.69(t,J＝12.4Hz,2H),2.23(d,J＝64.4Hz,2H),2.07(d,J＝11.8Hz,1H),1.78–1.63(m,2H),1.47(s,6H). LCMS(ESI+)m/z:596.4[M+H] +。HPLC method A:R T＝6.35min,purity:96.9％
实施例19：化合物19的合成
Figure PCTCN2023070285-appb-000118
步骤1：化合物19-2的合成：
在干燥的单口瓶中加入底物19-1(200mg,0.1mmol)和DMSO(5mL)，搅拌下，加入碳酸钾(470mg,3.4mmol)和对氟硝基苯(141mg,1mmol)，升温至110℃反应，LC-MS监测。反应结束后，冷却至室温，加入碘甲烷(141mg,1mmol)，升温至90℃反应，LC-MS监测。反应结束后，冷却至室温，滤除固体，滤液浓缩后用中压液相色谱(碱法)纯化得到产物19-2(50mg,19％产率)，LCMS(ESI +)m/z:262.3[M+H] +。
步骤2：化合物19-3的合成：
在干燥的单口瓶中加入底物19-2(50mg,0.19mmol)和甲醇(2mL)，搅拌溶解后，加入Pd/C(10mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，有机相进行减压蒸馏浓缩，得到产物19-3(40mg,crude)，LCMS(ESI +)m/z:232.2[M+H] +。
步骤3：化合物19的合成：
在干燥的单口瓶中加入底物IM-1(52mg,0.15mmol)，四氢呋喃(3mL)，搅拌溶解后，加入m-CPBA(121mg,0.6mmol,纯度85％)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(95.17mg,736.42μmol)，搅拌10min后，加入19-3(40mg,crude)，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物19(35mg,40.96％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.11(s,1H),8.80(s,1H),7.99-7.96(m,1H),7.75(s,1H),7.62(d,J＝7.7Hz,1H),7.47(s,2H),6.62(d,J＝8.3Hz,2H),6.19(d,J＝23.4Hz,1H),5.69-5.63(m,1H),4.99(d,J＝10.2Hz,1H),4.83(d,J＝17.1Hz,1H),4.67(s,2H),3.89(s,2H),3.51(s,2H),3.29(s,3H),2.97(s,3H),2.22(s,2H),2.00(d,J＝7.8Hz,2H),1.76(d,J＝14.1Hz,1H),1.46(s,6H). 1H NMR(600MHz,DMSO-d 6,D 2O)δ8.81(s,1H),8.01-7.98(m,1H),7.74(s,1H),7.62(d,J＝7.8Hz,1H),7.49(s,2H),6.64(d,J＝8.4Hz,2H),5.69-5.63(m,1H),5.02(d,J＝10.2Hz,1H),4.83(d,J＝17.0Hz,1H),4.68(s,2H),3.90-3.88(m,2H),3.43-3.42(m,4H),3.14–3.12(m,1H),2.97(s,3H),2.23–2.20(m,2H),2.03(s,2H),1.82(s,1H),1.47(s,6H).LCMS(E+)m/z:541.3[M+H] +,HPLC method B:R T＝5.65min,purity:93.2％.
实施例20：化合物20的合成
Figure PCTCN2023070285-appb-000119
步骤1：化合物20-2的合成：
在干燥的单口瓶中加入底物20-1(136mg,1mmol)和DMSO(8mL)，搅拌溶解后，加入碳酸钾(332mg,2.4mmol)和对氟硝基苯(141mg,1mmol)，加热至90℃反应，LC-MS监测。反应结束后，冷却至室温，加入水搅拌有固体析出，滤出固体，水洗涤三次，少量的甲醇洗三次，烘干得到产物20-2(180mg,81.8％产率)，LCMS(ESI +)m/z:221.2[M+H] +。
步骤2：化合物20-3的合成：
在干燥的单口瓶中加入底物20-2(180mg,0.82mmol)和甲醇(7mL)，搅拌下，加入Pd/C(18 mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，有机相减压浓缩，得到粗产物20-3(120mg,crude)，LCMS(ESI+)m/z:191.1[M+H]+。
步骤3：化合物20的合成：
在干燥的单口瓶中加入底物IM-1(52mg,0.15mmol)，四氢呋喃(3mL)，搅拌溶解后，加入m-CPBA(121mg,0.6mmol,纯度85％)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(98mg,758.28μmol)，搅拌10min后，加入化合物20-3(46mg,151.86μmol)，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物20(25mg,0.05mmol,33.84％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.07(s,1H),8.80(s,1H),8.02-8.01(m,1H),7.75(s,1H),7.60(d,J＝7.6Hz,1H),7.53–7.38(m,2H),6.62(d,J＝7.2Hz,2H),5.70-5.63(m,1H),5.33(s,1H),5.00(d,J＝10.2Hz,1H),4.83(d,J＝17.1Hz,1H),4.69(s,2H),4.60(s,1H),4.53(s,1H),3.75(d,J＝6.8Hz,1H),3.67(d,J＝7.4Hz,1H),3.50(d,J＝9.0Hz,1H),2.95(d,J＝9.0Hz,1H),1.93(d,J＝9.2Hz,1H),1.84(d,J＝8.8Hz,1H),1.47(s,6H). 1H NMR(600MHz,DMSO-d 6,D 2O)δ8.82(s,1H),8.05-8.02(m,1H),7.74(s,1H),7.62(d,J＝7.6Hz,1H),7.52(s,2H),6.63(d,J＝7.6Hz,2H),5.70-5.64(m,1H),5.03(d,J＝10.2Hz,1H),4.84(d,J＝17.0Hz,1H),4.70(s,2H),4.62(s,1H),4.51(s,1H),3.78(d,J＝7.4Hz,1H),3.68(d,J＝7.6Hz,1H),3.52(d,J＝9.4Hz,1H),2.96(d,J＝9.2Hz,1H),1.95(d,J＝9.0Hz,1H),1.86(d,J＝9.0Hz,1H),1.48(s,6H).LCMS(E+)m/z:500.1[M+H] +,HPLC method B:R T＝6.69min,purity:99.6％.
实施例21：化合物21的合成
Figure PCTCN2023070285-appb-000120
步骤1：化合物21-3的合成：
在干燥的单口瓶中加入底物21-1(3.0g,19.34mmol)和DMSO(20mL)，搅拌溶解后，加入碳酸钾(2.67g,19.34mmol)和21-2(3.82g,19.34mmol)，加热至100℃反应3小时，LC-MS监测。反应结束后，冷却至室温，加入水搅拌有固体析出，滤出固体，水洗涤三次，少量的甲醇洗三次，烘干得到产物21-3(6g,18.00mmol,93.06％产率)，LCMS(ESI +)m/z:334.4[M+H] +。
步骤2：化合物21-4的合成：
在干燥的单口瓶中加入底物21-3(6.67g,20.01mmol)，TFA(2.28g,20.01mmol)和DCM(50mL)搅拌溶解后，室温反应18小时，LC-MS监测。反应结束后，减压浓缩，加入水和乙酸乙酯萃取3次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，过滤后减压浓缩滤液，得到粗产物21-4(4g,crude)，LCMS(ESI +)m/z:234.3[M+H] +。
步骤3：化合物21-6的合成：
在干燥的单口瓶中加入底物21-4(3g,12.86mmol)，化合物21-5(1.46g,12.86mmol)，NaBH 3CN(1.2g,19.11mmol)和甲醇(30mL)搅拌溶解后，升温60℃反应18小时，LC-MS监测。反应结束后，减压浓缩，加入水和乙酸乙酯萃取3次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，过滤后减压浓缩滤液，用中压液相色谱纯化得到粗产物21-6(3g,9.08mmol,70.60％yield)，LCMS(ESI +)m/z:331.4[M+H] +。
步骤4：化合物21-7的合成：
在干燥的单口瓶中加入底物21-6(200mg,0.61mmol)和甲醇(10mL)，搅拌均匀，加入Pd/C(40mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物21-7(50mg,27.5％产率)，LCMS(ESI +)m/z:301[M+H] +。
步骤5：化合物21的合成：
在干燥的单口瓶中加入底物IM-1(17.8mg,50.08μmol)，四氢呋喃(2mL)，搅拌溶解后，加入m-CPBA(12.9mg,74.74μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(6.47mg,50.08μmol,8.72μL)，搅拌10min后，加入化合物21-7(15.05mg,50.08μmol)，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物21(5mg,8.16μmol,16.29％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.09(s,1H),8.82(s,1H),7.99–7.97(m,1H),7.78(d,J＝7.8Hz,1H),7.60(d,J＝7.8Hz,1H),7.57(s,1H),7.29–7.27(m,1H),6.72(d,J＝9.0Hz,1H),5.69–5.63(m,1H),5.33(s,1H),4.99(d,J＝10.2Hz,1H),4.82(d,J＝17.4Hz,1H),4.68(d,J＝5.9Hz,2H),3.95(s,1H),3.66(s,1H),3.20(q,J＝8.4Hz,2H),3.02(d,J＝8.4Hz,1H),2.68(d,J＝7.8Hz,2H),2.56(d,J＝9.0Hz,1H),2.22(s,3H),2.16(s,1H),2.12(s,3H),1.91(s,1H),1.88(s,1H),1.74-1.69(m,4H),1.46(s,6H),1.38–1.25(m,2H).LCMS(ESI +)m/z:610.6[M+H] +.HPLC method A:R T＝4.45min,purity:99.5％.
实施例22：化合物22的合成
Figure PCTCN2023070285-appb-000121
步骤1：化合物22-2的合成：
在干燥的单口瓶中加入底物22-1(158mg,499.31μmol)，TFA(3mL)和DCM(3mL)搅拌溶解后，室温反应18小时，LC-MS监测。反应结束后，减压浓缩，加入水和乙酸乙酯萃取3次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，过滤后减压浓缩滤液，得到粗产物22-2(100mg,crude)，LCMS(ESI +)m/z:217.3[M+H] +。
步骤2：化合物22-3的合成：
在干燥的单口瓶中加入底物22-2(100mg,462.28μmol)和DMSO(4mL)，搅拌溶解后，加入碳酸钾(97mg,701.88μmol)和化合物4-2(72mg,510.28μmol)，加热至100℃反应3小时，LC-MS监测。反应结束后，冷却至室温，加入水搅拌有固体析出，滤出固体，水洗涤三次，少量的甲醇洗三次，烘干得到产物22-3(150mg,444.56μmol,96.17％产率)，LCMS(ESI +)m/z:338.4[M+H] +。
步骤3：化合物22-4的合成：
在干燥的单口瓶中加入底物22-3(50mg,148.19μmol)和甲醇(4mL)，搅拌均匀，加入Pd/C(8mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物22-4(20mg,65.06μmol,43.90％产率)，LCMS(ESI +)m/z:308.4[M+H] +。
步骤4：化合物22的合成：
在干燥的单口瓶中加入底物22-4(24.70mg,80.34μmol)，四氢呋喃(2mL)，搅拌溶解，加入DIPEA(51.91mg,401.68μmol,69.96μL)和化合物IM-6(30mg,80.34μmol)，室温反应1h，LC-MS监测。反应结束后，减压浓缩，残余物用中压液相色谱纯化得到化合物22(5mg,7.30μmol,9.09％yield)。 1H NMR(600MHz,DMSO-d 6)δ10.10(s,1H),8.80(s,1H),8.02(s,1H),7.79-7.78(m,1H),7.61-7.55(m,3H),7.18-7.17(m,5H),6.77(d,J＝8.4Hz,2H),5.70–5.63(m,1H),5.33(s,1H),5.00(d,J＝10.3Hz,1H),4.83(d,J＝17.2Hz,1H),4.68(s,2H),3.59(d,J＝11.3Hz,2H),3.38(s,2H)3.08(d,J＝11.3Hz,2H),2.87(d,J＝10.6Hz,2H),2.26(d,J＝10.7Hz,2H),2.09(s,2H),1.70(d,J＝12.2Hz,1H),1.60(d,J＝12.1Hz,1H),1.47(s,6H). 1H NMR(600MHz,DMSO-d 6,D 2O)δ8.81(s,1H),8.03(s,1H),7.78(s,1H),7.61-7.58(m,3H),7.18(s,5H),6.78(d,J＝8.6Hz,2H),5.69-5.63(m,1H),5.02(d,J＝10.3Hz,1H),4.83(d,J＝17.1Hz,1H),4.68(s,2H),3.64(s,2H),3.39(s,2H),3.08(d,J＝10.9Hz,2H),2.87(d,J＝10.8Hz,2H),2.28(s,2H),2.10(s,2H),1.70(d,J＝11.9Hz,1H),1.60(d,J＝12.2Hz,1H),1.47(s,6H).LCMS(E+)m/z:617.4[M+H] +,HPLC method B:R T＝6.01min,purity:90.1％.
实施例23：化合物23的合成
Figure PCTCN2023070285-appb-000122
步骤1：化合物23-1的合成：
在干燥的单口瓶中加入底物22-1(200mg,632.04μmol)和甲醇(5mL)，搅拌均匀，加入Pd/C(20mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物23-1(140mg,crude)，LCMS(ESI +)m/z:227.3[M+H] +。
步骤2：化合物23-2的合成：
在干燥的单口瓶中加入底物23-1(128.31mg,566.97μmol)和DMSO(3mL)，搅拌溶解后，加入碳酸钾(96.74mg,0.7mmol)和对氟硝基苯(4-2,80mg,566.97μmol)，加热至90℃反应6小时，LC-MS监测。反应结束后，冷却至室温，加入水搅拌有固体析出，滤出固体，水洗涤三次，少量的甲醇洗三次，烘干得到产物23-2(120mg,crude)，LCMS(ESI +)m/z:348.4[M+H] +。
步骤3：化合物23-3的合成：
在干燥的单口瓶中加入底物23-2(69mg,198.61μmol)，TFA(3mL)和DCM(3mL)搅拌溶解后，室温反应18小时，LC-MS监测。反应结束后，减压浓缩，加入水和乙酸乙酯萃取3次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，过滤后减压浓缩滤液，得到粗产物23-3(49mg,crude)，LCMS(ESI +)m/z:248.3[M+H] +。
步骤4：化合物23-4的合成：
在干燥的单口瓶中加入底物23-3(49.46mg,0.2mmol)，加入甲醇(4mL)搅拌溶解后，加入甲醛(34.06mg,1.00mmol)和乙酸(11mL)，搅拌10分钟后，加入NaCNBH 3(25.14mg,400.00μmol)，升温至50℃反应2小时，LC-MS监测。反应结束后，减压浓缩，加入水和乙酸乙酯萃取3次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，过滤后减压浓缩滤液，得 到粗产物用中压液相色谱纯化得到化合物23-4(30mg,114.80μmol,57.40％产率)，LCMS(ESI +)m/z:262.3[M+H] +。
步骤5：化合物23-5的合成：
在干燥的单口瓶中加入底物23-4(30mg,114.80μmol)和甲醇(3mL)，搅拌均匀，加入Pd/C(8mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物23-5(20mg,crude)，LCMS(ESI +)m/z:232.3[M+H] +。
步骤6：化合物23的合成：
在干燥的单口瓶中加入底物23-5(18.58mg,80.34μmol)，四氢呋喃(2mL)，搅拌溶解，加入DIPEA(51.91mg,401.68μmol,69.96μL)和化合物IM-6(30mg,80.34μmol)，室温反应1h，LC-MS监测。反应结束后，减压浓缩，残余物用中压液相色谱纯化得到化合物23(8mg,13.58μmol,16.91％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.09(s,1H),8.80(s,1H),8.04(s,1H),7.76(d,J＝8.0Hz,1H),7.61-7.56(m,3H),6.73(d,J＝8.6Hz,2H),5.65-5.63(m,1H),5.33(s,1H),4.99(dd,J＝10.3,1.6Hz,1H),4.83(dd,J＝17.1,1.7Hz,1H),4.68(d,J＝6.1Hz,2H),3.57(d,J＝11.2Hz,2H),3.46(s,3H),3.00(dd,J＝11.3,4.8Hz,2H),2.88(s,2H),2.17-2.09(m,4H),1.66-1.54(m,2H),1.46(s,6H). 1H NMR(600MHz,DMSO-d 6,D 2O)δ8.80(s,1H),8.05(s,1H),7.76(s,1H),7.62–7.55(m,3H),6.75(s,2H),5.67-5.63(m,1H),5.02-5.01(m,1H),4.84–4.82(m,1H),4.68(d,J＝6.1Hz,2H),3.71(s,3H),3.58(d,J＝11.4Hz,2H),2.99-2.89(m,4H),2.12-2.04(m,4H),1.66–1.57(m,2H),1.47(s,6H).LCMS(E+)m/z:541.3[M+H] +,HPLC method B:R T＝5.29min,purity:94.1％.
实施例24：化合物24的合成
Figure PCTCN2023070285-appb-000123
步骤1：化合物24-2的合成：
在干燥的单口瓶中加入底物24-1(2g,10.25mmol)和四氯化碳(40mL)，搅拌均匀，加入NBS(2.74g,15.37mmol)和AIBN(269.24mg,1.64mmol)，氮气置换五次，升温至70℃搅拌回流12小时，LC-MS监测。反应结束后，减压浓缩，残余物用中压液相色谱纯化得到24-2(1.3g,4.74mmol,46.3％产率)，LCMS(ESI +)m/z:274.1[M+H] +。
步骤2：化合物24-4的合成：
在干燥的单口瓶中加入底物24-2(200mg,0.73mmol)和24-3(166.42mg,1.46mmol)，升温至50℃搅拌回流1小时，TLC监测。反应结束后，减压浓缩，加入少量乙酸乙酯，过滤 掉固体，滤液减压浓缩，残余物用中压液相色谱纯化得到24-4(180mg,0.65mmol,89.67％产率)，LCMS(ESI +)m/z:276.1[M+H] +。
步骤3：化合物24-5的合成：
在干燥的单口瓶中加入底物24-4(180mg,0.65mmol)和甲醇(3mL)，搅拌均匀，加入Pd/C(36mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物24-5(100mg,crude)，LCMS(ESI +)m/z:246.3[M+H] +。
步骤4：化合物24-6的合成：
向单口反应瓶中加入底物IM-3(0.2g,0.51mmol)，无水THF(5ml)搅拌溶解，加入m-CPBA(208.2g,1.02mmol,纯度85％)，常温下搅拌40分钟，LC-MS监测。反应物经减压浓缩后用中压液相色谱分离，得到化合物24-6(130mg,0.31mmol,60.0％产率)，LCMS(ESI +)m/z:423.5[M+H] +。
步骤5：化合物24的合成：
在干燥的微波管中加入底物24-6(31mg,73.38μmol)，24-5(36.00mg,146.75μmol)，TsOH(50.48mg,293.50μmol)和无水ACN(0.3mL)，搅拌溶解后，封管，微波加热至110℃反应4小时，LC-MS监测。反应结束后，冷却至室温，加入饱和碳酸氢钠溶液淬灭，用乙酸乙酯萃取3次，合并有机相，用饱和食盐水洗，有机相用无水硫酸钠干燥，减压浓缩后用中压液相色谱分离得到产物24(1.5mg,2.55μmol,3.48％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.52(s,1H),8.91(s,1H),8.46(s,1H),7.95(s,1H),7.77(dd,J＝8.2,2.2Hz,1H),7.55(d,J＝8.3Hz,1H),7.40(d,J＝7.9Hz,1H),6.64(d,J＝8.0Hz,1H),5.66(ddt,J＝16.4,10.2,6.0Hz,1H),5.02(dd,J＝10.3,1.6Hz,1H),4.90(dd,J＝17.1,1.6Hz,1H),4.80(s,2H),4.42(s,2H),4.08–3.97(m,1H),3.38(s,6H),2.89(d,J＝11.1Hz,2H),2.22(s,3H),2.07(t,J＝11.8Hz,2H),1.82(dd,J＝12.1,3.8Hz,2H),1.71(d,J＝13.3Hz,2H).LCMS(ESI +)m/z:588.1[M+H] +,HPLC method B:R T＝5.22min,purity:92.3％
实施例25：化合物25的合成
Figure PCTCN2023070285-appb-000124
步骤1：化合物25-2的合成：
在干燥的单口瓶中加入底物25-1(0.5g,2.36mmol)和DMSO(10mL)，搅拌溶解后，加入碳酸钾(651.05mg,4.71mmol)和对氟硝基苯(4-2,332.33mg,2.36mmol)，加热至100℃反应6小时，LC-MS监测。反应结束后，冷却至室温，加入水搅拌有固体析出，滤出固体，水洗涤三次，少量的甲醇洗三次，烘干得到产物25-2(0.7g,2.10mmol,89.15％产率)，LCMS(ESI +)m/z:333.4[M+H] +。
步骤2：化合物25-3的合成：
在干燥的单口瓶中加入底物25-2(0.5g,1.50mmol)和甲醇(10mL)，搅拌均匀，加入Pd/C(910mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物25-3(0.4g,1.32mmol,87.91％产率)，LCMS(ESI +) m/z:304.2[M+H] +。
步骤3：化合物25-4的合成：
在干燥的单口瓶中加入底物25-3(150mg,0.5mmol)和THF(4mL)，搅拌溶解后，加入LiAlH 4(112.57mg,2.97mmol)，加热至65℃反应2小时，LC-MS监测。反应结束后，冷却至室温，加入水搅拌有固体析出，滤出固体，水洗涤三次，少量的甲醇洗三次，烘干得到产物25-4(80mg,0.36mmol,74.46％产率)，LCMS(ESI +)m/z:218.3[M+H] +。
步骤4：化合物25的合成：
在干燥的单口瓶中加入底物IM-1(21.70mg,99.88μmol)，四氢呋喃(2mL)，搅拌溶解后，加入m-CPBA(25.86mg,149.82μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(64.54mg,499.40μmol,86.98μL)，搅拌10min后，加入25-4(21.70mg,99.88μmol)，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物25(9mg,16.06μmol,16.08％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.07(s,1H),8.80(s,1H),8.03-8.01(m,1H),7.75(s,1H),7.60(d,J＝7.8Hz,1H),7.51(s,2H),6.80(d,J＝8.4Hz,2H),5.70-5.99(m,1H),5.31(s,1H),5.00-4.98(m,1H),4.84-4.81(m,1H),4.68(d,J＝6.0Hz,2H),4.20(s,2H),2.47-2.44(m,2H),2.30-2.28(m,2H),2.06(s,3H),1.88(d,J＝6.6Hz,2H),1.83(d,J＝6.0Hz,2H),1.46(s,6H).LCMS(ESI +)m/z:527.3[M+H] +.HPLC method B:R T:7.83min,purity:94.0％.
实施例26：化合物26的合成
Figure PCTCN2023070285-appb-000125
步骤1、化合物26-3的合成：
在干燥的微波管中加入底物26-1(1.27g,12.72mmol)，26-2(2g,8.48mmol)，t-BuONa(1g,10.17mmol)和甲苯(15mL)，搅拌溶解后，用N 2除氧10min，加入Pd 2(dba) 3(778mg,0.85mmol)，BINAP(264.6mg,0.43mmol)，再用N 2除氧10min，封管后，油浴加热至110℃反应12小时，LC-MS监测。反应结束后，冷却至室温，硅藻土过滤，滤液减压蒸馏后用中压液相色谱分离得到产物26-3(1.57g,6.15mmol,72.58％产率)，LCMS(ESI +)m/z:255.2[M+H] +。
步骤2、化合物26-5的合成：
在干燥的单口瓶中加入底物26-3(650mg,2.55mmol)用丙酮(6mL)和水(7mL)溶解，加入26-4(637.87mg,3.82mmol)，Pd(OAc) 2(57.25mg,0.25mmol)和碳酸钠(542mg,2.55mmol)，氮气置换3次，氮气保护下加热至50℃反应12小时，LC-MS监测。反应结束后，冷却至室温，加入水和乙酸乙酯萃取三次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，残余杂质用中压液相色谱纯化得到产物26-5(240mg,807.13μmol,31.68％产率)，LCMS(ESI +)m/z:298.4[M+H] +。
步骤3：化合物26-6的合成：
在干燥的单口瓶中加入底物26-5(240mg,807.13μmol)和甲醇(10mL)，搅拌均匀， 加入Pd/C(30mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物26-6(160mg,598.43μmol,74.14％产率)，LCMS(ESI +)m/z:268.4[M+H] +。
步骤4：化合物26的合成：
在干燥的单口瓶中加入底物IM-1(47.5mg,132.89μmol)，四氢呋喃(0.5mL)，搅拌溶解后，加入m-CPBA(54mg,265.79μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(85.88mg,664.47μmol,115.74μL)，搅拌10min后，加入化合物26-6(21.70mg,99.88μmol)，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物26(1.5mg,2.35μmol,1.77％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.37(s,1H),8.90(s,1H),8.11(t,J＝8.2Hz,1H),7.80(dd,J＝8.3,6.2Hz,2H),7.63(d,J＝7.7Hz,1H),7.58(d,J＝8.4Hz,2H),7.54(d,J＝8.5Hz,2H),7.01(d,J＝8.8Hz,2H),5.68(ddt,J＝16.5,10.3,5.9Hz,1H),5.35(s,1H),5.01(d,J＝10.2Hz,1H),4.88–4.79(m,1H),4.70(d,J＝6.0Hz,2H),3.18(t,J＝5.0Hz,4H),2.47(t,J＝5.0Hz,4H),2.23(s,3H),1.47(s,6H).LCMS(ESI)m/z:577.3[M+H] +,HPLC method B:R T＝9.20min,purity:97.8％.
实施例27：化合物27的合成
Figure PCTCN2023070285-appb-000126
步骤1：化合物27-2的合成：
在干燥的单口瓶中加入底物27-1(400mg,2.02mmol)和DMSO(5mL)，搅拌溶解后，加入碳酸钾(836.50mg,6.05mmol)和对氟硝基苯(313.14mg,2.22mmol)，加热至65℃反应10小时，LC-MS监测。反应结束后，加入水和乙酸乙酯萃取3次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，减压浓缩后用中压液相色谱纯化得到产物27-2(633mg,1.98mmol,98.24％产率)，LCMS(ESI +)m/z:320.4[M+H] +。
步骤2：化合物27-3的合成：
在干燥的单口瓶中加入底物27-2(633mg,1.98mmol)和甲醇(5mL)，搅拌均匀，加入Pd/C(60mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物27-3(459mg,crude)，LCMS(ESI +)m/z:290.4[M+H] +。
步骤3：化合物27-4的合成：
在干燥的单口瓶中加入底物27-3(150mg,518.36μmol)和THF(5mL)，搅拌溶解后，加入LiAlH 4(19.67mg,518.36μmol)，加热至65℃反应4小时，LC-MS监测。反应结束后，在冰浴下加入10％氢氧化钠水溶液淬灭，过滤后，滤液减压浓缩后用中压液相色谱纯化得到产物27-4(36.59mg,180.00μmol,34.73％产率)，LCMS(ESI +)m/z:204.3[M+H] +。
步骤4：化合物27的合成：
在干燥的单口瓶中加入底物IM-1(53.61mg,0.15mmol)，四氢呋喃(0.5mL)，搅拌溶解后，加入m-CPBA(38.83mg,225.00μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(96.93mg,750.00μmol,130.63μL)，搅拌10min后，加入化合物27-4(36.59mg,180.00μmol)，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物27(18.9 mg,33.81μmol,22.54％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.10(s,1H),8.80(s,1H),8.03(s,1H),7.77(s,1H),7.60(d,J＝7.7Hz,3H),6.72(d,J＝8.5Hz,2H),5.70–5.61(m,1H),5.32(s,1H),4.99(dd,J＝10.3,1.6Hz,1H),4.83(dd,J＝17.1,1.7Hz,1H),4.68(d,J＝6.1Hz,2H),3.64(s,2H),3.46(d,J＝10.9Hz,2H),2.51(s,3H),2.05–1.98(m,2H),1.57(s,1H),1.46(s,6H).LCMS(E+)m/z:513.2[M+H] +,HPLC Method B R T＝11.32min,purity:92.6％.
实施例28：化合物28的合成
Figure PCTCN2023070285-appb-000127
步骤1：化合物28-2的合成：
在干燥的单口瓶中加入底物28-1(332mg,1.56mmol)和DMSO(5mL)，搅拌溶解后，加入碳酸钾(648.42mg,4.69mmol)和对氟硝基苯(242.73mg,1.72mmol)，加热至80℃反应12小时，LC-MS监测。反应结束后，加入水和乙酸乙酯萃取3次，合并有机相，饱和食盐水洗，无水硫酸钠干燥，减压浓缩后用中压液相色谱纯化得到产物28-2(512mg,1.54mmol,98.20％产率)，LCMS(ESI +)m/z:334.4[M+H] +。
步骤2：化合物28-3的合成：
在干燥的单口瓶中加入底物28-2(640mg,1.92mmol)和甲醇(5mL)，搅拌均匀，加入Pd/C(60mg)，氢气置换五次，室温搅拌反应，LC-MS监测。反应结束后，用硅藻土除去Pd/C，甲醇洗涤，有机相减压浓缩，得到产物28-3(570mg,crude)，LCMS(ESI +)m/z:304.2[M+H] +。
步骤3：化合物28-4的合成：
在干燥的单口瓶中加入底物28-3(200mg,659.20μmol)和THF(5mL)，搅拌溶解后，加入LiAlH 4(125.08mg,3.30mmol)，加热至65℃反应4小时，LC-MS监测。反应结束后，在冰浴下加入10％氢氧化钠水溶液淬灭，过滤后，滤液减压浓缩后用中压液相色谱纯化得到产物28-4(89mg,409.55μmol,62.13％产率)，LCMS(ESI +)m/z:218.2[M+H] +。
步骤4：化合物28的合成：
在干燥的单口瓶中加入底物IM-1(53.61mg,0.15mmol)，四氢呋喃(1mL)，搅拌溶解后，加入m-CPBA(38.83mg,225.00μmol)，室温反应1h，LC-MS监测。反应结束后，加入DIPEA(96.93mg,750.00μmol,130.63μL)，搅拌10min后，加入化合物28-4(32.60mg,150.00μmol)，LC-MS监测。反应完成后，减压浓缩，残余物用中压液相色谱(碱法)纯化得到化合物28(26.8mg,48.90μmol,32.60％产率)。 1H NMR(600MHz,DMSO-d 6)δ10.11(s,1H),8.81(s,1H),8.04(s,1H),7.75(s,1H),7.65–7.43(m,3H),6.79(d,J＝8.6Hz,2H),5.66(ddt,J＝16.4,10.2,6.0Hz,1H),5.32(s,1H),4.99(dd,J＝10.3,1.4Hz,1H),4.82(dd,J＝17.1,1.5Hz,1H),4.68(d,J＝5.9Hz,2H),3.35(d,J＝10.5Hz,2H),3.24(s,2H),2.81(d,J＝10.3Hz,2H),2.25(s,3H),2.00–1.94(m,2H),1.66(d,J＝7.6Hz,2H),1.46(s,6H).LCMS(E+)m/z:527.4[M+H] +,HPLC Method B R T＝10.46min,purity:96.1％.
实施例29：化合物29的合成
Figure PCTCN2023070285-appb-000128
步骤1：化合物29-2的合成
在干燥的单口瓶中加入底物29-1(233mg,891.63μmol)，甲醇(10mL)，搅拌溶解后，加入钯炭(10mg)，氢气置换五次，室温反应2小时，LC-MS监测。反应结束后，用硅藻土过滤，甲醇洗涤，有机相进行减压蒸馏浓缩，得到化合物29-2(200mg,866μmol)，LCMS(ESI)m/z:232.2[M+H] +。
步骤2：化合物29的合成
在干燥的单口瓶中，加入底物IM-1(38.63mg,108.07μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(30mg,162.10μmol)，室温下反应一个小时，再向反应液中加入N,N-二异丙基乙胺(20.95mg,162.10μmol)和29-2(25mg,0.18mmol)，室温反应过夜。LC-MS监测，反应结束后将反应液冷却至室温，减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物29(18mg,33.29μmol)。LCMS(ESI)m/z:541.4[M+H] +，HPLC Method B R T＝5.14min,purity>90.0％。 1H NMR(600MHz,Methanol-d 4)δ8.76(s,1H),7.95–7.93(m,1H),7.76–7.74(m,1H),7.62(d,J＝7.8Hz,1H),7.44(s,2H),6.70–6.62(m,2H),5.72–5.68(m,1H),5.03(d,J＝10.2Hz,1H),4.95–4.88(m,2H),4.80(d,J＝6.0Hz,2H),4.00(d,J＝8.6Hz,1H),3.94–3.89(m,1H),3.53–3.45(m,4H),3.35(s,3H),3.22–3.18(m,1H),2.41–2.33(m,2H),2.16–2.12(m,2H),1.98–1.95(m,1H),1.57(s,6H).
实施例30：化合物30的合成
Figure PCTCN2023070285-appb-000129
步骤1：化合物30-2的合成
在干燥的单口瓶中加入底物30-1(200mg,912.24μmol)溶于四氢呋喃(3mL)，加入三乙胺(461mg,4.56mmol)和三氟甲磺酸三氟乙酯(317mg,1.37mmol)。室温度升至80℃搅拌过夜。LC-MS监测。反应结束后减压蒸馏浓缩，得到化合物30-2(235mg,780μmol)，LCMS(ESI)m/z:302.1[M+H] +。
步骤2：化合物30-3的合成
在干燥的单口瓶中加入底物30-2(235mg,780μmol)，甲醇(3mL)，搅拌溶解后，加入钯炭(25mg)，氢气置换五次，室温反应2小时，LC-MS监测。反应结束后，用硅藻土过滤，甲醇洗涤，有机相进行减压蒸馏浓缩，得到化合物30-3(183mg,675μmol)，LCMS(ESI)m/z:272.2[M+H] +。
步骤3：化合物30的合成
在干燥的单口瓶中，加入底物IM-1(27mg,75.54μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(23mg,113.31μmol)，室温下反应一个小时，再向反应液中加入N,N-二异丙基乙胺(48.81mg,377.1μmol)和30-3(30.7mg,113.31μmol)，室温反应过夜。LC-MS监测，反应结束后将反应液冷却至室温，减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物30(10.7mg,18.43μmol)。LCMS(ESI)m/z:581.3[M+H] +，HPLC Method B Rt＝8.07min,purity>89.7％. 1H NMR(600MHz,DMSO-d 6)δ10.11(s,1H),8.80(s,1H),7.99-7.96(m,1H),7.75(s,1H),7.62(d,J＝7.8Hz,1H),7.47(s,2H),6.62(d,J＝8.4Hz,2H),6.19(d,J＝23.4Hz,1H),5.69-5.63(m,1H),4.99(d,J＝10.2Hz,1H),4.83(d,J＝17.4Hz,1H),4.67(s,2H),3.89(s,2H),3.51(s,2H),3.29(s,3H),2.97(s,3H),2.22(s,2H),2.00(d,J＝7.8Hz,2H),1.76(d,J＝14.4Hz,1H),1.46(s,6H).D 2O: 1H NMR(600MHz,DMSO-d 6)δ8.81(s,1H),8.01-7.98(m,1H),7.74(s,1H),7.62(d,J＝7.8Hz,1H),7.49(s,2H),6.64(d,J＝8.4Hz,2H),5.69-5.63(m,1H),5.02(d,J＝10.2Hz,1H),4.83(d,J＝17.4Hz,1H),4.68(s,2H),3.90-3.88(m,2H),3.43-3.42(m,4H),3.14–3.12(m,1H),2.97(s,3H),2.23–2.20(m,2H),2.03(s,2H),1.82(s,1H),1.47(s,6H)。
实施例31：化合物31的合成
Figure PCTCN2023070285-appb-000130
步骤1：化合物31-2的合成
在干燥的单口瓶中加入底物31-1(2.0g,7.80mmol)，甲醇(10mL)，搅拌溶解后，加入钯炭(200mg)，氢气置换五次，室温反应2小时，LC-MS监测。反应结束后，用硅藻土过滤，甲醇洗涤，有机相进行减压蒸馏浓缩，得到化合物31-2(1.6g,7.07mmol)，LCMS(ESI)m/z:232.2[M+H] +。
步骤2：化合物31的合成
在干燥的单口瓶中，加入底物IM-1(100mg,279.78μmol)，加入四氢呋喃(1.5mL)溶解。加入间氯过氧苯甲酸(120mg,559.55μmol)，室温下反应一个小时，再向反应液中加入N,N-二异丙基乙胺(180.79mg,1.40mmol)和31-2(126.61mg,559.55μmol)，室温反应过夜。LC-MS监测，反应结束后将反应液冷却至室温，减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物31(40mg,74.68μmol)。LCMS(ESI)m/z:536.2[M+H] +,HPLC method B:R T＝8.58min,purity:>96.1％. 1H NMR(600MHz,DMSO-d 6)δ10.33(s,1H),8.89(s,1H),8.04–8.02(m,1H),7.80–7.71(m,3H),7.61(d,J＝7.8Hz,1H),7.23(d,J＝8.4Hz,2H),6.81(d,J＝7.4Hz,1H),6.73–6.71(m,1H),6.70–6.67(m,2H),5.68–5.64(m,1H),5.32(s,1H),5.00(d,J＝10.2Hz,1H),4.83(d,J＝17.4Hz,1H),4.69(d,J＝6.0Hz,2H),4.27–4.26(m,2H),3.68–3.66(m,2H),1.46(s,7H)
实施例32：化合物32的合成
Figure PCTCN2023070285-appb-000131
步骤1：化合物32-1的合成
在干燥的单口瓶中将4-1(800mg，6.39mmol)溶于乙醇(10mL)，依次加入氢氧化钾(717mg，12.78mmol)，对硝基苯甲醛(1.16g，7.67mmol)。反应混合物室温搅拌过夜。LC-MS监测，反应结束后减压浓缩，残余物经MPLC纯化得到化合物32-1(863mg，3.34mmol)。LCMS(ESI)m/z:259.1[M+H] +。
步骤2：化合物32-2的合成
在单口瓶中加入三甲基碘化亚砜(2.94g，13.37mmol)、氢氧化钠(1.07g，26.73mmol)溶于四氢呋喃(20mL)，置换氮气，室温下反应1小时。加入32-1(863mg，3.34mmol)，再次置换氮气，65℃下搅拌1小时，LCMS监测反应。反应结束后减压浓缩除去溶剂，加入乙酸乙酯与水萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物32-2(493mg，1.81mmol)。LCMS(ESI)m/z:273.1[M+H] +。
步骤3：化合物32-3的合成
在干燥的单口瓶中加入底物32-2(493mg，1.81mmol)，甲醇(5mL)，搅拌溶解后，加入钯炭(50mg)，氢气置换五次，室温反应2小时，LC-MS监测。反应结束后，用硅藻土过滤，甲醇洗涤，有机相进行减压蒸馏浓缩，得到化合物32-3(395mg,1.63mmol)，LCMS(ESI)m/z:243.2[M+H] +。
步骤4：化合物32的合成
在干燥的单口瓶中，加入底物IM-1(36mg,100.72μmol)，加入四氢呋喃(1.5mL)溶解。加入间氯过氧苯甲酸(26mg,151μmol)，室温下反应一个小时，再向反应液中加入N,N-二异丙基乙胺(65mg,504μmol)和32-3(48.8mg,201μmol)，室温反应过夜。LC-MS监测，反应结束后将反应液冷却至室温，减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物32(7.2mg,13.05μmol)。LCMS(ESI)m/z:552.3[M+H] +,HPLC method A:R T＝9.90min,purity:>99.1％. 1H NMR(600MHz,DMSO-d 6)δ10.26(s,1H),8.88(s,1H),8.04–8.02(m 1H),7.75(d,J＝8.4Hz,1H),7.62(d,J＝8.4Hz,3H),7.26(d,J＝8.4Hz,2H),5.67–5.65(m,1H),5.34(s,1H),5.00(d,J＝10.2Hz,1H),4.83(d,J＝17.4Hz,1H),4.69(d,J＝6.0Hz,2H),2.96–2.93(m,2H),2.77–2.70(m,1H),2.49(d,J＝12.6Hz,1H),2.45–2.43(m,1H),2.21–2.20(m,1H),2.01-1.97(m,1H),1.92–1.89(m,2H),1.87–1.79(m,J＝2.6Hz,1H),1.67–1.62(m,1H),1.59(d,J＝9.6Hz,1H),1.46(s,6H)。
实施例33：化合物33的合成
Figure PCTCN2023070285-appb-000132
步骤1：化合物33-2的合成
在干燥的单口瓶中将23-5(100mg,404.38μmol)溶于四氢呋喃(5ml)，依次加入三乙胺(409.19mg,4.04mmol)，33-1(140.79mg,606.57μmol)。反应混合物80℃搅拌3小时。反应结束后减压浓缩，残余物用MPLC纯化得到化合物33-2(70mg,212.56μmol)。LCMS(ESI)m/z:330.1[M+H] +。
步骤2：化合物33-3的合成
向50mL圆底烧瓶中加入33-2(80mg，0.24mmol)溶解于甲醇(3mL)。加入催化量的钯炭(10mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物33-3(20mg,0.17mmol,)。LCMS(ESI)m/z:300.2[M+H] +。
步骤3：化合物33的合成
在干燥的单口瓶中加入底物IM-6(48.55mg,130.00μmol)，四氢呋喃(3mL)，搅拌溶解后，加入N,N-二异丙基乙胺(84.01mg,650.00μmol)和33-3(44mg,146.99μmol)，室温反应2小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物33(20mg,31.77μmol)。LCMS(ESI)m/z:609.2[M+H] +,HPLC method A:R T＝5.8min,purity:96.7％. 1H NMR(600MHz,DMSO-d 6)δ10.08(s,1H),8.80(s,1H),8.01-8.00(m,1H),7.77(s,1H),7.60(d,J＝7.8Hz,1H),7.54–7.40(m,2H),6.75(d,J＝8.4Hz,2H),5.67-5.63(m,1H),5.37(s,1H),5.00(d,J＝10.2Hz,1H),4.83(d,J＝16.8Hz,1H),4.69(s,2H),3.47(s,2H),3.08(s,4H),2.95(s,2H),2.70(s,2H),2.07(s,2H),1.66-1.59(m,2H),1.47(s,6H).D 2O: 1H NMR(600MHz,DMSO-d 6)δ8.81(s,1H),8.02-8.01(m,1H),7.75(s,1H),7.61(d,J＝7.2Hz,1H),7.54(s,2H),6.75(d,J＝7.8Hz,2H),5.68-5.64(m,1H),5.02(d,J＝10.2Hz,1H),4.84(d,J＝16.8Hz,1H),4.70(s,2H),3.52(d,J＝10.8Hz,2H),3.09–3.04(m,4H),2.94(d,J＝10.2Hz,2H),2.69(d,J＝10.2Hz,2H),2.08(s,2H),1.67-1.58(m,2H),1.48(s,6H)。
实施例34：化合物34的合成
Figure PCTCN2023070285-appb-000133
步骤1：化合物34-1的合成
在干燥的单口瓶中加入底物23-5(100mg,404.38μmol)，溶于N,N-二甲基甲酰胺(3mL)中，加入2-溴乙基甲基醚(84mg,606μmol)，碳酸钾(111.77mg,808.76μmol)和碘化钾(13.43mg,80.88μmol)，85℃下反应3小时。LC-MS监测。反应结束和将反应液冷却至室温，加水，乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物34-1(65mg,212.86μmol)。LCMS(ESI)m/z:306.2[M+H] +。
步骤2：化合物34-2的合成
向50mL圆底烧瓶中加入34-1(80mg,261.98μmol)溶解于甲醇(3mL)。加入催化量的钯炭(10mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物34-2(29mg,0.10mmol)。LCMS(ESI)m/z:276.2[M+H] +。
步骤3：化合物34的合成
在干燥的单口瓶中加入底物IM-6(37mg,99.08μmol)，四氢呋喃(3mL)，搅拌溶解后，加入N,N-二异丙基乙胺(64.03mg,495.41μmol)和34-2(28.65mg,104.04μmol)，室温反应 2小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物34(10mg,17.10μmol)。LCMS(ESI)m/z:585.3[M+H] +,HPLC method A:R T＝5.4min,purity:96.4％. 1H NMR(600MHz,DMSO-d 6)δ10.09(s,1H),8.80(s,1H),8.03(s,1H),7.76(d,J＝7.2Hz,1H),7.61–7.56(m,3H),6.75(s,2H),5.69-5.63(m,1H),5.32(s,1H),4.99(d,J＝10.2Hz,1H),4.83(d,J＝17.4,1H),4.68(d,J＝4.2Hz,2H),3.54(d,J＝10.2Hz,2H),3.40(s,4H),3.18(s,3H),3.06-2.98(m,4H),2.44-2.29(m,2H),2.13(s,2H),1.68–1.57(m,2H),1.46(s,6H).D 2O: 1H NMR(600MHz,DMSO-d 6)δ8.81(s,1H),8.03(s,1H),7.76-7.75(m,1H),7.61(d,J＝7.8Hz,1H)7.56–7.50(m,2H),6.77(s,2H),5.69-5.63(m,1H),5.01(d,J＝10.2Hz,1H),4.83(d,J＝16.8Hz,,1H),4.68(d,J＝4.8Hz,2H),3.63(s,2H),3.55(d,J＝10.8Hz,2H),3.41(s,2H),3.18(s,3H),3.05-2.96(m,4H),2.45-2.36(m,2H),2.14(s,2H),1.66-1.63(m,2H),1.47(s,6H)。
实施例35：化合物35的合成
Figure PCTCN2023070285-appb-000134
步骤1：化合物35-2的合成
100mL干燥的圆底烧瓶中，氮气保护下加入35-1(2.59g，11mmol)，加入四氢呋喃(25mL)溶解。温度降至-78℃，n-LiBu(5.5mL，2M in THF，11mmol)缓慢滴加进反应体系。-78℃下搅拌30分钟后，加入N-甲基-4-哌啶酮(1.24g,11.00mmol)。缓慢升至室温后搅拌1小时。用饱和NH 4Cl溶液淬灭反应，乙酸乙酯萃取3次。有机相用无水硫酸钠干燥后减压浓缩，残余物用柱层析纯化得到化合物35-2(2.63g,9.73mmol)。LCMS(ESI)m/z:270.1[M+H] +。
步骤2：化合物35-3的合成
在干燥的微波管中，氮气保护下加入底物35-2(675.4mg,2.5mmol)、氨水(1.75g,50.00mmol)、氧化亚铜(17.9mg,0.125mmol)、碘化钠(242.66mg,1.62mmol)、碳酸钾(69.10mg,0.5mmol)和N,N’-二甲基乙二胺(22mg,0.25mmol)，然后加入乙二醇(5mL)。在氮气环境下，110℃加热反应12小时。LC-MS监测，反应结束后反应体系冷却至室温，过滤，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物35-3(346mg,1.68mmol)。LCMS(ESI)m/z:207.2[M+H] +。
步骤3：化合物35的合成
在干燥的单口瓶中，加入底物IM-1(71.5mg,0.2mmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(51.8mg,0.3mmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(129.2mg,1.00mmol)和35-3(61.9mg,0.3mmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物35(16mg,31.03μmol)。 1H NMR(600MHz,DMSO-d 6)δ10.27(s,1H),8.88(s,1H),8.06-8.04(m,1H),7.76(d,J＝8.4Hz,1H),7.65(d,J＝26.4Hz,3H),7.43(d,J＝8.4Hz,2H),5.67–5.64(m,1H),5.34(s,1H),5.00(d,J＝10.2Hz,1H),4.83(d,J＝17.4Hz,1H),4.73(s,1H),4.68(d,J＝6.0Hz,2H),2.58(d,J＝10.8Hz,2H),2.40–2.38(m,2H),2.23(s,3H),2.01–1.91(m,2H),1.61–1.55(m,2H),1.46(s,6H).LCMS(ESI)m/z:516.3[M+H] +，HPLC R T＝4.68min,purity>92.7％。
实施例36：化合物36的合成
Figure PCTCN2023070285-appb-000135
步骤1：化合物36-2的合成
在干燥的单口瓶中加入36-1(5g,44.22mmol)，溶于二氯甲烷(50mL)。依次加入三乙胺(8.95g,88.44mmol,12.33mL)，4-二甲氨基吡啶(540.22mg,4.42mmol)和二碳酸二叔丁酯(10.62g,48.64mmol)。反应混合物在室温下搅拌2小时。LC-MS监测。反应结束后加水稀释，二氯甲烷萃取3次。有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物36-2(4.62g,21.67mmol)。LCMS(ESI)m/z:214.1[M+H] +。
步骤2：化合物36-3的合成
向50mL圆底烧瓶中加入36-2(4.62g,21.67mmol)溶解于乙醇(3mL)。加入催化量的钯炭(400mg)，在氢气氛围下室温搅拌6小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用乙醇洗涤两次，滤液减压浓缩得到化合物36-3(3.85g,21.01mmol)。LCMS(ESI)m/z:184.1[M+H] +。
步骤3：化合物36-4的合成
在干燥的单口瓶中加入底物36-3(3.85g,21.01mmol)溶于甲醇(40mL)，加入甲醛(1.26g,42.03mmol)和乙酸(2mL)，室温搅拌30分钟。加入氰基硼氢化钠(3.30g,52.54mmol)，温度升至50℃反应12小时。反应结束后，用水稀释，加入饱和碳酸氢钠调至碱性，二氯甲烷萃取三次。有机相经过无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物36-4(4.01g,18.98mmol)。LCMS(ESI)m/z:212.1[M+H] +。
步骤4：化合物36-5的合成
在干燥的单口瓶中加入36-4(4.01g,18.98mmol)溶于二氯甲烷(40ml)。加入三氟乙酸(21.64g,189.81mmol,14.53mL)，室温下反应30分钟。LC-MS监测，反应结束后减压蒸馏除去溶剂，得到化合物36-5(1.86g,16.73mmol)。LCMS(ESI)m/z:112.1[M+H] +.
步骤5：化合物36-6的合成
在干燥的单口瓶中将36-5(1.86g,16.73mmol)溶于二甲亚砜(15ml)，依次加入对氟硝基苯(2.36g,16.73mmol)，碳酸钾(5.78g,41.84mmol)。反应混合物在100℃搅拌过夜。LC-MS监测，反应结束后加水稀释，乙酸乙酯萃取三次，有机相用无水硫酸钠干燥后减压浓缩，残余物经柱层析纯化得到化合物36-6(3.56g,15.33mmol)。LCMS(ESI)m/z:233.1[M+H] +。
步骤6：化合物36-7的合成
向干燥的单口瓶中加入36-6(3.56g,15.33mmol)溶解于乙醇(35mL)。加入催化量的 钯炭(350mg)，在氢气氛围下室温搅拌3小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用乙醇洗涤两次，滤液减压浓缩得到化合物36-7(2.95g,14.59mmol)。LCMS(ESI)m/z:203.1[M+H] +。
步骤7：化合物36的合成
在干燥的单口瓶中，加入底物IM-1(45.51mg,225.00μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(38.83mg,225.00μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(96.93mg,750.00μmol)和36-7(53.61mg,0.15mmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物36(9mg,17.59μmol)。LCMS(ESI)m/z:512.2[M+H] +，HPLC Method B R T＝7.26min,purity>98.0％. 1H NMR(600MHz,DMSO-d 6)δ10.39(s,1H),8.91(s,1H),8.09(s,1H),7.87(s,1H),7.82(d,J＝8.4Hz,2H),7.78(d,J＝8.4Hz,1H),7.72(d,J＝9.0Hz,2H),7.64(d,J＝7.8Hz,1H),7.45(s,1H),5.71-5.66(m,1H),5.34(s,1H),5.00(d,J＝10.2Hz,1H),4.84(d,J＝17.4Hz,1H),4.70(d,J＝6.0Hz,2H),2.70(s,6H),1.47(s,6H)。
实施例37：化合物37的合成
Figure PCTCN2023070285-appb-000136
步骤1：化合物37-1的合成
在干燥的单口瓶中加入底物23-5(150mg,606.57μmol)，溶于N,N-二甲基甲酰胺(3mL)中，加入1,2-氟溴乙烷(84mg,661.65μmol)，碳酸钾(165mg,1.19mmol)和碘化钾(20mg,120.5μmol)，90℃下反应3小时。LC-MS监测。反应结束和将反应液冷却至室温，加水，过滤，甲醇洗涤。有机相减压浓缩得到化合物37-1(80mg,272.7μmol)。LCMS(ESI)m/z:394.2[M+H] +。
步骤2：化合物37-2的合成
向50mL圆底烧瓶中加入37-1(80mg,272.7μmol)溶解于甲醇(3mL)。加入催化量的钯炭(10mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物37-2(50mg,0.19mmol,)。LCMS(ESI)m/z:264.2[M+H] +。
步骤3：化合物37的合成
在干燥的单口瓶中加入底物IM-6(42mg,112.47μmol)，四氢呋喃(3mL)，搅拌溶解后，加入N,N-二异丙基乙胺(72.68mg,562.36μmol)和37-2(30mg,113.92μmol)，室温反应2小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物37(25mg,42.65μmol)。LCMS(ESI)m/z:585.3[M+H] +,HPLC method A:R T＝5.4min,purity:96.4％. 1H NMR(600MHz,Chloroform-d)δ8.74(s,1H),7.82(s,1H),7.71(d,J＝7.8Hz,1H),7.36(s,2H),7.26(d,J＝7.2Hz,1H),6.76(s,2H),5.67-5.60(m,1H),4.97(d,J＝10.2Hz,1H),4.87(d,J＝17.4Hz,1H),4.67(d,J＝6.0Hz,2H),4.55-4.74(m,2H),3.94(brs,1H),3.57-3.55(m,2H),3.10-2.93(m,4H),2.70-2.51(m,4H),2.12(s,2H),1.67(s,2H),1.51(s,6H),1.25(brs,1H).
实施例38：化合物38的合成
Figure PCTCN2023070285-appb-000137
步骤1：化合物38-1的合成
在干燥的单口瓶中加入IM-4(500mg,1.57mmol)溶于二氯甲烷(3ml)。加入三氟乙酸(1ml)，室温下反应1小时。LC-MS监测，反应结束后减压蒸馏除去溶剂，得到化合物38-1(330mg,1.51mmol)。LCMS(ESI)m/z:220.1[M+H] +.
步骤2：化合物38-2的合成
在干燥的单口瓶中加入底物38-1(100mg,456.12μmol)，溶于N,N-二甲基甲酰胺(2mL)中，加入2-溴乙醇(57.00mg,456.12μmol)，碳酸钾(94.55mg,684.18μmol)和碘化钾(15.14mg,91.22μmol)，90℃下反应2小时。LC-MS监测。反应结束后将反应液冷却至室温，加水，过滤，甲醇洗涤。有机相减压浓缩得到化合物38-2(93mg,353μmol)。LCMS(ESI)m/z:264.1[M+H] +。
步骤3：化合物38-3的合成
氮气保护下，在干燥的单口瓶中加入底物38-2(93mg,353.22μmol)，溶于四氢呋喃(2.5mL)中，加入三乙胺(142.97mg,1.41mmol)。体系温度降至0℃，加入乙酰氯(41.59mg,529.83μmol)。缓慢升温至室温，搅拌1小时。LC-MS监测。反应结束后减压浓缩得到化合物38-3(96mg，314.8μmol)。LCMS(ESI)m/z:292.1[M+H] +。
步骤4：化合物38-4的合成
向50mL圆底烧瓶中加入38-3(277mg,907.22μmol)溶解于甲醇(3mL)。加入催化量的钯炭(30mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物38-4(177mg,642μmol,)。LCMS(ESI)m/z:262.2[M+H] +。
步骤5：化合物38-5的合成
在干燥的单口瓶中，加入底物IM-1(40mg,111.91μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(38.62mg,223.82μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(72.32mg,559.55μmol)和38-4(30.81mg,111.91μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩得到粗品38-5(300mg,crude)。LCMS(ESI)m/z:571.3[M+H] +。
步骤6：化合物38的合成
在干燥的单口瓶中，加入底物38-5(300mg,crude)，加入甲醇(3mL)溶解。加入氢氧化钠(41.05mg,1.03mmol)和水(0.2mL)，室温反应30分钟。LC-MS监测，反应结束后减压浓缩，加水稀释，乙酸乙酯萃取3次。有机相用无水硫酸钠干燥，过滤，减压浓缩，粗 品通过制备高效液相色谱(碱性)纯化得到化合物38(10.36mg,19.09μmol)。LCMS(ESI)m/z:543.2[M+H] +.HPLC method A:R T＝4.82min,purity:100.0％. 1H NMR(600MHz,DMSO-d 6)δ10.04(s,1H),8.79(s,1H),8.02–7.99(m,1H),7.74(s,1H),7.59(d,J＝7.2Hz,1H),7.49(s,2H),6.55(d,J＝7.8Hz,2H),5.67-5.63(m,1H),5.32(s,1H),4.99(d,J＝10.2Hz,1H),4.82(d,J＝17.4Hz,1H),4.69-4.67(m,2H),4.37-4.35(m,1H),4.26(s,1H),3.54(s,1H),3.38-3.36(m,3H),3.14(d,J＝9.0Hz,1H),2.87(d,J＝9.0Hz,1H),2.48-2.46(m,2H),1.83-1.77(m,2H),1.46(s,6H)。
实施例39：化合物39的合成
Figure PCTCN2023070285-appb-000138
步骤1：化合物39的合成
在干燥的单口瓶中，加入底物IM-3(30.49mg,150.00μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(25.88mg,150.00μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(19.39mg,150.00μmol)和化合物27-4(30.49mg,150.00μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物39(26mg,38.83μmol)。LCMS(ESI)m/z:546.2[M+H] +，HPLC Method B R T＝5.93min,purity>81.5％. 1H NMR(600MHz,DMSO-d 6)δ10.07(s,1H),8.78(s,1H),7.78(s,1H),7.61(s,2H),7.32(d,J＝7.8Hz,1H),6.71(d,J＝7.8Hz,2H),6.59(d,J＝8.4Hz,1H),5.68–5.60(m,1H),5.00(d,J＝10.2Hz,1H),4.90(d,J＝17.4Hz,1H),4.75(s,2H),3.60(s,2H),3.44(d,J＝11.4Hz,2H),3.38(s,6H),3.35(d,J＝8.4Hz,2H),2.44(s,1H),2.00(s,3H),1.55–1.53(m,1H).
实施例40：化合物40的合成
Figure PCTCN2023070285-appb-000139
步骤1：化合物40-2的合成
在干燥的单口瓶中将40-1(0.4g,2mmol)溶于二甲亚砜(15mL)，依次加入对氟硝基苯(0.28g,2mmol)，碳酸钾(1.11g,4mmol)。反应混合物在100℃搅拌过夜。LC-MS监测，反应结束后加水稀释，乙酸乙酯萃取三次，有机相用无水硫酸钠干燥后减压浓缩，残余物经柱层析纯化得到化合物40-2(0.63g,2.56mmol)。LCMS(ESI)m/z:248.1[M+H] +。
步骤2：化合物40-3的合成
氮气保护下，在干燥的单口瓶中加入底物40-2(71.4mg,300μmol)，溶于四氢呋喃(2.5mL)中，加入三乙胺(121.4mg,1.2mmol)。体系温度降至0℃，加入乙酸酐(61.2mg,600μmol)。缓慢升温至室温，搅拌12小时。LC-MS监测。反应结束后减压浓缩，残余物经MPLC纯化得到化合物40-3(25.3mg，87.4μmol)。LCMS(ESI)m/z:290.2[M+H] +。
步骤3：化合物40-4的合成
向50mL圆底烧瓶中加入40-3(173mg，598μmol)溶解于甲醇(5mL)。加入催化量的钯炭(18mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物40-4(122mg,470μmol,)。LCMS(ESI)m/z:260.2[M+H] +。
步骤4：化合物40的合成
在干燥的单口瓶中，加入底物IM-1(35.7mg,100μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(25.85mg,150μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(64.54mg,500μmol)和40-4(51.81mg,0.2mmol)，温度升至60℃反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物40(18mg,31.65μmol)。LCMS(ESI)m/z:569.3[M+H] +，HPLC Method B Rt＝6.28min,purity>63.4％. 1H NMR(600MHz,DMSO-d 6)δ10.14(s,1H),8.82(s,1H),8.04(s,1H),7.89(s,1H),7.75(s,1H),7.67–7.47(m,3H),6.93(d,J＝8.4Hz,2H),5.68–5.64(m,1H),5.32(s,1H),4.99(d,J＝10.2Hz,1H),4.82(d,J＝17.4Hz,1H),4.68(s,2H),4.37–4.35(m,1H),4.13–4.06(m,1H),3.69(s,2H),3.62(d,J＝7.8Hz,1H),2.66–2.55(m,3H),2.39(s,1H),1.79(d,J＝13.2Hz,1H),1.59(d,J＝13.2Hz,1H),1.46(s,6H),1.45–1.42(m,1H),1.36–1.24(m,2H)。
实施例41：化合物41的合成
Figure PCTCN2023070285-appb-000140
步骤1：化合物41-1的合成
在干燥的单口瓶中加入底物38-1(140mg,638.57μmol)，溶于N,N-二甲基甲酰胺(3mL)中，加入2-碘丙烷(131mg,770.63μmol)，和碳酸钾(124mg,897.25μmol)，90℃下反应3小时。LC-MS监测。反应结束和将反应液冷却至室温，加水，乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物化合物41-1(80mg,306.14μmol)。LCMS(ESI)m/z:262.2[M+H] +。
步骤2：化合物41-2的合成
向50mL圆底烧瓶中加入41-1(80mg,306.14μmol)溶解于甲醇(3mL)。加入催化量的钯炭(20mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物41-2(60mg,crude)。LCMS(ESI)m/z:232.2[M+H] +。
步骤3：化合物41的合成
在干燥的单口瓶中加入底物IM-6(45mg,120.50μmol)，四氢呋喃(3mL)，搅拌溶解后，加入N,N-二异丙基乙胺(77.87mg,602.52μmol)和41-2(30mg,129.68μmol)，室温反应2小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物41(20mg,36.99μmol)。LCMS(ESI)m/z:541.3[M+H] +,HPLC method A:R T＝5.1min,purity:95.3％. 1H NMR(600MHz,DMSO-d 6)δ10.05(s,1H),8.79(s,1H),8.02–7.99(m,1H),7.78-7.75(m,1H),7.59(d,J＝7.8Hz,1H),7.55-7.41(m,2H),6.57(d,J＝7.8Hz,2H),5.69-5.63(m,1H),5.33(s,1H),4.99(d,J＝10.2Hz,1H),4.84(d,J＝16.8Hz,1H),4.68(s,2H),4.26(s,1H),3.71(s,1H),3.32-3.30(m,1H),3.16(d,J＝9.0Hz,1H),3.01(d,J＝7.8Hz, 1H),2.41-2.36(m,2H),1.81(s,2H),1.46(s,6H),0.98-0.93(m,3H).D 2O: 1H NMR(600MHz,DMSO-d 6)δ8.80(s,1H),8.03–7.99(m,1H),7.73(s,1H),7.60(d,J＝7.2Hz,1H),7.49-7.37(m,2H),6.59(d,J＝7.2Hz,2H),5.69-5.63(m,1H),5.02(d,J＝10.2Hz,1H),4.83(d,J＝16.8Hz,1H),4.68(s,2H),4.26(s,1H),3.78(s,1H),3.32(d,J＝7.8Hz,1H),3.19(d,J＝9.0Hz,1H),3.03(d,J＝9.0Hz,1H),2.42-2.35(m,2H),1.84(d,J＝6.6Hz,2H),1.47(s,6H),1.0-0.94(m,6H)。
实施例42：化合物42的合成
Figure PCTCN2023070285-appb-000141
步骤1：化合物42-1的合成
在干燥的单口瓶中加入27-2(330mg,1.03mmol)溶于二氯甲烷(5ml)。加入三氟乙酸(2ml)，室温下反应30分钟。LC-MS监测，反应结束后减压蒸馏除去溶剂，得到化合物42-1(280mg,crude)。LCMS(ESI)m/z:220.1[M+H] +。
步骤2：化合物42-2的合成
在干燥的单口瓶中加入底物42-1(300mg,1.37mmol)，溶于N,N-二甲基甲酰胺(3mL)中，加入2-碘丙烷(348.92mg,2.05mmol)，和碳酸钾(567.35mg,4.11mmol)，70℃下反应12小时。LC-MS监测。反应结束和将反应液冷却至室温，加水，乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物42-2(280mg,1.07mmol)。LCMS(ESI)m/z:262.2[M+H] +。
步骤3：化合物42-3的合成
向50mL圆底烧瓶中加入42-2(0.8g,3.06mmol)溶解于甲醇(10mL)。加入催化量的钯炭(80mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物42-3(500mg,2.16mmol)。LCMS(ESI)m/z:232.2[M+H] +。
步骤4：化合物42的合成
在干燥的单口瓶中，加入底物IM-1(42.89mg,120.00μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(31.07mg,180.00μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(77.54mg,600.00μmol)和42-3(33.31mg,144.00μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物42(30mg,51.77μmol)。LCMS(ESI)m/z:541.4[M+H] +，HPLC Method B R T＝7.02min,purity>93.3％. 1H NMR(600MHz,DMSO-d 6)δ10.09(s,1H),8.80(s,1H),8.03(s,1H),7.76(s,1H),7.60-7.47(m,3H),6.69(d,J＝8.4Hz,2H),5.68–5.64(m,1H),5.31(s,1H),5.00–4.98(m,1H),4.86–4.79(m,1H),4.68(d,J＝5.4Hz,2H),3.71(d,J＝6.0Hz,2H),3.42(d,J＝11.2Hz,2H),3.24(d,J＝10.8Hz,2H),2.50–2.43(m,1H),2.37–2.35(m,1H),1.50(d,J＝8.4Hz,1H),1.46(s,6H),0.88(d,J＝6.0Hz,6H)。
实施例43：化合物43的合成
Figure PCTCN2023070285-appb-000142
步骤1：化合物43-1的合成
在干燥的单口瓶中加入底物27-1(0.33g,1.66mmol)溶于甲醇(4mL)，加入甲醛(226.77mg,6.66mmol)和乙酸(0.5mL)，室温搅拌10分钟。加入氰基硼氢化钠(1.41g,6.66mmol)，室温反应12小时。反应结束后，用水稀释，二氯甲烷萃取三次，有机相经过无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物43-1(300mg,1.41mmol)。LCMS(ESI)m/z:213.2[M+H] +。
步骤2：化合物43-2的合成
在干燥的单口瓶中加入43-1(300mg,1.41mmol)溶于二氯甲烷(3ml)。加入三氟乙酸(1ml)，室温下反应30分钟。LC-MS监测，原料消失后减压蒸馏除去溶剂，得到化合物43-2(0.12g,1.07mmol)。
步骤3：化合物43-3的合成
在干燥的单口瓶中将43-2(0.22g,1.96mmol)溶于二甲亚砜(5ml)，依次加入对氟硝基苯(304.41mg,2.16mmol)，碳酸钾(1.36g,9.81mmol)。反应混合物在100℃搅拌3小时。LC-MS监测，反应结束后用水稀释，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物43-3(260mg,1.11mmol)。LCMS(ESI)m/z:234.1[M+H] +。
步骤4：化合物43-4的合成
向50mL圆底烧瓶中加入43-3(0.3g,1.29mmol)溶解于甲醇(5mL)。加入催化量的钯炭(15mg)，在氢气氛围下室温搅拌3小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物43-4(200mg,983.85μmol)。LCMS(ESI)m/z:204.2[M+H] +。
步骤5：化合物43的合成
在干燥的单口瓶中，加入底物IM-1(42.89mg,120.00μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(31.07mg,180.00μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(77.54mg,600.00μmol)和化合物43-4(29.27mg,144.00μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物43(32mg,55.12μmol)。LCMS(ESI)m/z:513.2[M+H] +,HPLC Method B R T＝6.47min,purity>88.3％. 1H NMR(600MHz,DMSO-d 6)δ10.05(s,1H),8.80(s,1H),7.99–7.97(m,1H),7.74(s,1H),7.60-7.58(m,1H),7.48(s,2H),6.45(d,J＝8.4Hz,2H),5.64–5.63(m,1H),5.31(s,1H),4.99(d,J＝10.2Hz,1H),4.83(d,J＝17.4Hz,1H),4.68(d,J＝5.6Hz,2H),4.23(d,J＝5.6Hz,2H),2.97(d,J＝10.8Hz,2H),2.71(d,J＝11.4Hz,2H),2.42–2.39(m,1H),2.08(s,3H),1.96(d,J＝7.2Hz,1H),1.46(s,6H)。
实施例44：化合物44的合成
Figure PCTCN2023070285-appb-000143
步骤1：化合物44-1的合成
在干燥的单口瓶中加入底物38-1(300mg,1.37mmol)，溶于N,N-二甲基甲酰胺(2mL)中，加入1,2-氟溴乙烷(173.72mg,1.37mmol)，碳酸钾(378mg,2.74mmol)和碘化钾(45.43mg,273.67μmol)，90℃下反应过夜。LC-MS监测。反应结束和将反应液冷却至室温，加水，过滤，甲醇洗涤。有机相减压浓缩得到化合物44-1(320mg,1.21mmol)。LCMS(ESI)m/z:266.1[M+H] +。
步骤2：化合物44-2的合成
向圆底烧瓶中加入44-1(320mg,1.21mmol)溶解于甲醇(5mL)。加入催化量的钯炭(30mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物44-2(200mg,849.98μmol)。LCMS(ESI)m/z:236.2[M+H] +。
步骤3：化合物44的合成
在干燥的单口瓶中，加入底物IM-1(74mg,207.03μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(90mg,414.07μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(133.79mg,1.04mmol,180.30μL)和44-2(97.43mg,414.07μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物44(11.5mg,21.12μmol)。LCMS(ESI)m/z:545.3[M+H] +,HPLC method A:R T＝4.95min,purity:>84.1％. 1H NMR(600MHz,DMSO-d 6)δ10.05(s,1H),8.79(s,1H),8.02–8.00(m,1H),7.74(s,1H),7.59(d,J＝7.8Hz,1H),7.50(s,2H),6.57(d,J＝8.4Hz,2H),5.68–5.65(m,1H),5.31(s,1H),4.99(d,J＝10.2,1H),4.82(d,J＝17.4Hz,1H),4.67(s,2H),4.49–4.42(m,1H),4.38–4.36(m,1H),4.29(s,1H),3.57(s,1H),3.35(d,J＝9.0Hz,1H),3.12(d,J＝9.0Hz,1H),2.90(d,J＝9.6Hz,1H),2.83–2.64(m,2H),2.53(d,J＝9.6Hz,1H),1.84(d,J＝9.6Hz,1H),1.79(d,J＝9.0Hz,1H)。
实施例45：化合物45的合成
Figure PCTCN2023070285-appb-000144
步骤1：化合物45-2的合成
在干燥的微波管中，氮气保护下加入底物36-1(1.13g,9.99mmol)、45-1(2.20g,10.99mmol)、碘化亚铜(1.90g,9.99mmol)、碳酸钾(1.38g,9.99mmol)和N,N’-二甲基乙二胺(880.93mg,9.99mmol)，然后加入1，4-二氧六环(15mL)。在氮气环境下，120℃加热反应3小时。LCMS监测，反应结束后反应体系冷却至室温，过滤，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物通过MPLC纯化得到化合物45-2(0.8g,3.44mmol)。 LCMS(ESI)m/z:233.1[M+H] +。
步骤2：化合物45-3的合成
向50mL圆底烧瓶中加入45-2(800mg,3.44mmol)溶解于甲醇(10mL)。加入催化量的钯炭(40mg)，在氢气氛围下室温搅拌3小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物45-3(500mg,2.47mmol)。LCMS(ESI)m/z:203.1[M+H] +。
步骤3：化合物45的合成
在干燥的单口瓶中，加入底物IM-1(39mg,109.11μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(28.25mg,163.67μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(70.51mg,545.56μmol,95.02μL)和45-3(33.10mg,163.67μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物45(32mg,62.55μmol)。LCMS(ESI)m/z:512.2[M+H] +，HPLC Method B R T＝7.60min,purity>100.0％. 1H NMR(600MHz,DMSO-d 6)δ10.47(s,1H),8.85(s,1H),8.41(s,1H),8.04-8.01(m,1H),7.88(d,J＝7.8Hz,1H),7.79–7.68(m,2H),7.52(d,J＝9.0Hz,2H),6.88(d,J＝8.4Hz,2H),5.71–5.64(m,1H),5.34(s,1H),5.00(d,J＝10.2Hz,1H),4.85–4.77(m,1H),4.65(d,J＝6.0Hz,2H),2.97(s,6H),1.46(s,6H).
实施例46：化合物46的合成
Figure PCTCN2023070285-appb-000145
步骤1：化合物46-2的合成
在干燥的单口瓶中，加入甲醇钠(297mg,5.52mmol)，硝基甲烷(306.35mg,5.02mmol)和甲醇(8mL)，反应混合物室温搅拌30分钟。加入底物46-1(1g,5.02mmol)，室温搅拌过夜。反应结束后减压浓缩，滴加乙酸调pH值至7.0。用二氯甲烷萃取3次。有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物46-2(640mg,2.46mmol)。
步骤2：化合物46-3的合成
向50mL圆底烧瓶中加入46-2(100mg,384.19μmol)溶解于甲醇(2mL)。加入催化量的钯炭(40mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物46-3(80mg,347.4μmol)。LCMS(ESI)m/z:236.2[M+H] +。
步骤3：化合物46-4的合成
在干燥的单口瓶中加入底物46-3(1g,4.34mmol)，溶于N,N-二甲基甲酰胺(10mL)中，加入碳酸钾(1.2g,8.68mmol)和氯乙酰氯(540.40mg,4.78mmol)，室温反应5小时。反应结束后加水稀释，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物通过柱层析纯化得到化合物46-4(480mg,1.56mmol)。LCMS(ESI)m/z:266.1[M+H] +。
步骤4：化合物46-5的合成
在干燥的单口瓶中加入底物46-4(60mg,195.58μmol)，溶于异丙醇(6mL)中，加入叔丁醇钾(112mg,998.13μmol)，室温搅拌3小时。反应结束后减压浓缩，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品46-5(50mg,crude)。LCMS(ESI) m/z:215.1[M+H] +。
步骤5：化合物46-6的合成
在干燥的单口瓶中加入底物46-5(26mg,96.18μmol)，溶于四氢呋喃(4.4mL)中，加入2M硼烷四氢呋喃溶液(0.19mL,384.72μmol)，70℃搅拌2小时。反应结束后减压浓缩，加入甲醇和N,N,N',N'-四甲基乙二胺，78℃搅拌过夜。反应结束后减压浓缩，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩得到粗品46-6(25mg,crude)。LCMS(ESI)m/z:257.2[M+H] +。
步骤6：化合物46-7的合成
在干燥的单口瓶中将46-6(25mg,97.53μmol)溶于二甲亚砜(2ml)，依次加入对氟硝基苯(13.76mg,97.53μmol)，碳酸钾(19mg,137.48μmol)。反应混合物在100℃搅拌5小时。LC-MS监测，反应结束后用水稀释，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物46-7(30mg,79.48μmol)。LCMS(ESI)m/z:234.1[M+H] +。
步骤7：化合物46-8的合成
在干燥的单口瓶中加入46-7(18mg,47.69μmol)溶于二氯甲烷(1ml)。加入三氟乙酸(1ml)，室温下反应30分钟。LC-MS监测，原料消失后减压蒸馏除去溶剂，得到化合物46-8(13mg,crude)。
步骤8：化合物46-9的合成
在干燥的单口瓶中加入底物46-8(13mg,46.88μmol)溶于甲醇(2mL)，加入甲醛(16mg,469.76μmol)和乙酸(50μL)，室温搅拌10分钟。加入氰基硼氢化钠(10mg,159.13μmol)，50℃反应2小时。反应结束后减压浓缩，残余物用MPLC纯化得到化合物46-9(10mg,34.32μmol)。LCMS(ESI)m/z:262.2[M+H] +。
步骤9：化合物46-10的合成
向50mL圆底烧瓶中加入46-9(50mg,171.62μmol)溶解于甲醇(3mL)。加入催化量的钯炭(15mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物46-10(30mg,114.7μmol)。LCMS(ESI)m/z:236.2[M+H] +。
步骤10：化合物46的合成
在干燥的单口瓶中加入底物IM-6(42mg,112.47μmol)，四氢呋喃(4mL)，搅拌溶解后，加入N,N-二异丙基乙胺(72.68mg,562.36μmol)和46-10(30mg,114.78μmol)，室温反应2小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物46(32mg,56.07μmol)。LCMS(ESI)m/z:571.2[M+H] +,HPLC method B:R T＝6.53min,purity:99.5％. 1H NMR(600MHz,DMSO-d 6)δ10.15(s,1H),8.83(s,1H),8.04(s,1H),7.75(d,J＝6.6Hz,1H),7.62–7.59(m,3H),6.91(d,J＝8.4Hz,2H),5.70-5.63(m,1H),5.34(s,1H),5.02–4.99(m,1H),4.83(d,J＝16.8Hz,1H),4.68(d,J＝5.4Hz,2H),3.81–3.74(m,2H),3.20(d,J＝12.0Hz,1H),3.16-3.14(m,1H),2.99-2.96(m,1H),2.89(d,J＝12.0Hz,1H),2.66-2.64(m,1H),2.32(s,1H),2.32-2.21(m,5H),1.74–1.66(m,2H),1.57-1.52(m,1H),1.46(s,6H),1.44–1.38(m,1H).D 2O: 1H NMR(600MHz,DMSO-d 6)δ8.83(s,1H),8.05(s,1H),7.74(d,J＝7.2Hz,1H),7.63–7.59(m,3H),6.92(d,J＝9.0Hz,2H),5.70-5.63(m,1H),5.02(d,J＝10.2Hz,1H),4.83(d,J＝17.4Hz,1H),4.69(d,J＝5.4Hz,2H),3.82–3.77(m,2H),3.18-3.13(m,2H),3.00-2.96(m,1H),2.91(d,J＝12.0Hz,1H),2.67-2.64(m,1H),2.51-2.44(m,2H),2.35-2.26(m,4H),1.71–1.67(m,2H),1.57–1.54(m,1H),1.50-1.47(m,7H)。
实施例47：化合物47的合成
Figure PCTCN2023070285-appb-000146
步骤1：化合物47-1的合成
在干燥的单口瓶中将4-1(323mg，2mmol)溶于乙醇(10ml)，依次加入氢氧化钾(337mg，6mmol)，对溴苯甲醛(370mg，2mmol)。反应混合物室温搅拌过夜。LC-MS监测，反应结束后减压浓缩，残余物经MPLC纯化得到化合物47-1(456mg，1.6mmol)。LCMS(ESI)m/z:292.1[M+H] +。
步骤2：化合物47-2的合成
在单口瓶中加入三甲基碘化亚砜(1.6g，8mmol)、氢氧化钠(0.64g，16mmol)溶于四氢呋喃(20mL)，置换氮气，室温下反应1小时。加入47-1(582mg，2mmol)，再次置换氮气，65℃下搅拌1小时，LC-MS监测反应。反应结束后减压浓缩除去溶剂，加入乙酸乙酯与水萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物47-2(284mg，0.93mmol)。LCMS(ESI)m/z:306.1[M+H] +。
步骤3：化合物47-3的合成
在干燥的单口瓶中，加入底物IM-3(78mg,0.2mol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(52mg,0.3mmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(129mg,1mmol)和氨水(0.1mL,0.4mmol)，室温反应2小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物47-3(58mg,0.16mmol)。LCMS(ESI)m/z:585.2[M+H] +。
步骤4：化合物47的合成
在干燥的微波管中，氮气保护下加入底物47-3(58mg,0.16mmol)、47-2(70mg,0.23mmol)、碘化亚铜(61mg,320.29μmol)、碳酸钾(44.2mg,319.83μmol)和N,N’-二甲基乙二胺(56mg,635.28μmol)，然后加入1，4-二氧六环(4mL)。在氮气环境下，110℃加热反应6小时。LCMS监测，反应结束后反应体系冷却至室温，减压浓缩除去溶剂，残余物通过MPLC纯化得到化合物47(61mg,104.33μmol)。LCMS(ESI)m/z:585.2[M+H] +,HPLC method B:R T＝6.54min,purity:100％. 1H NMR(600MHz,DMSO-d 6)δ10.23(s,1H),8.86(s,1H),7.80–7.77(m,1H),7.63(d,J＝8.4Hz,2H),7.30–7.25(m,3H),6.61(d,J＝8.0Hz,1H),5.65–5.62(m,1H),5.00(d,J＝10.2Hz,1H),4.90(d,J＝17.4Hz,1H),4.75(d,J＝6.0Hz,2H),3.37(s,6H),2.96–2.92(m,2H),2.74–2.72(m,1H),2.50–2.47(m,1H),2.44–2.43(m,1H),2.22–2.21(m,1H),1.99–1.98(m,1H),1.93–1.86(m,2H),1.83–1.82(m,1H),1.65–1.63(m,1H),1.60–1.57(m,1H).
步骤5：化合物47a和47b的合成
化合物47(20mg)通过SFC拆分得到47a(6mg)，LCMS(ESI)m/z:585.2[M+H] +,HPLC method B:R T＝6.72min,purity:98.7％.和47b(8.6mg)，LCMS(ESI)m/z:585.2[M+H] +,HPLC method B:R T＝6.75min,purity:99.6％。
实施例48：化合物48的合成
Figure PCTCN2023070285-appb-000147
步骤1：化合物48-1的合成
在干燥的单口瓶中加入底物27-2(100mg,456.12μmol)，溶于N,N-二甲基甲酰胺(2mL)中，加入1-溴-2-氟乙烷(86.86mg,684.18μmol)，碳酸钾(88.25mg,638.57μmol)和碘化钾(8mg,48.19μmol)，100℃下反应7.5小时。LC-MS监测。反应结束后将反应液冷却至室温，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩得到化合物48-1(60mg,226.17μmol)。LCMS(ESI)m/z:266.2[M+H] +。
步骤2：化合物48-2的合成
向50mL圆底烧瓶中加入48-1(60mg,226.17μmol)溶解于甲醇(5mL)。加入催化量的钯炭(15mg)，在氢气氛围下室温搅拌1小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物48-2(45mg,crude)。LCMS(ESI)m/z:236.2[M+H] +。
步骤3：化合物48的合成
在干燥的单口瓶中加入底物IM-6(42mg,112.47μmol)，四氢呋喃(4mL)，搅拌溶解后，加入N,N-二异丙基乙胺(72.68mg,562.36μmol)和48-2(42mg,112.47μmol)，室温反应4小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物48(45mg,74.45μmol)。LCMS(ESI)m/z:545.2[M+H] +,HPLC method B:R T＝6.81min,purity:90.1％. 1H NMR(600MHz,Chloroform-d)δ8.81(s,1H),7.86-7.84(m,1H),7.78-7.77(m,1H),7.48(s,2H),7.33(d,J＝7.8Hz,1H),6.73(d,J＝9.0Hz,2H),5.73-5.67(m,1H),5.04(d,J＝10.2Hz,1H),4.94(d,J＝16.8Hz,1H),4.74(d,J＝6.0Hz,2H),4.62-4.60(m,1H),4.54-4.52(m,1H),3.99(s,1H),3.92(d,J＝4.8Hz,2H),3.64(d,J＝10.8Hz,2H),3.39(d,J＝10.8Hz,2H),2.78-2.70(m,3H),1.68(d,J＝8.4Hz,1H),1.58(s,6H)。
实施例49：化合物49的合成
Figure PCTCN2023070285-appb-000148
步骤1：化合物49-1的合成
在干燥的单口瓶中加入底物27-2(100mg,456.12μmol)，溶于N,N-二甲基甲酰胺(2mL)中，加入环丁基溴(92.37mg,684.18μmol)，碳酸钾(158mg,1.14mmol)和碘化钾(8mg,48.19μmol)，100℃下反应32小时。LC-MS监测。反应结束后将反应液冷却至室温，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩得到化合物49-1(32mg,117.07μmol)。LCMS(ESI)m/z:274.2[M+H] +。
步骤2：化合物49-2的合成
向50mL圆底烧瓶中加入49-1(32mg,117.07μmol)溶解于甲醇(5mL)。加入催化量的钯炭(10mg)，在氢气氛围下室温搅拌1小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物49-2(28mg,crude)。LCMS(ESI)m/z:244.1[M+H] +。
步骤3：化合物49的合成
在干燥的单口瓶中加入底物IM-6(35.7mg,95.60μmol)，四氢呋喃(3mL)，搅拌溶解后，加入N,N-二异丙基乙胺(61.78mg,478.00μmol)和49-2(25.59mg,105.16μmol)，室温反应4小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物49(20.8mg,33.31μmol)。LCMS(ESI)m/z:553.2[M+H] +,HPLC method B:R T＝7.50min,purity:88.5％. 1H NMR(600MHz,Chloroform-d)δ8.82(s,1H),7.86-7.84(m,1H),7.78-7.77(m,1H),7.48(s,2H),7.33(d,J＝7.8Hz,1H),6.71(d,J＝8.4Hz,2H),5.74-5.67(m,1H),5.04(d,J＝10.2Hz,1H),4.94(d,J＝19.4Hz,1H),4.67(d,J＝5.4Hz,2H),3.94-3.88(m,3H),3.47(d,J＝10.2Hz,2H),3.35(d,J＝10.2Hz,2H),3.21(s,1H),2.81-2.72(m,1H),2.00-1.90(m,5H),1.78-1.74(m,1H),1.69-1.64(m,1H),1.58(s,6H)。
实施例50：化合物50的合成
Figure PCTCN2023070285-appb-000149
步骤1：化合物50-2的合成
在干燥的单口瓶中加入底物50-1(2g,14.91mmol)溶于甲醇(40mL)，加入甲醛(358.09mg,11.92mmol)和乙酸(89.51mg,1.49mmol)，室温搅拌15分钟。加入三乙酰氧基硼氢化钠(15.80g,74.53mmol)，室温反应3小时。反应结束后减压浓缩，二氯甲烷萃取三次，有机相经过无水硫酸钠干燥，过滤，减压浓缩，残余物用MPLC纯化得到化合物50-2(200mg,1.35mmol)。LCMS(ESI)m/z:149.1[M+H] +。
步骤2：化合物50-3的合成
氮气保护下在干燥的单口瓶中加入50-2(138mg,0.93mmol)，对氟硝基苯(282mg,1.4mmol)，Pd 2(dba) 3(85mg,0.093mmol)，XantPhos(108mg,0.18mmol)，叔丁醇钾(358mg,3.72mmol)和1，4-二氧六环(3mL)。反应混合物在氮气氛围下110℃搅拌3小时。LC-MS监测，反应结束后冷却至室温，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物50-3(20mg,0.074mmol)。LCMS(ESI)m/z:270.1[M+H] +。
步骤3：化合物50-4的合成
向50mL圆底烧瓶中加入50-3(20mg,74μmol)溶解于甲醇(5mL)。加入催化量的钯炭(10mg)，在氢气氛围下室温搅拌1小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物50-4(7.80mg,32.59μmol)。LCMS(ESI)m/z:240.2[M+H] +。
步骤4：化合物50的合成
在干燥的单口瓶中，加入底物IM-1(13.98mg,39.11μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(24.75mg,143.41μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(42.12mg,325.93μmol)和50-4(7.80mg,32.59μmol)，室温反应2小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物50(2mg,3.65μmol)。LCMS(ESI)m/z:549.2[M+H] +,HPLC method B:R T＝9.17min,purity: 95.7％. 1H NMR(600MHz,DMSO-d 6)δ10.28(s,1H),8.87(s,1H),8.03–7.99(m,1H),7.75(d,J＝8.4Hz,1H),7.70(d,J＝8.4Hz,2H),7.61(d,J＝7.8Hz,1H),7.15(d,J＝8.4Hz,2H),6.70–6.60(m,2H),6.53(d,J＝8.4Hz,1H),6.49–6.42(m,1H),5.71–5.62(m,1H),5.32(s,1H),5.02–4.96(m,1H),4.85–4.79(m,1H),4.68(d,J＝6.0Hz,2H),3.68–3.65(m,2H),3.30(d,J＝1.8Hz,2H),2.87(s,3H),1.46(s,6H),1.24(s,1H)
实施例51：化合物51的合成
Figure PCTCN2023070285-appb-000150
步骤1：化合物51-2的合成
在干燥的微波管中，氮气保护下加入底物51-1(44mg,195.48μmol)、IM-1-4(44mg,197.96μmol)、碘化亚铜(37.70mg,197.96μmol)、碳酸钾(38.3mg,227.14μmol)和N,N’-二甲基乙二胺(34.90mg,395.92μmol)，然后加入1，4-二氧六环(2mL)。在氮气环境下，120℃加热反应4小时。LCMS监测，反应结束后反应体系冷却至室温，减压浓缩除去溶剂，残余物通过MPLC纯化得到化合物51-2(26mg,70.95μmol)。LCMS(ESI)m/z:367.1[M+H] + .
步骤2：化合物51的合成
在干燥的单口瓶中，加入底物51-2(56mg,152.82μmol)，加入四氢呋喃(4mL)溶解。加入间氯过氧苯甲酸(42.06mg,244.52μmol)，50℃反应2小时，再向反应液中加入N,N-二异丙基乙胺(98.75mg,764.11μmol)和27-4(37.28mg,183.39μmol)，50℃反应16小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物51(11mg,21.09μmol)。LCMS(ESI)m/z:522.2[M+H] +,HPLC method B:R T＝8.05min,purity:96.8％. 1H NMR(600MHz,DMSO-d 6)δ10.05(s,1H),8.80(s,1H),8.22(d,J＝8.4Hz,1H),7.64–7.59(m,4H),6.67(d,J＝8.4Hz,2H),6.56(d,J＝3.6Hz,1H),5.75–5.65(m,1H),5.00(d,J＝10.2Hz,1H),4.86(d,J＝17.4Hz,1H),4.64(s,2H),4.30–4.26(m,2H),3.57(d,J＝6.0Hz,2H),3.41(d,J＝10.8Hz,2H),3.25(d,J＝11.4Hz,2H),2.42–2.41(m,1H),1.98(s,3H),1.52(d,J＝8.4Hz,1H),1.40–1.38(m,3H)。
实施例52：化合物52的合成
Figure PCTCN2023070285-appb-000151
步骤1：化合物52-2的合成
在干燥的单口瓶中加入底物52-1(1g,3.94mmol))，溶于N,N-二甲基甲酰胺(10mL)中，加入碘甲烷(1.40g,9.84mmol)，碳酸铯(5.13g,15.74mmol)，50℃下反应2小时。LC-MS监测。反应结束后将反应液冷却至室温，加水，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物52-2(1g,3.54mmol)。LCMS(ESI)m/z:283.1[M+H] +。
步骤2：化合物52-3合成
在干燥的微波管中，氮气保护下加入底物52-2(167.55mg,593.88μmol)、IM-1-4(110mg,494.90μmol)、碘化亚铜(9.43mg,49.49μmol)、碳酸钾(95.76mg,692.86μmol)和N,N’-二甲基乙二胺(8.73mg,98.98μmol)，然后加入N,N-二甲基甲酰胺(2mL)。在氮气环境下，110℃加热反应12小时。LCMS监测，反应结束后反应体系冷却至室温，减压浓缩除去溶剂，残余物通过MPLC纯化得到化合物52-3(16mg,37.78μmol)。LCMS(ESI)m/z:425.1[M+H] +。
步骤3：化合物52的合成
在干燥的单口瓶中，加入底物52-3(18.00mg,42.50μmol)，加入四氢呋喃(0.5mL)溶解。加入间氯过氧苯甲酸(11.00mg,63.76μmol)，室温反应10分钟，再向反应液中加入N,N-二异丙基乙胺(27.47mg,212.52μmol)和27-4(8.64mg,42.50μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物52(7.2mg,12.44μmol)。LCMS(ESI)m/z:579.1[M+H] +，HPLC Method B R T＝7.30min,purity>98.0％. 1H NMR(600MHz,DMSO-d 6)δ9.92(s,1H),8.77(s,1H),7.61(d,J＝1.8Hz,1H),7.56(d,J＝8.4Hz,1H),7.52(s,1H),7.39(s,1H),7.19(s,1H),6.59(s,3H),5.68–5.66(m,1H),5.09(s,1H),4.93(s,1H),4.24(s,2H),3.81(s,3H),3.80(s,2H),3.60(s,3H),3.56(d,J＝5.4Hz,2H),3.37(d,J＝10.8Hz,2H),3.24–3.18(m,2H),2.39(d,J＝2.4Hz,1H),1.96(s,3H),1.50(d,J＝8.4Hz,1H)。
实施例53：化合物53的合成
Figure PCTCN2023070285-appb-000152
步骤1：化合物53-2的合成
在干燥的单口瓶中加入底物53-1(2.1g,10.66mmol)，溶于N,N-二甲基甲酰胺(25mL)中，加入碘乙烷(4.99g,31.97mmol)，碳酸钾(4.22g,31.97mmol)，90℃下反应12小时。LC-MS监测。反应结束后将反应液冷却至室温，加水，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物53-2(1.38g,6.13mmol)。LCMS(ESI)m/z:226.0[M+H] +。
步骤2：化合物53-3的合成
氮气保护下在干燥的单口瓶中加入53-2(849mg,8.66mmol)，B(pin) 2(1.61g,6.35mmol)，Pd(dppf)Cl 2(236mg,0.29mmol)，叔丁醇钾(845mg,8.66mmol)和1，4-二氧六环(30mL)。反应混合物在氮气氛围下110℃搅拌16小时。LC-MS监测，反应结束后冷却至室温，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物53-3(680mg,2.5mmol)。LCMS(ESI)m/z:274.2[M+H] +。
步骤3：化合物53-4的合成
在干燥的单口瓶中加入底物53-3(0.47g,1.73mmol)，溶于乙醇(12mL)中。加入6M盐酸溶液(0.3mL,1.73mmol)，90℃下反应7小时。LC-MS监测。反应结束后减压浓缩，残 余物用MPLC纯化得到化合物53-4(180mg,0.95mmol)。LCMS(ESI)m/z:192.1[M+H] +。
步骤4：化合物53-5的合成
在干燥的单口瓶中加入底物53-4(217.99mg,1.15mmol)，溶于二氯甲烷(20mL)中。加入IM-1-4(170mg,764.85μmol)，吡啶(242.00mg,3.06mmol)，醋酸铜(277.84mg,1.53mmol)，室温搅拌24小时。LC-MS监测。反应结束后减压浓缩，残余物经MPLC纯化得到化合物53-5(31mg,84.60μmol)。LCMS(ESI)m/z:368.1[M+H] +。
步骤5：化合物53的合成
在干燥的单口瓶中，加入底物53-5(39mg,106.43μmol)，加入四氢呋喃(6mL)溶解。加入间氯过氧苯甲酸(20.20mg,117.07μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(137.55mg,1.06mmol)和27-4(23.80mg,117.07μmol)，室温反应2小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物53(8.3mg,15.91μmol)。LCMS(ESI)m/z:523.3[M+H] +,HPLC method B:R T＝7.18min,purity:98.3％. 1H NMR(600MHz,DMSO-d 6)δ10.14(s,1H),8.80(s,1H),8.14(s,1H),7.92(d,J＝8.4Hz,1H),7.80(s,1H),7.56–7.43(m,2H),7.28(s,1H),6.60(s,2H),5.76–5.62(m,1H),5.08(d,J＝10.2Hz,1H),4.95(d,J＝17.4Hz,1H),4.51–4.47(m,2H),4.35(s,1H),3.56(d,J＝5.4Hz,2H),3.38(d,J＝10.8Hz,2H),3.22(d,J＝11.2Hz,2H),2.45–2.38(m,1H),1.96(s,3H),1.50(d,J＝8.4Hz,1H),1.44–1.37(m,3H)。
实施例54：化合物54的合成
Figure PCTCN2023070285-appb-000153
步骤1：化合物54-2的合成
在干燥的单口瓶中加入底物54-1(300mg,1.60mmol)，溶于四氢呋喃(3mL)中，加入N,N'-羰基二咪唑(344.52mg,2.39mmol)，80℃下反应2小时。LC-MS监测。反应结束后将反应液冷却至室温，加水，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物54-2(260mg,1.22mmol)。LCMS(ESI)m/z:213.9[M+H] +。
步骤2：化合物54-3的合成
在干燥的单口瓶中加入底物54-2(620mg,2.90mmol)，溶于N,N-二甲基甲酰胺(6mL)中，加入碘乙烷(451.83mg,2.90mmol)，碳酸铯(1.12g,3.19mmol)，室温反应12小时。LC-MS监测。反应结束后将反应液冷却至室温，加水，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用MPLC纯化得到化合物54-3(279mg,1.15mmol)。LCMS(ESI)m/z:242.0[M+H] +。
步骤3：化合物54-4的合成
氮气保护下在干燥的单口瓶中加入54-3(220mg,908.83μmol)，B(pin) 2(346.18mg,1.36mmol)，Pd(dppf)Cl 2·二氯甲烷(74.22mg,90.88μmol)，碳酸钾(408.20mg,2.95mmol)和1，4-二氧六环(7mL)。反应混合物在氮气氛围下90℃搅拌16小时。LC-MS监测，反应结束后 冷却至室温，加水，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物54-4(140mg,484.20μmol)。LCMS(ESI)m/z:290.2[M+H] +。
步骤4：化合物54-5的合成
在干燥的单口瓶中加入底物54-4((140mg,484.20μmol)，溶于乙腈(2mL)中。加入6M盐酸溶液(80.70μL)，80℃下反应4小时。LC-MS监测。反应结束后减压浓缩，残余物用MPLC纯化得到化合物54-5(33mg,159.43μmol)。LCMS(ESI)m/z:208.1[M+H] +。
步骤5：化合物54-6的合成
在干燥的单口瓶中加入底物54-5(30mg,144.93μmol)，溶于二氯甲烷(3mL)中。加入IM-1-4(32.2mg,222.27μmol)，吡啶(11.46mg,144.93μmol)，醋酸铜(52.65mg,289.87μmol)，室温搅拌24小时。LC-MS监测。反应结束后减压浓缩，残余物经MPLC纯化得到化合物54-6(30mg,78.24μmol)。LCMS(ESI)m/z:384.1[M+H] +。
步骤6：化合物54的合成
在干燥的单口瓶中，加入底物54-6(30mg,78.24μmol)，加入四氢呋喃(2mL)溶解。加入间氯过氧苯甲酸(20.25mg,117.36μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(50.56mg,391.21μmol)和27-4(19.09mg,93.89μmol)，室温反应1.5小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物54(4.3mg,6.99μmol)。LCMS(ESI)m/z:539.1[M+H] +,HPLC method A:R T＝7.01min,purity:89.4％. 1H NMR(600MHz,DMSO-d 6)δ10.01(s,1H),8.79(s,1H),7.53-7.48(m,4H),7.26–7.24(m,1H),6.63-6.62(m,2H),5.71-5.66(m,1H),5.08(d,J＝10.2Hz,1H),4.98-4.95(m,1H),4.28-4.19(m,2H),3.89-3.86(m,2H),3.56(d,J＝4.8Hz,2H),3.38(d,J＝10.8Hz,2H),3.22(d,J＝10.8Hz,2H),2.41-2.38(m,1H),1.96(s,3H),1.50(d,J＝8.4Hz,1H),1.27–1.24(m,3H)。
实施例55：化合物55的合成
Figure PCTCN2023070285-appb-000154
步骤1：化合物55-2的合成
在干燥的单口瓶中，加入底物55-1(0.83g,4.28mmol)，加入N,N-二甲基甲酰胺(6mL)溶解。加入叔丁醇钾(960.29mg,8.56mmol)和三苯基氯甲烷(1.43g,5.13mmol)，室温反应过夜。LC-MS监测，反应结束后冷却至室温，加水，二氯甲烷萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经重结晶得到化合物55-2(1.53g,3.51mmol)。LCMS(ESI)m/z:437.1[M+H] +。
步骤2：化合物55-3的合成
在干燥的微波管中，氮气保护下加入底物55-2(0.88g,2.02mmol)、四氢吡咯(573.81mg, 8.07mmol)、碘化亚铜(38.41mg,201.70μmol)、叔丁醇钾(452.67mg,4.03mmol)和2-乙酰环己酮(56.55mg,403.40μmol)，然后加入N,N-二甲基甲酰胺(5mL)。在氮气环境下，80℃加热反应24小时。LCMS监测，反应结束后反应体系冷却至室温，减压浓缩除去溶剂，残余物通过MPLC纯化得到化合物55-3(250mg,658.77μmol)。LCMS(ESI)m/z:380.2[M+H] +。
步骤3：化合物55-4的合成
在干燥的单口瓶中加入55-3(140mg,368.91μmol)溶于二氯甲烷(2ml)。加入三氟乙酸(1ml)，室温下反应30分钟。LC-MS监测，原料消失后减压蒸馏除去溶剂，得到化合物55-4(22mg,160.37μmol)。LCMS(ESI)m/z:138.1[M+H] +。
步骤4：化合物55-5的合成
在干燥的单口瓶中将55-4(250mg,1.82mmol)溶于二甲亚砜(5ml)，依次加入对氟硝基苯(282.85mg,2.00mmol)，碳酸钾(2.52g,18.22mmol)。反应混合物在100℃搅拌12小时。LC-MS监测，反应结束后用水稀释，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物55-5(200mg,774.37μmol)。LCMS(ESI)m/z:259.1[M+H] +。
步骤5：化合物55-6的合成
在干燥的单口瓶中将55-5(9mg,34.85μmol)溶于四氢呋喃(0.5)和乙酸(0.1mL)溶液中，加入锌粉(45.57mg,696.93μmol)，室温搅拌30分钟。LC-MS监测，反应结束后用硅藻土过滤，滤液减压浓缩得到化合物55-6(6mg,26.28μmol)。LCMS(ESI)m/z:229.2[M+H] +。
步骤6：化合物55的合成
在干燥的单口瓶中，加入底物IM-1(42.27mg,118.27μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(30.61mg,177.40μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(76.43mg,591.35μmol)和55-6(27mg,118.27μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物55(2mg,3.72μmol)。LCMS(ESI)m/z:538.2[M+H] +，HPLC Method B R T＝8.23min,purity>97.9％. 1H NMR(600MHz,DMSO-d 6)δ10.39(s,1H),8.90(s,1H),8.10(s,1H),7.82(d,J＝8.4Hz,2H),7.78-7.77(m,2H),7.74–7.69(m,2H),7.64(d,J＝7.8Hz,1H),7.35(s,1H),5.72–5.64(m,1H),5.34(s,1H),5.00(d,J＝10.2Hz,1H),4.83(d,J＝17.4Hz,1H),4.69(d,J＝6.0Hz,2H),3.08–3.06(s,4H),1.92–1.89(m,4H),1.47(s,6H)
实施例56：化合物56的合成
Figure PCTCN2023070285-appb-000155
步骤1：化合物56的合成
在干燥的单口瓶中，加入底物52(2mg,3.46μmol)，加入甲醇(1mL)溶解。加入1M NaOH溶液(5μl,5.18μmol)室温搅拌30分钟。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物56(1.2mg,2.13μmol)。LCMS(ESI)m/z:565.3[M+H] +，HPLC Rt＝4.68min,purity>83.3％. 1H NMR(600MHz,Methanol-d 4)δ8.65(s,1H),7.60(d,J＝2.1Hz,1H),7.37(d,J＝8.6Hz,3H),7.10(s,1H),7.07(d,J＝8.2Hz,1H),6.52(d,J＝14.6Hz,2H),5.67–5.59(m,1H),5.06–5.00(m,1H),4.87(d,J＝17.4Hz,1H),4.26 (d,J＝5.5Hz,2H),3.73(s,3H),3.57(s,2H),3.50(d,J＝2.8Hz,2H),3.39(d,J＝11.0Hz,2H),2.46(s,1H),1.84(s,2H),1.79(s,3H),1.27(d,J＝2.9Hz,1H).
实施例57：化合物57的合成
Figure PCTCN2023070285-appb-000156
步骤1：化合物57-2合成
在干燥的微波管中，氮气保护下加入底物57-1(546.59mg,2.39mmol)、IM-1-4(444mg,2.00mmol)、碘化亚铜(762mg,4.00mmol)、碳酸钾(552mg,2.00mmol)和N,N’-二甲基乙二胺(705mg,2.00mmol)，然后加入1，4-二氧六环(10mL)。在氮气环境下，110℃加热反应16小时。LCMS监测，反应结束后反应体系冷却至室温，过滤，滤液减压浓缩，残余物通过MPLC纯化得到化合物57-2(140mg,377.94μmol)。LCMS(ESI)m/z:371.1[M+H] +。
步骤2：化合物57的合成
在干燥的单口瓶中，加入底物57-2(7.4mg,19.98μmol)，加入四氢呋喃(0.5mL)溶解。加入间氯过氧苯甲酸(7.64mg,44.27μmol)，室温反应10分钟，再向反应液中加入N,N-二异丙基乙胺(5.72mg,44.27μmol)和27-4(6mg,29.52μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物57(8mg,15.22μmol)。LCMS(ESI)m/z:526.3[M+H] +,HPLC R T＝6.38min,purity>94.2％。 1H NMR(600MHz,DMSO-d 6)δ9.95(s,1H),8.76(s,1H),7.54(s,2H),7.38(d,J＝9.0Hz,1H),7.27(d,J＝8.4Hz,1H),6.99(d,J＝8.5Hz,1H),6.64(d,J＝8.6Hz,2H),5.69–5.67(m,1H),5.62(d,J＝18.0Hz,1H),5.10(d,J＝10.2Hz,1H),4.94(d,J＝17.4Hz,1H),4.55(s,1H),4.41(d,J＝9.6Hz,1H),4.36(d,J＝9.6Hz,1H),4.22(s,1H),3.55(d,J＝6.0Hz,2H),3.39(d,J＝11.2Hz,2H),3.22(d,J＝11.2Hz,2H),2.43–2.38(m,1H),1.96(s,3H),1.57(s,3H),1.50(d,J＝8.4Hz,1H)。
实施例58：化合物58的合成
Figure PCTCN2023070285-appb-000157
步骤1：化合物58-1的合成
在干燥的单口瓶中加入底物38-1(65.29mg,297.82μmol)溶于1,2-二氯乙烷(5mL)，加入3-氧杂环丁酮(108mg,1.5mmol)和乙酸(0.5mL)，室温搅拌15分钟。加入三乙酰氧基硼氢化钠(315.60mg,1.49mmol)，室温反应10小时。反应结束后减压浓缩，残余物用MPLC纯化得到化合物58-1(60mg,217.94μmol)。LCMS(ESI)m/z:276.1[M+H] +。
步骤2：化合物58-2的合成
向50mL圆底烧瓶中加入58-1(60mg,217.94μmol)溶解于甲醇(5mL)。加入催化量的钯炭(15mg)，在氢气氛围下室温搅拌1小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物58-2(45mg,183.43μmol)。LCMS(ESI) m/z:246.2[M+H] +。
步骤3：化合物58的合成
在干燥的单口瓶中加入底物IM-6(41.84mg,112.04μmol)，四氢呋喃(2mL)，搅拌溶解后，加入N,N-二异丙基乙胺(72.40mg,560.20μmol)和58-2(30.23mg,123.24μmol)，室温反应2小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物58(35mg,62.16μmol)。LCMS(ESI)m/z:555.2[M+H] +,HPLC method B:R T＝6.27min,purity:98.5％. 1H NMR(600MHz,DMSO-d 6)δ10.10(s,1H),8.80(s,1H),8.03(s,1H),7.77(s,1H),7.61-7.47(m,3H),6.67(d,J＝7.8Hz,2H),5.70-5.63(m,1H),5.32(s,1H),4.99(d,J＝10.2Hz,1H),4.83(d,J＝16.8Hz,1H),4.68(d,J＝2.4Hz,2H),4.58–4.56(m,2H),4.28–4.26m,2H),3.75(d,J＝6.0Hz,2H),3.62-3.60(m,1H),3.28-3.26(m,4H),2.48-2.47(m,1H),1.54(d,J＝8.4Hz,1H),1.47(s,6H).D 2O: 1H NMR(600MHz,DMSO-d 6)δ8.81(s,1H),8.04(s,1H),7.75(s,1H),7.62-7.45(s,3H),6.69(d,J＝8.4Hz,2H),5.70-5.63(m,1H),5.03(d,J＝10.2Hz,1H),4.83(d,J＝16.8Hz,1H),4.69(d,J＝3.0Hz,2H),4.60–4.58(m,2H),4.32–4.29(m,2H),3.76(d,J＝5.4Hz,2H),3.63-3.62(m,1H),3.26–3.24(m,4H),2.52-2.51(m,1H),1.53(d,J＝8.4Hz,1H),1.48(s,6H).
实施例59：化合物59的合成
Figure PCTCN2023070285-appb-000158
步骤1：化合物59-1的合成
在干燥的单口瓶中加入底物46-6(250mg,975.27μmol)溶于甲醇(2mL)，加入甲醛(16mg,469.76μmol)和乙酸(0.5mL)，室温搅拌30分钟。加入氰基硼氢化钠(306.43mg,4.88mmol)，50℃反应2小时。TLC监测。反应结束后减压浓缩，残余物经柱层析纯化得到化合物59-1(130mg,480.83μmol)。LCMS(ESI)m/z:262.2[M+H] +。
步骤2：化合物59-2的合成
在干燥的单口瓶中加入59-1(54mg,199.73μmol)溶于二氯甲烷(2ml)。加入三氟乙酸(1ml)，室温下反应30分钟。LC-MS监测，原料消失后减压蒸馏除去溶剂，得到化合物59-2(30mg,176.21μmol)。
步骤3：化合物59-3的合成
在干燥的单口瓶中将59-2(30mg,176.21μmol)溶于二甲亚砜(2ml)，依次加入对氟硝基苯(24.86mg,176.21μmol)，NaH(21.15mg,881.05μmol)。反应混合物在100℃搅拌3小时。LC-MS监测，反应结束后用水淬灭，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过 滤，减压浓缩，残余物经柱层析纯化得到化合物59-3(35mg,120.13μmol)。LCMS(ESI)m/z:234.1[M+H] +。
步骤4：化合物59-4的合成
向50mL圆底烧瓶中加入59-3(35mg,120.13μmol)溶解于甲醇(5mL)。加入催化量的钯炭(15mg)，在氢气氛围下室温搅拌2小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物59-4(30mg,114.78μmol)。LCMS(ESI)m/z:262.2[M+H] +。
步骤5：化合物59的合成
在干燥的单口瓶中加入底物IM-6(42.86mg,114.78μmol)，四氢呋喃(2mL)，搅拌溶解后，加入N,N-二异丙基乙胺(74.17mg,573.92μmol)和59-4(30mg,114.78μmol)，室温反应2小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物59(3mg,4.75μmol)。LCMS(ESI)m/z:571.2[M+H] +,HPLC method B:R T＝7.61min,purity:90.3％. 1H NMR(600MHz,Chloroform-d)δ8.82(s,1H),7.89-7.76(m,2H),7.45-7.44(m,2H),7.35(d,J＝7.8Hz,1H),6.97(s,2H),5.73-5.67(m,1H),5.04(d,J＝10.2Hz,1H),4.94(d,J＝16.8,1.2Hz,1H),4.74(d,J＝6.0Hz,2H),3.97-3.83(m,3H),3.25-3.11(m,3H),2.58-2.33(m,6H),1.93(s,1H),1.78(s,1H),1.61(s,3H),1.58(s,6H)。
实施例60：化合物60的合成
Figure PCTCN2023070285-appb-000159
步骤1：化合物60-1的合成
在干燥的单口瓶中将IM-1-5(250mg,1.16mmol)溶于四氢呋喃(2ml)，温度降至0℃，加入NaH(83.30mg,3.47mmol)，在0℃下搅拌10分钟。加入碘甲烷(492.7mg,3.47mmol)，升至室温并搅拌6小时。LC-MS监测，反应结束后用水淬灭，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物60-1(210mg,912.64μmol)。LCMS(ESI)m/z:230.1[M+H] +。
步骤2：化合物60-2的合成
在干燥的微波管中，氮气保护下加入底物60-1(207.05mg,899.82μmol)、IM-1-4(200mg,899.82μmol)、碘化亚铜(342.74mg,1.80mmol)、碳酸钾(174.10mg,1.26mmol)和N,N’-二甲基乙二胺(705mg,2.00mmol)，然后加入1，4-二氧六环(4mL)。在氮气环境下，110℃加热反应2小时。LC-MS监测，反应结束后反应体系冷却至室温，加氨水(2mL)，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经MPLC纯化得到化合物60-2(80mg,215.37μmol)。LCMS(ESI)m/z:372.2[M+H] +。
步骤3：化合物60的合成
在干燥的单口瓶中，加入底物60-2(46mg,123.84μmol)，加入四氢呋喃(0.5mL)溶解。加入间氯过氧苯甲酸(32mg，185.76μmol)，室温反应10分钟，再向反应液中加入N,N-二异丙基乙胺(80.02mg,619.19μmol)和27-4(30.21mg,148.60μmol)，室温反应6小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物60(14.08mg,26.74μmol)。LCMS(ESI)m/z:527.2[M+H] +,HPLC method B:R T＝5.86min,purity:97.6％. 1H NMR(600MHz,DMSO-d 6)δ10.10(s,1H),8.80(s,1H),8.07-8.05(m,1H),7.83-7.82(m,1H),7.59(s,2H),7.46(d,J＝7.8Hz,1H),6.72(d,J＝7.8Hz,2H),5.70-5.63(m,1H),4.99 (d,J＝10.2Hz,1H),4.84-4.81(m,1H),4.69(d,J＝4.2Hz,2H),3.59(d,J＝3.6Hz,2H),3.43(d,J＝10.8Hz,2H),3.28(d,J＝10.8Hz,2H),3.09(s,3H),2.43(s,1H),1.99(s,3H),1.54(d,J＝7.8Hz,1H),1.49(s,6H)。
实施例61：化合物61的合成
Figure PCTCN2023070285-appb-000160
步骤1：化合物61-2的合成
在干燥的单口瓶中加入底物61-1(200mg,1.30mmol)，溶于N,N-二甲基甲酰胺(2.5mL)中，加入碘乙烷(406.24mg,2.60mmol)，碳酸钾(5.4g，3.91mmol)，75℃反应1小时。LC-MS监测。反应结束后将反应液冷却至室温，过滤，减压浓缩，残余物用MPLC纯化得到化合物61-2(140mg,770.83μmol)。LCMS(ESI)m/z:266.2[M+H] +。
步骤2：化合物61-3的合成
在干燥的单口瓶中加入底物61-2(130mg,715.77μmol)，溶于乙腈(2mL)中，加入三甲基溴硅烷(109.58mg,715.77μmol)，90℃反应4小时。LC-MS监测。反应结束后将反应液冷却至室温，减压浓缩，残余物用MPLC纯化得到化合物61-3(60mg,265.40μmol)。LCMS(ESI)m/z:266.2[M+H] +。
步骤3：化合物61-4的合成
在干燥的微波管中，氮气保护下加入底物61-3(36.99mg,163.60μmol)、IM-1-4(40mg,179.96μmol)、碘化亚铜(62.32mg,327.21μmol)、碳酸钾(31.65mg,229.05μmol)和N,N’-二甲基乙二胺(57.69mg,654.42μmol)，然后加入1，4-二氧六环(4mL)。在氮气环境下，110℃加热反应3小时。LCMS监测，反应结束后反应体系冷却至室温，减压浓缩，残余物经MPLC纯化得到化合物61-4(19mg,51.71μmol)。
步骤4：化合物61的合成
在干燥的单口瓶中，加入底物61-4(19mg,51.71μmol)，加入四氢呋喃(0.7mL)溶解。加入间氯过氧苯甲酸(13.39mg,77.57μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(33.42mg,258.55μmol)和27-4(10.51mg,51.71μmol)，室温反应10小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物61(3.89mg,7.44μmol)。LCMS(ESI)m/z:523.3[M+H] +,HPLC method A:R T＝4.98min,purity:98.6％. 1H NMR(600MHz,CDCl3)δ8.76(s,1H),8.05(d,J＝8.4Hz,1H),7.89(s,1H),7.78(d,J＝8.4Hz,1H),7.44(s,2H),6.67(d,J＝8.4Hz,2H),5.63-5.59(m,1H),4.93-4.90(m,3H),4.87–4.84(m,1H),4.46–4.42(m,2H),3.95(s,2H),3.58(d,J＝8.4Hz,2H),3.46(d,J＝8.4Hz,2H),2.93-2.87(m,1H),2.25(s,3H),1.71(d,J＝6.0Hz,1H),1.61–1.59(m,3H)。
实施例62：化合物62的合成
Figure PCTCN2023070285-appb-000161
步骤1：化合物62的合成
在干燥的微波管中，氮气保护下加入底物62-1(36.99mg,163.60μmol)、62-2(40.39mg,123.75μmol)、碘化亚铜(47.14mg,247.50μmol)、碳酸钾(68.41mg,495.01μmol)和N,N’-二甲基乙二胺(21.78mg,247.50μmol)，然后加入1，4-二氧六环(2mL)。在氮气环境下，110℃加热反应16小时。LC-MS监测，反应结束后反应体系冷却至室温，减压浓缩，残余物经MPLC纯化得到化合物62(0.7mg,1.23μmol)。LCMS(ESI)m/z:569.3[M+H] +,HPLC method A:R T＝6.03min,purity:73.2％. 1H NMR(600MHz,DMSO-d6)δ8.93–8.92(m,1H),8.07–8.03(m,1H),7.92–7.87(m,4H),7.88(d,J＝7.8Hz,1H)，7.72(d,J＝7.8Hz,1H)，5.76–5.71(m,1H),5.03–5.01(m,1H),4.92–4.89(m,1H),4.83–4.82(m,2H),4.66–4.63(m,1H),4.43–4.41(m,1H)，4.29–4.26(m,1H)，3.57(d,J＝11.4Hz,2H)，3.04–3.00(m,2H),2.95(s,3H),2.19(d,J＝14.4Hz,1H),2.16–1.51(m,4H),1.58–1.53(m,7H)
实施例63：化合物63的合成
Figure PCTCN2023070285-appb-000162
步骤1：化合物63-2的合成
在干燥的单口瓶中加入底物38-1(44mg,200.69μmol)溶于1,2-二氯乙烷(5mL)，加入63-1(171.79mg,1.00mmol)和乙酸(0.5mL)，室温搅拌15分钟。加入三乙酰氧基硼氢化钠(211.94mg,1mmol)，室温反应12小时。反应结束后减压浓缩，残余物用MPLC纯化得到化合物63-2((350mg,934.75μmol)。LCMS(ESI)m/z:375.2[M+H] +。
步骤2：化合物63-3的合成
在干燥的单口瓶中加入63-2(60mg,160.24μmol)溶于二氯甲烷(2ml)。加入三氟乙酸(1ml)，室温下反应30分钟。LC-MS监测，原料消失后减压蒸馏除去溶剂，得到化合物63-3(43mg,156.75μmol)。LCMS(ESI)m/z:275.2[M+H] +。
步骤3：化合物63-4的合成
在干燥的单口瓶中加入底物63-3(43mg,156.75μmol)溶于甲醇(3mL)，加入甲醛(26.69mg,783.76μmol)和乙酸(0.2mL)，室温搅拌10分钟。加入氰基硼氢化钠(19.70mg,313.51μmol)，50℃反应6小时。LC-MS监测。反应结束后减压浓缩，乙酸乙酯萃取，有机相经无水硫酸钠干燥，过滤，减压浓缩得到化合物63-4(35mg,121.38μmol)。LCMS(ESI)m/z:289.2[M+H] +。
步骤4：化合物63-5的合成
向50mL圆底烧瓶中加入63-4(35mg,120.13μmol)溶解于甲醇(3mL)。加入催化量 的钯炭(15mg)，在氢气氛围下室温搅拌1小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物63-5(28mg,71.90μmol)。LCMS(ESI)m/z:259.2[M+H] +。
步骤5：化合物63的合成
在干燥的单口瓶中加入底物IM-6(16.89mg,65.36μmol)，四氢呋喃(2mL)，搅拌溶解后，加入N,N-二异丙基乙胺(42.24mg,326.82μmol)和63-5(28mg,71.90μmol)，室温反应4小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物63(11mg,18.49μmol)。LCMS(ESI)m/z:568.4[M+H] +,HPLC method B:R T＝5.21min,purity:97.5％. 1H NMR(600MHz,DMSO-d 6)δ8.82-8.79(m,1H),7.99-7.91(m,1H),7.79-7.71(m,1H),7.59-7.55(m,1H),7.51-7.47(m,2H),6.71-6.69(m,2H),5.71-5.69(m,1H),5.67-5.61(m,1H),5.00-4.98(m,1H),4.83-4.56(m,3H),4.25–4.13(m,2H),4.02–3.89(m,4H),3.75–3.57(m,5H),3.28-3.21(m,3H),,2.42-2.38(m,1H),1.80-1.72(m,1H),1.46-1.42(m,6H).D 2O： 1H NMR(600MHz,333K,DMSO-d 6)δ8.77(s,1H),7.94(s,1H),7.74(s,1H),7.57(d,J＝7.2Hz,1H),7.47(s,2H),6.72(d,J＝9.0Hz,2H),5.68-5.62(m,1H),5.00(d,J＝10.2Hz,1H),4.85(d,J＝17.4Hz,1H),4.67(s,2H),4.17–3.62(m,10H),3.39–3.37(m,1H),3.18(s,3H),2.45(s,1H),1.77(s,1H),1.47(s,6H)。
实施例64：化合物64的合成
Figure PCTCN2023070285-appb-000163
步骤1：化合物64-1的合成
在干燥的单口瓶中加入底物38-1(109mg,497.17μmol)，溶于丙酮(3mL)中，加入烯丙基溴(90.1mg,745.76μmol)和碳酸钾(207mg,745.76μmol)，氮气氛围下室温反应2小时。LC-MS监测。反应结束后减压浓缩，残余物经MPLC纯化得到化合物64-1(128mg,497.03μmol)。LCMS(ESI)m/z:260.2[M+H] +。
步骤2：化合物64-2的合成
向干燥的单口瓶中加入64-1(128mg,497.03μmol)溶解于乙醇(10mL)。加入加入铁粉(138.92mg,2.49mmol)和氯化铵(399mg，7.46mmol)，反应升温至80℃并搅拌2小时。LC-MS监测。反应结束后降至室温，硅藻土过滤，滤液减压浓缩，残余物经MPLC纯化得到化合物64-2(25mg,109.02μmol)。LCMS(ESI)m/z:230.2[M+H] +。
步骤3：化合物64的合成
在干燥的单口瓶中，加入底物IM-1(18mg,50.36μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(13mg,137.36μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(9.7mg,75.05μmol)和64-2(21mg,91.58μmol)，室温反应2小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物64(6.2mg,11.51μmol)。LCMS(ESI)m/z:539.2[M+H] +,HPLC method B:R T＝5.59min,purity:92.7％。 1H NMR(400MHz,DMSO-d 6)δ8.80(s,1H),8.05–8.03(m,1H),7.79–7.77(m,2H),7.61(d,J＝7.8Hz,3H),6.72(d,J＝8.4Hz,2H),6.01–5.72(m,1H),5.72–5.54(m,1H),5.25–4.96(m,4H),4.83(d,J＝17.4Hz,1H),4.68(d,J＝6.0Hz,2H),3.44(d,J＝11.2Hz,2H),3.30(d,J＝11.2Hz,2H),3.18(s,2H),2.93(d,J＝6.0Hz,2H),1.55(d,J＝8.4Hz,1H),1.47(s,6H)。
实施例65：化合物65的合成
Figure PCTCN2023070285-appb-000164
步骤1：化合物65-1的合成
在干燥的单口瓶中加入底物38-1(87mg,396.83μmol)，溶于丙酮(3mL)中，加入碘乙烷(92.84mg,595.25μmol)和碳酸钾(83mg,1.19mmol)，氮气氛围下室温反应2小时。LC-MS监测。反应结束后减压浓缩，残余物经MPLC纯化得到化合物65-1(87mg,351.81μmol)。LCMS(ESI)m/z:248.1[M+H] +。
步骤2：化合物65-2的合成
向50mL圆底烧瓶中加入65-1(94mg,380.12μmol)溶解于甲醇(5mL)。加入催化量的钯炭(10mg)，在氢气氛围下室温搅拌1小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物65-2(80mg,368.14μmol)。LCMS(ESI)m/z:218.2[M+H] +。
步骤3：化合物65的合成
在干燥的单口瓶中，加入底物IM-1(18mg,50.36μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(13mg,137.36μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(9.7mg,75.05μmol)和65-2(19.9mg,91.58μmol)，室温反应2小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物65(6.2mg,11.77μmol)。LCMS(ESI)m/z:527.2[M+H] +,HPLC method B:R T＝6.27min,purity:76.2％. 1H NMR(400MHz,DMSO-d 6)δ10.09(s,1H),8.80(s,1H),8.06–8.02(m,1H),7.76(d,J＝8.0Hz,1H),7.60(d,J＝7.6Hz,3H),6.70(d,J＝8.4Hz,2H),5.74–5.55(m,1H),5.31(s,1H),5.04–4.94(m,1H),4.83(d,J＝17.2Hz,1H),4.68(d,J＝6.0Hz,2H),3.67(d,J＝5.6Hz,2H),3.42(d,J＝11.2Hz,2H),3.26(d,J＝11.2Hz,2H),2.42(d,J＝6.8Hz,1H),2.28(d,J＝7.2Hz,2H),1.55(s,1H),1.46(s,6H),0.93–0.91(m,3H)。
实施例66：化合物66的合成
Figure PCTCN2023070285-appb-000165
步骤1：化合物66-1的合成
在干燥的单口瓶中加入底物38-1(80mg,364.90μmol)，溶于N,N-二甲基甲酰胺(3mL)中，加入2-溴乙醇(68mg,544.16μmol)，碳酸钾(99mg,716.35μmol)和碘化钾(5mg,30.12μmol)，100℃下反应2小时。LC-MS监测。反应结束后将反应液冷却至室温，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩得到化合物66-1(70mg,265.86μmol)。LCMS(ESI)m/z:264.1[M+H] +。
步骤2：化合物66-2的合成
向50mL圆底烧瓶中加入66-1(70mg,265.86μmol)溶解于甲醇(3mL)。加入催化量的钯炭(15mg)，在氢气氛围下室温搅拌3小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物66-2(35mg,150μmol)。LCMS(ESI)m/z:234.2[M+H] +。
步骤3：化合物66的合成
在干燥的单口瓶中加入底物IM-6(50mg,128.39μmol)，四氢呋喃(4mL)，搅拌溶解后，加入N,N-二异丙基乙胺(82.97mg,641.97μmol)和66-2(32mg,57.32μmol)，室温反应4小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物66(45mg,74.45μmol)。LCMS(ESI)m/z:543.2[M+H] +,HPLC method B:R T＝5.69min,purity:97.2％. 1H NMR(600MHz,Chloroform-d)δ8.81(s,1H),7.87-7.84(m,1H),7.76(d,J＝7.8Hz,1H),7.47(s,2H),7.34(d,J＝7.8Hz,1H),6.72(d,J＝9.0Hz,2H),5.73-5.67(m,1H),5.04(d,J＝10.2Hz,1H),4.94(d,J＝16.8Hz,1H),4.73(d,J＝6.0Hz,2H),3.97(d,J＝5.4Hz,2H),3.67-3.63(m,4H),3.44(d,J＝10.8Hz,2H),2.82-2.80(m,1H),2.64(s,2H),1.72(d,J＝8.4Hz,1H),1.59(s,6H)。
实施例67：化合物67的合成
Figure PCTCN2023070285-appb-000166
步骤1：化合物67-1的合成
在干燥的单口瓶中加入底物38-1(80mg,364.90μmol)，溶于N,N-二甲基甲酰胺(3mL)中，加入2-溴乙基甲基醚(76mg,546.80μmol)，碳酸钾(99mg,716.35μmol)和碘化钾(5mg,30.12μmol)，100℃下反应6小时。LC-MS监测。反应结束后将反应液冷却至室温，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩得到化合物67-1(75mg,270.45μmol)。LCMS(ESI)m/z:264.1[M+H] +。
步骤2：化合物67-2的合成
向50mL圆底烧瓶中加入67-1(75mg,270.45μmol)溶解于甲醇(3mL)。加入催化量的钯炭(15mg)，在氢气氛围下室温搅拌3小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物67-2(53mg,214.28μmol)。LCMS(ESI)m/z:234.2[M+H] +。
步骤3：化合物67的合成
在干燥的单口瓶中加入底物IM-6(50mg,128.39μmol)，四氢呋喃(3mL)，搅拌溶解后，加入N,N-二异丙基乙胺(82.97mg,641.97μmol)和67-2(53mg,214.28μmol)，室温反应4小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物67(40mg,67.11μmol)。LCMS(ESI)m/z:557.3[M+H] +,HPLC method B:R T＝6.43min,purity:93.4％. 1H NMR(600MHz,Chloroform-d)δ8.82(s,1H),7.88-7.84(m,1H),7.77(d,J＝8.4Hz,1H),7.46(s,2H),7.34-7.32(m,1H),6.72(d,J＝8.4Hz,2H),5.76-5.66(m,1H),5.06–5.03(m,1H),4.97–4.92(m,1H),4.74(d,J＝6.0Hz,2H),3.95-3.93(m,2H),3.65(d,J＝10.8Hz,2H),3.52-3.50(m,2H),3.39(d,J＝10.8Hz,2H),3.35(s,3H),2.83-2.81(m,1H),2.66-2.64(m,2H),1.68(d,J＝8.4Hz,1H),1.59(s,6H)。
实施例68：化合物68的合成
Figure PCTCN2023070285-appb-000167
步骤1：化合物68-1的合成
在干燥的单口瓶中将乙酸(18mg,299.74μmol)和N,N-二异丙基乙胺(42.61mg,329.72μmol)溶于四氢呋喃(2mL)，温度降至0℃，加入HATU(49.93mg,131.39umol)，搅拌10分钟。加入38-1(65.72mg,299.74μmol)后搅拌30分钟。反应结束后，用水淬灭，乙酸乙酯萃取三次，有机相经过无水硫酸钠干燥，过滤，减压浓缩，残余物通过MPLC纯化得到化合物68-1(45mg,172.23μmol)。LCMS(ESI)m/z:262.1[M+H] +。
步骤2：化合物68-2的合成
向50mL圆底烧瓶中加入68-1(45mg,172.23μmol)溶解于甲醇(3mL)。加入催化量的钯炭(20mg)，在氢气氛围下室温搅拌1小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物68-2(29mg,214.28μmol)。LCMS(ESI)m/z:236.2[M+H] +。
化合物68的合成
在干燥的单口瓶中加入底物IM-6(50mg,128.39μmol)，四氢呋喃(3mL)，搅拌溶解后，加入N,N-二异丙基乙胺(82.97mg,641.97μmol)和68-2(29mg,125.38μmol)，室温反应4小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物68(51.3mg,89.10μmol)。LCMS(ESI)m/z:541.3[M+H] +,HPLC method B:R T＝6.04min,purity:93.9％. 1H NMR(600MHz,Chloroform-d)δ8.79(s,1H),7.87-7.83(m,1H),7.76(d,J＝8.4Hz,1H),7.45(d,J＝7.2Hz,2H),7.33(d,J＝7.6Hz,1H),6.68(d,J＝8.4Hz,2H),5.75-5.65(m,1H),5.05–5.03(m,1H),4.94(d,J＝17.4Hz,1H),4.74(d,J＝6.0Hz,2H),4.61-4.54(m,2H),4.09(brs,1H),3.97-3.95(m,1H),3.68-3.58(m,2H),3.43(d,J＝9.0Hz,1H),2.78-2.73(m,1H),1.94(s,3H),1.79(brs,1H),1.71(d,J＝8.4Hz,1H),1.59(s,6H)。
实施例69：化合物69的合成
Figure PCTCN2023070285-appb-000168
步骤1：化合物69-1的合成
在干燥的单口瓶中加入底物38-1(241.29mg,1.10mmol)，溶于N,N-二甲基甲酰胺(5mL)中，加入氯甲酸甲酯(104mg,1.10mmol)，碳酸钾(194mg,1.40mmol)，室温下反应5小时。LC-MS监测。反应结束后用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩得到化合物69-1(60mg,216.39μmol)。LCMS(ESI)m/z:278.1[M+H] +。
步骤2：化合物69-2的合成
向50mL圆底烧瓶中加入69-1(75mg,270.45μmol)溶解于甲醇(3mL)。加入催化量的钯炭(15mg)，在氢气氛围下室温搅拌1小时。LC-MS监测。反应结束后将反应液用硅藻土过滤，用甲醇洗涤两次，滤液减压浓缩得到化合物69-2(38mg,153.66μmol)。LCMS(ESI)m/z:248.1[M+H] +。
步骤3：化合物69的合成
在干燥的单口瓶中加入底物IM-6(50mg,128.39μmol)，四氢呋喃(3mL)，搅拌溶解后，加入N,N-二异丙基乙胺(82.97mg,641.97μmol)和69-2(38mg,153.66μmol)，室温反应4小时。LC-MS监测。反应完成后，减压蒸馏除去溶剂，残余物通过制备高效液相色谱(碱性)纯化得到化合物69(35mg,62.88μmol)。LCMS(ESI)m/z:557.2[M+H] +,HPLC method B:R T＝7.13min,purity:98.7％. 1H NMR(600MHz,Chloroform-d)δ8.79(s,1H),7.87-7.84(m,1H),7.77(d,J＝8.4Hz,1H),7.44(s,2H),7.33(d,J＝7.2Hz,1H),6.68(d,J＝8.4Hz,2H),5.75-5.65(m,1H),5.05–5.02(m,1H),4.96–4.91(m,1H),4.74(d,J＝6.0Hz,2H),4.39(d,J＝5.4Hz,2H),3.93-3.83(m,2H),3.65(s,3H),3.37(d,J＝10.2Hz,2H),2.74-2.69(m,1H),1.60-1.59(m,7H)。
实施例70：化合物70的合成
Figure PCTCN2023070285-appb-000169
步骤1：化合物70-2的合成
在干燥的单口瓶中将70-1(100mg,507.53μmol)溶于四氢呋喃(3ml)，温度降至0℃，加入NaH(14.62mg,609.04μmol)，在0℃下搅拌10分钟。加入碘乙烷(94.99mg,609.04μmol)，温度升至室温并搅拌2小时。LC-MS监测，反应结束后用水淬灭，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经MPLC纯化得到化合物70-2(65mg,288.78μmol)。LCMS(ESI)m/z:225.0[M+H] +。
步骤2：化合物70-3的合成
在干燥的单口瓶中将70-2(65mg,288.78μmol)溶于三氟乙酸(1ml)，加入乙酸酐(30.62mg,288.78μmol,0.5mL)，并升温至70℃搅拌4小时。LC-MS监测，反应结束后降至室温，减压浓缩，残余物经MPLC纯化得到化合物70-3(40mg,149.74μmol)。LCMS(ESI)m/z:267.0[M+H] +。
步骤3：化合物70-4的合成
在干燥的微波管中，氮气保护下加入底物70-3(32.78mg,122.70μmol)、IM-1-4(30mg,134.97μmol)、碘化亚铜(46.74mg,245.41μmol)、碳酸钾(23.74mg,171.78μmol)和N,N’-二甲基乙二胺(43.27mg,490.81μmol)，然后加入1，4-二氧六环(2mL)。在氮气环境下，110℃加热反应3小时。LC-MS监测，反应结束后反应体系冷却至室温，减压浓缩除去溶剂，残余物通过MPLC纯化得到化合物70-4(33mg,74.26μmol)。LCMS(ESI)m/z:409.1[M+H] +。
步骤4：化合物70的合成
在干燥的单口瓶中，加入底物70-4(59.71mg,146.17μmol)，加入四氢呋喃(1.5mL)溶解。加入间氯过氧苯甲酸(45.40mg,263.10μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(94.45mg,730.83μmol)和1-5(33.55mg,175.40μmol)，室温反应12小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物70(23mg,40.40μmol)。LCMS(ESI)m/z:552.2[M+H] +,HPLC method B:R T＝6.81min, purity:97.6％. 1H NMR(600MHz,DMSO-d 6)δ10.14(s,1H),8.84(s,1H),8.64(d,,J＝10.8Hz,2H),7.74(d,J＝8.4Hz,1H),7.56(s,2H),6.91-6.89(m,2H),5.71-5.66(m,1H),4.50–4.99(m,1H),4.85(d,J＝17.4Hz,1H),4.66-4.59(m,2H),4.35–4.32(m,2H),3.09-3.08(m,4H),2.49(s,3H),2.48-2.46(m,4H),2.23(s,3H),1.47–1.45(m,3H)。
实施例71：化合物71的合成
Figure PCTCN2023070285-appb-000170
步骤1：化合物71-1的合成
在干燥的单口瓶中将70-1(600mg,2.67mmol)溶于1，4-二氧六环(1ml)，加入三溴化吡啶(3.41g,10.66mmol)，室温搅拌16小时。LC-MS监测，反应结束后加水，二氯甲烷萃取3次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经MPLC纯化得到化合物71-1(230mg,576.62μmol)。LCMS(ESI)m/z:398.8[M+H] +。
步骤2：化合物71-2的合成
在干燥的单口瓶中将71-1(230mg,576.62μmol)溶于四氢呋喃(1.5mL)中，加入锌粉(45.57mg,696.93μmol)和饱和氯化铵溶液(1.5mL)，室温搅拌10分钟。LC-MS监测，反应结束后用硅藻土过滤，滤液减压浓缩，残余物经MPLC纯化得到化合物71-2(44mg,182.51μmol)。LCMS(ESI)m/z:241.0[M+H] +。
步骤3：化合物71-3的合成
在干燥的单口瓶中将71-2(250mg,1.16mmol)溶于四氢呋喃(2ml)，温度降至0℃，加入NaH(83.30mg,3.47mmol)，在0℃下搅拌10分钟。加入碘甲烷(492.7mg,3.47mmol)，升至室温并搅拌6小时。LC-MS监测，反应结束后用水淬灭，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物71-3(210mg,912.64μmol)。LCMS(ESI)m/z:269.0[M+H] +。
步骤4：化合物71-4的合成
在干燥的微波管中，氮气保护下加入底物71-3(17.61mg,65.44μmol)、IM-1-4(16mg,71.99μmol)、碘化亚铜(24.93mg,130.88μmol)、碳酸钾(12.66mg,91.62μmol)和N,N’-二甲基乙二胺(23.07mg,261.77μmol)，然后加入1，4-二氧六环(1mL)。在氮气环境下，110℃加热反应3小时。LC-MS监测，反应结束后反应体系冷却至室温，减压浓缩，残余物经MPLC纯化得到化合物71-4(2.01mg,4.91μmol)。LCMS(ESI)m/z:411.2[M+H] +。
步骤5：化合物71的合成
在干燥的单口瓶中，加入底物71-4(2.01mg,4.91μmol)，加入四氢呋喃(2mL)溶解。加入间氯过氧苯甲酸(1.52mg,8.83μmol)，室温反应1小时，再向反应液中加入N,N-二异丙基乙胺(3.17mg,24.54μmol,4.27μL)和1-5(938.70μg,4.91μmol)，室温反应8小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物71(2.3mg,3.45μmol)。LCMS(ESI)m/z:554.3[M+H] +,HPLC method B:R T＝5.89min,purity:83.2％. 1H NMR(600MHz,CDCL3)δ8.77(s,1H),7.51(d,J＝7.8Hz,1H),7.42(d,J＝1.8Hz,2H),7.36(d,J＝8.4Hz,1H),6.87-6.84(m,2H),5.70-5.63(m,1H),4.99(d,J＝10.2Hz,1H),4.92(d,J＝16.8Hz,1H),4.63(d,J＝5.4Hz,2H),3.80-3.77(m,2H),3.36-3.24(m,4H),2.87-2.80(m,4H),2.49-2.45(m,3H),1.36(s,6H),1.23–1.21(m,3H)。
实施例72：化合物72的合成
Figure PCTCN2023070285-appb-000171
步骤1：化合物72-21的合成
在干燥的单口瓶中加入底物72-1(88mg,395.92μmol)，溶于二氯甲烷(20mL)中。加入IM-1-4(170mg,764.85μmol)，吡啶(0.4mL)，醋酸铜(146mg,803.83μmol)，30℃搅拌24小时。LC-MS监测。反应结束后减压浓缩，残余物经MPLC纯化得到化合物72-2(28mg,79.00μmol)。LCMS(ESI)m/z:354.95[M+H] +。
步骤2：化合物72的合成
在干燥的单口瓶中，加入底物72-2(28mg,79.00μmol)，加入四氢呋喃(2mL)溶解。加入间氯过氧苯甲酸(27.26mg,157.99μmol)，室温反应1小时，再向反应液中加入N,N-二异丙基乙胺(16mg,83.65μmol)和1-5(938.70μg,4.91μmol)，室温反应2小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物72(9mg,17.72μmol)。LCMS(ESI)m/z:498.1[M+H] +,HPLC method B:R T＝8.01min,purity:98％. 1H NMR(400MHz,Chloroform-d)δ8.84(s,1H),7.85-7.81(m,2H),7.48–7.41(m,5H),6.86(d,J＝8.4Hz,2H),5.79-5.72(m,1H),5.18–5.09(m,2H),4.47(d,J＝6.0Hz,2H),3.32(s,4H),2.86(s,4H),2.55(s,3H)。
实施例73：化合物73的合成
Figure PCTCN2023070285-appb-000172
步骤1：化合物73-2的合成
在干燥的单口瓶中加入底物73-1(0.5g,3.28mmol)，溶于乙腈(5mL)中。加入吡啶(1.5mL)和Selectfluor试剂(1.05g,2.95mmol)，15℃下搅拌16小时。LC-MS监测。反应结束后加水，乙酸乙酯萃取3次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经prep-HPLC纯化得到化合物73-2(112mg,656.62μmol)。LCMS(ESI)m/z:171.0[M+H] +。
步骤2：化合物73-3的合成
在干燥的单口瓶中将73-2(0.112g,656.62μmol)溶于N,N-二甲基甲酰胺(3ml)，温度降至0℃，加入NaH(39.40mg,984.93μmol,60％purity)，在0℃下搅拌30分钟。加入碘乙烷(153.65mg,984.93μmol,78.79μL)，升至室温并搅拌16小时。LC-MS监测，反应结束后用饱和氯化铵溶液淬灭，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩， 残余物经柱层析纯化得到化合物73-3(120mg,604.16μmol)。LCMS(ESI)m/z:199.2[M+H] +。
步骤3：化合物73-4的合成
在干燥的微波管中，氮气保护下加入底物74-3(0.04g,201.39μmol)、IM-1-4(44.76mg,201.39μmol)、碘化亚铜(76.71mg,402.77μmol)、碘化钠(60.37mg,402.77μmol)，碳酸钾(69.58mg,503.46μmol)和N,N'-二甲基-1,2-环己二胺(114.58mg,805.54μmol)，然后加入苯甲醚(1.5mL)。在氮气环境下，130℃微波加热反应4小时。LC-MS监测，反应结束后反应体系冷却至室温，加入水和氨水(1mL)，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物73-4(20mg,52.03μmol)。LCMS(ESI)m/z:385.0[M+H] +。
步骤4：化合物73的合成
在干燥的单口瓶中，加入底物73-4(20mg,52.03μmol)，加入四氢呋喃(1.5mL)溶解。加入间氯过氧苯甲酸(19.01mg,93.65μmol,85％purity)，室温反应1小时，再向反应液中加入N,N-二异丙基乙胺(67.24mg,520.25μmol,90.62μL)和1-5(11.94mg,62.43μmol)，室温反应5小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物73(20.7mg,37.39μmol)。LCMS(ESI)m/z:528.3[M+H] +,HPLC method B:R T＝8.09min,purity:95.3％. 1H NMR(600MHz,DMSO-d 6)δ10.16(s,1H),8.84(s,1H),8.32(s,1H),7.67(s,1H),7.65(d,J＝8.4Hz,1H),7.61(s,2H),6.92(d,J＝8.4Hz,2H),5.74–5.68(m,1H),5.00(d,J＝10.2Hz,1H),4.86(d,J＝17.4Hz,1H),4.65(s,2H),4.26–4.22(m,2H),3.12–3.09(m,4H),2.47–2.45(m,4H),2.22(s,3H),1.39–1.36(m,3H)。
实施例74：化合物74的合成
Figure PCTCN2023070285-appb-000173
步骤1：化合物74-2的合成
在干燥的单口瓶中加入底物74-1(1.01g,3.99mmol)，溶于N,N-二甲基甲酰胺(30mL)中，加入甲基环氧丙烷(345.57mg,4.79mmol)，碳酸钾(1.66g,11.98mmol)，温度升至120℃反应8小时。LC-MS监测。反应结束后降至室温，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物74-2(680mg,2.09mmol)。LCMS(ESI)m/z:311.9[M+H] +。
步骤2：化合物74-3的合成
在干燥的单口瓶中将74-2(98mg,301.54μmol)溶于四氢呋喃(4ml)，温度降至0℃，分次加入NaH(24.12mg,603.08μmol,60％purity)，温度升至60℃并搅拌30小时。LC-MS监测，反应结束后降至室温，用饱和氯化铵水溶液淬灭，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经MPLC纯化得到化合物74-3(48mg,196.65μmol)。LCMS(ESI)m/z:244.0[M+H] +。
步骤3：化合物74-4的合成
在干燥的微波管中，氮气保护下加入底物74-3(47mg,192.56μmol)、IM-1-4(31.77mg,142.96μmol)、碘化亚铜(36.67mg,192.56μmol)、碳酸钾(38.30mg,277.14μmol)和N,N’-二甲基乙二胺(33.95mg,385.11μmol)，然后加入1，4-二氧六环(3mL)。在氮气环境下，120℃微波加热反应4小时。LC-MS监测，反应结束后反应体系冷却至室温，减压浓缩，残余物经柱层析纯化得到化合物74-4(12mg,31.13μmol)。LCMS(ESI)m/z:386.1[M+H] +。
步骤4：化合物74的合成
在干燥的单口瓶中，加入底物74-4(12mg,31.13μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(21.49mg,124.53μmol)，室温反应0.5小时，再向反应液中加入N,N-二异丙基乙胺(20.22mg,156.46μmol,27.25μL)和1-5(20mg,104.56μmol)，室温反应8小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物74(7.2mg,12.56μmol)。LCMS(ESI)m/z:529.2[M+H] +,HPLC method B:R T＝7.08min,purity:92.2％. 1H NMR(600MHz,Chloroform-d)δ8.80(s,1H),7.47(d,J＝7.8Hz,2H),7.37-7.30(m,2H),6.90(d,J＝8.4Hz,2H),5.74-5.68(m,1H),5.05(d,J＝10.2Hz,1H),4.98(d,J＝16.8Hz,1H),4.69(s,2H),4.11(s,2H),3.24(s,4H),2.69(s,4H),2.43(s,3H),1.41(s,6H)。
实施例75：化合物75的合成
Figure PCTCN2023070285-appb-000174
步骤1：化合物75-2的合成
在干燥的单口瓶中加入底物75-1(965mg,5.00mmol)，溶于N,N-二甲基甲酰胺(20mL)中，加入碘乙烷(383mg,4.70mmol)，N,N-二异丙基乙胺(1.29g,10.00mmol)，室温下反应1小时。TLC监测。反应结束后用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩残余物经柱层析纯化得到化合物75-2(650mg,3.22mmol)。LCMS(ESI)m/z:202.0[M+H] +。
步骤2：化合物75-3的合成
在干燥的单口瓶中将75-2(308mg,1.53mmol)溶于四氢呋喃(5mL)中，加入锌粉(1.6g,24.62mmol)和氯化铵(642mg,12.00mmol)，温度升至70℃搅拌3小时。LC-MS监测，反应结束后用硅藻土过滤，滤液减压浓缩，残余物经MPLC纯化得到化合物75-3(248mg,1.44mmol)。LCMS(ESI)m/z:172.1[M+H] +。
步骤3：化合物75-4的合成
在干燥的单口瓶中将75-3(248mg,1.44mmol)溶于原乙酸三乙酯(4ml)中，100℃下搅拌1小时。加入乙酸(1.05g,17.47mmol,1mL)，继续搅拌8小时。LC-MS监测，反应结束后降至室温，减压浓缩，乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物经MPLC纯化得到化合物75-4(220mg,1.12mmol)。LCMS(ESI)m/z:196.1[M+H] +。
步骤4：化合物75-5的合成
在干燥的微波管中，氮气保护下加入底物75-4(64mg,327.12μmol)、IM-1-4(72.71mg,327.12μmol)、碘化亚铜(124.60mg,654.23μmol)、碘化钠(98.06mg,654.23μmol)，碳酸钾(38.30mg,277.14μmol)和N,N'-二甲基-1,2-环己二胺(186.12mg,1.31mmol)，然后加入苯甲醚(2mL)。在氮气环境下，130℃微波加热反应10小时。LCMS监测，反应结束后反应体系冷却至室温，加入水和氨水(1mL)，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物75-5(15mg,39.32μmol)。LCMS(ESI)m/z:382.2[M+H] +。
步骤5：化合物75的合成
在干燥的单口瓶中，加入底物75-5(15mg,39.32μmol)，加入四氢呋喃(2mL)溶解。加入间氯过氧苯甲酸(20.36mg,117.97μmol)，室温反应1小时，再向反应液中加入N,N-二异丙基乙胺(25.36mg,196.25μmol,34.18μL)和1-5(18.77mg,98.12μmol)，室温反应8小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物75(3.2mg,5.12μmol)。LCMS(ESI)m/z:525.2[M+H] +,HPLC method B:R T＝6.16min,purity:84.0％. 1H NMR(600MHz,Chloroform-d)δ8.84(s,1H),8.07(d,J＝7.8Hz,1H),7.66(d,J＝7.2Hz,1H),7.46(d,J＝8.4Hz,2H),6.88(d,J＝8.4Hz,2H),5.75-5.68(m,1H),5.00(d,J＝10.2Hz,1H),4.89(d,J＝17.4Hz,1H),4.73(d,J＝3.6Hz,2H),4.32–4.28(m,2H),3.25(s,4H),2.71-2.68(m,7H),2.45(s,3H),1.47–1.42(m,3H)。
实施例76：化合物76的合成
Figure PCTCN2023070285-appb-000175
步骤1：化合物76的合成
在干燥的单口瓶中，加入底物51-2(26mg,70.95μmol)，加入四氢呋喃(2mL)溶解。加入间氯过氧苯甲酸(35mg,202.82μmol)，50℃反应2小时，再向反应液中加入N,N-二异丙基乙胺(45.62mg,353.00μmol)和IM-2(22mg,108.22μmol)，室温反应8小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物76(15mg,28.76μmol)。LCMS(ESI)m/z:522.3[M+H] +,HPLC method B:R T＝7.68min,purity:94.4％. 1H NMR(600MHz,Chloroform-d)δ8.83(s,1H),8.03(d,J＝7.8Hz,1H),7.53-7.43(m,3H),7.28(d,J＝3.6Hz,1H),6.54–6.52(m,3H),5.75-5.69(m,1H),5.00(d,J＝10.2Hz,1H),4.90((d,J＝17.4Hz,1H),4.76(s,2H),4.34-4.28(m,3H),3.78(s,1H),3.51–3.45(m,2H),3.21(s,1H),2.84(s,1H),2.53(s,3H),2.21(s,1H),2.06(d,J＝9.6Hz,1H),1.51–1.46(m,3H)。
实施例77：化合物77的合成
Figure PCTCN2023070285-appb-000176
步骤1：化合物77的合成
在干燥的单口瓶中，加入底物51-2(26mg,70.95μmol)，加入四氢呋喃(2mL)溶解。加入间氯过氧苯甲酸(35mg,202.82μmol)，55℃反应6小时，再向反应液中加入N,N-二异丙基乙胺(45.62mg,353.00μmol)和77-1(17mg,89.34μmol)，室温反应8小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物77(5mg,9.83μmol)。LCMS(ESI)m/z:509.6[M+H] +,HPLC method B:R T＝8.50min,purity:98.2％. 1H NMR(600MHz,DMSO-d 6)δ10.18(s,1H),8.87(s,1H),8.23(d,J＝7.8Hz,1H),7.67(d,J＝3.0Hz,3H),7.53(d,J＝7.8Hz,1H),7.16(d,J＝8.4Hz,2H),6.58(d,J＝3.6Hz,1H),5.74-5.68(m, 1H),5.00(d,J＝7.2Hz,1H),4.86(d,J＝16.8Hz,1H),4.61(s,2H),4.30–4.26(m,2H),2.86(d,J＝11.4Hz,2H),2.41-2.39(m,1H),2.19(s,3H),1.97-1.93(m,2H),1.71-1.62(m,4H),1.41–1.38(m,3H)。
实施例78：化合物78的合成
Figure PCTCN2023070285-appb-000177
步骤1：化合物78-1的合成
在干燥的单口瓶中将3,4-二氟硝基苯(159mg,999.43μmol)溶于二甲亚砜(3mL)，依次加入27-1(237.78mg,1.20mmol)，碳酸钾(137.92mg,999.43μmol)。反应混合物在100℃搅拌过夜。反应结束后，用水稀释，乙酸乙酯萃取三次，有机相经过无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物78-1(302mg,890μmol)。LCMS(ESI)m/z:338.2[M+H] +。
步骤2：化合物78-2的合成
在干燥的单口瓶中加入底物78-1(337.35mg,1mmol)溶于二氯甲烷(2mL)。缓慢加入三氟乙酸(1.54g,13.51mmol,1mL)，室温反应0.5小时，LC-MS监测。反应结束后，减压蒸馏除去溶剂得到化合物78-2(223mg,0.94mmol)。LCMS(ESI)m/z:238.1[M+H] +。
步骤3：化合物78-3的合成
在干燥的单口瓶中加入底物78-2(223mg,0.94mmol)溶于1,2-二氯乙烷(3mL)，加入甲醛(150.13mg,5.00mmol)，室温搅拌10分钟。加入三乙酰氧基硼氢化钠(1.06g,5.00mmol)，室温搅拌1小时。反应结束后，冷却至室温，用水稀释，二氯甲烷萃取三次，有机相经过无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物78-3(198mg,0.78mmol)。LCMS(ESI)m/z:252.1[M+H] +。
步骤4：化合物78-4的合成
在干燥的单口瓶中将78-3(251.26mg,1mmol)溶于四氢呋喃(10mL)和乙酸(0.5mL)溶液中，加入锌粉(1.95g,30.00mmol)，室温搅拌30分钟。LC-MS监测，反应结束后用硅藻土过滤，滤液减压浓缩得到化合物78-4(200mg,903.86μmol)。LCMS(ESI)m/z:222.1[M+H] +。
步骤5：化合物78的合成
在干燥的单口瓶中，加入底物IM-1(42.27mg,118.27μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(30.61mg,177.40μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(76.43mg,591.35μmol)和78-4(27mg,118.27μmol)，室温反应4小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物 78(2mg,3.72μmol)。LCMS(ESI)m/z:531.7[M+H] +.HPLC:R T＝7.53min,purity:85.0％. 1H NMR(600MHz,DMSO-d 6)δ10.28(s,1H),8.85(s,1H),8.002-7.99(m,1H),7.76(d,J＝7.8Hz,1H),7.71-7.67(m,1H),7.63(d,J＝7.8Hz,1H),7.34(d,J＝8.4Hz,1H),6.95-6.91(m,1H),5.70-5.64(m,1H),5.34(s,1H),5.00(d,J＝10.2Hz,1H),4.83(d,J＝17.4Hz,1H),4.68(d,J＝6.0Hz,2H),3.63(d,J＝11.1Hz,2H),3.50(d,J＝5.9Hz,2H),3.43(s,2H),3.17(s,2H),2.04(s,3H),1.46(s,6H)。
实施例79：化合物79的合成
Figure PCTCN2023070285-appb-000178
步骤1：化合物79-1的合成
在干燥的单口瓶中将3,4-二氟硝基苯(354.16mg,2mmol)溶于二甲亚砜(5mL)，依次加入27-1(475.83mg,2.40mmol)，碳酸钾(276.00mg,2.00mmol)。反应混合物在100℃搅拌1小时。反应结束后，用水稀释，乙酸乙酯萃取三次，有机相经过无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物79-1(635mg,1.79mmol)。LCMS(ESI)m/z:356.1[M+H] +。
步骤2：化合物79-2的合成
在干燥的单口瓶中加入底物79-1(635mg,1.79mmol)溶于二氯甲烷(5mL)。缓慢加入三氟乙酸(2mL)，室温反应0.5小时，LC-MS监测。反应结束后，减压蒸馏除去溶剂得到化合物79-2(300mg,1.18mmol)。LCMS(ESI)m/z:256.1[M+H] +。
步骤3：化合物79-3的合成
在干燥的单口瓶中加入底物79-2(150mg,587.73μmol)溶于1,2-二氯乙烷(2mL)，加入甲醛(88.24mg,2.94mmol)，室温搅拌10分钟。加入三乙酰氧基硼氢化钠(622.81mg,2.94mmol)，室温搅拌1小时。反应结束后，冷却至室温，用水稀释，二氯甲烷萃取三次，有机相经过无水硫酸钠干燥，过滤，减压浓缩得到化合物79-3(131mg,487μmol)。LCMS(ESI)m/z:270.1[M+H] +。
步骤4：化合物79-4的合成
在干燥的单口瓶中将79-3(131mg,487μmol)溶于四氢呋喃(3mL)和乙酸(0.2mL)溶液中，加入锌粉(0.96g,14.61mmol)，室温搅拌30分钟。LC-MS监测，反应结束后用硅藻土过滤，滤液减压浓缩得到化合物79-4(123mg,515μmol)。LCMS(ESI)m/z:240.1[M+H] +。
步骤5：化合物79的合成
在干燥的单口瓶中，加入底物IM-1(15mg,42.20μmol)，加入四氢呋喃(1mL)溶解。加入间氯过氧苯甲酸(14.09mg,84.40μmol)，室温反应30分钟，再向反应液中加入N,N-二异丙基乙胺(27.27mg,211.00μmol)和79-4(10.10mg,42.20μmol)，室温反应3小时。LC-MS 监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物79(1.5mg,2.48μmol)。LCMS(ESI)m/z:549.3[M+H] +.HPLC:R T＝7.95min,purity:90.6％. 1H NMR(600MHz,DMSO-d 6)δ10.51(s,1H),8.95(s,1H),8.03-7.99(m,1H),7.75(d,J＝12.0Hz,1H),7.67(d,J＝12.0Hz,1H),7.55(d,J＝7.8Hz,1H),5.71-5.64(m,1H),5.70-5.64(m,1H),5.35(s,1H),5.01-4.98(m,1H),4.84(d,J＝1.8Hz,1H),4.80(d,J＝1.8Hz,1H),4.69(d,J＝8.0Hz,1H),3.62(d,J＝15.6Hz,2H),3.17(d,J＝10.2Hz,2H),3.05(d,J＝10.2Hz,2H),2.67(d,J＝2.4Hz,1H),2.33(d,J＝3.0Hz,1H),2.21(s,3H),1.80(d,J＝12.0Hz,1H),1.46(s,6H)。
实施例80：化合物80的合成
Figure PCTCN2023070285-appb-000179
步骤1：化合物80-2的合成
在干燥的单口瓶中加入底物80-1(581.98mg,3.02mmol)，溶于N,N-二甲基甲酰胺(10mL)中，加入丙二酸二甲酯(436mg,3.30mmol)，碳酸铯(3g,9.05mmol)，温度升至90℃反应2小时。LC-MS监测。反应结束后降至室温，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物80-2(753mg,2.61mmol)。LCMS(ESI)m/z:289.1[M+H] +。
步骤2：化合物80-3的合成
在干燥的单口瓶中将80-2(753mg,2.61mmol)溶于乙醇(10mL)和乙酸(2mL)溶液中，加入铁粉(582.80mg,10.44mmol)，温度升至80℃反应2小时。LC-MS监测，反应结束后用硅藻土过滤，滤液减压浓缩，残余物经MPLC纯化得到化合物80-3(417mg,1.84mmol)。LCMS(ESI)m/z:227.1[M+H] +。
步骤3：化合物80-4的合成
在干燥的单口瓶中加入底物80-3(45mg,198.57μmol)，溶于乙腈(10mL)中，加入碘甲烷(0.22g,1.99mmol)，碳酸钾(111mg,794.29μmol)，60℃下反应8小时。LC-MS监测。反应结束后将反应液冷却至室温，加水，用乙酸乙酯萃取3次，有机相用无水硫酸钠干燥，过滤，减压浓缩，残余物用柱层析纯化得到化合物80-4(15mg,58.90μmol)。LCMS(ESI)m/z:255.1[M+H] +。
步骤4：化合物80-5的合成
在干燥的微波管中，氮气保护下加入底物80-4(15mg,58.90μmol)、IM-1-4(13.09mg,58.90μmol)、碘化亚铜(22.43mg,117.80μmol)、碘化钠(17.66mg,117.80μmol)，碳酸钾(25mg,176.70μmol)和N,N'-二甲基-1,2-环己二胺(32.2mg,235.6μmol)，然后加入苯甲醚(1.5mL)。在氮气环境下，130℃微波加热反应4小时。LCMS监测，反应结束后反应体系冷却至室温，加入水和氨水(1mL)，乙酸乙酯萃取三次，有机相经无水硫酸钠干燥，过滤，减压浓缩，残余物经柱层析纯化得到化合物80-5(10.5mg,23.84μmol)。LCMS(ESI)m/z:441.1[M+H] +。
步骤5：化合物80的合成
在干燥的单口瓶中，加入底物80-5(30mg,68.11μmol)，加入四氢呋喃(1.5mL)溶解。 加入间氯过氧苯甲酸(26.39mg,152.92μmol)，室温反应1小时，再向反应液中加入N,N-二异丙基乙胺(19.76mg,152.92μmol)和1-5(19.5mg,101.95μmol)，室温反应3小时。LC-MS监测，反应结束后减压浓缩，残余物用制备高效液相色谱(碱性)纯化，得到化合物80(5.7mg,9.77μmol)。LCMS(ESI)m/z:584.2[M+H] +.HPLC:R T＝6.37min,purity:98.8％. 1H NMR(600MHz,DMSO-d 6)δ10.14(s,1H),8.82(s,1H),7.80(d,J＝7.8Hz,2H),7.67–7.39(m,2H),6.92(d,J＝8.4Hz,2H),5.66–5.63(m,1H),4.99(d,J＝10.2Hz,1H),4.81(d,J＝17.4Hz,1H),4.46(s,2H),3.59(s,3H),3.28(s,3H),3.10(s,4H),2.48–2.43(m,4H),2.23(s,3H),1.58(s,3H)。生物学评价试验：
无特殊说明时，该部分实施例中部分生物学评价实验用化合物AZD1775作为对照，AZD1775(CAS号：955365-80-7)的结构信息如下：
Figure PCTCN2023070285-appb-000180
实验例1：通过TR-FRET方法评价化合物在WEE1蛋白与Tracer 178结合的效果
首先准备不同浓度梯度的化合物溶液。将化合物溶解于DMSO中，并将化合物进行4倍稀释，共10个剂量点，每个浓度设置2个平行重复，加入DMSO作为阳性对照(最大信号对照)和阴性对照(最小信号对照)，同时确保每个反应孔中的DMSO最终含量为0.25％。
将化合物用ECHO665加入384孔板中，然后加入Wee1蛋白溶液，蛋白配置于缓冲液(50mM HEPES pH 7.5,10mM MgCl2,1mM EGTA,0.01％Brij-35)WEE1(Thermo Fisher,Cat#PR7373A)中，蛋白最终浓度为15nM),反应底物Tracer 178(Invitrogen,PV5593)和MAb Anti-GST-Eu crypate(Cisbio,61GSTKLA)加入384孔板(Corning,cat#3574)中，1000rpm离心1min，将384孔反应板置于恒温摇床孵育60min,25℃，300rpm。其中Tracer 178和MAb Anti-GST-Eu crypate配置于缓冲液(50mM HEPES pH 7.5,10mM MgCl2,1mM EGTA,0.01％Brij-35)，且Tracer178最终反应浓度为50nM,MAb Anti-GST-Eu crypate的最终浓度为2nM，其中阴性对照(最小信号对照)使用等量的缓冲液来代替蛋白溶液。
孵育完成后，用BMG PHERAStar读数(用337nm波长为激发光，在620nm和665nm波长值为发射光读荧光信号值)。计算荧光信号比值：665/620*1000为最终的酶活性信号值，根据阳性对照(最大信号对照)和阴性对照(最小信号对照)获得的读数TR-FRET信号进行标准化，得到不同浓度化合物的抑制率。再通过GraphPad Prism 6以log(inhibitor)vs.response–Variable slope模式拟合计算得出化合物对酶活性抑制的IC50。拟合方程为：Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))，其中Y代表已知的百分剩余酶活性，X代表Log后的已知化合物的浓度。
按照上述方法对实施例化合物进行Wee1抑制活性检测，试验结果见表1，其中测定各化合物的IC 50按照说明分类如下：
“-”表示IC 50测定值10μM；
“+”表示IC 50测定值小于等于10μM大于1μM；
“++”表示IC 50测定值小于等于1μM大于100nM；
“+++”表示IC 50测定值小于等于100nM大于10nM；
“++++”表示IC 50测定值小于等于10nM大于5nM；
“+++++”表示IC 50测定值小于等于5nM。
表1、本发明化合物对Wee1激酶的抑制活性
化合物编号 IC 50/nM 化合物编号 IC 50/nM 化合物编号 IC 50/nM
AZD1775 ++++ 化合物1 ++++ 化合物3 +++++
化合物4 +++++ 化合物5 +++++ 化合物6 +++++
化合物7 +++++ 化合物8 ++++ 化合物9 +++++
化合物10 +++++ 化合物11 ++++ 化合物12 ++++
化合物13 ++++ 化合物14 ++++ 化合物15 ++++
化合物16 +++ 化合物17 ++++ 化合物18 ++++
化合物19 +++++ 化合物20 ++++ 化合物21 +++
化合物22 +++ 化合物23 +++ 化合物24 +++
化合物25 ++++ 化合物27 ++++ 化合物28 ++++
化合物29 ++++ 化合物30 +++++ 化合物31 +++
化合物32 +++ 化合物33 +++ 化合物34 +++
化合物35 +++ 化合物36 +++ 化合物37 +++
化合物38 +++ 化合物39 +++++ 化合物41 +++
化合物42 +++ 化合物43 +++ 化合物44 ++++
化合物45 +++ 化合物46 +++ 化合物47 +++++
化合物47a +++ 化合物47b +++ 化合物48 +++++
化合物49 +++++ 化合物50 ++ 化合物51 +++++
化合物52 +++ 化合物53 ++++ 化合物54 ++++
化合物55 +++ 化合物56 +++ 化合物57 +++
化合物58 ++++ 化合物60 ++++ 化合物61 +++++
化合物62 ++++ 化合物63 + 化合物64 +++
化合物65 ++++ 化合物66 ++++ 化合物67 ++++
化合物68 +++ 化合物69 +++ 化合物70 ++++
化合物71 +++ 化合物72 +++ 化合物73 +++
化合物74 +++ 化合物75 +++ 化合物76 +++
化合物77 ++++ 化合物78 +++ 化合物79 +++
上述实验表明，本发明公开化合物的对Wee1激酶有明显的抑制活性。
实验例2：细胞增殖抑制活性评价
1.通过Cell Titer-Glo方法评价化合物对H1299细胞抗增殖活性。
H1299(ATCC,cat#HTB-96)细胞按照750cells/well在培养基(90％1640(Hyclone,cat#16600082)+10％FBS(Corning,Cat#35-081-CV)+100ug/ml Normocin(InvivoGen,cat#Ant-nr-2))接种于384孔板中(Corning,3707)，37℃，5％CO 2孵育过夜，使其贴壁。
配置不同浓度梯度的化合物溶液。取DMSO溶解到浓度为10mM测试化合物和10mM参考化合物AZD1775，将化合物在培养基中进行系列稀释，共9个剂量点，每个浓度设置2个平行重复。不添加化合物的细胞生长组作为阳性对照(最大信号对照)，将培养基作为阴性对照(最小信号对照)，同时确保每个反应孔中的DMSO最终含量为0.2％。移除384孔板中的培养基后，将配置好的25ul的不同浓度化合物转移进孔板中，化合物和细胞在细胞培养箱37℃，5％CO 2孵育3天。
将384孔板从细胞培养箱中取出使其平衡1h至室温，再将25ul的Cell Titer-Glo检测试剂加入每个反应孔，摇床裂解2min后，室温孵育10min，用BMG PHERAStar读数 (Luminescence)。根据发光信号计算抑制率：先计算出阳性对照(最大信号对照)和阴性对照(最小信号对照)平均值，
以
Figure PCTCN2023070285-appb-000181
来计算出不同浓度化合物对细胞的抑制率。通过GraphPad Prism 6以log(inhibitor)vs.response–Variable slope模式拟合计算得出化合物对细胞活性抑制的IC50。拟合方程为：Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))，其中Y代表抑制率，X代表Log后的已知化合物的浓度。
2.通过Cell Titer-Glo方法评价化合物对MIA PaCa2细胞抗增殖活性。
MIA PACA2(ATCC,cat#CRL-1420)细胞按照750cells/wel在培养基(90％1640(Hyclone,cat#16600082)+10％FBS(Corning,Cat#35-081-CV)+100ug/ml Normocin(InvivoGen,cat#Ant-nr-2))种于在384孔板中(Corning,3707)，37℃，5％CO 2孵育过夜，使其贴壁。
配置不同浓度梯度的化合物溶液。取DMSO溶解到浓度为10mM测试化合物和10mM参考化合物AZD1775，将化合物进行系列稀释于培养基中，共9个剂量点，每个浓度设置2个平行重复。不添加化合物的细胞生长组作为阳性对照(最大信号对照)，将培养基作为阴性对照(最小信号对照)，同时确保每个反应孔中的DMSO最终含量为0.2％。移除384孔板中的培养基后，将配置好的25ul的不同浓度化合物转移进孔板中，化合物和细胞在细胞培养箱37℃，5％CO 2孵育3天。
将384孔板从细胞培养箱中取出使其平衡1h至室温，再将25ul的Cell Titer-Glo检测试剂加入每个反应孔，摇床裂解2min后，于孵育10min后，用BMG PHERAStar读数(Luminescence)。根据发光信号计算抑制率：先计算出阳性对照(最大信号对照)和阴性对照(最小信号对照)平均值，
以
Figure PCTCN2023070285-appb-000182
来计算出不同浓度化合物对细胞的抑制率。通过GraphPad Prism 6以log(inhibitor)vs.response–Variable slope模式拟合计算得出化合物对细胞活性抑制的IC50。拟合方程为：Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))，其中Y代表抑制率，X代表Log后的已知化合物的浓度。
按照上述方法对实施例化合物进行H1299和MIA PaCa2体外抗细胞增殖试验，试验结果见表2，其中测定各化合物的IC 50按照说明分类如下：
“-”表示IC 50测定值大于10μM；
“+”表示IC 50测定值小于等于10μM大于5μM；
“++”表示IC 50测定值小于等于5μM大于2μM；
“+++”表示IC 50测定值小于等于2μM大于1μM；
“++++”表示IC 50测定值小于等于1μM大于0.1μM；
“+++++”表示IC 50测定值小于等于0.1μM。
表2、本发明化合物对H1299、MIA PaCa-2体外抗细胞增殖抑制活性
化合物编号 H1299 MIA PaCa 2 化合物编号 H1299 MIA PaCa 2
AZD1775 ++++ ++++ 化合物1 ++ 未测试
化合物3 ++++ ++++ 化合物4 +++ 未测试
化合物5 ++++ 未测试 化合物6 ++++ 未测试
化合物7 ++++ 未测试 化合物8 + 未测试
化合物9 +++ 未测试 化合物10 ++++ 未测试
化合物11 ++++ ++++ 化合物12 ++++ ++++
化合物13 + + 化合物14 + ++
化合物15 - ++ 化合物16 - -
化合物17 ++++ +++ 化合物18 ++ ++++
化合物19 - - 化合物20 ++++ +++
化合物21 +++ ++++ 化合物22 ++++ +++
化合物23 - ++ 化合物24 + ++++
化合物25 +++ +++ 化合物27 ++++ ++++
化合物28 ++++ ++++ 化合物29 - -
化合物30 +++ +++ 化合物31 + +
化合物32 ++ ++ 化合物33 +++ ++
化合物34 + ++ 化合物35 ++ +++
化合物36 +++ +++ 化合物37 ++ ++++
化合物38 ++ ++++ 化合物39 ++++ +++++
化合物41 ++++ ++++ 化合物42 ++++ ++++
化合物43 ++ ++ 化合物44 ++++ ++++
化合物45 - + 化合物46 ++++ ++++
化合物47 ++++ ++++ 化合物47a ++++ +++
化合物47b ++ ++ 化合物48 ++++ ++++
化合物49 ++++ ++++ 化合物50 + -
化合物51 ++++ ++++ 化合物52 - -
化合物53 ++++ ++ 化合物54 ++ ++
化合物55 +++ +++ 化合物56 + +
化合物57 - - 化合物58 ++++ ++++
化合物60 ++++ ++++ 化合物61 ++ ++
化合物62 +++ ++++ 化合物63 - -
化合物64 ++++ ++++ 化合物65 ++++ ++++
化合物66 ++++ ++++ 化合物67 ++++ +++++
化合物68 +++ ++++ 化合物69 ++++ 未测试
化合物70 ++++ 未测试 化合物71 ++ 未测试
化合物72 + 未测试 化合物73 +++ 未测试
化合物74 - - 化合物75 +++ 未测试
化合物76 ++++ +++ 化合物77 +++ +++
化合物78 - +++ 化合物79 - 未测试
由表2可知，本发明化合物中大部分化合物对于H1299和MIA PaCa-2肿瘤细胞具有良好的增殖抑制活性，其中部分化合物，其增殖抑制活性优于对照化合物AZD1775。
实验例3：体外肝微粒体(小鼠和人)测试
1.工作液的配制：
微粒体从-80℃冰箱取出，在37℃水浴锅中迅速融解，置于冰上待用。将供试品用DMSO稀释配制成10mM的储备液，然后用乙腈稀释成0.5mM的次级储备液。使用Buffer C将微粒体稀释为0.75mg/ml；再加入次级储备液至化合物终浓度1.5μM为工作液，依据n＝2，5个时间点计算，每个化合物配制350μL，使用前置于冰上。用Buffer C将NADPH稀释为6mM的工作液，为启动液。配制含内标的乙腈溶液作为沉淀剂，内标选用Verapamil-HCl，浓度为 4ng/ml。
2.实验过程：
取一块圆底孔板，记做反应板，将各化合物配置好的工作液按照复样数和时间点分装到孔板中(0h的样品同样加在反应板上)，30μL/孔；反应板于37℃孵育10分钟。另取一块尖底孔板，记做沉淀板，每孔加入135μL沉淀剂；0h的样品在孵育10分钟后转移至沉淀板中，再加入15μL启动液，沉淀板在离心前置于冰上待用。
将稀释好的启动液足量加入至分装板中，方便排枪吸取操作。
反应在温孵震荡装置上进行，使用排枪吸取启动液15μL/样品，加入反应板中。稍震荡混匀以启动反应，使用计时器准确计时并记录；通常，反应时间较短的样品晚启动，反之早启动，为多块板操作终止反应留出足够时间。例：5,15,30,60min四个时间点的实验，60min的先启动，5min的后启动，便于为5min时间点组别留出足够的操作时间。
到反应时间后，使用排枪将反应板中的所有溶液吸出加入到沉淀板中以终止该时间点反应。所有反应终止后，将沉淀板在摇板机上600rpm震荡十分钟沉淀蛋白。离心机最大转数在4℃离心15分钟，取上清80μL，加入320μL纯水，混匀后进行LC-MS分析。
3.实验结果：如表3所示。
表3体外肝微粒体(小鼠和人)测试结果
化合物 T 1/2/min(M) T 1/2/min(H) 化合物 T 1/2/min(M) T 1/2/min(H)
AZD1775 25.99 38.12 化合物3 96.25 >120
化合物4 10.08 22.21 化合物6 5.72 5.16
化合物8 >120 未测试 化合物9 0.78 2.82
化合物10 1.34 8.31 化合物11 110.0 未测试
化合物12 31.50 未测试 化合物15 >120 未测试
化合物18 >120 未测试 化合物19 48.12 未测试
化合物23 38.72 未测试 化合物24 >120 未测试
化合物25 14.09 未测试 化合物27 33 105
化合物28 15.03 未测试 化合物37 21.72 未测试
化合物39 >120 未测试 化合物46 13.64 16.82
化合物51 14.65 19.04 化合物54 77 未测试
化合物57 43.86 未测试 化合物61 >120 未测试
化合物62 25.11 未测试 / / /
由表3可知，本发明化合物在体外肝微粒模型评价下具有良好的代谢稳定性质。
实验例4细胞渗透性评价(Caco-2模型)
Caco-2细胞购买自美国模式组织细胞收藏中心(Rockville，MD)。细胞培养液为含10％灭活胎牛血清和1％非必须氨基酸的改良Eagle’s培养基(MEM)。细胞接种于聚碳酸脂滤膜(货号：3396)并置于37℃，5％CO 2培养箱中培养。
细胞接种后培养21～28天可用于转运实验，并通过路西法黄的表观通透系数(P app)来表征和验证细胞单层的致密性。实验中将化合物溶解于DMSO中制备10mM的储备液，并使用含有25mM HEPES(pH 7.4)的汉克斯平衡盐溶液(HBSS，Invitrogen，Cat#14025-092)进行稀释得到工作液。将10μM的待测化合物工作液加入Caco-2顶膜侧(apical side)和基底侧(basolateral side)并于37℃孵育90分钟，孵育结束后，将顶膜侧和基底侧的样品稀释，并通过LC-MS/MS检测顶膜侧和基底侧化合物的浓度，并通过标准曲线定量计算化合物的浓度。测试结果如表4所示。
表4化合物在Caco-2模型上的渗透性数据
Figure PCTCN2023070285-appb-000183
由表4的实验结果可以得出，本发明化合物部分化合物在Caco-2模型上的细胞渗透性性质与对照化合物相当。
实验例5：血浆蛋白结合率(PPB)评价
1.实验过程
样品准备：将化合物用DMSO溶解为10mM的储备液，然后用PBS将化合物稀释为0.02mM的次级储备液，再使用空白血浆将上述0.02mM稀释至1μM，即为待孵育样品。
透析装置准备：先在平衡透析板的白色孔中加入400μL空白PBS，红色孔中加入200μL配置好的血浆样品，用封口膜将透析板进行封口
回收率孔板准备：准备两块96孔深孔板，标记为T0及T5，所有血浆样品以n＝2分别加入两板。T0板直接加入300μL乙腈(Verapamil-HCl，4ng/mL)，再补加50μL空白PBS混匀5min，放入4℃冰箱中静置至孵育实验结束。
实验操作：透析装置和T5板置于微孔板恒温振荡器中共同孵育5h(37℃，使用300rpm或最小转速)。孵育结束后，加入300μL乙腈(Verapamil-HCl，4ng/mL)，再补加50μL PBS溶液。透析孵育结束后，取一块新96孔深孔板。取50μL血浆孔样品加入96孔板对应位置，再加入300μL乙腈，补加50μL空白PBS；取50μL缓冲孔样品加入96孔板对应位置，再加入300μL乙腈，补加50μL空白血浆。T5板含血浆孔中加入300μL乙腈(Verapamil-HCl，4ng/mL)，再补加50μL PBS溶液。振荡5min以充分沉淀蛋白，4℃，20000g离心10分钟。取200μL上清液加入200μL纯水中，混匀后进行LC-MS/MS分析。
2.数据处理和参数计算
●血浆蛋白结合率＝[(Rpe-Rb)/Rpe]×100％
●回收率＝[(Rpe+Rb)/R5h]×100％
●稳定性＝(R5/R0)×100％
其中：
●R pe＝血浆侧供试品峰面积与内标比值
●R b＝缓冲液侧供试品峰面积与内标比值
●R 5＝孵箱稳定性样品峰面积与内标比值
●R 0＝冰箱稳定性样品峰面积与内标比值
3.测试结果如表5所示：
表5代表性化合物的血浆蛋白结合率(小鼠)
化合物 小鼠血浆PPB(％)
AZD1775 91.3
化合物3 85.8
化合物27 85.9
化合物46 82.1
化合物48 96.9
化合物49 95.8
化合物51 97.0
化合物53 96.5
由表5实验结果可知，本发明化合物具有良好的血浆蛋白结合能力。
实验例6：CYP450各亚型酶学抑制活性评价
酶学实验通过细胞色素P450对底物的氧化产生的荧光，定量检测小分子抑制剂对CYP450各亚型酶活性的抑制情况。实验在384孔板(Corning，Cat#3575)中进行，使用的反应缓冲液为：142.86mM Potassium Phosphate，pH 7.4。实验所用Solution A成分为：26.13mM NADP +(Sigma-aldrich，Cat#N0505)，65.77mM G6P(J&K，Cat#968161)及65.42mM MgCl 2(Sigma-aldrich，Cat#M2670)。实验所用的Solution B成分为：40U/mL G6PDH(Sigma-aldrich，Cat#G6378)。底物混合溶液成分为：0.05X Solution A，0.01X Solution B，50mM Potassium Phosphate，0.01mM BOMCC/0.01mM EOMCC/0.001mM DBOMF。对于CYP3A4和CYP2C9，反应体系分别为50μL或20μL，包括3nM CYP3A4或120nM CYP2C9，BOMCC底物混合溶液和不同浓度的待测化合物。对于CYP2C19，CYP2D6及CYP1A2，反应体系为20μL，包括12.5nM CYP2C19，80nM CYP2D6或1nM CYP1A2，EOMCC底物混合溶液和不同浓度的待测化合物。对于CYP2C8，反应体系为50μL，包括1.5nM CYP2C8，DBOMF底物混合溶液和不同浓度的待测化合物。化合物与酶预孵10分钟后，加入底物，并根据不同底物使用BMG PHERAStar读取不同波段的荧光信号(BOMCC/EOMCC Ex430nm/Em480nm，DBOMF Ex490nm/Em520nm)，反应间隔30秒或更多(根据实际实验孔数设置)，反应时长为30分钟。实验数据通过GraphPad Prism 6软件进行分析处理得到IC 50值，结果如表6所示。
表6化合物对不同亚型的CYPs抑制测试结果
Figure PCTCN2023070285-appb-000184
由表6实验结果可知，本发明化合物3无明显的细胞色素P450酶抑制活性。
实验例7：钾离子通道(hERG)抑制活性评价
实验目的：用手动膜片钳的方法检测待测化合物对hERG钾离子通道的影响。
实验步骤：
(一)实验材料：
A.CHO(中华仓鼠卵巢细胞)稳定转染细胞系培养
膜片钳实验所用细胞株为过表达hERG钾离子通道cDNA的第10代CHO细胞。
CHO hERG细胞在37℃、5％CO 2培养箱中用培养皿或培养瓶培养。电生理实验前24-48小时，将细胞滴于圆形玻片上在细胞培养液中培养，待细胞贴壁后用于实验。
细胞培养基(购自Invitrogen)成分：
·Ham’s F12培养基
·10％(v/v)热灭活FBS
·100μg/ml Hygromycin B(潮霉素)
·100μg/ml Geneticin(遗传霉素，G418)
B.化合物准备
化合物粉末溶解在细胞外液中，都经过常规的5到10分钟超声和振荡以保证化合物完全溶解。
用于电生理检测的化合物终浓度为5、20μM，DMSO的终浓度为0.1％。
(二)实验方案：
A.电生理记录实验过程
细胞膜电流记录使用HEKA EPC-10USB膜片钳放大器(德国HEKA Elektronik)。
1)取表面有大量单个CHO hERG细胞均匀生长的盖玻片，放置于倒置显微镜上的连续记录池中，灌流细胞外液(大约每分钟1毫升)并持续记录，等待电流稳定。
2)使用标准的全细胞记录模式记录单个细胞的HERG通道电流。首先将膜电压钳制在-80mV，给予细胞持续5s，+20mV电压刺激，以激活hERG钾通道，再复极化至-50mV，持续5s，产生外向尾电流，持续灌注待电流稳定，此时尾电流峰值即为对照电流值。
3)接着灌流含待测药物的细胞外液并持续记录直到药物对hERG电流的抑制作用到达稳定状态，此时尾电流峰值即为加药后电流值。
4)再次用细胞外溶液灌注细胞，直到hERG电流回复或接近加药物之前的水平，则可以继续灌流测试其它浓度或药物。可在每个细胞上测试一种或多种化合物或药物浓度。
5)以Cisapride(C4740-10mg，Sigma)作为实验中的阳性对照以保证所使用的细胞反应正常。
(三)质量控制
报告中的试验数据需要满足以下标准：
电生理记录参数
a)封接电阻>500MΩ
b)接触电阻(Ra)<10MΩ
c)初始尾电流幅度>200pA
d)电流rundown(自发性减小)<2％/min
e)漏电流<200pA或者hERG电流峰值的10％(在90％的记录时间之内)
测试结果如表7所示：
表7化合物的hERG抑制测试结果
Figure PCTCN2023070285-appb-000185
由表7实验结果可知，本发明化合物3无明显的hERG抑制活性，从本发明的试验结果可知，本发明的化合物，特别是优选的化合物在药物活性和毒副作用方面优于现有技术。
实验例8：小鼠单次给药药代动力学评价
本实验旨在研究雄性ICR小鼠给药后，血浆中的药代动力学情况
1.试验目的
本试验的目的是为了获得受试化合物在ICR小鼠的药物代谢动力学情况(含静脉和口服)
2.规范依从性
本试验(非GLP研究)供试品-检测，DMPK动物试验，DMPK分析均在成都先导完成，所有试验均遵循本试验方案，及相关机构的相关SOP。
3.试验材料、仪器和设备
3.1试验材料
3.1.1供试品
以下供试品由成都先导提供，并确保其质量符合要求。
名称/代码 受试化合物
性状 溶液
溶媒/剂型 5％DMSO-10％Solutol-85％HPBCD(20％,W/V)
保存条件 室温
配试液浓度 0.2mg/ml(静脉)，1mg/ml(口服)
配试液体积 3ml，3ml
3.1.2试验系统
种属：SPF级雄性ICR小鼠
体重/周龄：30g左右
数量：6只
实验动物来源：维通利华
4.试验过程
4.1溶媒配制
静注溶媒：5％DMSO-10％Solutol-85％HPBCD(20％,W/V)
“灌胃溶媒/剂型：5％DMSO-10％Solutol-85％HPBCD(20％,W/V)”
4.2受试物给予(途径)
静脉注射：给药剂量1mg/kg，给药体积5mL/kg
灌胃：给药剂量10mg/kg，给药体积10mL/kg
给药前超声5min
4.3受试物配制(浓度)
静脉：0.2mg/mL
灌胃：1mg/mL
给药前禁食过夜，给药后四小时喂食。
4.4样品采集
给药后5分钟(仅IV)、15分钟、30分钟、1小时、2小时、4小时、8小时、24小时分别于每个时间点经眼眶静脉丛穿刺采血(40-50μL)至含预喷涂EDTA-K2的抗凝管中，血液样品1小时内以10000rpm离心20分钟(离心前后至于湿冰上保存)取上层液即血浆，于-20℃及以下冰箱冷冻保存，以备LC-MS/MS分析。
4.5生物药品分析方法及检测:用LC-MS/MS分析检测。
5数据处理
样品通过LC-MS/MS检测各时间点的药物浓度。采用Phoenix WinNonlin 5.2非房室模型计算药代动力学参数末端消除半衰期(t 1/2)、药时曲线下面积(AUC)、表观分布容积(Vd)、清除率(CL)、平均驻留时间(MRT)、Cmax、生物利用度(F％)直接从血清浓度结果中获得。血药浓度及药代参数等采用均数±标准差(X±SD)。具体检测分析方法以方案修订的形式明确。
6试验结果如表8所示：
表8小鼠上的药代动力学参数
Figure PCTCN2023070285-appb-000186
Figure PCTCN2023070285-appb-000187
由实验表8可知，在小鼠体内药代动力学检测分析发现，本发明化合物48和49与对照化合物AZD1775的药代动力学性质相当，化合物51、53其药代动力学性质优于对照化合物AZD1775。

Claims (21)

  1. 式I所示的化合物、或其立体异构体、或其药学上可接受的盐：
    Figure PCTCN2023070285-appb-100001
    其中，所述的R 1选自-C 1～6烷基、-C 2～6烯基、-C 2～6炔基、-C 0～2亚烷基-CN、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)；所述的-C 0～2亚烷基、-C 1～6烷基、-C 2～6烯基、-C 2～6炔基、3～10元环烷基、3～10元杂环烷基可进一步被一个、两个、三个或四个独立的R 11取代；
    所述的R 11选自氢、C 1～6烷基、卤素取代的C 1～6烷基、卤素；
    R 2选自
    Figure PCTCN2023070285-appb-100002
    Figure PCTCN2023070285-appb-100003
    Figure PCTCN2023070285-appb-100004
    所述的R 21选自氢、C 1～6烷基、卤素取代的C 1～6烷基、-C 0～2亚烷基-C(O)OC 1～6烷基、-C 0～2亚烷基-COOH、-C(O)C 1～6烷基、卤素；
    所述的R 3选自
    Figure PCTCN2023070285-appb-100005
    Figure PCTCN2023070285-appb-100006
    X 1选自化学键、O、NR N1或者CR C1R C2；X 2选自N或者CR C1；所述的X 3选自O、NR N1或者CR C1R C2；
    n选自1、2或3；
    R N1选自氢、卤素、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C(O)(C 1～6烷基)；
    R C1、R C2分别独立地选自氢、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-C 0～2亚烷基-NH(C 1～6烷基)、-C 0～2亚烷基-N(C 1～6烷基)(C 1～6烷基)；
    R 4选自-(5～12元桥杂环烷基)；所述的桥杂环烷基可进一步被一个、两个、三个或四个独立的R 41取代；
    所述的R 41选自氢、氧代、-C 1～6烷基、-C 2～6烯基、卤素取代的C 1～6烷基、羟基取代的C 1～6烷基、卤素、氰基、硝基、-OH、-C 0～2亚烷基-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-C(O)R 42、-C 0～2亚烷基-C(O)NR 42R 43、-C 0～2亚烷基-C(O)OR 42、-C 0～2亚烷基-S(O)R 42、-C 0～2亚烷基-S(O)NR 42R 43、-C 0～2亚烷基-S(O)OR 42、-C 0～2亚烷基-S(O) 2R 42、-C 0～2亚烷基-S(O) 2NR 42R 43、-C 0～2亚烷基-S(O) 2OR 42、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；其中，所述的烷基、亚烷基、环烷基、杂环烷基、芳环、芳杂 环可进一步被一个、两个、三个或四个独立的R 44取代；
    R 42、R 43分别独立选自氢、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；
    R 44选自氢、氧代、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的-C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-C 0～2亚烷基-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)；
    或者，所述的R 41与R C1或R C2与其直接相连的原子一起形成3～10元碳环、3～10元杂环；
    所述的R 5选自氢、氧代、卤素、氰基、硝基、-OH、-NH 2、-C 1～6烷基、卤素取代的C 1～6烷基、羟基取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-C 0～2亚烷基-NH(C 1～6烷基)、-O-C 0～2亚烷基-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-O-(3～10元环烷基)、-O-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；其中，所述的烷基、亚烷基、环烷基、杂环烷基、芳环、芳杂环可进一步被一个、两个、三个或四个独立的R 51取代；
    所述的R 51选自氢、C 1～6烷基、卤素取代的C 1～6烷基、氧代、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-C 0～2亚烷基-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)；
    每个R 6分别独立选自氢、C 1～6烷基、卤素取代的C 1～6烷基、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)、-C 0～2亚烷基-(5～12元螺环)、-C 0～2亚烷基-(5～12元螺杂环)、-C 0～2亚烷基-(5～12元桥环)、-C 0～2亚烷基-(5～12元桥杂环)；
    其中，所述的A环选自5～12元螺环、5～12元螺杂环、5～12元桥环、5～12元桥杂环；其中螺环、螺杂环、桥环、桥杂环可进一步被一个、两个、三个或四个独立的R A1取代；
    每个R A1分别独立选自氢、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)、-C 0～2亚烷基-(5～12元螺环)、-C 0～2亚烷基-(5～12元螺杂环)、-C 0～2亚烷基-(5～12元桥环)、-C 0～2亚烷基-(5～12元桥杂环)；
    其中，所述的B环选自3～10元碳环、3～10元杂环、5～10元芳环、5～10元芳杂环、5～12元螺环、5～12元螺杂环、5～12元桥环、5～12元桥杂环、3～10元稠环、3～10元稠杂环；其中，所述的碳环、杂环、芳环、芳杂环、螺环、螺杂环、桥环、桥杂环、稠环、稠杂环可进一步被一个、两个、三个或四个独立的R B1取代；
    每个R B1分别独立选自氢、-C 1～6烷基、卤素取代的C 1～6烷基、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；
    R 7、R 8分别独立选自氢、卤素、氰基、硝基、-OH、-C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)；
    或R 7、R 8与其直接相连的原子形成3～10元稠环、3～10元稠杂环、3～10元螺环、3～10元螺杂环；所述的稠环、稠杂环、螺环、螺杂环可进一步被一个、两个、三个或四个独立的 R 71取代；
    每个R 71分别独立选自氢、C 1～6烷基、卤素取代的C 1～6烷基、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)；
    其中，所述的C环选自5～12元螺环、5～12元螺杂环、5～12元桥环、5～12元桥杂环、3～10元稠环、3～10元稠杂环；其中螺环、螺杂环、桥环、桥杂环、稠环、稠杂环可进一步被一个、两个、三个或四个独立的R C1取代；
    每个R C1分别独立地选自氢、卤素、氰基、硝基、-OH、C 1～6烷基、卤素取代的C 1～6烷基、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)、-C 0～2亚烷基-(3～10元环烷基)、-C 0～2亚烷基-(3～10元杂环烷基)、-C 0～2亚烷基-(5～10元芳环)、-C 0～2亚烷基-(5～10元芳杂环)、-C 0～2亚烷基-(5～12元螺环)、-C 0～2亚烷基-(5～12元螺杂环)、-C 0～2亚烷基-(5～12元桥环)、-C 0～2亚烷基-(5～12元桥杂环)；
    所述R 10选自氢、C 1～6烷基、卤素取代的C 1～6烷基；
    所述R 9选自-C 0～2亚烷基-C(O)NR 91R 92、-C(O)C 1～6烷基；每个R 91、R 92分别独立选自氢、C 1～6烷基、卤素取代的C 1～6烷基；
    或R 91、R 92与其直接相连的原子形成3～10元杂环，所述杂环可进一步被一个、两个、三个或四个独立的R 93取代；
    每个R 93分别独立选自氢、C 1～6烷基、卤素取代的C 1～6烷基、卤素、氰基、硝基、-OH、-O(C 1～6烷基)、-O(卤素取代的C 1～6烷基)、-NH 2、-NH(C 1～6烷基)、-N(C 1～6烷基)(C 1～6烷基)；
    当R 3为
    Figure PCTCN2023070285-appb-100007
    且B环为3元碳环，R1为
    Figure PCTCN2023070285-appb-100008
    时，R 2不为
    Figure PCTCN2023070285-appb-100009
    R 3为
    Figure PCTCN2023070285-appb-100010
    R 7、R 8分别为氢，R1为
    Figure PCTCN2023070285-appb-100011
    时、R 2不为
    Figure PCTCN2023070285-appb-100012
    R 3为
    Figure PCTCN2023070285-appb-100013
    X 1为键，R 4为
    Figure PCTCN2023070285-appb-100014
    R1为
    Figure PCTCN2023070285-appb-100015
    时，R 2不为
    Figure PCTCN2023070285-appb-100016
    R 3为
    Figure PCTCN2023070285-appb-100017
    X 1为键，R 4为
    Figure PCTCN2023070285-appb-100018
    R1为
    Figure PCTCN2023070285-appb-100019
    时，R 2不为
    Figure PCTCN2023070285-appb-100020
    R 3为
    Figure PCTCN2023070285-appb-100021
    R1为
    Figure PCTCN2023070285-appb-100022
    时，R 2为
    Figure PCTCN2023070285-appb-100023
    Figure PCTCN2023070285-appb-100024
    R3为
    Figure PCTCN2023070285-appb-100025
    R1为
    Figure PCTCN2023070285-appb-100026
    时，R 2不为
    Figure PCTCN2023070285-appb-100027
    R 2为
    Figure PCTCN2023070285-appb-100028
    R 21为甲基，R1为
    Figure PCTCN2023070285-appb-100029
    时，R 3不为
    Figure PCTCN2023070285-appb-100030
    R 2为
    Figure PCTCN2023070285-appb-100031
    R 21为氢，R1为
    Figure PCTCN2023070285-appb-100032
    时，R 3不为
    Figure PCTCN2023070285-appb-100033
    R 2为
    Figure PCTCN2023070285-appb-100034
    R 21为氢，R1为
    Figure PCTCN2023070285-appb-100035
    时，R 3不为
    Figure PCTCN2023070285-appb-100036
    R 2为
    Figure PCTCN2023070285-appb-100037
    R 21为氢，R1为
    Figure PCTCN2023070285-appb-100038
    时，R 3不为
    Figure PCTCN2023070285-appb-100039
    R 2为
    Figure PCTCN2023070285-appb-100040
    R1为
    Figure PCTCN2023070285-appb-100041
    时,R 3不为
    Figure PCTCN2023070285-appb-100042
  2. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的R 1选自甲基、乙基、丙基、异丙基、环丙基、
    Figure PCTCN2023070285-appb-100043
    Figure PCTCN2023070285-appb-100044
  3. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的R 2选自
    Figure PCTCN2023070285-appb-100045
    Figure PCTCN2023070285-appb-100046
    Figure PCTCN2023070285-appb-100047
  4. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的X 1选自化学键、O、NR N1或者CR C1R C2；
    R C1、R C2分别独立地选自氢、C 1～3烷基、卤素、卤素取代的C 1～3烷基、-C 1～2亚烷基-N(C 1～3烷基)(C 1～3烷基)；
    R N1选自氢、C 1～3烷基、卤素取代的C 1～3烷基、-(3～10元杂环烷基)。
  5. 根据权利要求4所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的R 4选自：
    Figure PCTCN2023070285-appb-100048
    其中，X选自O、NR 41；X 4选自O、NH或者CH 2；n 1选自1或2；所述的R 4可进一步被一个、两个、三个或四个独立的R 41取代；
    所述的R 41选自氢、氧代、C 1～3烷基、-C 2～6烯基、卤素取代的C 1～3烷基、羟基取代的C 1～6烷基、-C 0～2亚烷基-O(C 1～3烷基)、-NH 2、-NH(C 1～3烷基)、-N(C 1～3烷基)(C 1～3烷基)、-C(O)R 42、-C(O)NR 42R 43、-C(O)OR 42、-(3～10元环烷基)、-(3～10元杂环烷基)、-C 1～2亚烷基-(5～10元芳环)；其中，所述的烷基、亚烷基、环烷基、杂环烷基、芳环可进一步被一个、两个、三个或四个独立的R 44取代；
    R 42、R 43分别独立选自氢、卤素、-OH、C 1～3烷基、卤素取代的C 1～3烷基；
    R 44选自氢、C 1～3烷基、卤素取代的C 1～3烷基、-O(C 1～3烷基)。
  6. 根据权利要求5所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的R 4具体选自：
    Figure PCTCN2023070285-appb-100049
    Figure PCTCN2023070285-appb-100050
    Figure PCTCN2023070285-appb-100051
  7. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的R 5选自氢、卤素、-C 1～3烷基、卤素取代的C 1～3烷基、羟基取代的C 1～3烷基、-O(C 1～3烷基)、-NH(C 1～3烷基)、-O-C 2亚烷基-N(C 1～3烷基)(C 1～3烷基)、-O-(3～10元环烷基)、-O-(3～10元杂环烷基)，其中，所述的烷基、亚烷基、环烷基、杂环烷基可进一步被一个、两个、三个或四个独立的R 51取代；
    所述的R 51选自氢、C 1～3烷基、卤素取代的C 1～3烷基。
  8. 根据权利要求7所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的R 5具体选自甲基、乙基、乙氧基、F、羟基取代的甲基、
    Figure PCTCN2023070285-appb-100052
  9. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的R 6选自氢、-C 1～3烷基、-NH(C 1～3烷基)、-N(C 1～3烷基)(C 1～3烷基)。
  10. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的A环选自
    Figure PCTCN2023070285-appb-100053
  11. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的B环选自3～10元杂环、5～12元桥杂环、3～10元稠杂环；其中，所述的杂环、桥杂环、稠杂环可进一步被一个、两个、三个或四个独立的R B1取代；
    每个R B1分别独立选自氢、C 1～3烷基、卤素取代的C 1～3烷基。
  12. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述B环选自
    Figure PCTCN2023070285-appb-100054
    Figure PCTCN2023070285-appb-100055
  13. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述C环选自
    Figure PCTCN2023070285-appb-100056
  14. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的R 7、R 8分别独立地选自-OH、
    Figure PCTCN2023070285-appb-100057
    或R 7、R 8与其直接相连的原子形成
    Figure PCTCN2023070285-appb-100058
  15. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：所述的R 3选自
    Figure PCTCN2023070285-appb-100059
    Figure PCTCN2023070285-appb-100060
    Figure PCTCN2023070285-appb-100061
    Figure PCTCN2023070285-appb-100062
    Figure PCTCN2023070285-appb-100063
  16. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：式I所述的化合物具体为：
    Figure PCTCN2023070285-appb-100064
    Figure PCTCN2023070285-appb-100065
    Figure PCTCN2023070285-appb-100066
    Figure PCTCN2023070285-appb-100067
    Figure PCTCN2023070285-appb-100068
    Figure PCTCN2023070285-appb-100069
    Figure PCTCN2023070285-appb-100070
    Figure PCTCN2023070285-appb-100071
    Figure PCTCN2023070285-appb-100072
    Figure PCTCN2023070285-appb-100073
    Figure PCTCN2023070285-appb-100074
    Figure PCTCN2023070285-appb-100075
    Figure PCTCN2023070285-appb-100076
    Figure PCTCN2023070285-appb-100077
    Figure PCTCN2023070285-appb-100078
    Figure PCTCN2023070285-appb-100079
    Figure PCTCN2023070285-appb-100080
    Figure PCTCN2023070285-appb-100081
    Figure PCTCN2023070285-appb-100082
    Figure PCTCN2023070285-appb-100083
    Figure PCTCN2023070285-appb-100084
    Figure PCTCN2023070285-appb-100085
  17. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征在于：式I所述的化合物具体为：
    Figure PCTCN2023070285-appb-100086
    Figure PCTCN2023070285-appb-100087
    Figure PCTCN2023070285-appb-100088
    Figure PCTCN2023070285-appb-100089
    Figure PCTCN2023070285-appb-100090
    Figure PCTCN2023070285-appb-100091
  18. 根据权利要求1所述的化合物、或其立体异构体、或其药学上可接受的盐，其特征 在于：式I所述的化合物具体为：
    Figure PCTCN2023070285-appb-100092
  19. 权利要求1-18任一项所述的化合物、或其立体异构体、或其药学上可接受的盐在制备治疗WEE1介导的疾病的药物中的用途。
  20. 权利要求19所述的用途，其特征在于：所述WEE1介导的疾病是与炎症、自身免疫性疾病、感染性疾病、癌症、癌前期综合征相关的疾病中的一种或几种。
  21. 一种药物组合物，其特征在于：它是以权利要求1～18任一项所述的化合物、或其立体异构体、或其药学上可接受的盐作为药物活性成分，加上药学上可接受的辅料制备而成的制剂。
PCT/CN2023/070285 2022-01-18 2023-01-04 Wee1抑制剂及其制备和用途 WO2023138362A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3234845A CA3234845A1 (en) 2022-01-18 2023-01-04 Wee1 inhibitor, preparation therefor, and use thereof
AU2023209945A AU2023209945A1 (en) 2022-01-18 2023-01-04 Wee1 inhibitor, preparation therefor, and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210053373 2022-01-18
CN202210053373.X 2022-01-18

Publications (1)

Publication Number Publication Date
WO2023138362A1 true WO2023138362A1 (zh) 2023-07-27

Family

ID=87175962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/070285 WO2023138362A1 (zh) 2022-01-18 2023-01-04 Wee1抑制剂及其制备和用途

Country Status (5)

Country Link
CN (1) CN116462687A (zh)
AU (1) AU2023209945A1 (zh)
CA (1) CA3234845A1 (zh)
TW (1) TW202330537A (zh)
WO (1) WO2023138362A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024012549A1 (zh) * 2022-07-15 2024-01-18 映恩生物制药（苏州）有限公司 一种嘧啶并五元杂环化合物、其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432284A (zh) * 2006-04-27 2009-05-13 万有制药株式会社 二氢吡唑并嘧啶酮衍生物
US20100221211A1 (en) * 2007-10-23 2010-09-02 Hidetomo Furuyama Pyridone-substituted-dihydropyrazolopyrimidinone derivative
CN113402520A (zh) * 2020-03-16 2021-09-17 中国科学院上海药物研究所 Wee1蛋白降解剂
WO2021252667A1 (en) * 2020-06-11 2021-12-16 Recurium Ip Holdings, Llc Methods of making wee1 inhibitor compounds
WO2022011391A1 (en) * 2020-07-09 2022-01-13 Recurium Ip Holdings, Llc Salts and forms of a wee1 inhibitor
CN115707708A (zh) * 2021-08-19 2023-02-21 轩竹生物科技股份有限公司 Wee1激酶抑制剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432284A (zh) * 2006-04-27 2009-05-13 万有制药株式会社 二氢吡唑并嘧啶酮衍生物
US20100221211A1 (en) * 2007-10-23 2010-09-02 Hidetomo Furuyama Pyridone-substituted-dihydropyrazolopyrimidinone derivative
CN113402520A (zh) * 2020-03-16 2021-09-17 中国科学院上海药物研究所 Wee1蛋白降解剂
WO2021252667A1 (en) * 2020-06-11 2021-12-16 Recurium Ip Holdings, Llc Methods of making wee1 inhibitor compounds
WO2022011391A1 (en) * 2020-07-09 2022-01-13 Recurium Ip Holdings, Llc Salts and forms of a wee1 inhibitor
CN115707708A (zh) * 2021-08-19 2023-02-21 轩竹生物科技股份有限公司 Wee1激酶抑制剂

Also Published As

Publication number Publication date
AU2023209945A1 (en) 2024-04-18
CA3234845A1 (en) 2023-07-27
TW202330537A (zh) 2023-08-01
CN116462687A (zh) 2023-07-21

Similar Documents

Publication Publication Date Title
CN113365988B (zh) Shp2抑制剂及其应用
CN113316574B (zh) Shp2抑制剂及其应用
CN101720318B (zh) 用作Hsp90抑制剂的喹唑啉-肟衍生物
CN103459369B (zh) 胍化合物
CN103429585B (zh) 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物
TW202043217A (zh) Ｂｃｌ－２抑制劑
KR101782668B1 (ko) 인산화 효소 억제제와 이를 이용한 종양을 치료하는 방법.
CN108699032A (zh) 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途
CN109678859A (zh) 二氢嘧啶类化合物及其在药物中的应用
CN106661035B (zh) 用作布鲁顿氏酪氨酸激酶的抑制剂的吡唑并嘧啶衍生物
CN109790146B (zh) 药物化合物
CN113286794A (zh) Kras突变蛋白抑制剂
CN110248939A (zh) 作为rho-激酶抑制剂的酪氨酸酰胺衍生物
CN110248934B (zh) 杂芳基pad4抑制剂
CN112552295A (zh) Kras突变蛋白抑制剂
TW202110837A (zh) 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2017114510A1 (zh) 具有erk激酶抑制活性的化合物、其制备方法和用途
CN108191861B (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺
CN109111451A (zh) 二氢嘧啶类化合物及其在药物中的应用
CN111655681A (zh) 杂环基氨基取代的三唑类化合物作为Rho相关蛋白激酶的调节剂
CN115038688A (zh) Usp30抑制剂及其用途
KR102205354B1 (ko) 역형성 림프종 키나제(ａｌｋ) 억제제로서의 인돌로퀴놀론 화합물
WO2023138362A1 (zh) Wee1抑制剂及其制备和用途
WO2022268230A1 (zh) 作为kif18a抑制剂的化合物
CN115667226A (zh) 作为egfr抑制剂的三环化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23742678

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2023209945

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 3234845

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2023209945

Country of ref document: AU

Date of ref document: 20230104

Kind code of ref document: A